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2ABSTRACT
This thesis reports on a randomised controlled trial of medical and physical therapy in the 
management of chronic temporomandibular joint pain and dysfunction.
The literature review first explores the meaning and measurement of chronic pain. The 
anatomy and dynamic function of the temporomandibular joint and associated musculature is 
then introduced before describing the pain and dysfunction which affects this specific region. 
The development of terminology, classification and epidemiology is addressed to provide a 
basis for understanding the condition. A discussion of the presumed multifactorial aetiology 
and current management follows, with focus on the two areas of specific interest in this study 
the physical and medical therapies
The study methods, results and discussion are presented in accordance with the CONSORT 
(Consolidated Standards of Reporting Trials) guidelines.
A referral cohort of 1,038 subjects were screened and assessed. 250 subjects met inclusion 
criteria and agreed to participate with informed consent. Subjects were randomised into four 
groups: medical therapy, placebo, occlusal bite guard, medical therapy and occlusal bite guard. 
A three month treatment phase and a six month follow-up phase were then conducted.
The first section of the results examines the referral cohort. Demographic, clinical diagnostic, 
and psychosocial profile are reported with treatment uptake for the trial.
The second section examines the three month trial phase, treatment efficacy and outcome. The 
analysis of subgroups is explored, including the characteristics of responders and non- 
responders to therapy in addition to outcome measures in subjects with initially high pain 
scores and high levels of depression. The final section analyses reasons for patient withdrawal 
and non compliance before examining the follow up phase post therapy for maintenance of 
improvement.
Both primary and secondary outcome measures revealed significant improvement in pain 
amongst all four groups which was maintained during the follow-up phase.
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1 0 THE MEANING OF PAIN
1.1  Definitions of pain
Why do people suffer pain? Over the centuries, philosophers, theologians and physicians 
have struggled with this enigma. Even in the 21st century our understanding, although more 
enlightened, remains limited. ‘Pain7  originates from the Greek word ‘poena7  meaning a fine 
or penalty, which in Greek mythology, refers to a form of punishment on mankind. 
Everyone fears ‘poena7  yet no one escapes the universal but individual experience of ‘pain,7  
an integral aspect of life. For instance, it is acknowledged that without transient pain as an 
early warning system we eventually die due to tissue damage and uncontrolled infection as 
seen in congenital analgesia, a rare neurological condition where pain is not felt (Wall 
1999).  However, suffering and prolonged pain serves no useful purpose and it is this 
phenomenon, which is the most complex to unravel.
The Oxford English dictionary ,2005, defines pain as suffering of body or mind.  This 
identifies the two components involved in pain the physical or sensory body and the 
emotional or psychological mind. Both elements, rather than separate, are considered 
extricably intertwined, each element contributing to a lesser or greater degree in various 
pain conditions.  This leads us to the currently most acceptable definition of pain as defined 
by the International Association for the Study of Pain.  “An unpleasant sensory and 
emotional experience associated with actual or potential tissue damage or described in 
terms of such damage “(Merskey and Bogduk,1996). In order to appreciate the derivation 
of this definition it is first necessary to understand the progression of pain theory from the 
mechanistic, specificity theory to the current biopsychosocial model of pain.
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1.2 Theories of Pain
Epicurus (340-270B.C.) proposed injury to equate directly to pain (Everson 1991).  This 
philosophy of linear causation was influential in the development of pain theory and the 
mechanistic model of pain, dominant in western medicine until the mid 1960’s (Horn and 
Munafo, 1997)
1.2.1  Specificity theory
The mechanistic approach to pain was exemplified by Descartes who in1664 published a 
theory of pain transmission, which became known as the specificity theory (Melzack and 
Wall 1996). It was proposed that independent of other somatic sensation pain was 
conveyed from sensory apparatus by threads along a pathway from peripheral site to a 
central location in the brain. The receptors and specific pathways to the spinal cord and 
brain required investigation. Von Frey (1894) developed the theory by suggesting that free 
nerve endings numerously distributed on the skin surface were the specific peripheral pain 
receptors. Unique types of pain fibre were later discovered A-delta (A8) C and A-beta (Ap) 
of varying diameter and my  duration. Transmission, velocity and quality of pain experience 
varied between fibres, each proposed to have a specific pathway to a distinct area in the 
brain, (Melzack & Wall 1996). Keele (1957) discovered the spino-thalamic tract of the 
spinal cord a 'pain pathway’ essential for pain transmission to the brain.
The exact locations in the brain stem and thalamus of the nuclei, which receive and process 
pain information, continues to be unraveled (Melzack and Wall,1996, Horn and Munafo, 
1997). The contribution of the specificity theory has been invaluable in the discovery of 
peripheral sensory fibre specificity and the pain pathway. An assumption of aCHAPTER I
direct relationship between ‘pain receptor’ stimulation and the sensation of pain is however 
inadequate. Cartesian dualism separates mind and body, (Bonica,2001). Applied to pain this 
infers a sensory process with no modulation between stimulus and response and a disregard 
for any psychological factors. However, psychological studies confirm that pain perception 
and intensity of stimulus are not directly related. (Beecher, 1956, Melzack, Wall and Ty 
1982).
1.2.2  Summation theory of pain
Goldsheider (1894) proposed a summation or pattern theory.  Stimulus intensity and 
summation in the dorsal horn were considered critical determinants of pain production, 
(Melzack & Wall 1996). This theory acknowledged that any non-specific receptor, 
repeatedly stimulated, may produce pain with summation delayed or enhanced by 
pathology. This displaced the concept of there being only a specific type of pain receptor. 
Livingstone 1943, shifted the focus of attention to central summation. A reverberating 
circuit in the grey matter of the spinal cord initiated by normal sensory input leads to 
abnormal central activity with interpretation of stimuli as painful,(Melzack and Wall, 1996). 
Although this explains the importance of the central nervous system in phantom limb pain 
and causalgia it does not account for the inability of spinal cord lesions to abolish phantom 
limb pain or pain experienced in para or quadriplegics. The short falls of specificity and 
summation theories to accommodate several anomalies of the pain experience, including a 
more active role for the brain, needed to be further addressed.
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1.2.3  Gate Control theory
Melzack and Wall 1965, proposed the gate -control theory combining strengths of previous 
theories with new concepts.  The most novel feature was The gate7 , a neural mechanism in 
the dorsal horn of the spinal cord, which integrates ascending afferent signals from the 
peripheral nerves and modulates descending efferent signals from the brain and central 
nervous system (Melzack with Wall, 1996).
This was a modulatory rather than a direct transmission theory (Horn and Munafo 1997) 
Ascending signals from Ap, A6 and C fibres were known to terminate in the dorsal horn. 
The balance in activity between these large and small diameter fibers effectively “opened 
and closed” the gate facilitating or inhibiting neural transmission of pain. Ap, large diameter 
fibers, exhibiting an inhibiting effect on the relay of nerve impulses whilst preponderance of 
the slower conducting, small diameter A6 and C fibers increased pain transmission.
The cells comprising the substantia gelatinosa, in the dorsal horn, seemed to be responsible 
for modulating input from the afferent fibers to spinal cord transmission (T) cells, which 
then convey impulses to ascending spinal cord pathways (Wall 1964). It was proposed that 
gating mechanism influenced by the Central control Trigger is a further system of large 
diameter fast conducting fibers, which activate selective cognitive processes.
The descending neuronal impulses were also proposed to influence the gate, considered 
predominantly inhibiting, (Melzack and Wall 1996)
A central system was proposed relating to pain behavior and experience activated when T 
cell output exceeds critical level. These sites in the reticular and limbic systems of the
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brain correspond to cortical projection pathways for pain.  In addition, it was believed 
influence on the gating mechanism could be linked to a range of factors unrelated to 
specific sensory pain transmission such as cognitive influences, attention, meaning, anxiety, 
past experience and memory of pain. The mechanisms producing these effects were unclear 
when published yet a vital concept in explaining inter and intra individual variation in 
response to an identical injury. There was also finally an acknowledgement of the active role 
of the human brain in analyzing and influencing the perceptual and sensory world of pain. 
Although the gate remains a theoretical construct the existence of the neural mechanism in 
the dorsal hom is no longer disputed (Larbig 1991)The ability to integrate: psychological, 
behavioural and physiological components of pain into the one model created a more 
holistic approach and a paradigm shift in the understanding of pain (Grahek, 1991)
1.2.4  Bevond the gate and neural plasticity
The gate control theory presented pain as a dynamic process but long term changes in 
central nervous system or the extent of prolonged gate opening with sensitization to pain 
were not yet taken into account. (Loeser & Melzack 1999).
Altered function or hypersensitivity of the central nervous system following peripheral 
injury was suggested by Stuge in the 1880’s and a decade later by MacKenzie 1893 who 
considered the spinal cord the site of hypersensitivity (Coderre et al.  1993).Transient 
changes in the dorsal hom neuron sensitivity to further stimulation by noxious peripheral 
stimuli was found in the late 1970’s but sustained changes in central excitability was 
demonstrated in animal studies by Woolf et al. 1983.  Peripheral sensitization and increase 
in spinal cord excitability following noxious stimulation were maintained even after local
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anaesthetic at the site of injury, where 10 times the dosage of morphine was required to 
reverse excitability as to prevent establishment (Woolf and Wall 1986)
Peripheral damage was also shown to lead to expansion of the nociceptive fields of spinal 
neurons resulting in pain following stimulation at a site other than the original injury. 
Nociceptor function is known to be influenced temporarily by the inflammatory mediators 
surrounding the tissue injury during body healing (Loeser and Melzack, 1999). However, 
massive nociceptive input, due to excitatory toxic effects of amino acids can permanently 
change spinal cord function resulting in chronic long term pain following an acute injury 
(Dubner and Rude 1992;Doubell,Mannion and Woolf, 1999).
Increased excitability in neurons in the spinal and medullary dorsal hom caused 
spontaneous neuronal activity, lowered pain thresholds and hyperalgesia (Dubner and Rude 
1992) Pain transmission leading to central changes were demonstrated where repeated 
activation of C fibers resulted in an augmented response to subsequent C fibre input, 
termed the “wind up” phenomenon (Dikenson, 1991). Changes at both spinal and 
peripheral sites were suggested with interaction between excitatory amino acids, opioids, 
monoamines and non opioid peptides which may persist for days following injury. Scholz 
and Woolf, 2006, in an updated gate control theory, suggests altered gene expression in the 
dorsal root ganglion may be responsible for the persistent pathological process of pain 
arising from increased excitiation and decreased inhibition within the spinal cord.
Opioid mechanisms themselves also exhibit plasticity but to what extent changes are related 
to behavioural and psychological functioning is unknown (Lipman et al. 1990).
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“Central sensitization “ with activation of multiple cortical and sub cortical regions may be 
partly responsible for failure to provide substantial chronic pain relief from both surgical 
and medical interventions, (Price, Mao and Mayer 1997)
Clinical pain states such as phantom limb pain or pain below the level of spinal cord 
transection indicate the brain appears capable of generating pain in the absence of 
peripheral nociceptor or spinal cord input. A pattern- generating mechanism, or 
neuromatrix is hence thought to exist into which input data converge on an image of the 
body (Codere, 1993; Melzack, 1990). Perception of pain is generated by output from this 
neuromatrix regulated by sensory, affective and cognitive activity. Expectation and 
environmental cues may generate or perpetuate previously conditioned nerve impulse 
patterns producing somatic sensation. In contrast, modulation may diminish or prevent the 
perception of a normally noxious event.
1.3  Identification of pain
1.3.1  Nociception and perception
Nociception is derived from the Greek word “nox” meaning harm or damage and is the 
detection of noxious stimuli. A dual stage process, it involves transduction of a noxious 
stimulus by peripheral nerve endings, influenced by inflammation or neural change in their 
immediate environment followed by transmission of these signals to the central nervous 
system. Nociception is not synonymous with the subjective state of pain but activation of 
nociceptive pathways is usually the origin of the pain. However, nociceptive input can be 
modulated at every level of the afferent pathway from peripheral nerve to cerebral cortex.
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Restoration of transducer activity to the resting state by local anti inflammatories, local or 
regional anaesthesia or more sophisticated downstream modulation can all prevent 
nociception attaining the status of pain. If nociception results in pain, the experience of 
perception and tolerance are profoundly influenced by the context in which the event 
occurs notably the individual’s affective state, levels of distress, health, immunological 
status and previous pain experience.
The perception of pain can occur not only from the noxious stimulus of peripheral injury or 
disease but also from lesions of the central nervous system or without any observable 
cause. When a diagnosis for pain is identifiable, the cause where appropriate can be 
eliminated and appropriate treatment provided. However, diagnosis often gives limited 
indication of suffering or impact on life since physical findings do not correlate to the 
degree of observed pathology (Turk and Melzack, 1992). Distinct emotional and distress 
components also require evaluation since maintenance of pain may involve a complex 
interaction of psychosocial factors (Melzack and Wall, 1996).
Categorizing the type of pain in descriptive terms and duration; transient, acute or chronic; 
are however useful in aiding diagnosis and treatment approach.
1.3.2. Acute and chronic pain
Classically, a temporal distinction is made between a short acting episode of acute pain and 
longstanding constant or recurrent chronic pain.
The time period, which signifies a chronic condition, is arbitrary but usually ranges from a 
month to six months. Bonica (2001), describes pain persisting for a month beyond the
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usual course of an acute disease or a reasonable time for an injury to heal. Merskey and 
Bogduk (1996) defines chronicity in more precise terms as pain which has persisted for 
three months or longer and it is this definition which is currently accepted in research. Time 
factors in isolation can be misleading since chronic pain is not simply a persistence of acute 
pain. Fundamental differences exist in underlying pathology, symptoms, treatment response 
and management
Acute pain generally has an identifiable cause and sudden onset provoked by noxious 
stimuli as a result of local tissue damage from injury or disease, (Cousins, 1999, Carr and 
Goudas,1999). Stimulation of the autonomic nervous system causes anxiety or fear, which 
serves as a protective mechanism to seek assistance and take appropriate action to aid 
healing. Pain is therefore usually a symptom of an underlying pathological process most 
frequently inflammation, 85% (Peterson and Milgrom, 1989).
Diagnosis of the underlying cause of pain is hence the basis of successful treatment with a 
good response to analgesics. 90% of acute pain will resolve within 4 to 12 weeks 
irrespective of professional medical intervention (Nachemson, 1982). Reparative healing 
can occur without medication and pain report ceases before healing is complete. Medical 
intervention however may be useful to reduce pain by shortening the duration of the injury 
and speeding up the healing process (Loser and Melzack, 1999).
Chronic pain in contrast is more difficult to define since onset may be insidious with often 
no clearly identifiable pathology. It serves no obvious function often socially and 
psychologically destructive with vegetative signs of depression. Pain may appear to occur 
spontaneously or more commonly originates from an initial noxious stimuli but persist long 
after the event perpetuated and intensified by other factors. This transition from an
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acute to a chronic condition may follow an injury that exceeds the healing capabilities of 
the body or as a result of damage or alteration to the nervous system. Certain pain may be 
destined for chronicity from the outset ignoring time factors but related instead to aetiology 
and the bodies’ initial reaction to the noxious stimuli. In attempting to achieve homeostasis 
after an acute event the stress of pain involves genetically determined neuronal, hormonal, 
immunological and behavioral activities (Chrousos, 1992). Pain duration is not the 
distinguishing feature in chronic pain but the body’s inability to restore normal homeostatic 
levels of physiological function (Loeser and Melzack, 1999).
Identifying those patients likely to develop chronicity or preventing conversion from acute 
to chronic requires investigatioa This would be beneficial not only to the patient but to 
health care services since it is suggested that the 10% of chronic pain sufferers consume 
85% of costs associated with pain and sequelae (Linton, 1998). Early intervention for acute 
pain may in some situations prevent development of chronic disability (Linton, Hellsing, 
Anderson, 1993).
Demographic and psychological factors have been shown to be predictive of chronicity in 
several studies but results are inconsistent and provide only a preliminary overview of 
issues (Turk, 1997). Neurophysiological changes of plasticity at a cellular and molecular 
level are known to contribute to persistent pain (Doubell,Mannion and Woolf, 1999). 
Inflammatory mediators in the inflammatory process are associated with sustained 
peripheral sensitization of nociceptors (Steen et al, 1996). Following injury to the 
peripheral nerves or dorsal hom neurons following inflammation or trauma alterations 
occur in the dorsal root ganglion (Ma and Woolf, 1996; Hokfelt et al 1994). In addition a 
range of psychological factors influence pain modulation
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It is inappropriate to treat chronic pain as neglected acute pain as this can cause iatrogenic 
damage. Relief of pain symptoms takes priority since underlying pathology may be unclear. 
Pain perception often remains despite intervention and psychological approaches are 
required to alter the overall effect of pain on daily life.
Melzack (1998) suggests the brain may be capable of modifying pain information 
processing to minimize the impact of pain on the individual. Nociception is interpreted and 
perceived in a manner that diminishes suffering and pain behaviour.
1.3.3  Suffering
“Suffering occurs when the physical or psychological integrity of the person is threatened” 
(Cassell, 1982). Not all suffering is caused by pain but other negative responses such as 
fear, anxiety, stress, emotional loss and psychological status. The language of pain is used 
to describe suffering irrespective of cause and is therefore misleading (Loeser and Melzack, 
1999). Amplification or distortion of the patients’ experience of pain and suffering can 
occur through maladaptive behavioral processes (Reesor and Craig, 1988).
1  3 4 Pain behaviour
Pain behaviour is an outward manifestation of the inner subjective self (Hom and Munafo, 
1997). It is influenced by a host of factors which include: accepted behaviour within a 
cultural environment; social modelling; learning, memory and past experience; pain 
threshold, perception and tolerance and cognitive factors of coping, control, self efficacy 
and motivation. For instance, ethnicity, beliefs and attitudes amongst cultures are known to 
effect displays of pain behaviour and pain reporting (Skevington, 1995).Others observe
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the behavioural actions or avoidance of actions by an individual. These observations in 
addition to the individual history and physical examination reflect to the outside world the 
existence of pain and suffering.
1.3.5.The clinician’s role in empathizing with the pain patient 
Pain is personal and as such it is impossible to know exactly what someone else feels. 
Although we may try hard to empathise with the sufferer, in our attempt to understand the 
problem, it is sheer arrogance to presume we can measure and know what the other 
individual is experiencing. We cannot see or hear through their eyes or ears nor have we 
experienced life in the conscious world from their perspective.
Huxley, 1946 wrote “ I can sympathise with people’s pains but not with their pleasures. 
There is something curiously boring about somebody else’s happiness” This seems a very 
negative view of the inability of an individual to appreciate happieness. Could it be that he 
empathises with those who are depressed or who find difficulty in shifting from a negative 
to a more positive frame of mind, chronic pain patients for instance. A depressed pain 
patient may be able to sympathise with another depressed pain patient and discuss their 
misery yet almost envy happiness in others. Interestingly with time and patience one could 
envisage that the same patient, when treated in a positive manner, may begin to assume a 
more cheerful countenance and eventually start to appreciate the good in life. An effective 
clinician might therefore, be someone who is sensitive to the patient’s negative mood yet 
has the ability to draw on their own reserves to convey and engender positivity.
Empathetic listening and vicarious learning although helpful in appreciating our patient’s 
concerns and providing appropriate therapy requires large reserves of energy.  In order to
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retain the level of energy required for sensitive empathising, the clinician may need to be 
sufficiently detached to care effectively, for the benefit of both patient and clinician. Only 
by doing this can one hope to analyse, measure and treat pain in a more objective manner.
1.4  Measurement of Pain
1.4.1  Can pain be measured?
Pain and suffering is immeasurable. A multifaceted phenomenon one cannot underestimate 
the complexity of the human mind in pursuit of accurate scientific measurement. In the 
objective, systematic assessment of pain acute pain studies must focus on need and 
effectiveness of treatment analysis whilst chronic pain studies focus on the effect on 
function progress and outcome of therapy.
Technically the multiple dynamics of pain do not fit into a simple numerical construct and 
assumptions of relationships between depression and pain or intensity and distress can be 
problematical. Measurement tools investigating a single dimension of pain are limited. 
Measures obtained from multiple sources at least provide a broader view of the overall 
problem, (Williams and Keefe, 1991) The outward expression of pain behaviour is only a 
public manifestation of the inner experience of pain. Consequently, the observation, self 
report and attempt at physiologdal correlates is the only aid to understanding the 
experience. For practical purposes it is sometimes assumed that outward expression and 
inner experience are indistinguishable (Bates, 1987). This stems from the observation that 
sociocultural influence affects the perceptual component of pain and outward expression. 
Syrjala and Chapman (1984), takes this concept a stage further and provides evidence of 
the relationship between pain behaviour and experience. When patients were requested toChapter I
exaggerate facial expressions of pain, subject self reports of pain and autonomic 
physiological measures of response increased whilst inhibiting facial expressions of pain, 
autonomic and self reported pain responses decreased. They suggested expressive pain 
behaviour modulates both physiological components and subjective pain experience in 
a self-regulatory manner. If one stops concentrating on reading for a moment and smiles 
broadly (although feeling rather foolish smiling at nothing in particular) is it not true to say 
that one immediately feels more positive. Could it be that by our public behavioural display 
of cheerfulness is altering our general affect or mood. Facial expression coding has been 
employed in experimental studies but requires development in the clinical setting (Craig et 
al, 1992). In depression corrugator muscle change is hard to suppress and careful 
observation of facial expression may assist in determining patient exaggeration or masking 
of underlying pain (Poole and Craig, 1992).
Chapman 1984, disputes the concept of pain as a private experience but suggests that 
although pain is multidimensional it is a pattern of behaviour increasingly measured, 
studied and clinically controlled, objective rather than subjective.
1.4.2  The measurement of pain
To study pain scientifically it is essential to attempt some form of measurement, 
quantification and categorization to allow comparison of scores and statistical analysis.
The different dimensions of pain to be measured may be physiological, sensory, affective, 
behavioural, cognitive and impaction on life. Whilst measurement refers to qualifying a 
specific element of pain, assessment examines an interaction of factors on the experience of 
pain (McGrath and Unruh, 1987)
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Measures determine location, magnitude or intensity, quality of pain, duration and 
frequency in aiding and establishing mechanisms and differential diagnosis, to assist in 
choice of therapy in establishing relative efficacy of treatment.
Measures must be reliable, valid and sensitive. Reliability ensures test retest internal 
consistency; validity ensures congruency with other measures or observations denoting pain 
sensitivity indicating a precise reflection of magnitude and change in measurement. With 
simple scales reliability may exist at the expense of sensitivity. However, some measures 
may generate quantifiable data amenable to multivariate analysis. The global implications of 
a pain condition can be investigated in terms of intensity, related disability and depression 
with alteration in attention, behaviour, thought processes and non-specific physical 
symptoms (Dworkin ,1992).
1.4.3 Measurement and Assessment tools and techniques
These can be classified into: self- report scales, observational techniques and physiological 
techniques.
The three dimensions of the pain experience considered most relevant to investigate are 
intensity, location and affect (Jensen and Karoly, 1991). Pain intensity is a quantitative 
estimate of pain severity whilst a diagram is used to indicate location. Pain affect denotes 
emotional arousal and disruption engendered by the experience of pain with various 
dimensions requiring measurement of multiple items (Jensen and Karoly, 1991).
1.4.4 Self reporting pain scales
Self report pain rating scales range from simple methods to gain information of pain 
intensity with regard to pain and analgesia to the more complex structural questionnaire or
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interview, to incorporate numerous variables including coping skills and functional 
restrictions.
1.4.5  Simple pain rating scales:
There are three simple rating scales: Visual analogue scale (VAS), Numerical rating scale 
(NRS), Verbal rating scale (VRS). VAS, NRS and VRS are simple, quick, effective, 
reproducible and valid measures for use in a hospital clinic to ascertain pain intensity,(Turk 
and Melzack,2001).
VAS, in the simplest form, is a 10 cm horizontal or vertical line used as an increasing 
indicator with ‘no pain" at one end point and ‘worst pain’ at the opposing end.
Other aspects of pain have also been assessed using VAS including impact on life.
The individual is requested to make a single mark on the line corresponding to the level of 
pain. Scoring of the scale is achieved by measuring the distance from the start of the line 
for instance ‘no pain’ to the mark. This is in millimetres grading 0 to 100 points or cm’s 0 
to 10. Early studies showed those completing the scale preferred VAS to 4 or 5 point verbal 
rating scales (Joyce et al 1975)
In comparison to other simple methods, 4-11% foiled to complete the scale accurately, 
(Jensen et al 1994) It was felt 100 points are too many and that most patients use multiples 
of 5 or 10 in rating pain, reducing effective points to 11 or 21 .However, failure rates are 
significantly reduced when the measure is explained prior to completion (Wilkie et al,
1990)
Price 1994, reports the measurement properties of the scales are influenced by 3 factors; 
the length of the line, instructions on usage and specific words used to anchor the end
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points. Ogon et al 1996 investigated uniformity of score distribution and sensitivity of the 
VAS in different orientations and demonstrated higher sensitivity in the horizontal 
orientation for usual pain intensity.
Syijala and Chapman 1984 highlighted ease of completion by patients who are ill or with 
limited language capacity but also oversimplification of the pain experience.
A simple verbal scale is derived from VAS assigning numerical scores 0-3 or 4.
1.4.6 The Me Gill Pain Questionnaire fMPO) (Melzack 1975)
This is principally a verbal descriptive scale to examine intensity and quality of pain.
In addition to the descriptive scale there is other information considered necessary for 
evaluation of pain including an overall PPI 0-5 point verbal scale, words to describe 
temporal properties and a diagram to illustrate localization of pain.
Initially 102 pain descriptor words obtained from clinical literature were classified by 
physicians and university graduates into small groups describing different aspects of pain. 
Three major groups were identified sensory, affective and evaluative and 16 subclasses. 
(Melzack and Torgerson, 1971) Subclasses were given a descriptive label and consist of 
similar or related words, synonyms, synonymous meanings or subtle nuances.
4 miscellaneous subclasses were later added due to patients finding the absence of key 
words. The final classification represented the most meaning full and representative 
qualitative subclasses.
In the second stage of the study words within each subclass were assigned a pain intensity 
value using a numerical scale 1-5 from least to worst. Physicicans, students and patients all 
agreed on the relative position or rank ordering of words but not on the intensity values.
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There was a high level of agreement on rank ordering of pain descriptors from those of 
different cultural, socio-economic and educational backgrounds.
The MPQ was developed as an experimental tool for clinics and research to study the 
effects of various pain management. The scale can be completed as a five-minute interview 
or as self-report paper -  pencil completion when patients are requested to choose words, 
which describe their current feelings and sensation.
Three indices are obtained: -
•  The number of words chosen (NWC)
•  The present pain intensity (PPI)
•  The pain-rating index (PRI)
The NWC is a simple count of the number of words chosen from each scale. The PRI is the 
sum of the rank value of all the word sets. The word in each subclass is valued lowest value 
1, for least pain increasing upwards. Each word rank value chosen by the patient is summed 
to provide a score for sensory, affective, evaluative, miscellaneous and total.
PPI 1-5, none, mild, moderate, severe, very severe. These descriptions were taken from the 
evaluative category, chosen for representing equal distance on mean ranking interval scales 
to provide an overall pain intensity specification, (Melzack and Torgerson, 1971)
Sensitivity was considered a potential problem with only 5 categories but studies reveal 
close correlation with the evaluative score and VAS (Walsh and Leber, 1983)
MPQ provides an insight into qualities of pain experienced characterised by a distinctive 
selection of words. Consistency is noted in choice of words by patients suffering same or 
similar pain syndromes. MPQ is hence a potential aid to differential diagnosis. DubuissonChapter I
and Melzack, 1976 first demonstrated this discriminative capacity on 8 known pain 
syndromes. A multiple group discriminant analysis revealed distinctive verbal descriptors 
for each pain type. Allen and Weinmann 1982 and Melzack et al 1986 looking at headache 
and TN versus AFP respectively confirmed the typical pattern of pain associated with 
different acute and chronic clinical symptoms. Differences in patients with or without 
demonstrable organic pathology were also demonstrated in patterns of MPQ correlation, 
(Perry et al 1988,1991) There does not appear to have been any studies to differentiate 
between Atypical Facial Pain and Temporomandibular disorders.
Gaston -  Johansson et al (1990), report subjects of diverse ethnic-cultural and educational 
backgrounds use similar adjectives to describe commonly used words such as ‘pain’,
‘hurt’ and ‘ache’. Stability and strong test-re test reliability coefficients were demonstrated 
for the MPQ (Pearce, 1989). Lower coefficients for the actual 20 categories with time can 
be explained by fluctuation in quality of the same pain with time.Studies reveal the MPQ to 
be sensitive to pain reduction intervention (Pozehl et al 1995, Briggs 1996, Burchiel et al 
1996, Eija et al 1996, Nikolajsen et al 1996 and Tesfaye et al 1996).
1.4.7. The Short form Me Gill Pain Questionnaire SF-MPO
This was developed for research purposes when more detail is required than VAS or PPI 
but when there are clinical time restrictions,(Melzack, 1987).
It consists of 15 representative words from the standard long form category, 11 sensory 
and 4 affective. Overall pain intensity is provided by an additional PPI and VAS. Words 
were selected on their frequency of usage by patients suffering from a variety of pains. The 
word splitting was added as a key word in dental pain (Grushka and Sessle,1984). Each
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descriptor is ranked on an intensity scale from 0 to 3 none, mild, moderate, severe. 
Gagliese and Melzack, 1997 in a study of patients with chronic athritis showed consistency 
amongst age groups young, middle and elderly in the most frequently chosen 
pain descriptors and in the frequency of SF-MPQ appropriate completion, although the 
elderly chose fewer adjectives.
Similar to the long-form, the SF-MPQ may be capable of discriminating amongst different 
pain syndromes and has been used in a variety of studies on chronic and acute pain 
including response to medical intervention (al Balawi et al, 1996, Gagliese and Melzak, 
1997, Thomas et al 1995 Burchhardt et al 1992 Dudgeon et al 1992). High correlation 
exists between the SF-MPQ and the LF-MPQ major PRI indices (sensory (S) affective (A) 
and total (T) with sensitivity to clinical changes following therapy such as analgesic drugs 
and TENS (Melzak, 1987).
1.4.8 Physiological measures
Utilizing our earlier definition of pain, it is clear that observable, physical markers of 
disease activity and tissue damage are not necessarily analogous with the experience of 
pain, (Merskey and Bogduk, 1996). Clinical and radiographic signs of presumed pathology 
and assumed clinical significance can occur in asymptomatic individuals (Westesson et al, 
1989) Pathological indicators used alone as evidence of pain can therefore invoke 
unnecessary treatment and patient anxiety.
Physiological, autonomic and endocrine activity are associated with pain, particularly 
marked in situations of acute noxious stimuli, or trauma (Cousins, 1999) In arthritis, joint 
swelling and inflammation is often visible, in migraine pupil dilation may occur whilst
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skin flushing and epiphora may be observed in cluster headaches. However, presence or 
absence of signs is not indicative of pain.
More frequently measured physiological parameters of pain include: cardiovascular 
function; heart rate, blood flow and pressure, palmar sweating, respiratory ventilation rate, 
electromyographic activity of the musculature, electrodermal activity of skin conductance 
and resistance, thermography for skin temperature and neuroimaging of brain activity. Skin 
temperature measured using thermography indicates heat in the acute inflammation of 
arthritic conditions and decreased temperatuire in conditions of altered sympathetic 
nervous system activity.
Autonomic reflex activity in acute pain can cause catecholamine release increasing blood 
pressure, cardiac output and ventilation rate causing distress and fear.
Self report of the physiological responses associated with pain have been attempted to 
negate the problems of direct physical measurement (McCracken, 1992) Sweating, 
palpitations, dizzieness or faintness have been studied in relation to the fear and anxiety of 
pain. Fear implicated in the maintenance of pain behaviour and activity avoidance was 
investigated using the Pain Anxiety Symptoms Scale (PASS). This examines a composite of 
physiological, behavioural and cognitive items in chronic pain patients which correlates 
with measures of anxiety and disability. Report of physiological symptoms only represents 
gross changes but has been shown to be a useful instrument in assessing pain related fear. 
Autonomic activity is controlled by a range of internal and external stimuli, is difficult to 
quantify and may fluctuate despite constant pain. Similarly amongst infants and children the 
physiological indices of distress; heart rate, respiratory rate and palmar sweating are
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evident but not specific to noxious painful procedures since similar responses also occur in 
novel or nonnoxios stressful events (Hester, 1995) Generally, autonomic changes are 
therefore considered an unreliable indicator of clinical pain since changes may be 
indistinguishable form those of the  general stress response. B endorphin secreation is 
linked to both acute pain and stress resulting in a decrease in pain intensity. Plasma 
endorphin concentration is therefore a good indicator of pain modulation but not of 
nociception (Szyfelbein,1985, Bonica,2001).
In persistent chronic pain, physiological responses may habituate with time 
(Graceley, 1989b). Trophic changes may occur, altered vasomotor and sudomotor activity 
of the skin, enhanced pilomotor segmental reflex and subcutaneous trophoedematous 
changes (Gunn, 1978).
Electromyographic (EMG) recordings of static and dynamic muscle activity with careful 
electrode placement has proved useful but often provide inconsistent data in relation to 
patient reported pain (Watson et al, 1997, Bushnall et al 2000 )Measurement reliability and 
validity is technique dependant varying between surface electrodes, needles or fine 
wires. (Mohl and Crow, 1993). In facial musculature; age, sex, facial type, subcutaneous 
fat thickness and tooth grinding were all factors considered to affect diagnostic validity 
(Widmer,1990,  Mohl, 1990).
Radiography to quantify pathological signs using plain views, CT and MRI is inappropriate 
since it generally does not correlate to pain intensity and frequently produces false positive 
and negative signs. (Boden et al  1990, Jensen et al 1994c)
Brain activity in pain has been recorded using EEG and neuroimaging studies with SPECT 
(single photon emission computed tomography), PET and MRI, (Flor, 1992, Chen, 1993b,
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Casey and Minoshima,1997.) Functional neuroimaging has seen rapid research 
development in the past 10 years revealing great potential, but currently remains too 
complex to be a clinical measurement tool, requiring specialist equipment, technical 
expertise and skilled interpretation of images (Davis,2000, Flor, 2003, Whalley et al 2004)
1.4.9.Psvchological measures
Three major psychological dimensions of pain were proposed, (Melzak and Casey, 1968).
1) sensory -  discriminative
2) motivational -  affective
3) cognitive -  evaluative
Melzak and Casey, 1968, proposed physiological systems within the brain related to 3 
dimensions, sensory by rapidly conducting spinal systems, affective by reticular and limbic 
activity influenced mainly by slowly conducting spinal systems, discriminative and 
motivational by higher CNS processes. Interaction of these categories provides perceptual, 
motivational and cognitive information, which in turn could influence motor response in the 
complex pattern of pain (Melzak and Katz, 1999)
Turk et al 1985 identified four groups of pain behaviour.
1) distorted ambulation or posture
2) negative affect
3) facial/audible expressions of distress
4) avoidance of activity
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Vlaeyen et al 1987 further characterised pain patients by three dimensions suggesting 
treatment should be guided by patient’s location within a construct.
1) withdrawl- approach
2) high arousal -  low arousal
3) visible- audible
For instance, relaxation training may be more appropriate for the high arousal patient. This 
approach to assessment relies on classification of behavioural types and expression of 
suffering. It is concerned principally with identification and abolition of maladaptive 
behaviour patterns. Self reported pain and investigating a range of behavioural patterns, 
coping skills, adaptation and function attributes and meaning has been shown more useful 
examining therapeutic interventions. Fordyce, 1984, has explored what constitutes pain 
behaviour. Non-reinforcement of maladaptive pain behaviours by operant conditioning of 
chronic pain patients was devised by Fordyce, 1984. Treatment proved effective in 
reducing not only associated disability but also pain intensity (Fordyce et all985)
The concept of what constitutes pain behaviour continues. Pain behaviour may be 
interpreted as an outward manifestation of the inner subjective state. However, in this 
context pain behaviour is considered as a set of indicators of pain and suffering in order to 
elicit help, appropriate in acute stages of pain but eventually maladaptive when maintained 
long-term by operant conditioning.
Objective and systematic assessment of pain is required in both acute and chronic pain to 
ensure appropriate therapeutic intervention.
Karoly 1985 suggest overall aims of chronic pain assessment are to inform and guide, 
intervention, in four main areas.
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1) To determine patient readiness for treatment
2) To prioritise the focus of intervention
3) To quantify the disruptiveness of the problem
4) To assess nature and impact of patient’s implicit pain theory
1.5  Concepts of pain
The theoretical concepts and components of pain are gradually unravelled. Attempts are 
made to measure and understand the multidimensional phenomenon yet still one is left 
wondering. Acute pain can serve a protective function but why do people experience 
chronic pain?  In some respects, chronic pain could now be viewed as a disease entity. A 
combination of a neurodegenerative disease due to genetic and pathophysiological changes 
of the nervous system,(Scholz and Woolf 2006): in addition an environmental disease with 
regards to the individuals’ internal and external environment, (Cousins,2005).
Perhaps from a theological perspective we should examine Revelations 21v3-4, “..death 
shall be no more, neither shall there be mourning nor crying nor pain any more for the 
former things have passed away.” “...There shall be no more pain” and until then, we 
cannot hope to cure all pain during our lifetime on earth, we can only strive to ease the 
suffering in the world around us. This sentiment is reiterated in the words of Dr Albert 
Schweitzer, 1953,“Pain is a more common fear than death himself. We must all die but I can 
save him from days of torture, that is what I feel as my great and ever new privilege” The 
clinicians role in the management of facial pain is indeed a privilege. If we can alleviate or 
simply help the patient cope with pain we will have achieved something however small.
52Ch a pter II
THE TEMPOROMANDIBULAR JOINT AND TEMPOROMANDIBULAR
DISORDERS
ANATOMY, PHYSIOLOGY, PATHOLOGY, TERMINOLOGY, 
CLASSIFICATION AND EPIDEMIOLOGY
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2.0  The Temporomandibular joint (TMJ)
In the following chapters, I will now concentrate directly on the study of pain related 
to the temporomandibular joint (TMJ) and associated muscles. In focusing so intently 
on a specific anatomical site I shall endeavour not to loose sight of the fact that pain 
can never be studied in isolation. Whatever the condition, pain is a dynamic, 
perceptual process affecting the suffering human being in their entirety.
2.0.1 Temporomandibular disorders 1TMP1
Pain and dysfunction of the TMJ is the most common chronic orofacial pain condition; 
yet, with respect to aetiology it is difficult to define and classify accurately.
The current definition of TMD is:
•  Pain in the preauricular area, TMJ, or muscles of mastication
•  With or without limitation or deviations in mandibular range of motion
•  With or without TMJ sounds during jaw function 
(Dworkin and Drangsholt, 2005)
In order to understand the disorders of the TMJ one must first appreciate the normal 
functional anatomy and physiology. Differential diagnoses must be excluded and the 
condition confirmed by recognition of the reported symptoms and presenting signs, 
together with a careful history and clinical examination. Terminology and 
classification are then explored, followed by the epidemiology of the condition, 
aetiology and management.
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2.1 ANATOMY
2.1.1 The joints
The bilateral temporomandibular joints form the craniomandibular articulation 
between the condylar heads of the mandible and the inferior surface of the temporal 
bones. These two complex, synovial joints permit significant movement between the 
two bones, each covered with an articular surface and united by a capsule creating a 
joint cavity filled with synovial fluid. In addition to being synovial, the joints are 
described as ginglimoarthroidal due to the articular surfaces being seperated by an 
interposed articular disc, (Okeson,1996). This creates superior and inferior joint 
compartments, allowing hinge and translatory movements respectively.
Intra articular components
Temporal bone
Articuar surface
Intra articular disc
Articular surface
Inferior joint compartment
Superior joint compartment
Condylar head (mandibular bone)
Articular eminence
Glenoid fossa  __
Condylar head
Figure 1
Basic movements
Hinge
Translation (gliding)
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2.1.2  The joint components
2.1.2.1 Bone structure
The head of the condyle, glenoid or condylar fossa and articular eminence or tubercle are 
the boney components of the joint. Each are covered on the articular surface by fibrous 
connective tissue not the hyaline cartilage seen generally in synovial joints,(Norman et 
al,1990). This may have unusual reparative implications,(Meikle,1992).A scattered 
arrangement of cartilage cells within the condylar head, also ensures an ability to modify and 
remodel the shape allowing adaptation to functional stress,(Ten Cate, 1998, Avery, 2000).
2.1.2.2 Disc
Composed of dense fibrous connective tissue, pear shaped, non uniform in thickness
with four distinct zones, thinnest in the central intermediate zone,(Williams,1999).
Intra articular disc
(superior view)
Anterior band (zone) 
Intermediate zone 
Posterior band (zone)
Bilaminar region (zone)
Posterior band (zone) 
Intermediate zone 
Anterior band (zone) 
Bilaminar region (zone)
Intra articular disc 
(lateral view)
Figure 2
Anterior temporal 
attachment
Lateral wall of capsule
Medial wall
Posterior temporal 
attachment
Superior joint compartment
Posterior temporal 
attachment
Condylar head
Posterior mandibular 
attachment
Anterior mandibular 
attachment
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2.1.2.3  Capsule and synovium
The fibrous capsule enclosing the intra articular components is lined by synovial membrane. 
Within this membrane synovial cells in the lymphatic capillaries of the villi produce synovial 
fluid to bathe the joint surface,(Griffin and Sharpe, 1960).On average there is 1.2ml of fluid in 
the superior joint space and 0.9ml in the inferior joint space,(Toller,1974). Alterations to 
quantity and viscosity of synovial fluid influencing normal joint function or creating a vacuum 
effect have been suggested, (Nitzan et al,1992) However, the  mechanics of  joint turbology 
still require further investigation,(Nitzan et al,2001,2004)
2.1.2.4  Ligaments
Laterally the capsule is strengthened by the fibrous band of the lateral temporomandibular 
ligament. This runs obliquely downwards and backwards from the zygomatic arch to the 
lateral posterior border of the mandibular neck. Relaxed at mandibular rest position but 
tightened in jaw protrusion,(McMinn,1995).
The accessory sheno and stylo mandibular ligaments are separate from the capsule. The 
stylomandibular ligament, a sheet of facia condensed between the carotid and submandibular glands 
connects the styloid process to the angle of the mandible. The sphenomandibular ligament extends 
from the spine of the sphenoid to the lingula of the mandibular foramen,(Williams et al,1989). 
Interestingly, when the mouth is open the lower attachment is at the axis of rotation of the mandible 
and remains constant in length and tension at all mandibular positions,(McMinn,1995)
Figure 3
Styloid process 
Fibrous capsule
Lingula
TMJ ligaments
Lateral temporomandibular 
ligament (not visible medially)
Sphenomandiular ligament
Stylomandibular ligament
Medial aspect of mandible.
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C
Figure 5: Masseter
2.1.2.5  Muscles of mastication
The principal muscles associated with the joints are the bilateral temporalis, masseter, 
medial and lateral pterygoids
Figure 4: Temporalis  .
The broad temporalis muscle has almost horizontal
posterior fibres and vertical anterior fibres, superficial
and deep heads converge to a central tendon inserted
on the coronoid process. The muscle is covered by a
sheet of fibrous temporal facia roofing over the
temporal fossa,(Johnson and Moore, 1997).
The masseter, composed of three layers originates 
from the zygomatic arch to insert into the ramus and 
angle of the mandible,(Johnson and Moore, 1997).
Figure 6: Pterygoids
The medial pterygoid originates from the medial 
aspect of the lateral pterygoid plate and small area 
of the maxillary tuberosity to insert into the 
inferior surface of the ramus and the angle of the 
mandible. Whilst the lateral pterygoid originates 
from the greater wing of the sphenoid and lateral 
aspect of the lateral pterygoid plate inserting into the pterygoid fovea,anterior neck of 
the condyle and capsule,(Williams et al,1999).
The mandibular branch of the trigeminal nerve supply the musculature and the joint.
Inferior view of 
the mandible
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2.2  PHYSIOLOGY -  Static and dynamic function
The action of  jaw muscles are combined to allow complex movement. Individual 
muscle contribution can be analysed by EMG activity placing electrodes on or over 
muscles to monitor electrical activity,(Ferguson,1988).
Mandibular movements can be defined as hinge and translation which combine to 
produce functional depression (opening), elevation (closing), protrusion, retrusion and 
lateral excursion,(Williams et al,1989). Functional movements in turn combine to 
produce the dynamic movements of eating, composed of incision and chewing cycles. 
The rapid and complex jaw movements require precise neural control demonstrated to 
some extent  by the jaw reflexes,(Fergusson, 1988).
Elevation or closing of the mandible is produced by the contraction of the temporalis, 
masseter and medial pterygoid. Depression or jaw opening is achieved by hinge and 
gliding movement. The lateral pterygoid pulls the condylar head forward whilst the 
chin is moved downwards by the infra and supra hyoid muscles, principally the 
digastric. In protrusion, lateral pterygoid pulls the condylar head and the articular disc 
forward along the articular tubercle with contribution from the superficial masseter. 
Retrusion is principally achieved by the horizontal fibres of temporalis. In lateral 
movement the ipsilateral condylar head remains within the mandibular fossa whilst the 
contralateral head is translated forward on the articular tubercle. The mandible is 
rotated about a vertical axis passing just behind the ipsilateral head not through it so 
consequently the head makes a small lateral movement called Bennett 
shift,(McMinn,1995). Jaw movement can be examined during clinical examination to 
observe limitations and dysfunction.
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2 3 PATHOLOGY
Pathological alteration to the joint can result from a variety of causes;
1) Congenital,developmental (aplasia, hypoplasia, hyperplasia)
2) Neoplastic disorders (benign and malignant)
3) Trauma (Intracapsular and extracapsular)
4) Ankylosis (Intracapsular, extracapsular,boney and non boney)
5) Arthritides (Inflammatory, Infective, Degenerative)
6) Musculoskeletal disorders.
Musculoskeletal disorders may present as pain and dysfunction, related to arthralgia 
(joint pain), mylagia (muscle pain) and internal derangement of the joint. Internal 
derangement is a result of uncoordinated movement of the intra articular components 
with resultant clicking, sticking or locking of the joint, with or without pain.
TMJ pain related to the musculoskeletal system is the most common non infective, 
pain condition of the orofacial region, (Lipton et al,1983, Dworkin et al,1983). The 
diagnosis is dependant on presenting signs and symptoms, history and examination.
2.4  Temporomandibular joint pain and dysfunction
2.4.1  Diagnosis
The lack of any objective diagnostic tests, such as tissue biopsy to differentiate those 
with or without the condition, is a similar situation to other musculoskeletal pain, 
(Lund, 1995,Widmer, 1995).Other diagnostic techniques; including jaw tracking 
devices, thermography, sonography and  electromyographic (EMG) analysis of 
masticatory muscle activity are not reliable indicators for diagnosis, (Laskin and
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Greene, 1990,Widmer et al, 1990, Mohl et al,1990).A careful history, examination and 
use of selective imaging is currently the best substitute available,( Lund et al, 1995).
2.4.2 History
The pain history in the form of presenting complaints and history of presenting 
complaints, medical, family and social history provide the essential key to the 
diagnosis, (Feinmann et al,1984, Speculand et al, 1984).This important concept will be 
more fully appreciated when considering the aetiology of the condition in Chapter 3. 
The history itself is complimented by the clinical and radiographic examination.
2.4.3 Clinical examination
Clinical examination includes a standard inspection of the hands, face and posture; 
cervical examination including swellings and lymphadenopathy; neurological 
examination and intra oral examination of the dentition and soft tissues. The 
specialised examination of the TMJ aims to investigate joint and muscle tenderness, 
limitation in mandibular movement, joint sounds and functional occlusion.
2.4.3.1  Palpation of joints and muscles
Reported pain or tenderness in usually assessed by the application of pressure to 
specific anatomical sites. Pressure is usually applied with the ventral aspect of the 
index finger or both index and middle fingers with a standard pressure for 3-5 seconds. 
The mandible should be in a position where the teeth are clenched then slightly apart 
to avoid active muscle contraction. Joint palpation is achieved by positioning a finger 
in the preauricular region,anterior to the tragus of the ear, to locate the lateral pole of 
the condylar head. A finger placed into the external auditory meatus, with mouth
61Ch apter II
opening, allows palpation of the posterior aspect of the condylar head.fDworkin et
al,1990)
The associated muscles are palpated for pain and in addition swelling, hypertrophy, 
atrophy and symmetrical contraction, (Clarke et al,1989). Sites of tenderness vary 
within the same muscle of an individual patient so the entire muscle should be 
palpated. Temporalis anterior and posterior fibres; origin, body and insertion of 
masseter are the simplest and most reliable muscles to palpate. Additional sites 
included in the examination are the submandibular region for medial pterygoid, 
suprahyoids and anterior digastric; stylohyoid and posterior digastric between 
sternocleidomastoid and posterior border of the mandible and intra orally temporalis 
tendon insertion, superior, anterior aspect of coronoid and lateral pterygoid in the 
posterior lateral aspect of the maxilla,(Ohrbach,1999).
Interexaminer reliability (0.4-0.6 acceptable agreement, 0.6-1 good agreement) (Petrie 
and Sabin,2003) was investigated for palpation sites in several studies. Dworkin et 
al,1988, found 0.47 for extra oral muscles, 0.27 for intra oral muscles and 0.47 for the 
TMJ, similar findings to Goulet and Clark, 1990. At present an alternative is to 
consider muscle palpation tenderness as a single composite score for all muscle groups 
consequently producing higher reliability (Dworkin et al,1988, Fricton and 
Schiffman,1986 and Dworkin et al,1990)
A pressure algometer is an instrument used for quantified measurement of pressure 
pain threshold. It indicates that tenderness remains relatively stable for minutes to 
hours as a valid diagnostic sign but becomes less stable over time and response may 
vary within the same day,(Orbach and Gale,1989.)Pressure pain threshold scores to 
discriminate patients from non patients or for use in differential diagnosis is currently 
not feasible.
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Factors affecting reliability of patient response to palpation include the amount and 
duration of pressure applied and exact location of palpation site. Confounding factors 
will affect reported pain including culture,age, gender and pain duration. For 
epidemiological studies an optimal pressure of 0.9kg for extra oral muscles and 0.45kg 
for intraoral muscles and TMJ sperate patients from non patients (Dworkin et al,1990). 
Clinical studies however have shown optimal pressure to vary dependant on the 
different muscles examined ranging from an optimal 2kg/cm2 for superficial masseter 
and 3.1 kg/cm2 for temporalis body (Goulet and Clark, 1990.) Physiological and 
psychological factors including; patient's affective state at the time of the examination, 
sensitization of peripheral nociceptors or second order neurones, altered thalamic 
processing, perceptual and neurological measures will influence patient response, 
(Ohrbach,1998).
For clinical purposes joint and muscle palpation should be adapted to the individual 
patient and to the specific muscle region, (Orbach and Gale, 1989).
2.4.3.2  Limitation in mandibular movement
Evaluation of mandibular movements includes the vertical opening,closing range and 
movement pattern together with horizontal lateral and protrusive excursions,(Clark et 
al,1986).
The opening range of motion can include pain free, unassisted maximal and assisted 
maximal opening. All three measurements have excellent inter examiner reliability 
(Kappa 0.9-0.98)  and provide relatively stable results over short periods of time, 
(Widmer et al, 1992). Distances are measured using a mm ruler from the incisal 
margin of the maxillary incisor to the opposing mandibular central incisor. A
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calibrated mm ruler is considered adequate for measurement so increased precision 
with electronic instrumentation is not warranted, (Ohrbach,  1999).
Establishing values for normal and abnormal mouth opening is debatable. Goulet and 
Clark, 1990, calculated the odds ratio of patients having a pain free opening less than 
45mm to be 3:1. This high cut off has sensitivity of 79% and specificity of 71% so few 
patients will have a mouth opening greater than 45mm but some non patients will open 
less than 45mm. Patients with  a presumed average mouth opening may report this to 
be much less than normal. Absolute values will be dependant on interindividual 
variation particularly relating to gender, body size, age and clinical history.
In one study males average mouth opening was around 52.9mm and females 49.4mm 
differing by 3.5mm and in another males 47.9mm and females 45.4mm varying by 
2.5mm (Dworkin et al,1990)
Determination of horizontal excursive movements and vertical opening patterns; 
straight, corrected and uncorrected deviations are also examined. The midline or mid 
sagittal reference point is located on maxillary and mandibular incisors and for 
horizontal movement a mm ruler used to assess extent of lateral movement. Inter 
examiner reliability is less than the vertical measure,(Kappa 0.7),(Dworkin et al 
1990).This is partly because jaw movement and pattern improves with practice (Clark 
et al,1989) In protrusion, measurement of deviation and deflection are even less 
reliable, (Widmer, 1992).
2.4.3.3  Joint sounds
Auscultation and palpation of the TMJ is used to distinguish the presence of  joint 
sounds. Alone, this is not considered a reliable diagnostic tool compared to joint and 
muscle palpation or mandibular movement, (Pollman,1980, Mohl,1999).
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Within the asymptomatic population the prevelance of any joint sounds is reported to 
be about 34% (Dworkin et al, 1990,Gross and Gale, 1983). Single or multiple sounds 
can also vary in character from one assessment to the next, appear and 
disappear. (Dworkin et al,1988,Truelove et al ,1987,Dworkin et al, 1990)
Clicking and crepitus are however reliably distinguishable from one another, (Clark et 
al, 1989,Dworkin et al,1990, Goulet and Clark, 1990 ,Webeke et al,1989). Crepitus 
occurs in cases of arthrosis whilst causes of clicking are variable and are defined in 
table 1. Moderate diagnostic validity has been achieved in the diagnosis of internal 
derangement clicking, sensitivity 0.78 and specificity 0.52, whilst diagnosis of crepitus 
in arthrosis has a sensitivity of only 0.4 but a specificity of 0.9, (Paesani et al, 1992). 
Amongst techniques employed to determine joint sounds,finger palpation is the 
preferred clinical method, improving diagnostic specificity although lowering 
sensitivity, (Widmer,1992) Instruments such as the stethoscope are capable of 
detecting more subtle sounds. These sounds are not considered diagnostically 
meaningful and in addition discrimination of pathological versus normal mechanical 
sounds are consequently more difficult to determine,.(Dworkin et al, 1988,Dworkin et 
al,1990).
Electronic sonography recording TMJ sounds for later characterisation has not been 
found to be advantageous due to surrounding sound contamination (Mohl et al,1990, 
Widmer,1989, Widmer et al ,1990 and Gallo et al,1991)
Joint noises or clicking may be present without pain and are then often considered a 
benign nuisance or social embarrassment more than a debilitating ailment. However, 
when pain is present on clicking, elimination of pain is the main objective. 
Unfortunately for the patient, joint sounds may remain unchanged despite the 
improvement in pain post treatment (Ohrbach and Dworkin, 1998).
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Kleinberg,(1991) clearly defined causes of TMJ clicking as outlined in table 1.
Table 1: Causes of clicking
DYSFUNCTION
1) Click associated with deviation in form 
of condyle, disc and temporal fossa
2) Click associated with neuromuscular 
dysfunction
3) Eminence click
4)Click with anterior disc 
displacement
5)Click associated with hypermobility
6)Tethered disc click
CAUSE
Mechanical obstruction to condylar
translation might arise from morphologic
changes and remodeling of articular
surfacesand disc perforations.
Uncoordinated movement of the TMJ
disc may be due to dysfunction of the
controlling musculature.
Associated with forced joint opening and
with a protrusive opening arc.
Anterior displacement of the disc
in the joint space causes a click to occur
as the condylar head moves across the
posterior ridge of the disc This occurs on 
mouth opening and closing producing a
reciprocal or double click.. This may
progress to closed lock when the
condylar head is unable to pass the
posterior ridge, resulting in limitation of
mouth opening.
Condylar head clicks over anterior ridge 
of disc with wide mouth opening. 
Posterior disc attachment damaged as a 
result of trauma may prevent normal 
translation of the TMJ disc on mouth 
opening.
Reciprocal click may occur as the 
condylar head passes over the anterior 
band of the meniscus on 
opening and closing of the mouth.
(Klineberg,!^!)*
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Reducible anterior disc displacement is the clicking condition most frequently 
encountered
Figure 7: TMJ disc displacement
Anterio-medially displaced 
disc
Condylar head
2.4.4 Further investigations
2.4 4.1  Radiographic examination and imaging techniques
In conjunction with clinical history and examination, imaging of the TMJ may provide 
additional information with regards to joint pathology or differential diagnosis. 
Indications for imaging are dependant on positive examination findings and history 
suggestive of recent and or progressive pathology, (McNeill, 1990) .
Intra oral radiographs may be necessary to exclude specific dental disease whilst an 
orthopantomograph provides an overview of the dentition, maxillary sinuses and gross 
joint structure. An appreciation of the broad variation in normal appearance is 
necessary to recognise joint abnormalities (Aquilino et al,1985, Dixon et al,1984, 
Drace and Enzman,1990.) However, osseous changes are often not detectable on 
radiological examination and intraarticular derangements are not visible, hence 
diagnosis remains mostly dependent on clinical judgement, (Westesson,1985).
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Larheim, 1995, advocates CT for TMJ hard tissue imaging in selected cases where 
pathological lesions such as tumours are suspected. MRI has replaced arthrography as 
the imaging technique to determine internal derangements (Rao, 1995).There are 
however, indications that pain and dysfunction may be independent of disc position. 
Westesson et al, 1989, demonstrated abnormal disc displacement in 15% of 
asymptomatic healthy controls. Similarly, 50% of patients with closed lock were found 
to have normally shaped discs, (Nitzan and Dolwick, 1991).
2.4.4.2  Blood tests
In addition to radiographic or imaging techniques, blood tests ranging from full blood 
count and erythrocyte sedimentation rate, antinuclear antibodies, latex fixation tests 
and  serum uric acid may be appropriate in specific cases to exclude or confirm 
systemic disorders and differential diagnoses, (Ohrbach, 1999).
Having established a diagnosis, the name given to the condition varies considerably.
2.5  Terminology - TMJ pain and dysfunction
Terminology, a tedious technicality or an essential directive? Confusion and disparity 
in opinion regarding aeitiology is evident in the abundance of names ascribed to the 
painful condition affecting the TMJ joint and associated muscles. More than a dozen 
names have been introduced since Costen first described “a syndrome of ear and sinus 
symptoms dependent upon disturbed function of the TMJ”(Costen 1934).He described 
a staggering 14 different symptoms and despite new avenues of thought it has been the 
symptomatology of the  condition not the aetiology which has remained the focus for 
labelling the condition.
Early names include Costen’s syndrome, replaced by the Temperomandibular joint
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pain dysfunction syndrome(Schwartz,1956), the Myofascial pain dysfunction 
syndrome(Laskin, 1969) .The Temporomandibular pain dysfunction syndrome 
(Molin,1973) and Tempromandibular joint dysfunction syndrome (Toller, 1974) 
Historically , the condition had become categorized as a syndrome suggesting 
exclusive signs and symptoms. Facial arthromyalgia (FAM) avoids the term 
‘syndrome’ and was introduced as a far more sensible descriptive term which can be 
easily explained to the patient (Harris, 1974)
Meanwhile, the presumed source of pain ossilated between the muscles and the joint, 
reflected in the emphasis in choice of terms TMJ or myofascial.  Descriptive terms in 
Germany included “occlusomandibular disturbance” and “myoarthropathy of the 
TMJ”,(cited by Okeson and Lexington, 1997).“Temporomandibular joint disturbances” 
were replaced by “functional TMJ disturbances”(Ramjford and Ash, 1971). The 
definition of internal derangement of the TMJ justified separating TMJ dysfunction 
from the more generalized myofascial pains.
In contrast, broader more collective terms were then introduced to include symptoms 
not necessarily related directly to the TMJ with the use of the term Cranomandibular 
disorders,( Me Neill, 1983).In 1986, the IASP combined temporomandibular pain 
dysfunction and tension headache under the same broad category of ‘craniofacial pain 
of musculoskeletal origin,(Merskey,1986).TMJ pain as a localised symptom of a more 
generalised condition such as fibromyalgia has also been suggested, (Blasberg and 
Chalmers, 1989,Wolfe et al ,1992,Plesch et al,1996).
The American Academy of Orofacial Pain and the American Dental Association 
Presidents Conference on examination, diagnosis and management of 
temporomandibular disorders recommended that orofacial pain and mandibular 
dysfunction be termed TMD(Temporomandibular disorders),(Bell,1982). This is a
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broad term, encompassing specific and nonspecific clinical disorders related to the 
TMJ and functional disturbances of the masticatory system.
TMD has been categorized as>
-Pain in the TMJ region or muscles of mastication.
-Limitation or deviation in mandibular range of motion.
-TMJ sounds during jaw function.  (American Dental Association, 1983)
The term is synonymous with craniomandibular disorders and facial arthromyalgia. 
The term acknowledges that symptoms of the TMJ may arise as a result of numerous 
related disorders rather than a single entity or syndrome and that some patients may 
have multiple disorders of varying aetiology and pathology.
In some respects such a broad collective term is perhaps too diffuse and needs refining 
to exclude obvious pathology which may otherwise mask aetiology  and impede our 
further understanding of the remainder of the conditions. I would favour 
the introduction of a further term; Temporomandibular Arthromyalgia(TMAM). 
Derived from the precise term FAM but emphasizing the identity with the broader 
term of TMD.  This would categorize the as yet non specific joint internal 
derangement disorders and the associated myofacial pain and dysfunction disorders 
into acute and chronic, related specifically to the TMJ.  However, this would add yet 
a further dimension or burden to the already over subscribed collection of terms!
I shall refer to TMD as the internationally recognised inclusive term for TMJ pain and 
dysfunction,although I shall  in fact restrict my studies to the subcategory of TMAM. 
In order to communicate effectively within a profession a universal label, or 
interchangeable labels, must first be agreed upon.  We must then ensure we are all 
discussing the same condition and here the role of classification is of paramount 
importance.
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Introduced by:- Form of classification:-
Weinmann and Sicher, 1951 Three groups: (a) Vitamin deficiencies, (b) Endocrine disorders, (c) Arthritis
Schwartz, 1959 Distinguished (a) Organic joint disorders (b) Masticatory muscle disorders
Bell, 1960 Six groups divided by (a) Intracapsular (joint disorders)
(b) Extracapsular muscle disorders
Farrar, 1972 Eight clinical areas of dysfunction a)masticatory muscle hyperactivity
b) decreased range of mandibular motion secondary to degenerative joint disease
c) muscle incoordination  d) anterior dislocation of the disc e) capsulitis f) synovitis 
g) loose capsular ligaments h) strained capsular ligaments
HeUrimo, 1974 Two indices (a) Ai -  An amnestic dysfunction index (self report)
(b) Di -  Clinical dysfunction index (clinical examination)
Block, 1980 A broad system based on anatomy and aetiology of pain in the head, neck and shoulders,in 
accordance with rheumatology and neurology
AAOP(  American Academy of Orofacial Pain) 
McNeil etal, 1980
Grouped into functional disorders of the masticatory system (Craniomandibular TMJ 
disorders)
ADA (American Dental Association), 
Griffiths, 1983
Five categories described TMD (Tempromandibular disorders) introduced by Bell
Eversole and Machado, 1985 Simplified taxonomy..Myofacial pain dysfunction separated from TMJ internal 
derangement..Recognised overlap of signs and symptoms in myogenous and arthrogenous 
conditions.
Hierarchical scheme.
IASP (International Association for the Study of Pain) 1986 Medical multidimensional classification of pain disorders 
which included category III craniofacial pain of musculoskeletal origin 
with two subcategories: (i)Temporomandibular pain and dysfunction syndrome 
(ii)Osteoarthritis of the TMJ 
Five axes: (a)Regions,(b)Systems (c)Temporal characteristics of pain: pattern of occurence 
(d)patients statement of intensity . time since onset of pain (e) aetiology
CMI (The Craniomandibular Index) 
Fricton and Schiffinan, 1986
Continous scales categorizing degree of severity in multiple domains including
(a) Muscle palpation index (MPI)
(b) Muscle dysfunction index (MDI)
(c) Total symptom severity index (SSI).
C
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IIHC (International headache classification) 
World Health Organization, Okeson ,1988.
Thirteen categories of headache. (Inclusive consideration of all head pain)
11th category: headache or facial pain associated with disorders of cranium, neck, eyes, nose, 
sinuses, teeth, mouth or other facial / cranial structures.No elaboration on specific 
subcategories related to TMJ and masticatory muscle disorders are included.
Okesson proposed classification for TMJ, additions to the IHC
A minimum of five episodes of pain in the temporomandibular region,with at least two of the 
following four clinical signs 1) increased myofacial tenderness 2) restricted opening 3) disk 
displacement 4) signs of arthritis or arthrosis. Subdivided into episodic less than 6-12 months 
or chronic more than 6-12 months.
Stegenga et al, 1989 Provided insight into intracapsular disorders
a)Articular:Inflammatory,Noninflammatory  b) Nonarticular disorders 
Osteoarthritis and Internal derangement divided according to staging over time
AACD (American Academy of Craniomandibular disorders) 1990 Two main groups (a) joint disorders (b) muscle disorders, integrating TMD into the broader 
context of head,neck and facial pain by utilising and expanding category 11 of the IHS 
classification system.
AAHNFP and TMJO (American Academy of Head, Neck, Facial Pain and TMJ 
Orthopedics), Talley et al,1990
Five TMD categories, two nonTMD categories
Nineteen subcategories under the main category of myofaical disorders separated by the 
specific tendon or muscle involved
ICCMO (International College of Cranio-Mandibular Orthopaedics 
Bergamini and Prayer-Galetti,1990
Three groups: I -  Presence of oclusal flags, II -  Musculoskeletal disorders associated with 
myofacial trigger points of the head and neck, HI -  Organic osteoarticular damage of 
musculoskeleton of the head and neck.
Truelove et al, 1992 Multiple diagnostic joint and muscle groups. (Non hierarchical) 
Operational criteria determining type and severity of the disorder
Research Diagnostic Criteria RDC/TMD 
Dworkin and le Resche, 1992
Formalised dual diagnosis (Non hierarchical,operationalised criteria)
Axis I- Physical condition (3 groups -  wih a possible 8 diagnoses)
(a) muscles disorders, (b) disc displacements, (b) arthralgia, arthritis, arthrosis 
Axis II -  Psychosocial issues (Global severity of pain, disability and depression)
AAOFP (American Academy of Orofacial Pain), 
McNeil 1993
Specific TMD subcategories to be included in 11th category of IHS classification
AAOFP (American Academy of Orofacial Pain) 
Okesson,1995
Updated  subcategories of TMD for 11th category of HIS classification
The TMJ scale, Levitt, 1994 Global scale with contributions from scales for pain report, joint dysfunction, palpation pain, 
stress, chronicity and  psychological factors
Developed for use in Dental practice. Based on self report findings rather than examination but 
attempted to classify psychological factors and pain impact.
AAOFP (American Academy of Orofacial Pain), 1996 TMD subcategories provided as input for the IHS classification 
Non hierarchical.
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2 6 Classification -  TMJ pain and dysfunction
Taxonomy, to classify disease, represents a construct or set of constructs. These are 
developed to clarify a plethora of available information and in turn require evaluation 
to ensure validity and reliability, specificity and sensitivity, (Dworkin and 
LeResche,1992).
Ideally the system for TMD should be comparable to those of other chronic pain 
conditions and be useful to researcher, clinician and ultimately benefit the patient. 
Classification of TMD is instrumental to our further understanding of aetiology, 
natural history, prognosis and treatment, yet impeded by the same lack of knowledge. 
(Dworkin and Le Resche, 1992). This conundrum of TMD classification initiated a 
broad field of exploration which still continues after nearly half a century of dedicated 
research.
Classification systems over the years have utilized a variety of parameters to group the 
disorders according to: signs and symptoms, anatomical or functional sites; 
presumed aetiology; pathophysiology or a mixture of parameters.  Some are 
hierarchical in character or context assessing severity of the condition .Others assign 
subjects to multiple categories and are non hierarchical continuous or even global 
rating scales which attempt to incorporate a measure of pain impact and psychological 
functioning.
Table 2 gives a brief summary of some of the main classification systems introduced 
over the past 50 years.
Most classification systems have been designed for epidemiological research.
Helkimo, 1974, completed a cross sectional population based epidemiological study of 
TMD using one of the first developed classification systems of  jaw pain severity
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and dysfunction. Two separate indices were developed “An amnestic dysfunction 
index Ai” based on self report and the “Clinical dysfunction index Di” based on 
clinical examination. These indices have since been employed in over 100 
epidemiological studies yet reliability, validity and utility of indices remain 
untested(Van der Weele and Dibbets, 1987).
Rugh and Solberg,1985, Katz, 1985 identified development of a uniform classification 
system as an essential element in the study of TMD and this was discussed at the 
National Institute of Health Technology Assessment, 1996.
A group of international investigators collaborated in the design of The Research 
Diagnostic Criteria for TMD (RDC/TMD) a currently reliable taxanomic system for 
classifying the subtypes of TMD using a dual axis system to measure two dimensions 
of TMD pain,( Dworkin and LeResche,1992).
Axis I
Axis I investigates the physical component using standardised clinical examination and 
a few self report questions to establish clinical diagnosis.
Group I - Muscle disorders (Myalgia) (a)Myofascial pain (b) Myofascial pain without 
limited opening (c) Myofacial pain with limited opening
Group II -  Disc displacements (a) with reduction (b) without reduction with limited 
opening (c) without reduction without limited opening
Group in -  Arthralgia,arthritis,arthrosis (a) Arthralgia (b) Osteoarthritis of the TMJ (c) 
Osteoarthrosis of the TMJ 
Axis II
Axis II explores psychosocial status of distress and dysfunction associated with 
TMD,based on standardised psychometric instruments. The global severity of the 
condition is considered incorporating pain intensity, disability, depression and non-
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specific symptoms.
It has been suggested that it may be more appropriate to seperate orofacial disability 
into a third axis (Turk et al 1995) There was also concern the dual axis system derived 
theoretically may not reflect the true patient population with TMD. However, initial 
reliability and clinical utility of the multiaxial system appears favourable (Garofalo et 
al, 1998, Ohrbach and Dworkin 1998)
An alternative multiaxial approach of classifying psychosocial status involves 
identifying patient profiles or subgroups using an empirically derived approach, Turk 
and Rudy, 1987. Similar to The RDC/TMD a clinical diagnosis is made and then a 
multiaxial assessment of pain (MAP) classifies chronic pain patients by integrating 
psychosocial and behavioural data. Using the MPI, recurring patterns of data appear 
to represent homogenous subgroups. Cluster analysis on the MPI scales in chronic pain 
patients identified three patient groups, dysfunctional, interpersonally distressed and 
adaptive copers, (Turk and Rudy, 1990). This has been repeated in further chronic pain 
studies by Talo (1992) and Jamieson et al.(1994) . Rudy et al,1989, specifically 
examined TMD and again identified these three clustered groups. Each group were 
independent of age, pain chronicity and general TMD symptoms of palpable muscle 
pain, limited mouth opening and joint sounds or CT examination. The identification of 
these subgroups is an interesting concept. When comparing TMD to head pain and low 
back pain all diagnostic groups are represented in the three MAP subgroups. Pain 
disorders in different anatomical sites and arising from disparate causes have been 
found to respond to similar treatments,(Woolf,2004). Similarities between chronic pain 
patients may be more pertinent than the diagnostic groups themselves. This may have 
implications in tailoring treatment to reflect the psychological profile of the patient 
rather than the physical factors, (Turk et al, 1996). Rudy et al, 1995, reminds us that
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TMD cannot be understood by psychological indicators alone. Woda et al,2005, 
developed an interesting taxonomy of idiopathic orofacial pain and found similarities 
between Facial arthromylgia (TMD) and Atypical facial pain using psychological and 
physical parameters. Currently clinical and radiographic markers do not relate to any 
particular psychosocial or behavioural variable and TMD subgroups cannot be clearly 
determined on behavioural patterns. Despite much progress in this field, the need for a 
unified classification system still exists, Bryant and Sessle,1995. The challenge of 
classifying physical and psychological diagnoses therefore remains in order to identify 
appropriate management for the physical and psychological characteristics of each 
patient, (Turk et al,  1996).
Subcategories with common signs and symptoms are likely to respond to similar 
treatment but from a clinical perspective it is unnecessary to further subdivide groups 
if they can be managed by the same therapy. Subcategories are useful from a research 
perspective but in certain situations it is necessary to establish a general cohort of 
individuals with overall signs and symptoms of TMD.
Drangsholt and Le Resche,1999, highlight the concept that most classification systems 
miss the essential ingredient of a simple question or questions to classify prescence or 
absence of musculoskeletal TMD pain. Specific questions regarding TMD were 
examined for validity amongst a group of Canadian patients. They used nine questions 
relating to TMD pain at rest and on function, finding 75% sensitivity and 75% 
specificity for two or more positive responses compared to the Helkimo clinical index. 
Macfarlane, 2004 in an epidemiological study used a self-completed questionnaire to 
predict the most likely specific orofacial pain syndrome. Widmer, 1995, used written 
questionnaires and telephone interviews to identify individuals with TMD. When 
results were compared with the findings on clinical examination 82% of cases had
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been correctly calssified. The same question slightly modified in format was used in 
the RDC. “ Do you have pain in or around your jaw joint in the muscles of your face or 
in your ears at rest.” A reliable and valid set of questions to include the identification 
of subcategories, accepted internationally, has yet to be developed which can replace a 
thorough history, physical and radiographic examination.
2.7  Epidemiology -  TMJ pain and dysfunction
2.7.1 - Epidemiological  studies-Prevalence
Many studies have attempted to determine prevalence of TMD but the now accepted 
methods of epidemiological research have not always been adhered to.
Inadequate sample size or non representative samples of a population were commonly 
encountered as well as no age or gender specific proportions given, no spread or 
dispersion data and no report on subgroups.  Case definitions often did not include 
pain or were dependant on physical examination and are not explicit of severity or 
duration. Drangshot and Le Resche, 1999, using multiple searching methods to look at 
the past 30 years literature, identified 196 of which 133 English language studies exist 
of cross sectional and cohort studies reporting signs and symptom prevalance  of 
TMD, published as original research in peer reviewed journals. Excluding studies 
assessing only signs, non painful symptoms, compound problems or examining 
selected populations43 studies remained, 34 in adults and 9 in juveniles.
These were then grouped into TMJ categories of ambient pain or unspecified (rest or 
rest and function) and functional pain (on jaw opening and clicking).
2.7.2 Prevalance of functional TMD.
16 population based studies report gender specific prevalence of functional TMD  over 
a range of 2-6%. Prevalance amongst females was generally higher but female to male
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ratio ranged from 0.67 and 4.0. A comparison of functional versus ambient pain within 
the same studies revealed a higher ambient  prevalence of about 70%.
2.7.3 Prevalance of ambient or unspecified TMD,
13 population based studies reported prevalence of ambient or unspecified TMD in 
males to range from 0-10% and in females 2-18%.  Female to male gender ratio ranged 
from 1.2 to 2.6 but most studies reporting a 2 to 1  ratio.  Studies reporting on age 
relationship revealed a varied pattern but none resembled the exponential increase in 
prevalence with age seen in chronic disabling conditions such as Rheumatoid 
arthritis. In early studies there appeared little or no change with age (Helkimo,1976). 
Lipton et al 1993, Matsuka et al 1996, found an inverse relationship of pain declining 
with increasing age. Agerberg and Bergenholtz 1989, showed the reverse, that pain 
increased with age, whilst normal distribution with greatest prevalance around 25 - 54 
years was found by (Dworkin et al 1990, Goulet et al 1995.)
2.7.4 Seasonal alterations in TMD.
One study investigated the effect of seasons on TMD pain and showed amongst 136 
female subjects a small but statistically significant increase in pain during the winter 
months (Gallagher et al 1995, Raphael and Marbach 1992a,b).Further studies on 
seasonal relationship may give rise to an unknown aetiology.
2.7.5 Diurnal variation
Goulet et al 1995 and Dao et al 1994 showed increased pain symptoms as the day 
progressed.  In a small case controlled study however, daily pain patterns were found 
to differ for bruxing and myofacial pain patients.  Bruxing patients reported morning 
pain whilst myofacial pain increased as the day progressed (Dao et al 1998).
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2.7.6 Global effect of TMD
TMD is a common condition.  1  in 3 adults develop TMD during their lifetime 
(Dworkin and Le Resche, 1993).  10% of women and 6% of men are affected each 
year which in the USA amounts to 20 million adult cases per annum.  Assuming 
similar proportions across cultures would give a population prevalence of450 million 
adults world-wide (Dragsholt and Le Resche, 1999).
2.7.7 Health Care
Drangsholt and Le Resche, 1999, reviewing demand for TMD treatment revealed that 
from 11 studies 2-7.5% of the population in North America and Scandanavia had 
sought treatment for TMD during their lifetime. Estimating V* - 1/3 of persons with 
TMD pain during a year seek treatment, 50-75% of patients Ist visit a dentist, the 
remainder a physician (Glaros et al, 1995, Turp et al 1998).
Incorrect or delayed diagnosis and referral were found in several studies of both 
dentists and physicians (Foreman et al 1994, Glaros 1995).  This is not thought to 
indicate a lack of interest or training in the condition but may reflect the controversy 
which exists over treatment (von Korff et al 1988).
The first clinician visit usually determines subsequent referral, dentists refer to 
dentists, physicians to other physicians (Foremen et al 1994 and Glaros 1995). 
Alternative medicine is also sought, when pain does not respond to traditional 
treatment but this is not included in surveys of overall treatment cost. (Turp 1998), 
Foreman et al 1994).
2.7.8 Race
Only two studies report measurable differences in TMD between racial groups.
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Khan 1990 reported rural African countries to have a lower proportion of TMD pain 
than found in North America and Europe but difference may be related to research 
methods and definition of TMD.
Lipton et al 1993 showed slightly lower prevalence of  jaw joint and facial pain in 
African Americans compared to white Americans but this was not adjusted for SES or 
gender.
Wildmalm et al 1995 in a small cross sectional study  of 4-6 year olds, in contrast, 
showed a higher proportion of self reported TMD in African American children but 
again did not adjust for SES or possible difference in ethnic interpretation of questions. 
Studies to compare developed and developing countries  with or without social health 
care  systems have been proposed  but a universally accepted case definition has first 
to be established for TMD with similar meaning across languages (Moore and 
Dworkin, 1988).
2.7.9  Individual patient considerations
TMD shares many important features with other chronic pain conditions with regard to 
psychological distress and individual burden (Dworkin, 1995).
Five different chronic pain conditions : TMD, back pain, severe headache, chest pains 
and abdominal pain were compared in 1,016 people from an HMO population based 
cross sectional cohort study.
TMD chronic pain had similar individual impact and ‘burden’ as the other 4 pain 
conditions with comparable pain severity, duration, inability to undertake activities 
because of pain, psychological distress (anxiety, depression, somatization) and major 
depression (von Korff et al 1988a).
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Negative impact on an individual has been reported in several non population clinic 
studies.  A l/3rd of TMJ chronic pain centre patients reported disturbed sleep, 
depression and a less satisfying life than previously (Murray et al, 1996).  A rather 
extreme life impact was recorded from a TMD pain support group where patients 
reported spending Can$ 30,000 on treatment, losing job, home belongings and 
remaining in persistent pain (Garro et al 1994).
Despite these rather extreme figures it is estimated TMD does place a significant 
burden on a V* of affected individuals, at a time of individual peak productivity (aged 
20-50).
2.7.10  Economic considerations
TMD as a economic cost to society has been divided into
(i) Direct costs of health care provision
(ii) Indirect costs due to work disruption, loss or decreased productivity. (Lipton and 
Stewart, 1997)
Direct cost has been estimated in 2 studies examining annual cost of speciality TMD 
health care per patient in the USA. (Shimshak et al 1997) showed inpatient costs of 
US$935 and outpatient costs of US$1,738 per year within an HMO not including 
psychiatric care, outside the HMO.  These figures were double the costs of all the other 
HMO members, von Korff 1995, from data available from a more cost efficient 
HMO estimate a more conservative US$304 not including intra oral appliance 
production.
In 1990, a national dental survey of occlusal appliance production, mainly used to treat 
TMD was calculated to cost US$990 million a year.  This represented 2.9% of the 
dental services total US expenditure for the year (Pierce et al 1995).
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An estimate of annual cost would be around 2 billion, assuming 5.3 million people 
present annually with TMD at a minimal cost estimate of US$400 per person per year 
(Drangsholt and Le Resche, 1999).
Indirect costs ultimately have an economic effect on society.  Such figures are 
presently unknown but are likely to be much greater than direct costs as shown in 
migraine studies (Lipton and Stewart, 1997). Unemployment and decreased work 
effectiveness has been investigated. Unemployment was found to be 5 times higher 
than the regional average when “high disability” and “severe limitation” was reported 
by 28.6% of TMD patients similar to figures for back pain 26.6% and severe headache 
22.2% (von Korff 1992).
Decreased efficiency at work was reported by 64% of selected myofacial pain patients 
compared to 7.7% of patients with non painful bruxisim (Dao et al 1994).
Work interference was reported by 26.1% of patients referred to a cranio facial pain 
unit (Murray 1996).
An age and gender specific pattern similar to migraine, namely female predominance 
over the age range 15-50 was only indicated in two studies, (von Korff et al 1988a and 
Goulet et al 1995).
2.7.11  Children and Adolescent TMD Pain Prevalence 
2 7 11  1  Ambient TMD pain
9 studies of self report pain prevalence up to the age of 18 were around 2-6%. 
Estimates ranged from 0.7% in 11-16 year olds (Sieber et al 1997) up to 18.6% in 12 
year old Finish children (Heikenheimo et al 1989).
Four of the studies were gender specific but female and male prevalence ratios were 
between 0.5 and 2.0 indicating no consistency in reporting of pain by gender.List et
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al,1999, Drangsholt,2005 report TMD related pain to be more common in females than 
males.
2.7.11.2 Functional TMD Pain
12 studies report pain with jaw function overall ranging from 0.2-12%.
Prevalence differences before and after puberty could not be compared since 
prevalence was not usually analysed by age.  A number of studies that did report 
results separately above and below the age of 14 showed an increase (Brandt 1985, 
Heikenheimo et al 1989 and Motegi et al 1992) one showed a decrease (Nilner and 
Lassing 1981) and others reported no discemable difference, with age. (Kitai et al 
1997).
In conclusion to the prevalence studies, signs and symptoms of TMD are observed in 
childhood but increase in severity and frequency in young adults, appearing twice as 
frequently in adult females as in males and decling into old age.
2.7.11.3 Analytic epidemiological studies of Incidence
To calculate incidence, a cohort of subjects without the disorder must be followed over 
time.  20 cohort studies on TMD have been published but 13 do not report TMD pain 
as a measure, (Drangsholt and Le Resche, 1999).
Three cohort studies do report the incidence of TMD pain or give enough data to 
calculate incidence figures of 1.6%-3 .9% per year, (Kitai et al 1997, von Korff et al 
1993, Heikinheimo et al 1990).
Incidence in relation to age is currently unknown. Only one study has reported 
incidence in females which was higher (von Korff et al 1993).
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Incidence data will eventually be able to show how many people and at what age they 
develop symptoms.  Obstacles to such information are numerous, the time and expense 
involved in following a sufficiently large group of people without a history of TMD 
over a relatively long time interval with frequent queries is the main problem in 
establishing sufficient power to detect an effective answer. Only one cohort study had 
sufficient numbers 1,016 to measure the low incidence rates around 2-3 new cases per 
100 persons per year (von Korff 1993).
Cumming et al 1990 indicate epidemiological methods are under development for 
studying recurrent conditions like TMD where initial onset may occur early in life with 
recurrent episodes differing in pain location, character and severity.
The  interpretation of incidence rates for episodic and recurring disorders, as noted for 
other chronic musculo skeletal problems is difficult (Lawrence et al 1998) This could 
be extrapolated to TMD and perhaps makes interpretation of results ambiguous. 
Certainly in longtitudinal studies, the majority of TMD showed fluctuation in report of 
signs and symptoms during the follow up (Kitai et al 1997).
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3 0 AETIOLOGY
3 .1  Introduction- The controversial field of TMD
The aetiology and management of TMD has been one of the most contentious areas of 
dentistry over the past 50 years causing immense polarization of views (Molin,1999). 
Concepts have ranged from the mechanistic occlusal theories to the increasingly 
accepted biopsychosocial concepts which encompass a more holistic approach to 
management and suggest a multifactorial aetiology.
3.1.1  Historical perspective  - Is TMD a relatively new ailment?
The ancient Egyptian technique of repositioning a dislocated jaw is reiterated by the 
ancient Greeks who describe techniques still used today (cited in Shwartz, 1959). This 
is often quoted as evidence that TMD is an ancient condition with dislocation being an 
advanced feature of muscle tension and disturbed TMJ coordination constituting 
TMD,(Molin,1999).However, dislocation of the TMJ can result from a variety of 
reasons and it does not seem totally improbable that dislocation may have resulted 
from a purely physiological forced mouth opening and or psychological reasons 
unrelated to TMD.
From an anthropological view point ancient skulls can be shown to exhibit extreme 
occlusal wear. This could be interpreted as excessive parafunctional bruxism due to the 
life and death stresses of ancient civilization resulting in TMD or perhaps more 
feasibly as a dietary consequence of eating unrefined foods.
Not until the beginning of the 19th Century does any writing re-emerge relating to 
problems of the TMJ. It is perhaps no coincidence that dentistry too was in a stage of 
rapid progress.  New materials and techniques were being developed for prostheses 
and hence the study of mandibular movement, occlusion and any effect on the TMJ
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were under close scrutiny. In 1918, Prentiss an anatomist and his dental colleague 
Summa reported lesions in the TMJ from a study of dental conditions in human 
cadavers.  They proposed the lesions to have occurred from defective bites causing 
excessive load on the joints (Prentiss, 1918).
The masticatory system is a beautifully crafted feat of architecture and structural 
engineering.  A dual ginglymoarthroidal joint enmeshed by intricately woven 
ligaments and muscles and balanced by an interdigitating occlusion. Each tooth itself a 
sculptured landscape of mountains and valleys. It is not difficult at this point in the 
literature to appreciate the logical concern that might arise regarding the iatrogenic 
damage imposed by altering the occlusion.  Dental treatment, restorative or prosthetic 
could never hope to attain the perfection of a natural dentition. This could only be 
aspired towards years later by damage limitation with the introduction of prophylactic 
fluoride, conservative management and where intervention is required with ever more 
sophisticated biocompatible materials.
It would seem that it was the preoccupation with occlusion per se that was the major 
mistake.  The preconceived ‘ideal’ occlusion was considered a desirable if not 
essential prerequisite for an healthy masticatory system.  An iatrogenically damaged 
occlusion was not simply in need of further restoration but the natural dentition was 
also under scrutiny.  Malocclusion, in some cases, prophylactically treated to prevent 
the development of TMD.
The occurrence of occlusal disturbance in the natural dentition was vastly over 
estimated . Clarke, 1982, comments that “the masticatory system must either be unique 
in the body’s evolutionary development in its failure to fulfill its function properly or 
else our comprehension of the system has mistakenly led us to describe as 
abnormalities conditions that in fact may be normal and play no role in bruxism and
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TMD.” Examining the occlusion in more detail I will now examine the evidence, if 
indeed it exists, for the role of the anatomy in TMD aetiology.
3.2  Aetiological factors - Anatomical structure
The biomechanical structures, which have been implicated in aetiology, are related 
both to the occlusion and the musculature and boney skeleton. Changes in the teeth are 
answerable in the muscles and muscular changes subsequently answerable in the jaw.
3.2.1  Occlusion
Historically, occlusal variation was perceived as the principle aetiological factor for 
TMD. Now the occlusal role is less clear and most associations appear to occur 
secondary to joint alterations and increasing age, (Pullinger et al, 1993). To 
comprehend occlusal impact the static, dynamic, functional and Para functional 
components of occlusion require analysis both in isolation and in combination.
3.2.1.1 Static occlusal relations
3 .2.1.1.1 Loss of posterior occlusal support
Reduction in occluso vertical dimension (OVP1
This is one of the oldest theories of TMJ disturbance dating back to Costen, 1934. 
Nearly 60 years later, animal studies suggest raised OVD causes rapid morphological 
adaptive response in the TMJ ( Rashed and Sharawy, 1993).
However, reviews indicate that moderate changes in OVD (4-6mm) do not cause TMD 
symptoms or masticatory muscle hyperactivity,( Rivera-Morales and Mohl, 1991).Lost 
molar support was correlated with boney changes in the TMJ’s in skull studies, 
(Whittaker et al,  1985). Similar findings were also recorded from osteoarthritic change,
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(Alkerman et al, 1988, Tegelberg and Kopp, 1987, Holmlund et al, 1989). However, 
these subjects were not necessarily in discomfort. It is unclear whether individuals are 
more likely to develop signs of TMJ osteoarthritis because of lost posterior teeth or 
that posterior tooth loss is correlated with increased age and increased likelihood of 
osteoarthrosis development. When age is controlled as a confounding factor the 
association between osteoarthrotic change and number of teeth is lost, (Whittaker et al, 
1990 and Wildmalm et al, 1994).
Loss of 3 to 5 teeth and unequal tooth loss between the left and right sides of the 
mouth revealed a higher prevalence of TMD than control subjects, (Franks, 1967). 
However, more recent cross sectional studies of non patient populations provided no 
evidence of a link between TMD and loss of molars, (Pullinger et al, 1990, Muir and 
Goss, 1990, Lundeen et al, 1990, Leake et al, 1994, Holmlund and Axelsson, 1994).
3.2.1.1.2  Cross bite
Cross bites generally have been shown to be unrelated to TMD, (De Boever and van den 
Berghe, 1989,Runge et al, 1989, Cachotti et al 1991, Seligman and Pullinger, 1991). 
However, investigating cross bites in more detail, it is the bilateral anterior or posterior 
crossbites that are unrelated to TMD. The unilateral maxillary posterior lingual cross 
bites, occurring in 10% of the adult population, does appear to be more common in 
TMD patients, (Pullinger et al, 1993). This includes those with non reducing and 
reducing disc displacement with or without reduction. It has been suggested therefore 
that in a few cases the adaptive demands on the masticatory system may be at the 
expense of articular disc adjustment and development of internal derangement, 
(Pullinger et al, 1993).
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These findings support the correction of a unilateral cross bite in children but probably 
not in adults where skeletal adaptation will already have occurred.
3.2.1.1.3 Over iet (Horizontal overlap of teeth)
Increased over jet has been reported to be related both to TMD symptoms and OA 
change (Tsolka et al, 1994). Most studies do not support the relationship to TMD, 
(Runge et al,1989, Roberts, 1987,Cachiotti et al, 1991). An over jet greater than 6mm is 
uncommon in the healthy population but has significant association to TMJ disease. 
Seligman and Pullinger, 1991 (shown OJ>5mm v uncommon in a healthy non-patient 
population). Over jet more than 4mm was linked to OA but not TMJD suggestive that 
some increased OJ in adults might be secondary to condylar repositioning seen in 
advanced OA, (Pullinger et al, 1993).
3.2.1.1.4 Overbite (Vertical overlap of anterior teeth) (OB) 
and anterior open bite 1AOB1
Reduced OB and skeletal AOB has been associated with condylar changes, (Akerman 
et al, 1988, Williamson et al, 1990,Pullinger and Seligman, 1993). AOB was seen in 
Rheumatoid arthritis, Osteoarthrosis and myalgia cases but also in those with TMJ 
internal derangement disorders ,(Helkimo, 1974,Tegelberg and Kopp, 1987, Pullinger 
et al, 1988).Increased OB is generally not associated with TMD , (Heloe et al, 1980, 
Pederson and Hansen, 1987, Riolo et al,1987, Cachiotti et al, 1991).Runge et al,  1989, 
relates joint sounds to large OB and masticatory muscle tenderness .
These static occlusal factors found in TMD patients of increased OJ, reduced OB, 
AOB, unilateral posterior cross bite, occlusal slides >2mm and lack of posterior tooth
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contact may be the result of changes in condyle position following intracapsular 
alteration rather than the cause of the problem, (Vanderas,1994, Juniper, 1994).
3-2.1.2.Functional occlusal relations 
3.2.1.2.1 Occlusal guidance
Teeth provide anterior guidance whilst the TMJ provides posterior guidance on jaw 
movement. Anterior teeth are generally considered preferable since posterior tooth are 
considered to cause interferences.
Occlusal guidance patterns on lateral excursion, namely group function or canine 
guidance has been considered influential in TMD signs and symptoms,(Ingervall et al, 
19800.However, the association is not confirmed from other studies, (Bush, 1985, 
Runge et al, 1989.)
3. 2.1.2.2 Retruded contact position / Intercusoal position 
fRCP) (centric relation) / fICPI (centric occlusion)
A slide between RCP and ICP, less than 1mm, is common amongst around 90% of the 
general population, (Ramjford and Ash, 1983).However, length and direction of slides 
are influenced by the tooth shape and position. A long or lateral component to the 
slide is considered more awkward to adapt towards particularly a lateral slide from 
RCP to ICP, (Solberg et al 1979). Wassell,1989, reports there is no real evidence 
relating length of slide to TMJ dysfunction. Sagittal slides >2mm were only found 
amongst TMD groups and those with degenerative change within the TMJ but a slide > 
5mm was required to be highly associated with TMD (Pullinger et al,  1993).
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3.21.2.3  Occlusal interferences
These are tooth contacts, which hinder functional occlusal jaw movement,(Ramjford 
and Ash, 1983). Uneven intercuspal or deflective tooth contacts have been studied 
particularly in the last 30 years, ( Ramjford 1961, Berry and Singh, 1984). 
Uncordinated dysfunctional muscles or more commonly occlusal discrepancies such as 
tooth loss, abherent development or poor restorations may cause uneven intercuspal 
contact. Kampe and Hannerz, 1987, found a higher incidence of sub clinical 
dysfunction amongst subjects with restorations compared to those with none. 
Non-working side interferences are believed to have a damaging effect on mandibular 
movement, (Schillingburg et al,  1981). A non-working side interference combined 
with a slide from RCP to ICP is more common in TMD patients but did not increase 
with severity of signs and symptoms, (Mohlin and Kopp, 1978).Deflective contacts 
and interferences may only be detected in dysfunctional patients when muscles relax 
with a splint, for example, and the mandible repositions. Effective treatment is 
therefore required before correct occlusal analysis can be performed. Many studies 
perform occlusal evaluation whilst subjects are still dysfunctional which therefore 
renders the findings inaccurate and may account for the variation in reported results. 
Establishing appropriate and reproducible methods, for assessing accurate occlusal 
examination of interferences and deflective contacts, is difficult to achieve when 
overcoming mandibular posturing. Guarding of the neuromuscular system may mask 
interferences and prematurities. Wearing a stabilization appliance may assist in muscle 
relaxation and determining the true occlusal interferences. Occlusal evaluation 
undertaken prior to treatment, whilst patients are still muscularly dysfunctional, will 
not reveal the true interferences,(Wassell, 1989).
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Occlusal abnormalities in nonpatients cause no dysfunction if they are within the 
neuromuscular adaptive capacity, (Ramjford and Ash, 1983). The reaction of a patient 
to the same occlusal abnormality may be affected by distress and emotional problems 
and may be beyond their normal neuromuscular adaptive capacity, (Wassell 1989). 
Therefore although occlusal discrepancies are found in most individuals it still remains 
important to determine whether the occlusion of TMD patients differs in any way from 
normal subjects.
The relative contribution of occlusal factors has been investigated using logistic 
regression analysis, (De Laat et al, 1986, Pullinger et al, 1993). 10-25% of specific 
TMD diagnoses were explained by occlusal variants in adults. Increased OA change 
and myofacial pain was associated with the following: RCP to ICP slides greater than 
2mm, overjet over 6mm and AOB; internal derangements with unilateral maxillary 
lingual cross bite; internal derangement and OA change with more than 6 missing 
posterior teeth. Most associations were however deemed secondary to joint 
alterations,(Pullinger, 1993).
Clark et al, 1997, however, states “the relationship between occlusion and TMD is not 
convincing, powerful or practical enough to make any recommendations about a causal 
association.” More recent studies again indicate malocclusion is not  a significant 
factor in TMD pathogenesis,(Kitai,1997, Minagi,1997,Goldstein,1999). 
Matsumoto,2002, found no statistical difference between two groups of individuals 
with normal occlusion or malocclusion and concluded a negative association of 
occlusion to TMD.
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3.2.2  Skeletal factors
Genetic, developmental, infectious, traumatic and iatrogenic factors can all result in 
skeletal malformation, inter and intra arch discrepancies, yet the role of skeletal 
malformation in TMD is difficult to determine. For instance, there is often an 
increased prevalence of occlusal interferences associated with malocclusion for 
instance in Class III deep OB, AOB and cross bite but few reports of increased 
prevalence of dysfunction, (Egermark- Eriksson et al, 1987).
3.2.2.1  Class IL  increased OJ. decreased OB.
Class Q division 2 occlusal relationship does not displace the mandible posteriorly, 
(Demisch et al, 1992). Retrognathia in children is commonly associated with internal 
derangement of the TMJ with disc displacement but the skeletal abnormality may not 
be the cause, (Schellhas et al, 1993).
Lobbezzo-Scholte et al, 1995, Hackney et al, 1993, found forward head posture did not 
increase internal derangement of the TMJ.
A steep or acute articular eminence has been considered an aetiological factor in TMD. 
It is suggested the small surface area of the eminence gives rise to a larger 
concentration of occlusal force encouraging OA change, (Nickel and McLaughlin, 
1994a).Meanwhile, unilateral joint sounds were found to be more common with the 
less steep condylar movement path, (Wabeke et al, 1995). Panmekiate et al, 1991, in 
an arthrographic study found the posterior slope of the TMJ articular eminence to be 
less prominent where there was anterior disc displacement without reduction, 
compared to superior disc position and anterior disc displacement with reduction.
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3.3  Aetiological factors -  Physical Trauma
Force which exceeds normal functional; loading, intensity and duration of the 
masticatory system, may  potentially cause dysfunction and subsequent pathology 
(Okessonl995).
Physical trauma can broadly be divided into direct and indirect and is more commonly 
reported in TMD patients than controls (Skolnich et al,1994, Braun et al, 1992, 
Pullinger and Seligman, 1991)
3.3.1  Direct trauma
Direct, macro trauma, such as a blow to the jaw causes an impact injury.  Damage 
ranges from boney fracture to muscular bruising.  TMJ structural damage may lead to 
the cardinal signs of inflammation with loss of function. Tearing of the retrodiscal 
tissues during trauma is associated with disc displacement disorders 
(Vichaichalermvong et al 1993). Rest can lead to recovery of this acute phase debility 
but in some cases permanent damage may occur especially where perpetuating factors 
delay healing.Burgess,1991, record localised TMD symptoms 24-72 hrs after direct 
trauma. However, symptom onset arising after the event causes difficulty in 
establishing the true aetiology (Katzberg et al,1985).
Prolonged or extensive mouth opening when yawning, shouting or unusual stretching, 
twisting and compressing forces during biting and eating have all been cited as 
initiating  or aggravating TMD (Harkins and Marteney, 1985).  Iatrogenic trauma from 
dental procedures or oral intubation for GA need further investigation (Harkins and 
Marteney, 1985,Taylor and Way, 1968).
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3.3.2.Indirect trauma
Cervical hyper extension / hyper flexion injury, commonly referred to as “whiplash” 
has been reported to cause a higher prevalence of TMD than occurs in a control 
population particularly when the teeth are apart on impact(Weinberg and 
Lepointe, 1987,Braun et al 1992, Kronn, 1993,Ogle and Hertz,2000).
Szabo et al,1994, however showed human volunteers in motor vehicle rear collision 
impact tests did not reveal jaw movement. Kasch et al, 2002 in a prospective 
controlled trial of rear collision suggest whiplash is not a major factor in the 
development of TMD.
Computer modelling also suggests certain motor vehicle injuries, despite flexion- 
extension events in the neck do not produce similar movement in TMJ (Howard et 
al,1991). Alternatively, cervical structures injured in acceleration deceleration injuries 
may give rise to pain in the cervical area which is referred to the trigeminal site, 
resulting in symptoms of TMD (Szabo et al 1994)
However, a causal relationship between indirect trauma and jaw symptoms has not yet 
been substantiated and aetiological  significance at present remains uncertain 
(Burgess, 1991,Goldberg, 1990).
3.3.3  Microtrauma
Microtrauma has been used to describe “repetitive-strain” type  injury of the TMJ and 
musculature.  These may include parafiinctional activity such as: bruxism (non­
functional grinding); clenching; lip, finger nail or pencil biting; chewing gum habit or 
postural imbalances such as: abnormal protrusive jaw posturing, phone bracing, use of 
snorkelling mouth piece, playing musical instruments or singing.
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3.3.4  Parafunction
In general it is suggested parafunction does not result in TMD (Marbach,1992, 
Scholte,1993, Luz and 01iviera,1994).  However, it has been suggested particular 
subgroups of TMD are precipitated  or perpetuated by parafunctional habits or 
abnormal jaw posturing (Rugh, 1988,Faulkner, 1990ab,Schiffman et al 1992, 
Nitzan,1994, Dao et al 1994, Attanasio,2000.)Experimentally induced parafunction has 
been shown to cause pain similar to that reported by TMD patients (Christensen, 1975, 
Moss et al, 1984, Scott and Lundeen,1990).
Neurological disease for example cerebral palsy and extra pyramidal conditions 
including epilepsy and orofacial dyskinesia can cause intense and persistent para 
function(Fahn,1985).  Muscle hyperactivity in relation to emotional distress is 
mediated via the cortex and hypothalamus (Weiner et al,1993).  Stress, anxiety, sleep 
disorders, medications including neuroleptics, certain elicit drugs and alcohol 
aggravate intensity and frequency of parafunctional bruxism and cause excessive tooth 
wear (Rugh, 1988, Redfeam et al,1998, Robinson et al,2005). Carlsson,2003, suggests 
daytime clenching and nocturnal grinding are two separate entities. Interestingly, 
clenching does not cause NM fatigue, as sustained muscle activity is compensated for 
by slower firing rates or recruitment of motor neurons (Junge and Clark, 1993).The 
similarly idiopathic tension headache has been shown to be unrelated to muscle 
tension(01eson&Jensenl991)  Arthrogenous TMJ disorders also do not appear to be 
associated to muscle hyperactivity(De Leeuw et al,1994).
3 .3 .5 Bruxism
A virtually universal condition in humans, anthropologists believe that bruxism may 
even be beneficial flattening occlusal surfaces and increasing chewing efficiency
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(Varrela,1990). Nocturnal bruxism occurs during light non-REM sleep, regardless of 
occlusion (Dahlstrom,  1989, Lavigne et al,  1999). In the past, theories related to 
human bruxism related to muscle over exertion, pain, fatigue and spasm in masticatory 
muscles resulting in  a vicious cycle maintaining and aggravating TMD symptoms 
mediated through psychological distress, (Laskin,1969). This theory is now considered 
largely erroneous, Stohler et al,1996. Nevertheless, 60% of individuals with TMD also 
have a bruxism habit,(Alvarez-Arenal,2002). Interestingly, parafunctional activity and 
internal distress is seen in animals and the term ‘stereotypies’ used to describe 
parafunctional behaviour. In confined spaces cows roll their tongues, tethered pigs 
bite on their chains, horses crib-bite and dogs chase their tails (Redbo,1992). 
Antidepressant medication in the form of Prozac given to dogs, chasing their tails, in 
the USA was found to stop this repetitive activity.
3.3.6  Attrition and bruxism
Dental attrition was believed to be the most common marker of bruxism,(Holmgren et 
al,1993). Yet, comparing TMD patients and asymptomatic controls the severity of 
observed attrition is indestinguishable (Pullinger and Seligman, 1993, Rugh, 1992). 
John,2002, Pergamalian et al,2003 found incisal tooth wear, possibly a consequence of 
bruxism, was not found to induce TMD and bruxism was not correlated to myalgia. 
However, attrition may not be representative of an ongoing habit and hence cannot 
predict current bruxism levels (Dao et al,1994). Attrition appears to occur in bursts due 
to unspecified factors and is therefore perhaps episodic in nature (Lundh et al,1987, 
Johansson et al 1993).Erosive diets, eating disorders, occlusal forces, environmental 
factors, protrusive guidance changes in OB & OJ correlated with age and gender can 
also influence dental attrition patterns (Silnees et al,1993, Johansson et al,1994,
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Waltimo et al,1994).  Self report questionnaires or clinical evidence of tooth wear are 
inadequate measures.  Direct  measurement using EMG and sleep laboratory may 
assist in classification of the role of parafunction in TMD and patterns of muscle 
contraction, (Okesson,1996).  Glaros et al, 2004, induced an experimental model of 
TMD -like symptoms in 3/10 asymptomatic individuals by encouraging jaw clenching 
and increasing masseter muscle activity through increasing EMG activity through 
biofeedback. Manfrendi, 2003, found bruxism to be related to muscle disorders rather 
than joint pathologies.
3.4  Aetiology - Psychosocial trauma
Since biblical times the “grinding and gnashing of teeth” depicts an image of a soul in 
torment.  It may well be this associated mental picture of bruxism, pain and emotional 
turmoil that initially drew clinicians to analyse the role of psychological factors 
amongst TMD patients.
3.4.1  Emotional distress «  muscle hyperactivity and parafunctional habits
Schwartz(1955) led a multidisciplinary collaboration which introduced a 
psychophysiological model for TMD. The team psychiatrist regarded parafunction as a 
subconscious outlet for internal stress, as a result of anxiety and long standing life 
conflicts (Moulton, 1955).  The importance of the patients emotional constitution in 
relation to masticatory muscle tension was emphasised and directed the gradual 
paradigm shift towards the significance of psychological factors in TMD aetiology. 
Masticatory muscle over use producing spasm, pain and fatigue were proposed to 
establish a vicious cycle of symptom aggrevation and maintenance (Laskin,1969).
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Later modifications to the theory suggest a consequence of the psychophysiological 
disorder leads to limited joint movement and joint sounds (Laskin 1986).
Emotional and experimental stress result in increased masseter muscle activity (Yemm 
1979 a,b). EMG recordings did not reveal raised levels of muscle activity in TMD 
patients compared to controls, but TMD patients showed a more persistent muscle 
contraction over time suggesting pain may eventually arise due to muscle fatigue. 
However, these findings were not supported by Moss and Adams 1984.
Rugh and Solberg 1977 also linked emotional stress and episodes of difficult life 
change with bruxism. Similarly, emotional  stress and high force parafiinctional 
activities were proposed to lead to muscle and joint pain, limited movement and joint 
sounds (Rugh and Solberg, 1992).
The influence of psychological factors on parafunction has since been disputed. 
However, pain patients demonstrated more anxiety and increased muscle tension at 
rest. Similarly, when exposed to experimental stress, increased heart rate and systolic 
blood pressure compared to controls(Carlson et al 1993).
3 .5 Personality characteristics and the pain prone patient
In adddition to hypertension and increased heart rate, there are a number of conditions 
notably chronic pain conditions influenced by psycho physiology,(Feinmann et 
al, 1984a, Katon et al, 1990.)
The relationship between certain personality characteristics and a predisposition to 
specific somatic disorders was first assumed by (Dunbar 1935).
Rugh and Solberg, 1976 in an extensive literature search did not link TMD to a 
specific personality trait.  Likewise, there was no difference in state and trait anxiety 
levels in TMD patients and controls, (Marbach 1978). A detailed medical history of
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patients with idiopathic facial pain will often reveal that the patient has experienced 
one or more episodes of chronic pain elsewhere in the body: tension headache, 
neckacke backacke, irritable bowel pain,pelvic pain, menorrhagia and pruritus (Berry 
1969, Gold et all 975, List,2001,  John,2003).  This highlights the concept of pain 
vulnerability with different pains occuring at different stages in a patients life 
(Engel, 1959, Feinmann and Harris, 1984,)  In  childhood, ear or abdominal pain,
TMD and dysmenorrhia in young adults and pruritus, iritable bowel, neck and 
backache in later life.  Unless recognised as a generalised problem attempts to attribute 
a differential diagnosis to each pain episode will be unsuccessful and misleading 
(Feinmann et al,1984, Aghabeigi et al,1992,).
3.6  Pain and the role of gender
The high prevalence of TMD amongst females is supported by studies of various 
design,(LeResche,199 (LeReche,2001)7, Epker,1999, Rauhala,2000, Macfarlane,
2002, Huang,2002, Rantale,2003). One explanation to account for the higher female 
predominance in the TMD clinic population is that females seek health care more 
readily than males (LeResche,2001). However, hormonal influence in the possible 
pathological mechanism of TMD has also been suggested,(LeReschel997, 
MacFarlane,2002). It has been suggested oestrogen receptors in the TMJ may induce 
pathology due to hormonal activation of the cytokine production pathway, (Gollehon, 
2001, Phillips,2001).Other patho-mechanisms suggest males and females may not 
process pain signals in the same manner with different perception and reaction to 
pain,(Bradburg,2003). Lavelle,2002, suggests intensity of pain relates to need for 
treatment rather than severity of the pathological process and females with high levels
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of anxiety were found less receptive to treament with less reduction in pain compared 
to males,(Rollman,2003).
3.7  Emotional life stress, vulnerablitv and cooing ability
Chronic pain may arise in response to life stress.  Acute stress in the form of an 
adverse life event such as a bereavement or trauma or on going stress including: 
chronic illness in the family or family conflict; social isolation; marital, employment or 
financial difficulties and in children schooling problems, parental strife or divorce. In 
contrast positive life events such as promotion, marriage or moving house may also be 
psychological stressors related to pain onset. Inadequate and unstable parental support 
in children appears to be life long predisposing factors in vulnerable individuals which 
can lead to chronic somatisation, (Feinmann and Harris 1984, Speculand 1984).
Acute and chronic social stress can have a synergistic effect, in comorbid anxiety, pain 
and depression,(Campbell,2003). Higher levels of stressful life events have been 
reported in idiopathic facial pain patients.(Aghabeigi et al,1992).
Schnurr et al,1990,  suggest TMD patients do not appear to be significantly different 
from other pain patients or healthy controls in personality type, response to illness, 
attitudes towards healthcare or ways of coping with stress.
Marbach et al.  1992 and Southwell et al.  1990, did not establish a difference between 
TMD patients and controls with regard to adverse life events. However, patients had 
fewer sources of emotional support and hence found difficulty coping.  The overall 
effect on the individual depends on the ability to adapt to stress. Adaptation or 
‘coping’ ability is now a significant area of research activity on stress and chronic 
pain, (Keefel992, Lazarus, 1993). Poor psychosocial adjustment is one of the factors 
associated with failure of long-term treatment in orofacial pain,(Feinmannml993). The
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direction of the pain-depression relationship in TMD has not been
established,(Rollman,2000).It is however considered that long-term pain in general
leads to depression rather than vice versa (Campbell,2003, Marbach,1999).
The analogy between stress, pain and chronic illness remains unclear.To explain the 
nature of the painful peripheral experience in relation to a central psychological 
disturbance it is necessary to investigate central biological markers.
3.8  Biochemistry- correlating pain with signs of depression
3.8.1 State markers
A number of biological abnormalities have been shown to represent current state 
markers of chronic pain and endogenous depression. These include: 
hypercortisolaemia, abnormal dexamethasone suppression test, low concentration of 
serum and urine melatonin levels, low CSF 5-hydroxyindolaceitic acid , low platelet 
monoamine oxidase activity and low palatelet 3H- imipramine binding, (Tominagen, 
1999,Campbell,2003).Bradykinin may also be implicated in the pathogenesis of 
TMD,(Suzuki,2003).
3.8.2 Trait markers
Impaired conjugation of tyramine sulphate, analysed in urine, is a trait or constant 
marker of endogenous depression and chronic facial pain although the basis for the 
defect is not clear.(Aghabeigi, 1993)
Such findings provide further support for the theory that a common biological 
pathogenesis may subserve both depression and chronic pain, (Aghabeighi, 1983). 
McGregor 2003, suggests elevated urinary levels of amino acids might be related to 
hyperalgesia.
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3.8.3  Correlating pain with biochemical signs of inflammation
Aleksandovskii 1988, demonstrated increased free radical generation associated with 
stress and pain in animals. Facial pain patients reveal evidence of increased oxygen 
free radical activity in their plasma and synovial fluid (Wasil, 1990). Nevertheless, 
there is no significant differences between painful and symptom free sides of the TMJ 
(Aghabeigi,1990)
The TMJ capsule was found to contain neuropeptide rich nerve endings and 
neuropeptides in painful joints (Holmlund et al, 1991)
Analysis of synovial fluid  reveals abnormal concentration of plasma proteins or 
neurotransmitters (Israel, 1989, Kopp et al,1983, Quinn and Bezan,1990, Appelgren et 
al 1993). In addition, degradation of enzymes, metabolic by products, pain 
transmitters, inflammation and degeneration in the TMJ were observed. 
Aghabeighi,1990, meanwhile demonstrated 15 HETE, a metabolite of the hyperalgesic 
eicosanoid 15 HPETE, in the synovial fluid. Sakamaki, 2001, suggests plasminogen 
activator, plasmin and kalikrein macromolecules may be involved in the pathogenesis 
of synovitis and resorption of the TMJ.
Alterations in synovial fluid lubrication and viscosity may initiate clicking and internal 
derangement of the TMJ ,(Toller, 1961). The friction on the disc may cause impaired 
movement and adhesion, due to free radical induced damage to the fibrocartilage. 
Harris, 1995, proposed that the series of biochemical events in TMD involve release of 
substance P and CGRP which cause vasodilatation and inflammation generating free 
radicals from leucocytes.The localised free radicals damage the cell membranes to 
produce algaesic eicosanoids: PGF2 and 15 HPETE. The combination of 15 HPETE 
and substance P produces chronic pain not inhibited by the NSAID’s (Nakarmura- 
Craig and Smith, 1988)
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In summary emotional distress in association with local physical stress in a 
biochemically and psychologically vulnerable subject promotes release of 
neuropeptides in the target tissue joint capsule or muscles producing synovitis, 
capsulitis and or myofascial pain (Harris, 1990)
3.9 The biopsvchosocial approach to TMD
The psychological factors not the occlusion has finally begun to cause a paradigm shift 
in the underlying management of TMD, (Marbach and Raphael, 1999).
Molin, 1999, succintly describes how the focus of attention must shift from “bite to 
mind”. Psychological factors clearly appear to play a critical role in TMD yet the quest 
for the underlying psychopathology and physical pathological processes continues. 
Adopting the ‘biopsychosocial model of pain’, is essential in order to understand more 
fully the relationship between the pathogenesis of chronic pain and psychosocial 
factors,(Ong,2003). Diagnosis and management based on physical and psychological 
axes allows both these aspects to be analysed and provides an hollistic approach to 
patient care. If treatment does not embrace the interaction of biomedical and 
psychosocial factors, therapeutic outcome may be favourable but only temporary, 
(Hampf,1993, Sherman, 2001).Therefore, appropriate and accountable treatment can 
only be provided when adhering to the biopsychosocial model,(Goldstein,1999).
3.10 Risk factors and chronicitv in TMD
The biopsychosocial model has also been used to identify psychosocial factors 
prediciting the development of chronicity amongst acute TMD cases, indicating a 
positive correlation with muscular groups. (Epker,1999).
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Recently, risk factors for myofascial pain and arthralgia were identified to be trauma, 
parafunctional habits, third molar surgery, somatization and female gender, (Huang, 
2002, Conti, 2003).Rantala,2003, related pathogenesis to work, social and 
psychological factors. The psychological factors appear to play a more prominent role 
when pain is of a muscular basis, (Auerbach, 2001,Yap,2002). Individuals with 
masticatory muscle pain tend to report greater levels of depression and anxiety than 
matched controls, (Carlson, 1998).
The conversion from acute to long term chronic pain may result from the body’s 
inability to restore normal physiological function (Loeser,1999). The onset, 
perpetuation and exacerbation of chronic pain may in turn be influenced by 
psychosocial factors,(Neligh,1996,Fricton, 1996).Those patients who develop chronic 
TMD do appear to have more psychosocial distress prior to developing chronicity than 
those whose acute symptoms subside,(Phillips,2001).Early intervention with clear 
explanation and discussion of the condition with support in addressing psychosocial 
issues may therefore aid in preventing the development of chronicity. (Epker,1999).
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4.0 MANAGEMENT
4.1 Aims
The primary aim of management is similar in many respects to treating other rheumatic 
or orthopaedic disorders (McNeil, 1993). To relieve or decrease pain and suffering, to 
decrease adverse loading, to restore function and to restore normal daily activities of 
talking, eating and yawning.
In the majority of cases treatment is focused on prevention and cure although palliative 
forms of care may be required in the more unyielding cases. Choice of treatment is to 
some extent dependent on the nature of the contributing aetiological factors. This 
should be gleaned from a detailed history although not always clearly identifiable due 
to the complex combination of factors. Presentation of the condition may be in acute or 
chronic form, transient and self-limiting or constant and unremitting.
The decision is which patients require treatment, when, how and with what choice of 
treatment?
Treatment can broadly be divided into:-
•  Conservative
•  Psychological
•  Physical
•  Medical
•  Surgical
The first line of action is of course conservative, with a clear explanation of the 
condition, informed reassurance and advice on management. Patients can only be 
active and informed partners in managing their own disease if given comprehensive 
information (Tattershall 1989). Mayberry, 1996, emphasises a simple handout is
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invaluable for communication and reassurance. Self-management was reported to help 
60 to 90% of patients with TMD, (Wright and Schiffman,  1995). The effect of 
reassurance undoubtedly reflects the high placebo response associated with reduced 
anxiety, the strength of the doctor-patient relationship and the expectations of the 
patient and the clinician.
When choosing further treatment a vast array of options exist many of which have 
unproven benefit. A schism is said to exist between the researcher and clinician into 
treatment decisions for the TMJ patient (Von Korff, 1988, Bader and Sturgers, 1995). 
The failure to practice evidence based medicine and to incorporate the principles 
derived from clinical epidemiology, is believed to lie at the source of this problem, 
(Raphael and Marbach, 1997).
4.2  Evidence based medicine (EBM)
The traditional treatment paradigm has relied upon: clinical training, basic principles of 
pathophysiology, textbooks, subsequent experience and clinical observation to evaluate 
effectiveness of treatments The resultant problems arising have included: -
1) Heterogeneity in treatment practice, depending on site of referral, patients with 
virtually identical signs and symptoms of TMD receive drastically different treatment.
2) Unpredictability of outcome (Clark, 1988)
3) Adverse effects of treatment.
4) Cost due to several treatments
The difference between EBM and the traditional treatment paradigm resides in the 
source upon which clinicians rely to base treatment. Evidence based medicine does not 
reject clinical training and experience but augments this with a critical synthesis of
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research evidence, to update knowledge by active and critical evaluation (Mohl and 
Ohrbach, 1992).
Following a traditional treatment paradigm three outcomes are possible; the patient 
improves, the patient does not improve or the patient does not return for follow-up and 
treatment remains unknown. The factors that lead to incorrect conclusions of treatment 
efficacy when relying on clinical observation alone, may therefore include:
1) Placebo effect of treatment
2) Statistical regression towards the mean
3) Spontaneous remission
4) Natural variability of signs and symptoms
5) Failure to consider treatment drop out
6) Bias in self-reporting of symptom remission 
(Marbach and Raphael, 1997)
The strength of inference on effectiveness of treatment must therefore shift to the well 
designed studies preferably double blind randomised controlled clinical trials. The 
National Institute of Health Technology Assessment on the management of TMD 
Disorders held in Bethesda, Maryland in 1996, concluded that “... Data does not support 
the superiority of any method for initial management of most TMD problems...Efficacy 
of most treatment is unknown because they have not been evaluated adequately in long 
term studies or virtually none in randomised controlled trials (RCT's) Most patients 
experience improvement or relief of symptoms with conservative treatment and patients 
should receive initial management using non invasive and reversible therapy.  In a 
small percentage of patients surgical intervention may be considered where significant
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and persistent pain, dysfunction and internal derangement of the TMJ exist. Cognitive 
behavioural therapies were felt to be effective approaches in managing chronic pain.” 
Marbach and Raphael, 1997, explains “when the scientifically accepted knowledge of 
treatment efficacy is poor, safety becomes a primary consideration. The safest 
treatments are non invasive and reversible.”
The treatment of TMD will now be reviewed from an evidence based medicine 
approach with emphasis on examining the medical and physical therapies to be used in 
the RCT.
4.3  Conservative management
All patients should receive counselling, education and informed reassurance at their initial 
consultation, reinforced at future appointments. The most important aspect of therapy is a 
warm, positive and reassuring attitude on behalf of the clinician,(Griffiths, 1987). As the 
first line of treatment, a clear explanation of the condition, informed reassurance, advice on 
management and a simple handout, has been reported to help 40 -  60 % of patients, 
without the need for further intervention (Wright and Schiffman, 1995).
4 4  PSYCHOLOGICAL THERAPIES
4.4.1  Simple behavioural modification
Conservative management and the interaction between clinician and patient, is the 
simplest form of psychological therapy. Modification of maladaptive habits can often 
be achieved by the patient when informed at the initial consultation. Awareness of 
raised stress levels can result in the patient incorporating simple relaxation strategies 
into daily life. Abnormal jaw posturing, clenching or chewing habits, during the day 
when under stress, can be modified by self monitoring procedures. Persistent habits
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may require reinforcement of advice or a short structured programme by clinicians 
trained in behavioural modification (Rugh, 1987).
The effectiveness of a short skills training programme in physical self-regulation, 
controlled breathing, postural relaxation and proprioceptive re-education proved 
effective in short and long-term management of muscular facial pain in a randomised 
controlled trial, (Carlson et al,2001). Habit reversal therapy in TMD, with control 
groups, again revealed pain reduction, accompanied by reduction in oral habits with 
minimal clinical contact but therapeutic self-reliance, (Townsen, 2001).
Significant, adverse contributing factors may result in refractory pain which requires 
more significant behavioural modification. A more structured approach to management 
is required with progressive relaxation therapy, counselling and cognitive restructuring 
provided by a clinical psychologist.
4.4.2  Cognitive behavioural therapies
Cognitive behavioural therapy (CBT), divided into cognitive restructuring and 
behavioural coping skills has proven beneficial to patients suffering from chronic pain, 
(Turner, 2001).
In simplified terms; cognitive therapy allows patients to examine thought patterns and 
how they can distort and influence quality of life; whilst behavioural therapy is used to 
alter responses and habitual reactions to situations by developing relaxation and coping 
skills. Interventions in CBT include: setting goals, challenging negative thoughts, 
relaxation and breathing skills, visualization exercises, developing coping strategies, 
assertiveness and stress  management, (Morley,1999). Turk (1994) describes the inter 
related components of treatment to include: education, skills acquisition, cognitive and 
behavioural rehearsal, homework, generalization and maintenance.
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CBT has been found effective in reducing pain and disability in TMD, particularly in 
combination with other treatment modalities including medication, (Harrison et 
al,1997) and biofeedback (Gardea et al, 2001).
Dworkin, 1994, found TMD patients suffering from dysfunctional profiles, coupled to 
high distress and pain, did not benefit from brief CBT alone. The need for more 
research in the application of CBT in TMD was emphasised (Turner,  1995).
Dworkin et al, 2002, conducted a randomised controlled trial to examine the 
intervention of six sessions of CBT. He concluded that patients with psychosocial 
disability in relation to TMD showed improvement in pain variables and this may 
suggest dysfunctional patients respond well to a more comprehensive trial of CBT.
It is interesting to note that individuals who suffer from dysfunctional profiles or 
patterns of TMD, notably high distress and pain were associated with both failure of 
conservative and surgical therapy, (Dahlstrom, 1997). Patients who are conscientiously 
supported and appropriately referred for specialist care, do not seek help through 
litigation. The converse is unfortunately true in the situation of prolonged and 
unsuccessful physical and surgical therapy, (Harris et al, 1993). In a tertiary referral 
centre patients have frequently received numerous unsuccessful therapies and are 
therefore more likely to exhibit dysfunctional behaviour. CBT is frequently required as 
adjunctive therapy and severely dysfunctional patients or those suffering from anxiety, 
depression or with a history of concomitant psychiatric illness may require direct 
referral to a liaison Psychiatrist or Psychiatric team.
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4 5 PHYSICAL THERAPIES
These include: posture training, simple mechanical exercise and mobilization; thermal 
application of hot and cold; biofeedback techniques using EMG to monitor muscle 
activity; TENs to achieve temporary relief of chronic localized joint and muscle pain; 
US, short wave diathermy, iontophoresis; injections; acupuncture and occlusal splint 
therapy.
4.5.1 Posture training
Posture training is focused on preventing unnecessary increased muscle contraction and 
aims to maintain a relaxed orthostatic posture, preventing protrusion of the mandible 
and increased head, neck, shoulder, masticatory and tongue muscle activity.
The head assumes greater effective weight the more anterior it is positioned in relation 
to the spinal cord. At rest the teeth should be a few millimetres apart, the mandible 
relaxed and the tongue resting in the floor of the mouth, the anterior portion resting 
against the anterior palate.
The benefits of posture training in TMD were recognised as an area for further 
investigation (Darlow et al, 1987). A training programme of physical self-regulation: 
breathing, postural relaxation and proprioceptive re-education has been found beneficial 
in short and longterm management of myofacial pain,(Carlson,2001).
4.5.2 Thermal application
Heat and cold applied to the skin, block pain in the underlying masticatory muscles and 
TMJ for a short time span of around 20 minutes. This can help muscle relaxation of 
previously sore, tense muscles, reducing spindle response and enabling the start of 
effective physical exercises to restore function, (Lehmann, 1999).
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The application of superficial heat in its simplest form includes a hot compress, warm 
towel, covered hot water bottle or infra- red waves for (10-20 minutes). However heat 
is contraindicated in cases of acute inflammation and infection.
Ethyl chloride spray, a vapour-coolant applied to the surface of the skin over 
masticatory muscles, followed by the individual actively stretching muscles is termed 
the spay-stretch technique. Skin should not become frosted and the eyes, ears and nasal 
mucosa should be protected during application. Benefit is thought to be gained by 
inactivation of myofacial trigger points. (Travell et al,1983, Jaeger and Reeves, 1986).
4.5.3  Mechanical exercises
Jaw exercise is important in maintaining normal comfort, function and stability of the 
TMJ and associated musculature.
Exercise aims to improve mobility of the jaw, strengthen and enhance coordination of 
muscles and to eliminate habitual and damaging jaw movement and posturing (Au and 
Klineberg,  1993, Clark et al 1990, Carlson et al, 1991).
Three types of generally recognised exercises include:
•  Repetitive, to achieve coordinated, rhythmic muscle activity.
•  Isotonic, to increase range of motion.
•  Isometric, to increase muscle strength.
Opening/closing, protrusion/retrusion and lateral excursion are the principle 
movements.
Exercises can be staged from small to maximal movement and then against resistance 
provided by the hands to increase strength. Contraction of agonist muscles results in 
relaxation of antagonists. Initially adjunctive therapy, such as thermal application to 
relax hyperactive masticatory muscles may be necessary prior to exercising.
115Ch a pter IV
Encouragement to exercise the jaw is advised, particularly in the light of recent 
evidence that suggests TMD patients exhibit a reluctance to exercise the jaw for fear of 
re injury, (Newton-John et al, 2005).
Contraindications to physical exercises include unhealed fractures, acute arthritis and 
acute infection in the facial region.
4.5.4 Biofeedback and EMG (Electromyography feedback)
Biofeedback mechanisms can be utilized in relaxation therapy. The equipment consists 
of: a pair of surface electrodes, a millivoltmeter with amplifier, visual and auditory 
display to allow the patient to observe the physiological response of muscle contraction 
and relaxation. Muscle tension of the masticatory muscles whilst clenching the teeth 
can be observed and the individual taught to relax the muscles accordingly. Controlled 
studies reveal a decrease in muscle activity and nocturnal bruxism but the benefit is 
only short-term, (Pierce and Gale, 1988, Erlandson and Poppen, 1989).
4.5.5 4 Mind-body’ therapies
Yoga, relaxation, meditation, imagery, hypnosis and biofeedback are considered ‘mind- 
body’ therapies (Astin, 2004). Schaelaekens, 2003, reports the anxiety and pain 
complex may be the most common indication for hypnosis in the dental setting. The 
aim of relaxation is to decrease sympathetically mediated metabolic activity 
(Jessup1994). A state of relaxation achieved by techniques which relieve individual 
stress levels may be beneficial in conditions where stress is an important factor in the 
genesis and maintenance of pain such as musculoskeletal disorders, (Gura,2002). 
Hypnotic induced reduction in duration, frequency and intensity of TMD pain has been 
observed, (Siomon, 2000, Winocur,2002). Further RCT are required.
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4.5.6 Ultra sound (US), short wave diathermy
This mode of treatment involves deep heat transmission through tissue, up to a depth of 
5cm. Heat energy is converted from high frequency oscillation of the transducer head, 
(Ziskin et al,  1990)
The temporary analgesic and muscle relaxation effect is supposedly a combination of 
mechanical vibration and thermal energy. Deep tissues may increase in temperature up 
to 45°C, increasing elasticity and plasticity of collagen, a useful adjunct prior to 
exercise.
Musculoskeletal chronic pain of the joints, extra capsular soft tissues, muscle 
contraction and tendonitis has been reportedly treated by US in the literature but there 
are no RCT for TMD (Esposito et al, 1984, Talatter et al, 1986).
Further research is required to determine optimal frequency, intensity and duration of 
treatment including number and exposure length of sessions, (Mohl et al,  1990, Hashish 
et al, 1986).
US should be avoided during TMJ growth or in patients with pacemakers. Metal 
objects such as earrings and necklaces should be removed from the area to be treated.
4.5.7 Phonophoresis and Iontophoresis
Phonophoresis uses US to carry medication into tissues, whilst Iontophoresis uses an 
electrical gradient to drive an ionic form of medication, usually corticosteroids, into the 
tissue. (Lark and Gangaros, 1990, Schiffman and Braun, 1993). The efficacy of the 
former is unknown and the latter requires further evidence (Wise,  1982, Reid et al, 
1994). A RCT of iontophoretic delivery of dexamthasone and lidocaine improved 
mandibular function but did not reduce pain,(Schiffman et al,1996)
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4.5.8 Injections
Local anaesthetic injections into myofascial trigger points have been used in the 
management of myofacial pain alone and in combination with muscle stretching and 
mobilization (Jaeger and Skootsky,  1987, Phero et al, 1987). Lignocaine (Procaine) 
1-2% without adrenaline (epinephrine) and diluted to 0.5% with sterile saline is 
recommended for trigger point injections because of low myotoxicity (Ritchie and 
Greene, 1985).
Interruption of muscle pain cycles may result in pain relief beyond the duration of the 
anaesthetic. It is recommended that myoneural block therapy should not be used as 
initial or sole therapy but only as an adjunct to other physical therapy, pharmacotherpy 
and behavioural techniques, (Phero et al, 1987).
4.5.9 Acupuncture
The mechanism of action, for acupuncture, is not fully understood but is believed to 
rely on neural and humoural pathways (Rosted, 1998). Wong, 2003 in a case series 
suggested combined therapy of acupuncture with occlusal splint and point injections to 
be useful in managing TMD. Acupuncture alone, in several randomised controlled 
studies has been shown comparable to more conventional therapy but generally less 
acceptable to patients due to the use of needles (Raustia et al, 1985, Johansson et al, 
1991, List et al,  1993, Myers, 2002).The level of analgesia induced by this method may 
therefore be modified by stress and anxiety (Wilderstrom-Noga, 1998).
4.5.10 Electrotherapy
Electrotherapy includes TENs (Transcutaneous electrical nerve stimulation), EGS 
(Electrogalvanic stimulation) and microvoltage stimulation which may produce
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thermal, histochemical and physiological changes in the muscles and joints.
TENs is used primarily for temporary relief of chronic localized joint and muscle pain 
using low voltage, low amperage, biphasic current of varied frequency causing low 
threshold sensory stimulation to block pain impulses (Dubner, 1978, Moystad et 
al,1990).The electrical stimulation of acupuncture needles in comparison to TENs has 
not shown a significant difference if applied in the same dermatome,(Butler,2001).In a 
recent study no substantial improvement of TMD signs and symptoms was managed 
with TENs,(Alvarez-Arenal,2002).
EGS uses high-voltage, low amperage, monophasic current of varied frequency 
(Binder, 198 l).Micro current electrical stimulation is designed to produce a 
microvoltage similar to that which occurs at the synaptic junction. Payne, 1994, 
revealed no significant results in patients treated with EGS compared to a control 
group.
Both TENs and EGC may decrease muscle pain and hyperactivity and aid in muscle re­
education but clinical evidence for electrotherapy usage in TMD remains lacking.
4 6 OCCLUSAL APPLIANCES
Variable terminology for the same appliance includes: Interocclusal splints, intraoral 
appliances, bite guards, bite planes, night guards, orthopaedic appliances, orthotics and 
orthoses. The item can be defined as any removable appliance used to relieve the 
symptoms of TMJ and associated muscular pain and dysfunction. They are normally 
constructed of acrylic resin with occasional wire attachments for retention.
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4.6.1  Historical perspective
Historically, the purpose of occlusal appliances has been to treat a variety of symptoms 
which can be related to three specific sites: TMJ, associated musculature and teeth.
1) TMJ -Relieve pain and dysfunction
-Alteration of  joint loading and stabilization 
-Alter structural alignment of condyles and discs
2) Muscles - Relaxation of painful and/or dysfunctional masticatory musculature.
- Decrease abnormal muscle activity to:- -Improve neuromuscular coordination
-Reduce aberrant and parafunctional habits 
(clenching and bruxism)
3) Teeth - Stabilize the occlusion in static and dynamic relationship.
- Eliminate occlusal interferences
- Redistribute force to prevent adverse occlusal loading
- Protect teeth from excessive wear and mobility
The main aim of treatment is to relieve pain. However, clicking may be present with or 
without pain and is a result of uncoordinated movement of the condylar head and TMJ 
disc. Reducible anterior disc displacement is the clicking condition which splint therapy 
most frequently attempts to treat and is discussed later in the review.
With regard to the musculoskeletal pain and dysfunction the three main categories for 
treatment are myalgia (muscle pain), limitation in mouth opening and mandibular 
incoordination. Appliance design varies according to specific or multiple aims of 
therapy.To explain how occlusal appliances are believed to function it is necessary to 
examine the five distinct theories as reviewed by Clark, 1984 and Colt, 1991.
120Ch a pter IV
4.6.2  Theories
4.6.2.1 Occlusal disengagement theory.
This theory advocates the patient is given an “interference free, ideal occlusal scheme” 
to decrease or prevent abnormal muscle activity so providing stability to the TMJ’s, 
(Ramfjord and Ash, 1971, Posselt, 1968). The splint is designed with simultaneous, 
bilateral, occlusal contact of all teeth in centric relation with canine and/or anterior 
tooth guidance in excursive movements. The anterior bite plane or more commonly the 
full maxillary stabilization appliance, fulfils this role.
Dawson ,1989, clearly explains the basic function of splints is to prevent the existing 
occlusion from controlling jaw relationship in maximum intercuspation. When partially 
or completely covered the splint material in effect becomes the new occluding surface. 
The mandible and hence condylar axis is dictated by the new ideal occlusion 
established by the splint.  Secondary to the disengagement of the occlusion and control 
of  jaw relationship, the splint will help distribute occlusal force, reduce tooth wear and 
stabilize unexposed and weak teeth.
4.6.2.2 Occlusal vertical dimension (OVD) theory
Costen ,1934 and Goodfriend ,1933, first suggested OVD theory, which was further 
elaborated by Block, 1947 and Christensen, 1970.  Based on restoring previously lost 
OVD it was aimed to reduce or eliminate aberrant muscle activity which had arisen due 
to an abnormal vertical dimension.
Re-establishing “original” OVD however proves difficult.  Dawson ,1989, points out 
that occlusal appliances always involve some increase in OVD but the change in OVD 
does not afreet the position of the condylar axis in centric relation.  Condylar rotation 
stays on a fixed axis in centric relations for 15mm or more of opening before forward
121CHAPTER IV
translation. Up to the point of translation, changes in the vertical axis do not effect the 
position of condylar axis.
4.6.2.3  Maxillomandibular realignment theory
This was suggested by Lerman, 1974, Lieb, 1977 and Jankelson, 1979.  The mandible is 
thought to assume an abnormal unbalanced position relative to the maxilla in maximum 
intercusspation (ICP).  Altering this relationship to a more physiologically and 
anatomically correct jaw position it is theorized dysfunctional musculoskeletal 
symptoms can be improved or eliminated by achieving “neuromuscular balance”.
At present there are three ways to determine the need for mandibular realignment. 
Firstly, Dawson,  1974, describes a “ligamentous determined jaw position” or centric 
relation position.  Obtaining this position involves clinical jaw manipulation in a hinge 
type movement whilst maintaining upward and backward pressure to ensure seating the 
condyles in the TMJ fossae.
Secondly, Lieb ,1977, describes identification and marking of anatomical land marks on 
maxillary and mandibular dental casts. These are used  to align and reorientate the 
models for construction of a splint.  Skeletal and dental asymmetries and irregularities 
occur in a significant proportion of the population and  there have also been no 
objective studies examining the efficacy of such a radical approach.
The third approach is a muscle-determined positioning of the mandible found by two 
techniques.  Jankelson,  1979, used a TENS transcutaneous electrical stimulation of low 
frequency applied to the preauricular area to stimulate the trigeminal nerve.  It is 
postulated motor nerve excitation of the trigeminal, produces a jaw closing trajectory 
resulting in a neuronmuscularly balanced jaw position.  This is recorded and a splint 
constructed. Intercuspal position is usually anterior on such appliances causing
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alteration to the occlusal relationship, again clinical studies have not been undertaken. 
The second technique uses a fluid-filled bag that theoretically dictates neuromuscular 
realignment of the mandible ignoring the position dictated by teeth, Lerman, 1974. 
There has been no reported clinical testing of this appliance.
4.6.2  4. Temporomandibular joint repositioning theory
This was proposed by Farrar, 1972, Gaush and Kilmer,  1977, Weinberg,  1979, 
Thompson, 1954, Witzig and Spahl, 1987. The concept is to correct the position of the 
condyle in the fossa and so improve the function of the TMJ.  The position of the 
condyle is usually determined radiographically but there may be errors in joint position 
measurements, especially with flat plane transcranial views. Variations in condylar 
position also exist in an asymptomatic population, (Pullinger et al, 1985).
Another theory attempts to locate the condyle in a specific therapeutic position in the 
fossa, to treat specific intracapuslar derangement, (Gaush and Kulmer, 1977).  By 
placing the mandible in a new position, change in disc condyle relationship is hopefully 
achieved.  Holding the mandible in a forward position is thought to allow healing of 
retrodiscal tissue.  A repositioning splint is used for this purpose.  If disc repositioning 
occurs and there is resolution of the click then the mandible can be moved sequentially 
to the pre-treatment normal anatomical position by repeated splint adjustments. 
Hopefully clicking will not reoccur. In some cases irreversible alterations of the 
occlusion have been undertaken to allow permanent reposition of the mandible 
anteriorly. The resolution of one problem may produce more serious occlusal problems. 
Short term relief of a click may cause long term dysfunctional condylar remodelling 
and expense due to problems in occlusal stabilization.
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4.6.2.5  Cognitive awareness theory.
This was proposed by Greene and Laskin, 1972,  Rugh and Robins, 1981.  This relies on 
the concept that any intra oral appliance in the mouth is a constant reminder for the 
patient to alter behaviour regarding the jaw position, tooth contact and abnormal muscle 
activity.  This increased awareness of  jaw position, change in oral tactile stimuli and 
decreased oral volume caused by the splint can help in altering or reducing harmful 
behaviour such as parafiinctional activity.  This theory would of course therefore apply 
to any design of splint.
4.6.2.6 An overview of splint therapy
Appliances to cover the occlusal surface of teeth to cause an effect on the jaw joint 
were first described over 120 years ago by Kingsley, 1877. Although materials have 
improved and new theories on function proposed, the basic aims of treatment and 
design have changed little. A definitive mechanism or theory of splint action remains 
elusive. However, new imaging techniques, an awareness of psycho- physiological 
interaction and the promotion of good scientific clinical research brings us nearer to a 
clearer understanding of what constitutes the most appropriate form of therapy for 
patients suffering from Facial Arthromyalgia(Temporomandibular joint dysfunction).
At present clinicians must be content to follow the recommendations of non-invasive 
and reversible therapy in the initial management of the disorder as proposed by the 
National Institute of Health Technology (1996).Not all occlusal appliances can be 
regarded as providing an irreversible form of therapy. Functional and morphologic 
changes in the occlusion following long-term use of certain appliances can occur.
With any appliance, complications of psychological dependence can occur and poor 
oral hygiene of the appliance and teeth can cause caries or periodontal problems.
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Currently, the full coverage stabilization appliance offers reversible therapy with no 
permanent occlusal alteration. It has therefore been scrutinized more thoroughly than 
other appliances in the review to access potential clinical efficacy.
4.6.3  Appliance design
Occlusal appliances are designed to be directive (predetermined occlusal position) or 
permissive (no predetermined occlusal position), constructed from resilient or hard 
materials and to provide either full or partial coverage of the occlusion.
4.6.4  Partial coverage occlusal appliance
Some but not all opposing teeth are in contact with the appliance. Anterior or 
posterior teeth are covered in the maxillary or mandibular arch.
Table 3a: Partial coverage appliances
Anterior partial coverage appliances Posterior partial coverage appliances
♦ Anterior bite plane/plate
- Hawley Appliance
- Sved Appliance
- Immediate plate
♦ Posterior bite plane/plate/onlay
♦ Posterior occlusal pivots
♦ Repositioning appliance 
- MORA (Mandibular orthopaedic 
repositioning appliance)
♦ Anterior jig 
- Lucia jig
4.6.4.1 Anterior partial coverage appliances
4.6.4.1.1 Anterior Bite Plane.
This is generally a rigid construction for the maxilla with a contact surface provided for 
mandibular anterior teeth only with no contact of the posterior teeth.  The aims 
were to disengage the occlusal forces on posterior teeth to allow muscle relaxation
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and establish a new occlusal vertical dimension, (Posselt, 1963).
Hawley, 1919, published an original article describing a retainer with a biteplane. He 
designed a palatal coverage appliance with a flat platform behind the maxillary incisors 
to increase vertical contact between opposing mandibular anterior teeth 
A labial arch wire was used to avoid splaying of maxillary anterior teeth. The 
design could cause trauma to the gingival tissues in the plate and was hence later 
modified.
Sved, 1944, introduced an acrylic appliance which extended a few millimeters over 
the incisal edge of the maxillary anterior teeth, with once again a palatal plane for 
contact of opposing mandibular anterior teeth, but also retention clasps on bilateral 
distal molars.  Posselt, 1963, recommended the Sved appliance for treatment of 
TMJ disorders.  Ease of fabrication, fitting and adjustment, together with the 
reported initial effective reduction in symptoms, popularized use.
Both biteplanes are in theory potentially orthodontic appliances which result in tooth 
movement after prolonged usage.  Occlusal forces are altered with a tendency for 
vertical eruption of the unrestrained posterior teeth, intrusion of anterior teeth and 
development of an anterior open bite.
The main disadvantages are therefore the potential loss of occlusal stability.
4.6.4.1.2.  Anterior immediate palatal plate.
Langer,1975, described a short term emergency measure for patients with limited 
mouth opening and masticatory muscle trismus. The acrylic appliance is fabricated 
directly into the mouth and seated over the anterior teeth to prevent closure of the 
mandible into maximum intercusspation.
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4.6.4.1 3 Anterior jig (Lucia Jig)
Lucia ,1985, designed a jig to obtain multiple centric relation bite registration. The 
appliance was also suggested to treat some TMJ disorders, (Guinn, 1985).The hard 
acrylic appliance usually covers only the maxillary central incisors with a palatal plane 
to guide the mandible into centric relation.
The disadvantages of using such an appliance are the need for close supervision 
since occlusal forces are solely directed to the incisors whilst concern may arise over 
possible aspiration of the jig due to the small size.
4.6.4.2  Posterior partial coverage appliances.
4.6.4.2.1  Posterior bite plate/plane/onlav appliance.
Appliances have been made for either the upper or lower arch.  The aim was to raise the 
bite to compensate for the loss of occlusal vertical dimension and hence their use 
became popular because of the theories of Monson, 1921 and later Lindblom, 1953. 
Posterior onlays were also considered to relocate the condyle in the middle of the 
mandibular fossa during jaw closure, (Weinberg, 1979).  In simple form 
the plate consists of two acrylic resin blocks covering premolar and molar teeth joined 
by a lingual bar, (Lerman, 1974).  The plate is popular with patients due to easy speech 
adaptation and lack of visibility.  Unfortunately dentoalveolar changes due to intrusion 
of posterior teeth, extrusion of anterior teeth and resultant lateral posterior open bite 
may develop, with full time wear as demonstrated in animal experiments, (Ramfjord 
and Blankenship, 1987).  Such unwanted occlusal changes are the major disadvantage. 
However, it is interesting to note that deliberate axial movement has been used
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increasingly as a modality to create space for restorative procedures where the teeth are 
wom,(Dallet et al,  1975 , Ibbetson and Setchell, 1989).
4.6.4.2.2.Posterior occlusal pivots.
This method involves single, bilateral premolar or molar tooth contact in order to 
disengage the dentition and relieve mechanical loading on the TMJ. Niemann ,1984, 
describes pivots as a diagnostic aid in TMJ dysfunction whilst the pivot appliance 
treatment is described by Sears, 1956. It was proposed that pivots provided jaw rest and 
relaxation with establishment of a new occluso-vertical dimension.
Clinically, composite or acrylic ridges can be applied to the chosen bilateral tooth 
region on a mandibular or maxillary onlay appliance.  Alternatively, material is bonded 
directly to the teeth or cast metal pivot restorations constructed.  Cast or bonded pivots 
necessitate continual wear which one could imagine to be most uncomfortable for the 
patient.  The particular location of the pivots would tend to affect TMJ loading in 
relation to altered masticatory muscle vectors.  The generation of lateral or vertical 
occlusal forces on teeth are however unpredictable.  Contact with opposing teeth may 
simply increase vertical dimension or position the mandible protrusively or retrusively. 
There is potential for tooth mobility and intrusion but significant distraction or 
unloading of the TMJ’s is thought unlikely without external chin retraction, (Louis, 
1990).Pivots in general are therefore not recommended due to discomfort in use and 
irreversible tooth movement, (Ramjford and Ash, 1986).
4.6.4.2.3  Mandibular orthopaedic repositioning appliance. (MORAI
The mandibular orthopaedic repositioning appliance (MORA) or Gelb splint was 
popularly used in the 1970’s and described by Lieb,1977.
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It is a hard, acrylic, mandibular, posterior, coverage splint with a lingual connecting 
bar and occlusal indentations to position the mandible protrusively. Despite comfort 
and relief of pain, appliances may lead to severe occlusal alteration even after 1-2 
weeks,(Ash ,1984).
The malocclusion which develops is often more severe than that experienced with 
full coverage repositioning appliances.  Vlachos,1995, explains that since MORA’s 
cover posterior teeth only, dentoalveolar changes of posterior teeth intrusion and 
eruption of anterior teeth may compound the occlusal alterations which occur as a result 
of the newly repositioned condyles.  The extent of posterior open bite which develops is 
therefore dependent on the amount of anterior positioning in relation to the path of 
altered condylar movement and with respect to the initial, anterior teeth, 
open bite and over jet.
To reposition teeth post therapy often requires extensive orthodontic, restorative, 
prosthetic or even surgical procedures, (Haden, 1982).
Occlusal corrections can involve unsuccessful attempts to extrude the posterior 
teeth using a Sved appliance with posterior stepping of the mandible into an 
intercuspal position.  Even if tooth movement is achieved, relapse of the posterior 
open bite and return of symptoms may develop within a few months, (Ash, 1986). 
Maloney and Howard, 1986, in a long-term study also suggest symptoms tend to 
reappear and report usage is based on anecdotal evidence with a lack of scientific 
data.  Warnings against the use of MORA appliances have been issued by (Ash, 1986 
and Abbott, 1991).
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4.6.5  Full coverage occlusal appliances
The maxillary or mandibular dental arch is completely covered.  Appliances are either 
constructed in resilient or hard material and act in either a passive or directive manner. 
Table 3b: Full coverage appliances
♦ Anterior Repositioning appliance
♦ Resilient Interocclusal appliance
♦ Stabilization appliance
4.6.5.1  Anterior Repositioning appliances
These devices developed following theories of internal derangement of the TMJ 
expressed by Farrar and McCarty, 1971.  The aim was to alter jaw and tooth position in 
static and functional occlusion and so recapture the anteriorly displaced disc into an 
ideal position with respect to the condyles, (Clark, 1986). To achieve this, the bite is 
raised and the mandible is repositioned downwards and forward, beyond any reciprocal 
click.  Correction of the disc-condyle relationship long-term is not necessarily the aim 
once relief of symptoms is achieved. Kiricos,1987, using MRI imaging questioned the 
necessity for ideal disc location.  Clicking may decrease but it is not usually eliminated. 
Clicking is usually non progressive and may appear and disappear with or without 
treatment, (Greene and Laskin, 1988).  Long term studies suggest clicking is the 
symptom most resistant to splint therapy, (Agerberg, 1974).
Designs vary but generally rely on occlusal indentations and guiding planes in hard 
acrylic to produce altered mandibular position, (Farrar, 1972, Weinberg,  1979). Further 
adjustment is required during therapy to refine jaw position. Splints may fit the maxilla 
or mandible and occasionally in the case of LARS (Ligated anterior repositioning 
splint) are attached to the upper arch.  Mandibular appliances have indentations only,
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whilst maxillary appliances have guide ramps and indentations and so are more 
effective in protrusive guidance of the mandible.  Since both appliances are full 
coverage, dentoalveolar changes of tooth extrusion or intrusion should not occur. 
However, when the jaw is protruded, due to downward movement of the condyles as 
they translate forward, a space is created between the posterior teeth known as the 
‘Christensen phenomenon’,Huffman and Regonos,1989. As a result of this, 
repositioning the condyle in a downward, forward position can cause development  of 
irreversible occlusal changes with severe posterior open bite,(Vlachos, 1995).
Hanson et al ,1985, Anderson et al,1985, showed the splint worn full time 
performed well in shortterm studies. Clark, 1984, reviewing 25 cases suggested 
suitability of the splint for treatment of disc displacement with reduction.
Moloney and Howard, 1986, Okesson ,1988, found in clinical studies that achieving 
a new occlusion with the disc recaptured was not successful in the long term and 
it was suggested the stabilizing splint was a more effective alternative.
Greene and Laskin ,1972, disputed the claim that repositioning appliances could 
replace an anteriorly displaced disc.  Lundh and Wetesson ,1989, in their study of 
11 cases reported 82% success at 3 years in maintaining position of the disc but 
raised the issue of treatment cost in relation to symptom severity.  They also noted that 
patients with disc displacement can be successfully treated without permanent 
repositioning of the condyle due to adaptation of the retrodiscal tissues, a finding 
previously noted by (Scapiro, 1983).
Originally it was considered that appliances should be worn constantly including 
meals to establish the new jaw position, (Farrar, 1965).  Although initial full time 
wear is thought to reduce symptoms most rapidly, part time use has now been
131Ch apter IV
advocated to reduce irreversible occlusal change (Okeson, 1993). Nocturnal use only, 
may reduce joint pain and prevent intermittent disc displacement without reduction on 
awakening with marked reduction for potential occlusal changes due to limited wear, 
(Okeson, 1996).  Davies and Gray, 1987, in their study on the pattern of splint usage 
found however that 24 hour wear gave the most significant relief of symptoms.
Full time use of the repositioning splint may be effective in decreasing pain and 
dysfunction but the potentially undesirable occlusal consequences must be considered 
to avoid the need for extensive restorative and orthodontic treatment.  Therefore, when 
TMJ symptoms resolve, ideally the pre-treatment mandibular position should be re­
established.  This is achieved by gradually adjusting the appliance to allow posterior 
jaw relocation (Okeson, 1995). This can be a very time consuming process.  On 
accomplishing the original occlusal relationship, the pain may return possibly due to 
lack of retrodiscal tissue adaptation.  An anterior positioning appliance will again 
relieve symptoms and more time is then allowed for tissue adaptation before once again 
attempting to relocate the TMJ. Permanent occlusal therapy in theory should therefore 
be avoidable, (Okeson, 1995).
4.6.5.2.  Resilient interocclusal appliances.
Constructed of polyvinyl, these are flexible, soft appliances worn on the maxillary or 
mandibular dental arch.  Straight forward and quick to make, the splint is comfortable 
and frequently worn as a protective sports bite guard, (Bodenham, 1970).
Matthews, 1942,Krogh- Poulsen and 01sson,1968, Block et al,1978, have all suggested 
this simple appliance might be used for patients with a clenching or bruxism habit or 
symptoms of TMJ pain. Ingersoll and Karens, 1952, Posselt, 1968, noted the appliances 
are not easily adjusted and have poor durability in use.  Okeson ,1987 and Harkens et
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al, 1988, reported mixed results whilst Singh and Berry, 1985, report concern over the 
effects on occlusal contacts.  Wright et al ,1995, in a short term study of soft splints 
suggest efficacy relates to dental appliance stability and that occlusal changes do not 
occur when stable interdental contacts already exist. If a positive improvement does 
occur with these appliances it may in fact be related to a cognitive awareness in perhaps 
altering patients teeth clenching or abnormal muscle behavioural patterns.
Short term treatment in adults appears to be useful in reducing masticatory muscle pain, 
(Pettergill et al,  1998). Short term treatment of children with mixed dentition seem most 
appropriate as the appliance is reported to have minimal effect on dental development, 
(Wright et al,  1995).
4.65.3. Stabilization appliancesfFlat plane, gnathologic, muscle relaxation splints) 
These provide essentially reversible therapy for facial arthromyalgia since there should 
be no permanent occlusal changes.  The benefits of this design are to resist alterations 
in tooth and jaw position whilst providing stable contacts to engage all opposing teeth. 
Nelson, 1995, explains that in order to achieve this, the material for construction should 
be thermally and dimensionally stable, although convenient to use and should resist 
occlusal forces generated by the patient.  Coverage of one arch should provide non- 
traumatic occlusal contact for all opposing teeth without dictating a mandibular position 
on closure.  Jaw position on closure is generally just anterior to an unstrained centric 
relation but initial guidance into retruded axis position may be required if muscle 
splinting is significant, (Clark, 1988).
Splints have been designed for the mandibular arch such as the Tanner Appliance 
or the Maxillary Arch the most popular type being the Michigan splint.
Although a mandibular appliance has the advantage of being less visible and
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allowing easier adaptation in speech if worn during the day, establishing vertical 
occlusal contact may be awkward with the maxillary anterior teeth.  Nelson, 1995, 
indicates class III or posterior buccal cross bite relations may be the exceptions in 
favouring a mandibular design.  Maxillary appliances however allow vertical occlusal 
contact with the mandibular incisors for the majority of oveijet, over bite incisor 
relations.  It is also easier to incorporate anterior and lateral canine guidance in a 
maxillary appliance particularly where there is marked oveijet.  Maxillary appliances 
generally offer superior stability to mandibular appliances noted by Clark, 1988. Despite 
a number of variations in design, the one most widely advocated is the modification of 
the Michigan splint emphasizing canine guidance as described by (Ramjford ,1966). 
This is a heat cured acrylic, clear appliance.  Heat cured polymethyl methacrylate 
is considered the most suitable material, (Steele et al, 1992).  Ramjford and Ash, 1985, 
indicate that the splint should be adjusted so that all opposing teeth achieve 
simultaneous, stable, occlusal contacts.  They also specify there should be no occlusal 
interferences and preferably no incisal guidance with a mild gradual cuspid rise 
incorporated  starting 0.5mm from centric occlusion and sufficiently steep to separate 
posterior teeth during lateral and protrusive excursive jaw movements so avoiding non 
working side interferences.
McNeill, 1993, explains the appliance is designed to protect teeth, decrease bruxism, 
relax musculature and redistribute forces.  Tsuga et al ,1989, found a positive effect on 
TMJ symptoms and short term effectiveness of the appliance.
Jaraback, 1956 and Solberg et al,  1975, demonstrated an immediate drop in 
EMG activity on wearing a stabilization splint with return to normal levels on its 
removal.  Clark et al, 1979, found no uniformity in patient response 
to stabilizing splints.  For 25 TMJ patients treated for two weeks 52% showed
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reduced EMG activity, 28% no change and 20% increased EMG activity.
Willamson and Lundquist, 1983, suggest anterior guidance of the splint has an 
important effect on the EMG activity of the musculature.
Wilkinson et al, 1992, in an uncontrolled investigation compared patterns of splint 
usage and found nocturnal wear was as effective as 24 hour wear for mainly muscle 
related pain.  Nocturnal wear only was also recommended in an uncontrolled study by 
Davies and Gray, 1997.
Clinical studies using stabilization appliances frequently combine usage with other 
modes of therapy including occlusal adjustment and prosthetics, (Franks, 1965, Zarb 
and Thompson,  1970, Agerberg and Carlsson, 1974, Magnusson and Carlsson, 1980). 
Combined therapy then results in 70-90% clinical success, (Clark, 1984). When used as 
the only form of therapy similar results are quoted, (Carraro and Caffesse, 1978, 
Gohrian and Neff, 1980, Okeson et al, 1982, Tsuga et al, 1989).
Carraro and Caffesse, 1978, is a case series of 170 patients. Splints were worn full time 
apart from meal times. 82% of patients responded positively to therapy. 37% were 
cured and 45% improved. Pain symptoms were easier to resolve than dysfunctional 
symptoms. Clicking being the most difficult to eliminate.
Gohrian and Neff, 1980, looking at a series of 17 patients treated with occlusal splints 
day and night  for 3 weeks to a year, reported an overall 84% favourable response in 
relief of symptoms.
Okeson et al, 1982, in a case series selected 33 patients from a TMJ clinic population 
and treated them with a maxillary stabilization appliance for one month. Again 85% 
(28/33) showed decreased observable pain scores and improved interincisal opening. 
Tsuga et al,1989, described a series of 30 selected cases, with more than 2 major 
symptoms of TMJ pain, clicking or limitation. Patients wore appliances for 13 weeks.
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87% responded favourably to therapy and 50% had complete relief of pain after 4 
weeks (p<0.01) suggesting good short term effectiveness. However, as with all case 
series it is impossible to determine whether improvement is due to treatment alone. 
Controlled studies comparing the stabilization occlusal splint with a comparison or 
control group therefore require examination. The first two studies showed no 
superiority for occlusal appliances but both were nonrandomised. Green and Laskin, 
1972, compared occluding and nonoccluding splints but concluded both to be equally 
effective. Nemcovsky, 1992, compares alprazolam, splint or combined therapy again 
with all treatments equally effective. For more reliable evidence of efficacy one must 
investigate randomised controlled clinical trials.
Lundh et al, 1992, compares a group of patients receiving occlusal splints to a group of 
patients receiving no treatment. In the later group patients are simply placed on a 
waiting list. The results reported both groups improved similarly. However, patients 
were not prohibited from taking other treatment and were provided with pain 
medication as required. The no treatment group may therefore have been benefiting 
from other effective therapy. In preference to a no treatment group randomised studies 
comparing alternative treatment should therefore be considered.
Okeson et al, 1983, investigated intraoral splints versus relaxation techniques. Oral 
appliances were reported the superior form of treatment. However, this finding was not 
supported in a later study, (Winocur,2002).
Linde et al, 1992, compares oral appliances versus TENS with superiority of the intra 
oral appliances . However, the efficacy of TENS is in question. Dao et al,1990, showed 
TENS to have no advantage over placebo in which case intraoral appliances may have 
been unwittingly compared to placebo.
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List et al., 1992, compares intraoral appliances versus acupuncture and found both to 
reduce symptoms but acupuncture to be more effective. Unfortunately, the authors 
noted that random assignment failed to equate the pre-treatment group differences 
which decreases the inference of treatment efficacy.
Dahlstrom et al,1982, compared stabilization appliance with EMG biofeedback and 
found no significant differencein the improvement of dysfunction between groups.
Turk et al., 1993, again compares intraoral appliances versus biofeedback. However, 
oral appliances were found to be more effective at 6 weeks but not at 6 months. 
Treatment compliance was not monitored however and hence a discontinuation in splint 
wear may have occurred at some point before the 6 month review.
In place of alternative treatment, placebo treatment has been used. A placebo is used in 
an attempt to equalize patient’s expectations of improvement and can be used to blind 
patients and staff to treatment grouping. Marbach and Raphael, 1996, explains a 
‘placebo’ bite plane to be a hard acrylic splint covering only the palate with no active 
occluding surface but believed by the patient to be equally effective to a standard 
appliance.
Greene and Laskin, 1972, compared occluding and nonoccluding splints and found both 
equally effective with 40% improvement with a placebo bite guard, but this study was 
non randomized.
Rubinoff et al.,  1987, randomly assigned 28 patients to either conventional or palatal 
splint therapy with two clinicians one providing therapy and a second blind examiner. It 
was found the conventional splint appeared to relieve clinical signs of dysfunction more 
effectively but was statistically insignificant but both splints relieved symptoms equally 
and concluded no treatment outcome difference between groups. Unfortunately sample
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sizes were small and random assignment failed to equate groups with regard to pre­
treatment symptoms.
Marbach and Raphael,  1996, calculates that pre-treatment levels in the active splint 
group were significantly lower initially. Magnitude of symptom reduction was therefore 
relatively limited creating difficulty in demonstrating any significant pain reducing 
effect in the conventional therapy group.
Dao et al, 1994, does effectively equate groups by random assignment of 63 patients 
prior to treatment. There were three groups a palatal splint worn 24 hours a day, a hard 
acrylic appliance worn 24 hours a day or 30 minutes a day. In conclusion all treatments 
were equally effective at reducing pain related symptoms at 10 weeks. At 5-7 weeks 
treatment however the active appliance was significantly more effective in reducing 
pain intensity at rest. This may reflect decreased efficacy of the appliance after 7 weeks 
or poor compliance with the patients no longer wearing the appliance 24 hours a day 
after 7 weeks. Feinmann and Harris, 1984, found subjects wearing an oral appliance 
decreased to only a third compliance after 9 weeks of therapy. Another factor to 
consider is the value of the palatal splint as a placebo. At present the precise 
physiologic mechanism of splint therapy is still unclear with multiple theories to 
explain splint action. Palatal splints would not have an active effect if functional 
unloading or muscle hyperactivity were the active mechanisms. However, this may not 
be the situation if one considers the cognitive awareness theory of an appliance as 
proposed by Clark,  1984.1f the cognitive awareness theory is considered to contribute 
significantly to the action of splints then palatal splints might in fact be exerting this 
unintentionally. A palatal splint or indeed any form of appliance can not be regarded as 
a valid placebo. Marbach and Raphael, 1996, suggested studies employing palatal 
splints may inadvertently have over controlled for the active treatment component
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simply levelling treatment outcome on cognitive factors and so missing any potential 
benefit of the conventional appliance. Design of a placebo that effectively controls for 
the active component of splint therapy, is extremely difficult unless an underlying 
mechanism of splint action can be scientifically determined by future research. In the 
meantime, short term efficacy of splint therapy was indicated in the well designed 
studies of Turk et al, 1993 and Dao et al., 1994, but not long-term. Dao et al,  1994, 
explains that although the study questions the long-term therapeutic value of splints at 
present there is no clear evidence that any other treatment has a better curative capacity. 
A systematic review of RCT’s for occlusal treatment found splint therapy to be superior 
to 3 control treatments, comparable to 12 and superior or comparable to 4 passive 
controls, (Forssell et al, 1999). Raphael et al, 2001, suggest a modest effect  in 
symptom improvement for localised pain compared to placebo however; two further 
studies suggest more significant results. Wahlund, 2003, found occlusal appliances in 
TMD therapy of adolescents to be superior to combined relaxation training and brief 
information p<0.05 In a further randomised controlled trial, stabilization appliances 
were shown to be more effective in myalgic TMD for reduction in signs and symptoms, 
(Ekberg,2003).
Compliance in wearing appliances including careful examination to detect any negative 
effects of therapy needs further investigation in well controlled randomised clinical 
trials. Until a definitive therapy is established for treating Facial Arthromyalgia,(TMD) 
stabilizing splints remain a useful, conservative and reversible form of adjunctive 
therapy in TMJ management.
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4.6 Occlusal adjustment
This is an invasive and irreversible form of therapy which involves occlusal 
equilibration or alteration of the occlusion by prosthodontic or orthodontic 
repositioning. A systematic review of randomised controlled trials of occlusal treatment 
was published by Forssell et al, 1999.Occlusal adjustment was found comparable to two 
and inferior to one control treatment and comparable to passive control in one study. 
Tsukiyama et al, 2001, in an evidence-based assessment of occlusal adjustment again 
found usage to be unconvincing due to lack of experimental evidence.
Most recently, Koh and Robinson, 2004, in a comprehensive review of the literature 
and meta analysis found no evidence for treatment or prevention of TMD with occlusal 
adjustment and advised clinicians against recommending such management.
4.7 Surgical therapy
Although non compliant with the recommendations of non-invasive and conservative 
procedures, surgery does have a role in the management of specific TMJ disorders. 
Ankylosis, growth disorders, neoplasia and some trauma obviously require surgery, yet 
indications for the more common disorders of recurrent dislocation, joint internal 
derangement and osteoarthritis are less clear. Careful case selection is required to avoid 
the potential complicating factors particularly psychological issues,(Poker and 
Hopper, 1990).
Clinical symptoms often do not correlate with imaging studies. TMJ arthrography and 
nowadays MRI, magnetic resonance imaging, is of value in depicting disc position, 
(Rao, 1995). However, there is variable position of the normal meniscus, 30% of 
asymptomatic patients have abnormal disc position on MRI and 25% of symptomatic
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patients have normal disc position,( Westesson et al, 1989). Excessive reliance on the 
diagnostic value of imaging can lead to over diagnosis of internal derangement and 
hence over treatment. More emphasis should therefore be placed on the history and 
clinical examination than results of imaging studies alone,(Buckley et al,1993).
TMJ surgery includes a range of procedures from the relatively minor Arthrocentesis or 
joint lavage, closed arthroscopy to open joint surgery of arthrotomy, joint exploration, 
major joint reconstruction and extraarticular procedures.
Arthrotomy is only indicated in patients who meet the surgical criteria of advanced 
TMJ disease,(Okeson,1996). Numerous approaches to the TMJ are described but a 
preauricular incision is most commonly used with exposure of the superior and if 
required inferior joint spaces,(Quinn,1998).
Arthrotomy provides scope for a range of procedures from the simple lavage and 
debridement to disc repositioning, discectomy or arthroplasty bone recontouring. In the 
past, condylectomy, high condylar shave and condylotomy were also performed. A 
modified condylotomy or intraoral vertical ramus osteotomy is a closed procedure 
where the joint is not entered,(Poker and Hopper, 1990).
Complications of surgery include occlusal alterations, facial nerve damage, pain, in the 
past failed implants, fractures or dislocations of the condyle or condyle-disc 
relationship,(Okeson, 1996).
Arthroscopy of the TMJ was first described by the Japanese in 1975 before spreading to 
Europe and the USA,(Ohnishi,1975). Initially described as a diagnostic technique 
therapeutic applications were later developed,(Hollmlund and Helsing,1988, 
Dolwick,1997)
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Indications for arthroscopy might include internal derangement pain, decreased mouth 
opening and clicking, degenerative joint disease, synovitis, hypo and hyper mobility, 
(Nitzan, 1990Alpem et al, 1997,).
Diagnostic and therapeutic operative procedures include lavage of the joint space with 
saline, ablation of fibrous adhesions in the upper joint space for treatment of closed 
lock, painful limited mouth opening, anterior disc release with restoration of mobility 
and position by dissection, cauterisation or laser treatment, biopsy of lesions and finally 
instillation of medication in the form of steroids, hyaluronate or morphine. The 
procedure is normally performed under GA but compared to open joint surgery is 
minimally invasive with less surgical trauma, lower morbidity, faster healing time and 
more rapid recovery,(Bronstein,1989, Dolwick,1997). It is dependent however not only 
on surgical skills but expensive equipment and technology, arthroscope, light source, 
TV camera and monitor. Arthroscopy allows direct observation and sampling of the 
joint tissues and the three dimensional joint space is viewed on the two-dimensional 
screen image. This may reveal capillary hyperaemia or fibrous adhesions. Incision of 
adhesions, debridement and lavage can then be performed and the surgical site closed 
with suture and steri strip dressing.
In contrast to arthroscopy, arthrocentesis involves simple intra-articular irrigation or 
lavage of the TMJ. Reports on the success of arthrocentesis have been favourable. It has 
been suggested that this method may be as effective as arthroscopy particularly when 
used with joint mobilization in the treatment of acute onset closed lock and to relieve 
disc adhesions in the glenoid fossa,(Nitzan et al,1991, Dimitrioulis et al,1995).
It is simple to perform, equipment is inexpensive and the procedure is far less invasive 
and can be carries out under LA,(Nitzan,1991). The success of arthrocentesis or 
arthroscopy in management of closed lock suggests restricted gliding movement of the
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condyle over the articular eminence may be due to reversible adhesion of the disc to the 
glenoid fossa caused by a vacuum effect or alteration in synovial fluid, Quinn, 1990). 
Although surgical management of TMJ dysfunction is quoted in retrospective studies as 
being effective in decreasing pain and increasing range of motion in 80% of patients, 
long-term randomised controlled trials are limited,(Okeson, 1996). In one RCT 
arthroscopy was not significantly better than physical therapy in treatment of restricted 
jaw movement and pain from articular disease, (Stegenga et al,1993). TMJ surgery is 
only suitable for selected cases due to potential complications, the high prevalence of 
behavioural and psychosocial contributory factors in TMD and the wide availability of 
non-invasive management,(Okeson,1996). Surgical intervention should be reserved for 
a small percentage of patients with significant persistent pain and dysfunction with 
demonstrable internal disc derangement (Harris et al ,1995).
4 8 PHARMACLOLOG1CAL THERAPY
Reported medical therapy in the management of TMD include simple non-opioid 
analgesics, anxiolytics and muscle relaxants, antidepressants, corticosteroids, opioids 
and even botulinum toxin. A qualitative systematic review of pharmacological 
interventions in the treatment of TMD suggests more, large RCT’s are required to 
determine efficacy,(List et al,2003).
4.8.1  Non opiod analgesics
This group constitutes a variety of drugs with diverse chemical structure but similar 
therapeutic effect. Well-established in acute pain, side effects are negligible when 
dosage recommendations are followed (Kehlet, 1999). Long-term administration 
however, is well documented to result in serious toxicity and adverse effects, (Holovet
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et al 1991, Laporte et al, 1991, Kaufman et al, 1993). Justins, 1996, found NSAIDs and 
paracetamol, only have proven benefit in chronic inflammatory musculoskeletal  pain. 
Treatment benefit in generalised chronic pain must only be seriously considered in 
relation to toxicity. Paracetamol, although widely used, has an analgesic effect 20-30 % 
lower than NSAIDs, (Weibalch and vonAhanm 1995, McQuay et al 1997, Moore, 
1997). NSAIDs are analgesic for mild to moderate acute pain, antipyretic and anti­
inflammatory, (Greene, 1991, Hargreaves, 1987).
Table 4a: Simple (Non opioid) analgesics
♦ Analine derivatives -  Paracetamol
♦ Salicylates -  Asprin (Acetyl salicylic acid)
♦ Non steroidal anti inflammatory drugs (NSAIDs) (COX-1 inhibitors)
•  Indoles -  Indomethacin
•  Proprionic acid derivatives -  Ibuprofen, Naproxen, Ketaprofen, Lorioxicam,
Mefanamic acid and  Tolfenamc acid.
♦ COX-2 inhibitors - Refocoxib, Vioxx
Despite large numbers of trials published on NSAIDs systematic reviews reject the 
majority leaving an almost inadequate number of acceptable studies to allow conclusive 
results. Assessment is therefore based on adverse effect profile and pharmacokinetic 
considerations rather than superiority as an analgesic,(Gowley,  1999).
A systematic review of NSAIDs in Rheumatoid and Osteoarthritis in acute and chronic 
pain (Moore, Pendrey, Tamer and Emery,) failed to identify a particular NSAID which 
consistently provided superior analgesia compared to others. Development of newer 
NSAID's did not significantly improve efficacy or decrease side effects, (Merry and 
Power, 1995).
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4.8.2  Route of administration
NSAIDs are administered by a variety of routes IV, IM, PR, O, topical. No advantage 
was demonstrated in preference to the standard oral route (Tramer et al,1988). The only 
exception was the application of topical drug in chronic and acute pain where there was 
decreased incidence of GI side effects compared to oral administration but similar 
analgesic effect for both, (Moore, 1998).
4.8.3.Side effects
A meta analysis of 16 controlled studies suggest a threefold increase in the risk of 
developing adverse GI events in NSAID users, compared to controls with greater risk 
over 60 years of age,( Gabriel et al, 1991).
The major toxic effect of NSAIDs are gastroduodenal damage variable incidence of 
gastric ulcers (18-47 %) and duodenal ulcers (2-8%), (Roderick et al,1993,
Stalnikowicz and Rachmilewitz,1993). Misoprostol significantly reduces the incidence 
of gastric ulcers with a similar effect to ranitidine on duodenal ulcers. Kidney blood 
flow is altered by NSAIDs by interference with PGE synthesis in the kidney affecting 
autoregulation of blood flow and glomerular filtration, (Clive and Stoff, 1984).
In chronic NSAID use the inhibitory effect on kidney PGE  production can lead to 
acute, reversible kidney failure in 0.5-1 % of patients (Welton and Hamilton, 1991).In 
patients with a pre-existing decreased kidney blood perfusion, haemodynamically 
mediated acute kidney failure may be a significant side effect. A nine fold increase risk 
of end stage kidney disease was reported in a retrospective analysis. In demonstrated an 
association between patients with end stage kidney disease requiring haemodyalisis and 
chronic NSAID use (>5,000 tablets per lifetime), (Pemeger et al, 1994).
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Pharmacological effects are achieved by inhibiting prostaglandin (PGE) synthesis via 
the action of the enzyme cycloxygenase (COX) of which two isoforms exist, COX -1 
and COX-2. NSAIDs are COX-1 inhibitors. The COX-1 isoform is present in most 
tissue and consequently NSAIDs exert a widespread action, not limited to the site of 
injury. The result is considerable pharmacological effects including alteration to the 
normal function of the GI mucosa and kidney blood flow.
4 8 4 COX-2 inhibitors
The COX-2 enzyme is induced in inflamed tissue by the action of cytokines and 
cellular mediators. Inhibitors of COX-2 should hence provide analgesia with fewer 
side-effects, (Kurumabeil et al, 1996). The introduction of COX-2 inhibitors were 
promising to be beneficial in acute short-term pain treatment and observations in 
patients with chronic inflammatory pain indicated reduced side effect incidence with 
maintained analgesic efficacy,(Hawkey, 1999).However, concern has recently risen 
over the safety profile in relation to cardiotoxicity and several COX-2  inhibitors have 
been withdrawn, (Drazen ,2005, Luo et al,2005.).
4.8.5  Combined or balanced analgesia
The rationale of combined analgesics was to improve the efficacy and decrease side 
effects. The aim was to achieve this by combining smaller doses than are usually 
required of each drug. A NSAID or paracetamol are combined with a weak opioid for 
example codeine or propoxyphene.
Different sites of action for each drug relys on a synergistic or additive analgesic 
response. Moore, 1997, found in the treatment of acute pain, a statistically significant 
analgesic effect was achieved with codeine and paracetamol compared to paracetamol
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alone, one additional patient in nine obtaining 50 % pain relief from the combination 
drug. Eisenberg, 1999, in a meta analysis of NSAIDs alone or in combination with 
weak opioids, in the treatment of cancer pains revealed the same extent of analgesia for 
both formulations. Weak opioids were required in substantial dosage before an 
observed additional analgesic effect could be achieved suggesting little benefit with all 
the disadvantages of high dose stronger opioids. This queries the role of the fixed 
combination of NSAID and opioids for use in any pain condition and questions the 
validity of stage two in the WHO analgesic ladder. (McQuay, 1999).
4.8.6.  NSAID treatment of chronic orofacial pain and TMD
In this field there are very few well controlled studies, but benefit has been reported, 
(Truelove, 1994). Recommendations on usage are often extrapolated from cases of 
chronic inflammatory conditions such as arthritis. It is suggested a short trial of a 
NSAID be considered for patients with an apparent inflammatory component to the 
pain, such as acute symptoms of TMD associated with trauma, (Dionne 1997). Two 
placebo controlled studies suggest NSAIDs to be ineffective in the treatment of chronic 
orofacial pain. There was no therapeutic advantage for the NSAID Piroxicam 20mg 
daily compared to placebo in 28 patients with TMD, (Gordon et al, 1990). Likewise 
chronic orofacial pain of myogenic origin was found to respond in a similar manner to 
placebo or the NSAID, Ibuprofen, 2,400 mg daily for four weeks,( Singer et al ,1987). 
Juniper, 1993, advocated the use of NSAIDs during acute exacerbations of pain. Yuasa 
et al, 2001, found combined NSAID and mouth opening exercises over 4 weeks to 
produce objective improvement in 60% of TMD cases with disc displacement without 
reduction compared to 33 % improvement in a non treatment control group.
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4.8.7.  Opioids in chronic non-malignant pain
Long-term administration of opioids for non-malignant pain is controversial and up 
until 10 years ago was felt inappropriate,( Hardy, 1991). Concern centres around the 
potential for addiction and withdrawal in terms physical dependence and tolerance 
requiring an increased dosage. In a therapeutic context the use of sustained release 
formulations minimise cyclic fluctuations whilst maladaptive behaviour should not 
occur if monitoring of dosage is properly regulated. A survey of 1,912 randomly 
selected physicians in the USA revealed widespread prescribing in medical practice 
with careful adherence to the stringent protocols required, (Turk et al, 1994).
When other treatment has failed, several recent studies do therefore support usage in 
chronic non malignant pain. Zenz et al, 1992, in an open study of 100 chronic pain 
patients on sustained opioids revealed 51% good pain relief and 28% partial pain relief 
with no respiratory depression. Ark install et al, 1995 in a double blind controlled trial 
of 46 patients showed significant analgesia and pain improvement on the disability 
index with sustained release oral codeine but higher incidence of nausea than with 
placebo. Moulin et al 1996, led a randomised double blind crossover study of patients 
non responsive to codeine, NSAIDs and antidepressants. Oral morphine 60 mg bd 
produced significant pain relief with little effect on cognitive function or memory. 
Opiates are once again clearly recognised in the control of chronic pain, (Mac Pherson, 
2000, IASP, 2000).
4 8 8  Opioids in TMD
Intra articular morphine has been used in a randomised double blind controlled study 
showing a significant increase in pain threshold in diseased joints,(List, 2001). No 
direct evidence based evaluation has been made of long-term administration of oral
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opioids for patients with severe TMD. Treatment at present hence requires careful 
patient selection to avoid those with a personality disorder or drug seeking behaviour 
and establishment of a clear patient contract with careful monitoring to regulate dosage 
and to avoid side effects or escalation in dosage. Carefully selected cases have been 
shown to have excellent analgesic results, (Harris, 2000). Further evaluation is required 
in randomised controlled trials for severe intractable TMJ pain for example post TMJ 
surgery and having first exhausted the alternative medical therapies.
4.8.9.  Benzodiazepines (Anxiolytics and muscle relaxantsl
Diazepam 2-5mg at night can reduce nocturnal bruxism and acute TMD pain in short 
term administration (Rugh, 1988). Similarly, Clonazepam reduces painful TMD, head 
and neck symptoms with nocturnal doses of 0.25-lmg as demonstrated in a 30 day 
double blind trial of a small sample of 10, (Harkins, 1991).
Singer et al, 1987, found significant pain relief with diazepam compared to ibuprofen 
and placebo in a double blind trial of 39 chronic myalgic orofacial pain patients. 
Interestingly, there was also a tendency towards improvement in depression and 
anxiety, although results should be considered cautiously in view of the limited 
numbers of 9-11 per group.
Alprazolam, a more potent anxiolytic than diazepam, was found to decrease local pain 
and muscle tenderness and increase mandibular movement without reduction in joint 
sounds. However, results also suggest that the flat plane occlusal splint to be as 
effective as alprazolam with no significant improvement in symptoms when combining 
splint and alprazolam, (Nemcorsky et al, 1992).
In view of the longstanding professional concern of the potential for dependence, 
sedative effects and possible exacerbation of depression, this family of drugs should
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only be considered with caution for short term administration in acute episodes of 
myogenous pain and contraindicated for long-term use in chronic conditions 
(Dellemijin, 1994, Dionne, 1997)
4.8.10. Corticosteroids
Corticosteroids as powerful anti-inflammatory agents have been administered by 
injection and topical application in cases of osteoarthritis, myalgia and trismus but long 
term results are equivocal (Wenneberg, 1991,Dionne, 1997).There is no evidence to 
support the use of systemic corticosteroids and intra articular injections may reduce 
pain symptoms but repeated injections can cause significant tissue destruction, 
(Dennuci,1996).
4.8.11. Botulinum toxin
Botulinum toxin injections were a suggested treatment for TMD, (Freund, 2000). 
However, a randomised controlled trial did not support the use of botulinum toxin A in 
patients with moderate to severe chronic myalgia pain. Results concluded patients 
receiving treatment had reduced jaw opening compared to a placebo group, (Nixdorf, 
2002).
4.8  .12 Antidenressants  -  In the treatment of chronic orofacial pain
Antidepressant drugs have been used in the management of chronic pain for nearly 
40years, since the early I960’s.  Despite this length  of time, no antidepressant in the 
UK has a product licence specifically for this purpose (McQuay and Moore 1999).The 
therapeutic recommendations from the biomedical  literature “supports the clinical use 
of antidepressants for chronic non malignant pain when other treatment has failed or
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depression accompanies pain” (Dionne 1997).  However, depression is not always 
associated with pain.  In four separate reviews of controlled studies, looking at the use 
of antidepressants for pain management, analgesic effects were found to be mainly 
independent of antidepressant activity (Egburke and Chaffee 1990, Magni 1991, 
Onghena and Van Houdenhove 1992 and McQuay 1996).This suggests a specific 
analgesic action in addition to antidepressant or sedative effect of these drugs.
4.8.13  Background -  Association of pain and depression
The concept that pain and depression may share a common biological pathogenesis has 
led to much debate on whether certain individuals may be more vulnerable to the 
development of pain or depression.
Biological systems markers shared by chronic pain and or depressed patients include: 
hypercortisolaemia, abnormal dexamethasone suppression test and low serum and urine 
melatonin levels (von Knorring, 1988).  Tyramine conjugation excretion deficit, was 
used as a trait marker for endogenous depression (Aghabeigi et al,1993).  This was also 
found to be present in patients with chronic TMJ and orofacial pain even in the absence 
of depression (Hale et al,1986).
Chronic pain and depression as different representations of a similar central 
neurochemical alteration was first suggested by (Stembach 1976).  It was proposed that 
pain is inhibited by adequate circulating levels of the monoamines, NA nor adrenaline, 
5HT (serotonin) and possibly DA (dopamine) within the brain.
Chronic pain was believed to deplete brain neurotransmitter levels of 5HT, particularly 
in the region of the dorsal raphe nucleus. Almay et al, 1987, showed patients with 
idiopathic pain syndromes exhibit low concentrations of serotonin metabolites in their 
CSF.  This low level does not however alter during the course of the condition and may
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represent a marker of increased risk of developing a chronic pain syndrome (von 
Knorring, 1988).  The low level may also explain lack of analgesic with opiates, the 
association of chronic pain with depression and effectiveness of antidepressants which 
increase the level of this neurotransmitter.
Antidepressant drug action involves increased monoamine neurotransmitter availability 
in the synaptic cleft, with alteration in density and functional responsivity of both or 
either adrenergic and serotonergic receptors, (Palozidou, 1997, Pettergill, 1997, Sudoh, 
2002). Neurotransmitter breakdown is prevented in the case of MAOI whilst 
neurotransmitter reuptake to the preganglionic neuron terminal is inhibited with the 
TCAs and SSRIs.
4.8.14  SSRI  ( Selective serotonin reuptake inhibitors)
Serotonin ( 5, hydroxytryptamine, 5HT) is a monoamine. Wilcox, 1999, in reviewing 
serotonin, explains that intrathecal administration of serotonin in animals can either 
inhibit or stimulate nociceptive reflex dependent on dosage and species.  Similarly 
activation of descending serotonin releasing systems can elicit excitation or inhibition. 
It is suggested that the three distinct serotonin receptor subtypes 5HT ID, 5HT 2, 5HT 
3 may account for these variable responses.  The 5HT ID receptor subtype mediates 
selective inhibition of nociceptive neurones  (El Yassir et el 1998, Alhader and Wilcox 
1993).
Following identification of serotonin receptors, production of selective agonists and 
antagonists were developed with antidepressants and analgesic action.  Blockade of 
serotonin reuptake may account in part for the analgesic activity of TCA and SSRI 
drugs (Kahl and Wilcox 1984, Hurang and Wilcox 1987).
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SSRI (Selective serotonin reuptake inhibitors) have become the most popular class of 
drugs in this group.  Fluoxetine was the first SSRI to be introduced in the USA but only 
became available in Europe in 1983.  Large multicentre placebo controlled studies of 
fluoxetine in the treatment of depression revealed antidepressant efficacy similar to the 
TCA, (Montgomery, 1989).
Although efficacy is not necessarily superior to the first generation antidepressants, 
MAOI and TCA, there appears to be a reduced side effect profile, better tolerance and 
less toxicity in overdose (Leonard 1993).
Examining placebo controlled studies with a reference comparator or standalone active 
comparator studies using TCA such as amitriptyline or dothiapine report no significant 
difference between groups.  Occasionally studies report increased efficacy with SSRI 
(Feigher et al,  1989, Muijen et al, 1988) or decreased efficacy (Anderson et al,  1986). 
Meta analysis of databases is also used to assess relative efficacy.  Fluoxetine has 
similar efficacy to the TCAs (Pande and Sayler, 1993) as do SSRIs in general 
(Montgomery et al, 1994).  There are no direct comparative studies between SSRIs so 
categorically one is not more affective than another.
4.8.15  Pharmacokinetics and pharmacodynamics of SSRI.
The SSRIs vary in their selectivity and potency for 5HT receptors.  Fluoxetine is 
converted to the active metabolite nor-fluoxetine, which is three times more selective 
and potent for serotonin.  Clinical efficacy is hence more important than fluoxetine. 
Fluoxetine itself is rapidly absorbed and distributed with a time to peak plasma 
concentration of 2-8 hrs. Plasma levels achieved with SSRIs is subject to wide 
interindividual variation. Although reports suggest poorer response associated with high
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plasma concentrations of some SSRIs the drugs are not associated with a narrow 
therapeutic window (Altamura and Montgomery, 1990, Montgomery et al,  1981). 
Clearance times vary, fluoxetine remaining in the blood stream for the longest with a Vz 
life of 1-3 days, whilst the active metabolite nor fluoxetine has a half life of 7-15 days. 
Although persistence of the drug into the blood stream has advantages when there is 
irregular compliance there is an increased risk of drug interaction when discontinuing 
and changing to an alternative drug.
Combined SSRI and MAOI can lead to serotonin syndrome which is potentially lethal 
and can also lead to rapid death from hyperthermia (Stembach, 1991).  An SSRI should 
only be started after 2 weeks of stopping MAOI and conversely MAOI should be 
started only after at least 5/52 of stopping fluoxetine.
A variety of other drugs have been reported to interact with the SSRIs.  Several SSRTS 
including fluoxetine are metabolised by the P450-P2-D6 cytochrome system.  Several 
antiarythmics, beta blockers, neuroleptics and TCAs such as amitriptyline, nortriptyline 
and domipramine are also metabolised by the same system.  Consequently interactions 
between SSRIs and TCAs have been reported due to increased drug plasma levels 
(Aranow et al, 1989, Bauman and Bertschy, 1993, Vandel et al, 1992). This is less 
important with SSRIs but TCAs have a narrower safety margin and may already be 
used at doses close to the toxic limit.
Inhibition of the enzyme system more rapidly occurs in certain individuals due to 
genetic polymorphism of the system in 7% of Caucasians who are poor metabolisers of 
these drugs.  The required caution with concomitant therapy hence becomes even more 
persistent .The major clinical advantage of SSRIs is the improved side effect profile and 
better tolerance.
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4.8.16 Safety and Tolerabilitv. (Side effects).
SSRI’S are less sedative than TCA with few antimuscarinic effects and low 
cardiotoxcity.  They do not cause weight gain and in some cases result in weight loss. 
The most common side effects are gastrointestinal disturbance (nausea, diarrhoea and 
vomiting).  This is usually mild decreasing with continued treatment but dose 
dependent, higher doses often causing nausea.  Early in treatment a few patients may 
experience anxiety or agitation related to the 5-HT 1C agonist properties of fluoxetine 
(Zhang, 1993). Extra pyramidal movement disorders can occur with SSRIs including 
Fluoxetine due to the role of serotonin in dopamine autoregulation. (Baldwin et 
al, 1991,Bouchard et al,1989,Brod, 1989,Levinson et al, 1991,Tate, 1989).
4.8.17 Optimum dosage.
Optimum therapeutic dosage relies on observing the effect of drugs in animals, dose 
titration studies and fixed dose studies.
In dose titration, the dose is increased to maximum toleration at which a response is 
observed.  However, due to delayed response a low dose may be attributed to a later 
higher dose. The unnecessary high dose may give rise to increased side effects without 
enhancing efficiency.
Table 4b: Studies investigating the effect of Fluoxetine versus placebo
Study N Results
Wernicke et al, 1987 336 Fluoxetine 20mg > Placebo 
Fluoxetine 40mg > Placebo
Wernicke et al, 1987 354 Fluoxetine 5 mg > Placebo 
Fluoxetine 20mg > Placebo 
Fluoxetine 40mg > Placebo
Fabre abd Crimson, 1985 37 Fluoxetine  > Placebo
Rickels et al,  1986 38 Fluoxetine  > Placebo
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The most reliable studies are the fixed dose comparing response to a range of doses 
given in a fixed dosage regimen. Initial studies of fluoxetine used 80mg/day maximum 
dose.  Later fixed dose studies showed that 20mg and 40mg were significantly better 
than placebo.  The 60mg dose although effective were associated with increased side 
effects and increased number of withdrawals from medication because of side effects 
(Wernicke et al, 1987). In a fixed dose study of 5mg, 20mg, and 40mg fluoxetine, all 
doses were found to be significantly better than placebo although a larger treatment 
effect was seen with 20mg and 40mg doses (Wernicke et al,1988).  In long term 
studies, fluoxetine 20-40mg as prophylaxis, maintenance therapy was found to reduce 
the risk of new episodes of depression (Rosenbaum et al, 1993, Montgomery et al, 
1988).
4.8.18  Optimal dosage in pain relief.
There is some controversy regarding optimal dosage of antidepressants to achieve 
analgesia. Onghena and Van Houdenhove, 1992, in a systematic review showed similar 
analgesic properties were obtained with lower than normal established doses 
of antidepressant drugs.  If therapeutic effect of antidepressants were achieved through 
alleviation of depression, doses would be similar to those required to treat depression. 
However, if analgesia is achieved independent of the alleviation of depression then 
perhaps a lower dosage of antidepressant would be expected. McQuay et al, 1993, did 
not show this response. In a double blind multiple dose study he established a direct 
dose-response relationship, where 75mg amitriptyline provided improved analgesia and 
improved sleep in comparison to 25mg or 50mg.This was unrelated to mood but 
accompanied by significantly greater incidence of adverse effects. Zitman et al 1990,
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also reports 75mg amitriptyline produced analgesia and improved sleep over six weeks 
but considered the effect only modest.
Sharav et al, 1987, however, demonstrated low dose amitriptyline (mean dosage 
23.6mg) was as effective for chronic orofacial pain as a higher dose (mean 129mg),
75 mg - 150 mg being the usual daily antidepressant dose.
McQuay, 1992, also showed a daily dose of 25mg amitriptyline for three weeks was 
superior to placebo in patients with a variety of chronic non malignant pain.
Optimal dosage of SSRIs in pain relief remains unexplored at the current time. 
Research on the efficacy of drugs specific to the serotonin receptors are limited in 
chronic orofacial pain. The serotonin anatagonist iprazochrome, was used to treat 30 
patients with Atypical facial pain but results were equivocal, (Hampf, 1989). However, 
in a group of 178 chronic facial pain patients, Fluoxetine was found to decrease pain 
severity and distress in non depressed patients (Harrison et al, 1997).
4.8.19  Historical perspective- Antidepressants in the treatment of chronic facial pain. 
(Webb & Lascelles, 1962) suggested orofacial pain might result from an underlying 
depressive disorder. Early studies proposed a direct correlation between depression and 
orofacial pain.  A double blind controlled trial of 40 AFP patients showed the efficacy 
of phenalzine, Nardil, a MAOI (Lascelles, 1966).  27 patients with tension headache 
and depressive symptoms were found to have more relief from amitriptyline a TCA 
than placebo (Lance & Curran 1964) Similarly tension headache patients with 
concomitant anxiety and depression responded well to amitriptyline at 8 weeks, 
(Okasha et al 1973).The compound carbamezapine (Tegretol) which has the same 
tricyclic nucleus as imipramine, a tricyclic antidepressant, was found to have both 
anticonvulsant and analgesic properties. (Evans, 1973).
157Ch apter IV
Tricyclic antidepressant drugs for the treatment of chronic orofacial pain was 
recommended by (Harris, 1974). An uncontrolled trial of the TCA (Amitryptyline) was 
found to be of benefit in 5 out of 8 patients in a paper published by (Gessel,1975). A 
two centre double blind controlled trial of Dothiepin was found to relieve pain in 71% 
of patients at 9 weeks (Feinmann, 1984). Withdrawal of the drug at 6 months led to 
relapse and necessitated reintroduction of dothiepin to control pain. Long-term follow- 
up at 4 years after initial treatment showed pain improvement can be maintained over 
time. It was suggested that long-term administration may be required for long-term 
symptom control, (Feinmann, 1993).
Sharav et al, 1987, demonstrated low doses of 25mg were as effective as high doses of 
lOOmg of amitryptyline in the reduction of pain, independent of antidepressant effect. 
Harrison et al. 1997, demonstrated the efficacy of the SSRI, fluoxetine in the treatment 
of mixed chronic orofacial pain. In the three later studies pain and depression were 
found to be independent, (Feinmann et al,1984, Sharav et al,1987, Harrison et al ,1997). 
Low dosage tricyclic antidepressant efficacy for chronic pain relief, independent of 
depression, was later reiterated (McQuay, 1996, Plesh, 2000).
4.8.20  Randomised controlled trials of antidepressants in chronic orofacial pain
There are an estimated 50 placebo controlled trials in the literature regarding the use of 
antidepressants in chronic pain. However, only 6 of these studies evaluated usage in 
orofacial pain and provide the most relevant information at the present time.
(Lascelles, 1966, Feinmann, 1983, Sharav, 1987, Harrison, 1997, Plesh, 2000, 
Raigrodski, 2001) The first of these studies was published over 30 years ago.
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4.8.21  Conclusion
None of these studies were specifically investigating the effect of antidepressant 
medication in FAM (TMJD). All studies contained groups of patients with a 
heterogeneous mixture of chronic orofacial pain conditions. Since no randomised 
controlled trials existed in the mid-1990’s which concentrated solely on TMD, a need 
was identified to investigate the efficacy of antidepressant medical therapy versus 
physical therapy in the management of TMD.
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Table 4c: Antidepressant medication in chronic orofacial pain -  controlled trials
Author Year Medication Design Diagnosis
Number of subjects
Pain improvement
Lascelles et al 1966 Phenalzine (Nardil) MAOI 
15mgtds  vs placebo
Cross over trial 
4 weeks
Mixed heterogenous 
Chronic facial pain 
(depressed) N=40
At 4 weeks. Improvement 
in:
Pain 75%
Depression 30%
Feinmann and Harris 1984 Dothiepin (dose titration method) 
vs placebo vs soft acrylic bite guard
Parallel groups 
9 weeks, 6 months and 4 
years longterm follow-up
Mixed heterogenous 
Chronic facial pain 
(depressed/nondepressed) 
N=93
At 9 weeks. 
71% pain free.
Sharav et al 1987 Amitryptyline 30mg,150mg 
vs placebo
Cross over trial 
4 weeks
Musculoskeletal facial 
pain N=28
(depressed/nondepressed)
Low dosage as effective as 
high dosage in reduction of 
pain.
Harrison et al 1997 Fluoxetine 20mg vs placebo 
vs CBT and fluoxetine 
vs CBT and placebo
Parallel groups 
3 months
6months and 9 months 
and 1 year follow up
Chronic (atypical) facial 
pain and Facial 
Arthromyalgia (TMD) 
(depressed/nondepressed) 
N=181
Pain reduction at 3 months 
with fluoxetine compared to 
placebo and maintained 
when drug therapy ceased 
(16-33%)
Plesh et al, 2000 Amitryptyline 10-30mg Pilot study (no control) 
6 weeks
and 1 year follow up
TMD (2 groups) 
Myofascial and 
myofascial and TMJ pain 
N=25
Effective in reducing pain 
and significant improvement 
in global treatment 
effectiveness
Raigrodski et al 2001 Amitryptyline 25mg Cross over trial 
4 weeks
Bruxism and pain 
N=10
No significant reduction in 
pain intensity (p>0.05) 
Significant reduction in 
perception of stress 
(p<0.05)
Forssell et al 2004 Venlafaxine 75mg vs  placebo Cross over trial
Two 4 week periods with
a 2 week ‘wash out’
Chronic atypical facial
pain
N=30
Moderate effect. No 
significant reduction in pain 
severity but moderate pain 
relief as more additional 
analgesics consumed in 
placebo group.
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5.0 Aims and Objectives of the study
The aims of the investigation are:
Primary aims:
(1)  To compare medical (antidepressant medication) and physical (occlusal appliance) 
therapy in the management of TMD, both alone and in combination, using a randomised, 
placebo controlled trial.
Secondary aims:
(2)  To describe the characteristics of those referred to a TMD research study.
(3)  To examine the character of TMD pain and associated clinical features.
(4)  To describe the psychosocial features associated with TMD.
(5)  To measure amelioration or deterioration in pain severity, interference, frequency, signs, 
symptoms, co morbid pain conditions, depression and other psychosocial factors.
(6)  To explore differences in characteristics and response of subgroups in the TMD cohort:
(i)  with or  without depression, (ii) high or low levels of pain at baseline
(iii) those responding to therapy.
(7)  To examine adherence and adverse events of therapy.
(8)  To examine the post study effect on outcome during follow-up at six and nine months.
The objectives of the investigation are:
(1)  To evaluate, using a RCT, with a primary outcome measure of >50% pain  improvement, 
on a VAS.
(la)  The efficacy of medical therapy: a selective serotonin reuptake inhibitor: fluoxetine, 
Prozac in comparison to placebo.
(lb)  The efficacy of physical therapy: a maxillary, Michigan style, stabilisation appliance in 
comparison to medical therapy.
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(lc)  The efficacy of the combination of medical and physical therapy in a RCT and to 
determine whether there is a synergistic effect from combining the two therapeutic 
modalities.
(2)  To report the demographic and epidemiological features of the referral and study cohort 
and to compare the results to other TMD clinic populations.
(3)  To describe the character, duration, severity, interference, frequency and pain free 
intervals of TMD pain, together with associated clinical features related to the orofacial 
region and co morbid chronic body pains, to determine which factors predominantly 
present in the diagnosis of TMD.
(4)  To describe the psychosocial features of those with TMD, notably the patient’s 
perspective of pain and impact on daily life, sensory and affective components of pain, 
depression and illness attitudes and beliefs, using self report questionnaires.
(5)  To determine changes in secondaiy outcome measures; severity, interference, frequency, 
signs and symptoms of TMD, co morbid pain conditions and psychosocial features; post 
treatment.
(6)  To undertake subgroup analysis in order to explore
(i)  The influence of depression at baseline on outcome measures.
(ii)  The influence of an initially high or low recording of pain severity on outcome 
measures.
(iii)  The difference in baseline characteristics of responders and non responders to 
therapy.
(7)  To examine adherence, reasons for nonadherence and adverse events experienced during 
therapy and to identify differences in these factors between therapeutic groups.
(8)  To follow-up patients at six and nine months to determine if there is any maintenance or 
relapse in improvement post treatment.
The underlying themes of the investigation are stated in a series of hypotheses.
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5.1  Hypotheses
To be derived from the RCT. primary outcome measures- Chapter VII
(la)  An SSRI (fluoxetine;Prozac) in daily oral doses of 20-40mg is more effective than
placebo in the treatment of patients with chronic TMD.
(lb)  A combination of an SSRI (fluoxedne;Prozac) and a bite guard are more
effective than fluoxetine or bite guard alone in the treatment of chronic TMD.
To be derived from the baseline data of the referral study cohort - Chapter VI
(2)  The demographic and epidemiological features of the study cohort, are consistent 
with the patient population seen within a secondary or tertiary TMJ clinic.
(3)  The duration, character and location of TMD pain described are typical of a patient 
population seen within a secondary or tertiary TMJ clinic.
To be derived from the RCT. secondary outcome measures-Chanter VII
(4a)  A significant improvement in the ‘clinician recorded’ intensity, interference and
frequency of patient TMD pain, is only observed in the dual therapy group.
(4b)  A significant improvement in the ‘self recorded’ impact of TMD pain on daily life;
MPI severity, interference, life control and affective distress is only observed in the 
dual therapy group.
(4c)  There is a significant difference in ‘self recorded’ BDI depression scores between the 
commencement and completion of the study.
(4d)  There is a significant difference in ‘self recorded’ Kellner illness attitude and beliefs 
between commencement and completion of the study.
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(5a)  There is a significant improvement in the signs and symptoms of TMD between the 
commencement and completion of the study.
(5b)  A significant improvement in the signs and symptoms of TMD are only seen in those 
wearing a bite guard.
(5c)  There is a significant difference in the number of co-morbid pain conditions reported 
between the commencement and completion of the study.
(5d)  A significant improvement in co-morbid pain conditions are only seen in those taking 
SSRI (fluoxetine).
To be derived from the post hoc subgroup analysis - Chapter VIII
(6a)  A significant and measurable improvement in pain is only seen in those patients 
without depression at baseline
(6b)  A significant and measurable improvement in pain measures are only seen in 
those patients with initially high pain scores
(6c)  Clinical and pain history characteristics at baseline separate the treatment
responders from the non responders.
To be derived from adherence and adverse events data recorded during the RCT- Chapter IX
(7)  The four therapeutic groups were equally adherent to therapy
(8)  There was no significant difference in adverse events between active and placebo 
medication
To be derived from post RCT follow-up analysis- Chapter IX
(9)  The improvement in pain measures at the end of the RCT are maintained 
at six and nine month follow-up.
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5.1  Study Design
The intention was to conduct a randomised, double blind for drug treatment, controlled 
trial at the Eastman Dental Hospital (1996-1999) to assess the value of selected medical 
versus physical or combined therapy in the management of patients with chronic TMD. The 
referral cohort  were assessed using self report questionnaires, clinical history and 
examination to determine diagnosis. Patients eligible for inclusion and who consented to 
treatment were randomly allocated to one of four intervention groups, (table 5)
Table 5: Four intervention groups:
(1) Medical therapy -  A selective serotonin reuptake inhibitor(SSRI) fluoxetine;Prozac
(2) Medical therapy - placebo
(3) Physical therapy -  Maxillary,hard acrylic stabilisation appliance (splint)
(4) Combined medical and physical therapy -  SSRI and splint.
5.2  Study treatment phase
The randomised treatment phase of the study was three months with subsequent follow-up 
appointments at six and nine months. During the three months trial period monthly review 
appointments were arranged to assess and monitor progress.
Results of treatment uptake and retention in the trial were analysed for regular interim 
reporting. The epidemiological characteristics of the referral cohort were described during 
the trial. However, analysis of treatment outcome was not investigated until closure of the 
research programme.
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5.3  Required sample size and power calculation
It was proposed that 120 patients, 30 in each group were required to compare 
treatment efficacy.
Group size was determined using the following power calculation: - 
Assume a = 0.05 (significance level of 5%)
1  - p = 80% (statistical power of 80%)
(za +  zp ) =  6 .172 (Where Za and zp are the ordinates for the normal distribution)
The calculation to determine sufficient numbers to detect a 30% difference between 
placebo and active drug treatment.
m = (z^ + zp) { 7 ii (1 - 7ii) + n2  (1 - n2)} / 5 
= 7.849  { 0.4 ( 1-0.4) + 0.7( 1-0.7)}/ 0.3
= 31
Thus at least 30 patients were required per group for 80% power at 5% significance level. 
This allowed the presence of potential interaction between treatments in the combined 
therapy groups.
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5.4  Study location and personnel
5.4.1 Site of investigation
The investigation was based in the Oral and Maxillofacial Surgery Department at the 
Eastman Dental Hospital. All patient assessment, treatment and administration was 
conducted on site. All record forms, computerised database and medication were stored on 
site in a locked office .
5.4.2 Research workers
The author was the principal investigator working in conjunction with the lecturer in the 
Department of Conservation, Mr. Paul O’Neill who dealt with occlusal impressions, fitting 
and adjustment of the splint and occlusal queries.
The author undertook overall management of the study, supervision and co-ordination of 
auxiliary clinical, nursing and clerical staff. Screening, assessment and required 
investigation of all new patients, discussion of alternative treatment or treatment on the 
study, consent and appropriate correspondence with the GDP and GP. Medical therapy in 
the three treatment groups was also the responsibility of the author.
A dental nurse and research assistant were responsible for the random allocation and 
recording of the patients to the four respective groups, data input, collection and scoring of 
questionnaires and patient appointments.
Statistical advice was sought from the Eastman Dental Hospital
The study was supervised by Dr. Charlotte Feinmann, Mr Richard Ibbetson
and Prof. Malcolm Harris
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5.5 Financial Support
Medication was generously donated by Lilly Pharmaceutical Company. The project was 
funded by a Department of Health Grant and Locally Organised Research funding.
5.6 Ethical aspects
Approval for the project was obtained from the Ethics Committee at the Eastman Dental 
Hospital, JREC application number:79384.
Informed, signed consent was obtained from all patients who agreed to participate in the 
study. This was witnessed and signed by both the interviewer (the author) and an observer 
(the dental nurse). (Appendix 1)
The information received prior to consent was both verbal and written. (Appendix 2)
The possibility of side effects most commonly encountered when taking medication was 
made known to the patients.
The patients Dental and Medical Practitioner were informed of the patients participation in 
the study to enable the doctor to have the opportunity to inform the author if there was any 
extenuating circumstances which should exclude the patient from the study. (Appendix 3)
5.7 Subject selection
In selection of patients it was our intention to preclude long standing chronic pain patients 
often seen as tertiary referrals within the hospital departments. The intention was to recruit 
patients who had developed chronic TMD of recent onset, more than three months 
duration, hence exposed to minimal treatment intervention. New referrals from outside 
dental practitioners were therefore most suited to this particular study.
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5.8 Source of referrals
In January 1995, letters were sent to all the Heads of Department within the Eastman 
Dental Hospital requesting new patient referrals corresponding to a series of specified 
criteria. The response from within the hospital was minimal as anticipated due partly to 
concurrent facial pain projects already in progress and utilising the majority of new patient 
referrals.
The strategy adopted was therefore to send letters directly to 1,730 GDPs within the 
London area requesting referral of patients whom they felt may be suitable,  would be 
interested and hopefully benefit from treatment within our study. Letter (Appendix 4)
The initial response was excellent and on average 15 patients were referred per week. A 
reminder letter was sent out in April to participating GDP’s to maintain the good response. 
A further letter thanking GDP’s for their referrals to date and requesting further patients 
was undertaken. In addition a questionnaire to assess satisfaction with the service provided 
was issued in January, 1997.
5.9 Criteria for participant eligibility
5.9.1  Inclusion criteria
Patients suitable for inclusion were those who presented with diagnostic findings consistent 
with chronic TMD. This entailed: pain in one or both TMJ’s with or without; clicking, 
limited mouth opening or tenderness in the associated musculature. In addition it was 
necessary for the patient to present with sufficient teeth for construction of an upper 
occlusal, hard acrylic splint. The patients may be dentate or partially dentate but with at 
least two or three clinically sound molars in the maxillary and mandibular arches.
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5.9.2  Exclusion criteria
Patients unsuitable for inclusion were those: -
•  with inadequate plaque control, extensive or active periodontal disease.
•  with active caries.
•  undergoing extensive or complex restorative treatment.
In the prescence of active dental pathology the use of occlusal appliances would be 
inappropriate. Usage may aggrevate concurrent dental disease especially when oral 
hygiene is not optimal.
•  aged below 16 or over 55 years old.
The lower age limit was to ensure patients were able to consent to treatment. The upper 
age limit was to preclude the likely condition of osteoarthrosis which tends to be more 
frequently observed over the age of fifty five years.
•  pain for less than three months
TMJ pain of short duration, less than three months, would indicate acute not 
chronic TMD and does not fit the diagnostic classification for this study.
•  history of a joint condition which appears long and intractable
TMJ osteoarthritic pathology or longstanding TMD already treated unsuccessfully by 
occlusal appliances and antidepressant medical therapies were not included but more 
appropriate referrals arranged to accommodate these patients’ needs.
•  patients currently prescribed antidepressant medication
•  adverse medical history contraindicating the prescribing of antidepressant 
medication
To avoid any potential drug interactions.
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5.10  Planned assessment procedure
The measurement of pain is complex, as previously discussed (Chapter 1). Individual 
suffering and pain perception is virtually impossible to quantify due to broad subjective 
interpretation. However, it is best accomplished in chronic pain studies, by focusing on 
functional progress and outcome of therapy, by means of a series of validated self-report 
questionnaires.
From the literature review of TMD classification (Chapter 2) it was apparent that this well 
documented chronic pain condition is most appropriately assessed by analysing the intergral 
biophysical and psychosocial components of the pain experience.
To embrace the biopsychosocial model of pain, assessment and analysis focus on the two 
integrated components of TMD classification highlighted in the literature.
(a)  Clinical examination and history
(b)  Pain and psychological questionnaires
173Chapter V MATERIALS AND METHODS
Figure 8b: Planned assessment of study participants -  Action flow-chart
Recruitment letters sent to GDP’s requesting referral of selected patients
Selection:
- Pain in one or both TMJ’s  +/- 
clicking, limitation in mouth  opening 
or tenderness in associated 
musculature, for > 3 months.
- Dentate or partially dentate > 2-3 
molars in the maxillary and mandibular 
arches
Exclusion:
- Active caries and or  periodontal 
disease
- Undergoing extensive or complex 
restorative treatment
- Intractable or longstanding TMJ 
pain unresponsive to previous 
treatment
Referred to TMJ project 
First attendance.
- Assesment
- Self-report pain questionnaires
- Clinical history proforma
- Dental examination
- Radiographs
- Diagnosis explained
lElieible to participate : Non eligible to participate :
- Verbal and written explanation of 
study provided by clinician
- Consent form signed
- Random allocation
------------------------------------------------- ^ -----
Alternative treatment commenced or 
appropriate referral arranged
Treatment groups
Splint Splint + SSRI
-  ____i ..  .  .
SSRI 
-  .  .......t
Placebo 
. . . .... .  i   _  _
Blood tests taken
Letter written to referring GDP and GP
Impressions for splint construction
Commence allocated treatment: 
Splint fitted 
Medication started
Withdrawn from study :
Previously undisclosed medical history 
contraindicating antidepressant 
medication
Abnormal blood results GP informed
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5.11 Study conduct and implementation
5.12 Initial screening- first attendance
On arrival at the out patient clinic potential participants in the study were registered and 
then asked to complete a series of standardised self-report pain questionnaires 
(Appendix 7)
1) The Multidimensional Pain Inventory.
2) The McGill Short Pain Questionnaire (MPQ)
3) The Kellner Illness Attitude Scale
4) The Beck Depression Inventory (BDI)
5.12.1 Pain and psychometric assessment
5.12.1.1 The Multidimensional Pain Inventory (Kearns et al, 1985)
This is a questionnaire comprised of 66 items divided into 3 sections.
(I) To assess the patients perspective of pain and impact on daily life.
(ii) To assess how ‘significant other people’ namely spouse or close friends respond 
to the patient as a result of the pain.
(iii) To assess the frequency with which the patient participates in commonly 
performed activities.
Thirteen scales each with scores ranging from 0-6 are derived from the questionnaire 
measuring;
•  pain severity
•  distress
•  interference of pain with daily life
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•  control over one’s own life and pain
•  response of significant other: support, punishing, solicitous or distracting.
•  effect upon ability to : do household chores
outdoor work 
activities away from home 
social activities 
general activities
5.12.1.2  Short McGill Pain Questionnaire (SF-MPQ) (Melzack, 1987)
This is a modified version of the original long- form McGill Pain Questionnaire (LF- 
MPQ) described by ( Melzack, 1975.) The SF- MPQ measures the subjective quality 
and intensity of pain using 15 descriptive terms for pain.
Descriptors 1-11 represent sensory dimensions.
Descriptors 12-15 represent affective dimensions 
Each descriptor is rated on an intensity scale of 0 - 3,
0= none, 1= mild, 2= moderate and 3—  severe.
Three pain scores are derived, the sum of the (a) sensory (b) affective (c) total intensity 
rank value of the words chosen. The summed score ranges from 0 to 45 and a % is used 
to represent the patient’s usual pain. This ensures a representative score is achieved 
proportional to the questions answered as opposed to an absolute score, which makes 
allowance for missing data.
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Present pain intensity (PPI)
This intensity rating scale, also found in the LF-MPQ, categorises current pain on a scale 
of 0-5.
0=no pain, l=mild, 2=discomforting, 3= distressing, 4=horrible, 5= excruciating.
Visual analogue scale (VAS)
Introduced by Scott and Hutchinson 1976,this consists of a 10cm line used to assess 
present pain intensity. The line represents a pictorial scale of no pain at one end to 
unbearable pain at the opposing end.
Both the VAS and PPI describe intensity of pain but not quality of pain.
5.12.1.3 Kellner Illness attitude scale  (Kellner, 1981)
The questions relate to the patients understanding of illness and false beliefs in having a 
disease and fear of a disease. Scores range from 0 to 6, The higher the score the 
stronger the hypochondriacal and disease phobia beliefs.
5.12.1.4 The Beck Denression Index  (Beck et al, 1978)
Originally designed to measure severity of depression in a psychiatric population it is a 
useful means of assessing patient’s mood and level of depressioa The 21-item scale 
contains affective, cognitive, somatic and behavioural items, scored 0-3 with a maximum 
score of 63.
Scores 0 -9 are classified as not depressed 
10-14 borderline depression 
15 -20 mild depression
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All questionnaires were completed by the patient prior to being seen for assessment by 
the clinician. It was explained to the patient this was a method of pain assessment to 
help us understand the patient’s pain and that all information given was confidential.
A cursory check was made to ensure all questions were completed in full and BDI 
calculated to ensure patients were not suffering from severe depression.
5.12.2  Diagnostic assessment
All patients were seen by the author in the Oral and Maxillofacial surgery department at 
the Eastman Dental Hospital at the initial consultation. A full pain, dental, medical and 
social history were obtained from the patient. Physical examination of the head and neck 
was undertaken, extra oral and intra oral.
All details were recorded on the EDH pain proforma. (Appendix 6) and later transcribed 
to the Hospital notes.
Radiographs were taken. A standard orthopantomograph (OPG) was taken for all 
patients to screen for gross pathology. The presence of partially erupted or unerupted 
wisdom teeth was noted.
Additional radiographs were only taken if indicated by clinical signs and symptoms. 
Occipitomental (OM) views - to exclude sinus pathology or fractured zygoma.
Periapical views - to exclude specific dental pathology; caries, periodontal disease, 
periapical infection or cracked tooth.
Posterior-anterior and Lateral oblique - to exclude a fractured mandible.
Planmeca open and closed view -for suspected unilateral closed lock of the TMJ 
Transpharyngeal radiographs (Tome’s view) - for suspected dislocation of the mandible
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Assimilating the information gained at the consultation, a diagnosis was made.
5.12.3 Diagnostic Criteria
A diagnosis of Temporomandibular joint dysfunction was determined by history, 
physical and radiographic examination Described as a preauricular dull ache or 
discomfort constant or intermittent with or with out occasional sharp episodes. The 
patient may also experience other symptoms such as clicking or sticking in the joint, 
difficulty opening the mouth and pain in the jaw muscles extending up into the head and 
down into the neck. Ear symptoms such as a sense of fullness, popping, buzzing and 
dizziness may also occur. Diagnosis was explained to the patient and standard 
reassurance and conservative advice given.
5.12.4 Study exclusion criteria
The exclusion criteria included:-
1. Unsuitable presentation of TMJ symptoms. Frequent clicking of the TMJ was evident 
but no pain or tenderness.
2. Mildness of symptoms or significant reduction or resolution of symptoms since 
referral. In these cases explanation of the diagnosis and conservative advice were all that 
were required to reassure the patient.
3. Incorrect original diagnosis of pain eg. atypical odontalgia, cracked tooth syndrome, 
migranous neuralgia, temporal arteritis, trigeminal neuralgia, pain of dental origin; 
caries, periodontal disease and pericoronitis.
4. Inadequate teeth for construction of a splint
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5. Adverse medical history or current medication, which contraindicated the prescribing 
of fluoxetine.
6. Difficulty in travelling to appointments
7. Time commitment in attending appointments and or occasionally lack of patient 
interest.
8. Reluctance or refusal of patients to consider taking antidepressant medication.
9. Inappropriate age, below 16 years or above 55 years.
10. Significant psychological disturbance or substance abuse.
5.12.5  Alternative treatment for those excluded from the study
Mild cases were given conservative advice and discharged to the continuing care of the 
GDP. Instructions on bite guard construction and follow up regimes were often sent to 
the GDP. Any patient suitable but unwilling to participate in the study was not included 
in the trial series but was treated either with splint therapy by the GDP or medical 
therapy within the Oral and Maxillofacial surgery department. A significant number of 
patients were allocated to be participants for the pain management programme with 
relaxation or self-hypnosis for facial pain, which was undertaken in the department 
A small number of patients who had already tried splint therapy were allocated to the 
project comparing medical therapy versus cognitive behavioural therapy.
In cases were medical therapy and or psychological support are the most appropriate 
forms of treatment a small number of patients have been maintained on the facial pain 
clinics under the care of Prof. Malcolm Harris and Dr. Charlotte Feinmann.
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5.12.6 Patient Consent
For those allocated to the study, the nature of the investigation was explained verbally 
with opportunity for the patient to ask questions. An information sheet was also 
provided for the patient to read and to keep (Appendix 2)
A written consent was obtained from those who agreed to participate. (Appendix 1)
The methods employed in acquiring consent were in accordance with both the MRC 
guidelines and the Helsinki Declaration, which indicate potential subjects should be 
informed of the aims, methods, anticipated benefits and potential hazards of treatment 
and must be at liberty to abstain from the project at any time.
The patients general dental and medical practitioners were informed by a detailed letter 
of the patients condition and explained that the patient had kindly agreed to take part in 
the study and that consequently it was proposed to include the patient in a clinical trial. 
Details of the study were included. (Appendix 3)
5.12.7 Sampling- Patient selection
Patients with the correct diagnosis, who fit the selection criteria and who consented to 
participate in the study were randomly allocated to one of four groups. Patients were 
assessed at monthly intervals during the three months treatment period and 
subsequently at further three-month intervals up to nine months. Additional or 
alternative treatment were given as deemed appropriate during the nine month follow up 
period.
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5.12.8 Allocation
Patients were randomly allocated to one of four groups, using the method of block 
randomisation. Randomisation was undertaken by a third party, namely a member of the 
administration or dental nursing staff. A sealed envelope was opened indicating group 
participation and recorded in a locked register. The participating patient and clinician 
were informed whether the patient was to be prescribed medication, splint or 
combination therapy. Medical therapy was double-blinded so neither patient nor clinician 
administering interventive treatment and assessing outcome were aware of the assigned 
treatment.
For those who were to receive medication a blood test was performed at this juncture to 
check FBC (full blood count), Hb (haemaglobin), LFT (liver function tests), U&E’s 
(urea and electrolytes) and RhF (rheumatoid factor)
For those allocated to the splint group an appointment was arranged for impressions, 
wax bite and face bow recordings with the Restorative lecturer. The work was then sent 
to Kurban Dental laboratories for construction of a Michigan splint.
During treatment within the study patients were requested to only embark on minimal 
essential dental treatment and to refrain from alternative pain therapies.
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5.13  Treatment Groups
5.13.1 Physical therapy (Michigan splint)
Details of construction and adjustment (Appendix 10)
5.13.2 Medical therapy (fluoxetine or placebo)
Double blind medical therapy- The clinical investigators and patients involved in the 
study were blind to medical therapy allocation of drug or placebo. Drugs were coded A 
or B and the codes for unblinding were held by the Pharmacy Department at the 
Middlesex Hospital and with a third party at the Eastman Dental Hospital, a supervisor 
and an administrator, in case of an emergency.
Identical green capsules, in appearance and taste, contained either the medication, 
fluoxetine, 20mg or placebo. These were provided by Eli Lilly, Belgium. The drugs were 
packaged by the Middlesex Hospital, UCLH, pharmacy  packaging department in 
identical brown glass bottles with childproof lids. Twenty-eight capsules were contained 
in each bottle. The later were labelled with the words ‘Facial Arthromyalgia (TMJD) 
study’ with the name and address of the hospital, a code number and expiry date.
The correct drugs were selected by the research nurse from the locked drugs proof 
cabinet. The patient’s name, hospital number, the days date and number of tablets to be 
taken daily were hand written on the bottle and the expiry date checked before handing 
to the patient at the end of the review appointment.
5.13.3 Combined medical and physical therapy
Patients in this group received both a Michigan splint and Fluoxetine medication.
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5.14  Progress and monitoring of treatment
All patients were reviewed at 1  month intervals for 3 months and then 3 monthly 
intervals up to 9 months. At each 3 month visit a series of questionnaires; an interview 
and examination were undertaken.
•  The self-report pain questionnaires were completed by the patient (Appendix 7)
•  A follow up form was completed by the clinician at one-month intervals and 
three-month intervals. (Appendix 9)
This included severity, frequency, character of pain, current site and distribution, recent 
emotional disturbance and associated stress related complaints. A clinical examination to 
assess tenderness to palpation, TMJ noise and interincisal mouth opening were 
recorded.
•  A separate form was also completed at the five review appointments for medical 
or physical therapy (Appendix 9)
Notes were recorded of splint comfort, compliance of wear and required adjustments. 
Alternatively or in addition medical compliance, side effects and dosage were recorded. 
The dosage was doubled from 20mg to 40 mg at the two month review appointment.
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Figure 9a :Medication bottles and capsules provided forpatients in  groups 1,2& 4.
Figure 9b : Flat plane stabilization appliance provided for  patients in groups 3 and 4.
185Figure 10: Appointments planned for each treatment group
Group Assessment and 
randomisation
Week
0
Week 1 Week 2 Week 3 Week
4
Week 8 Week
12
Week
24
Week
36
Splint *   ✓ I S Rl R2 4R3 4F6 4F9
Splint and SSRI 4   ^ 4 I  M S Rl R2 4R3 4F6 4F9
SSRI 4 ^ 4 M Rl R2 4R3 4F6 4F9
Placebo 4 ^ 4 M Rl R2 4R3 4F6 4F9
Key:
*4  Self-report pain questionnaires completed by patient.
Clinical assessment, history, examination, radiographs and correspondence with GP and GDP.
4  Blood tests
M  Review blood results and start medication 
I  Impressions and interocclusal records
5  Fit splint
R  Review appointments, during trial phase (Rl-1 month, R2- 2 months, R3- 3 months)
F  Follow up appointments (F6-6 months, F9- 9 months)
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Figure 11: Treatment of Study participants - Action flow chart
Week Medication (SSRI) Placebo Medication (SSRI) and splint Splint
Assessment
Assessment and random allocation to one of the four groups
Blood test
0
Check blood results,start 20mg capsule daily
Impressions and interocclusal records
1
2 Splint fitted
3
4 One month follow up form, review medication, 20mg daily.
One month follow up form, review splint.
5
6
7
8 Two month fo low up form, review medication increase to 40mg daily
Two month follow up form, review splint
9
10
11
12 End of trial phase - Review splint and / or medication and modify treatment plan 
Three month follow up forms and self report questionnaires.
24 Six month follow up forms and self report pain questionnaires
36 Nine month follow up forms and self report pain questionnaires
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5.15 Withdrawal criteria
Patients were withdrawn from the study if there was a significant alteration in the patients 
medical condition or if side effects were deemed intolerable.
5.16 Follow up after the three-month trial
At the conclusion of the three month trial period, patients who had gained benefit from the 
splint therapy continued usage but discontinued if it had been found non beneficial. Patients 
who had improved on medical therapy and wished to continue on treatment remained on 
medication usually at the 40mg dosage. Those where pain had failed to respond to therapy 
or had worsened were reassessed and in some cases withdrawn from continuation in the 
study. Further data was however collected from these patients to include in the intention to 
treat analysis. An alternative antidepressant medication, lofepramine 70mg nocte was 
prescribed in some cases or referral for surgical management in the form of an arthroscopy 
for internal derangement of the TMJ and closed lock.
The patient’s general medical and dental practitioners were kept informed of their patient’s 
progress and of any further treatment given.
After the three months assessment patients were seen at three monthly intervals to follow 
the course of their symptoms and to monitor continued treatment requirements. Further 
questionnaires were completed up until the nine-month trial end point.
5.17 End of trial and management of intractable pain patients
The majority of patients were discharged back to their referring practitioner and letters 
written accordingly. A small number of patients were maintained on facial pain clinics for
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review of symptoms and further treatment.
5.18 Data analysis
SPSS an abbreviation of Statistical Product and Service Solutions (formerly Statistical 
Packages for the Social Sciences),version 8.0 -  11.01 for windows, was the data base used 
for all data processing and analysis.
5.19 Statistical methods
Statistical advice was given by John Bullman and David Moles at the Eastman Dental 
Hospital.
Descriptive statistics were used to examine the clinic population and TMD study cohort. 
Parametric and non-parametric tests were applied to compare group subsets and treatment 
efficacy. Recordings at baseline, with repeated measures during the treatment phase and or 
at the end of the trail period of three months were analysed. Follow up data was also 
analysed at six months and nine months post therapy.
In addition to the analysis of those competing treatment, intention to treat analyses, for all 
those originally allocated to treatment and imputation analyses for incomplete data were 
performed where appropriate and presented separately in graphical and tabular format. Sub 
group analysis of depressed, initially high pain scores and the characteristics of those who 
responded to therapy were also noted.
A numbers needed to treat (NNT) analysis was used for the primary outcome measure of 
greater than 50% pain improvement.
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5.19.1  Numbers needed to treat (NNT) analysis
Therapeutic outcome of a specific treatment can be described using the NNT (Lampacis et 
al,1988, Cook and Sackett,1995, McQuay and Moore, 1998).It is a useful summary 
applicable to clinical practice and indicating the most appropriate choice of treatment.
Placebo (control) Active treatment
Total number of patients N Cont N act
Clinical endpoint, Imp com Impact
improvement achieved
NNT  = 1 1
(Imp  act /   N   act ) (Impcont /N cont )  ARR
Where ARR, the absolute risk reduction is the difference between the event rate in the 
experimental group and the control group.
An NNT of 1  indicates an ideal (100%) benefit where every patient given the treatment has 
a favourable outcome. This would be the aim of an antibiotic or analgesics in acute pain, 
although effective treatments are more usually in the range 2-4 and prophylactic treatment 
20-40,(Moore,1999).
In this study, the definition for target improvement, as specified in the protocol was >25% 
pain relief. In the medical literature pain relief is frequently quoted as >50%. Consequently 
the power calculation for this trial was undertaken with the higher 50% percentage, so that 
both 50% and 25% pain relief could be investigated.
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5.19.2  Statistical analysis for secondary outcome measures
Non parametric statistical analysis was undertaken for categorical, ranked, ordered and 
dichotomous secondary outcome measures apart from interincisal mouth opening which 
was clearly an interval scale. Visual analogue scale (VAS) 0-10cm, for recording pain 
intensity was analysed using both parametric and nonparametric analysis.
Intra group analysis was undertaken using the non-parametric Freidman two-way ANOVA 
and where significance was indicated Wilcoxons tests performed post hoc. For 
dichotomous data Cochran and McNemar tests were performed. For parametric data a 
repeated measures ANOVA was performed with paired sample t-tests between individual 
time points.
Intergroup analysis, to assess difference in efficacy between treatment groups was 
performed using the nonparametric Kruskall-Wallis test and if required Mann-Whitney post 
hoc tests. For dichotomous data Chi squared tests were performed and for parametric 
interval data one-way ANOVA.
Completers analysis, for those patients who completed the study with no protocol 
deviations; intention-to-treat analysis, for those individuals who failed to complete initially 
allocated treatment and imputation analysis (last score brought forward), for those with 
incomplete data, were performed where appropriate.
Multivariate analysis; logistic regression and discriminant analysis were used to assess 
individual factors as predictors of outcome.
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6.0  An overview of the study
6.0.1 Hypotheses
To be derived from the RCT. primary outcome measures- Chapter VII
(la)  An SSRI (fluoxetine;Prozac) in daily oral doses of 20-40mg is more effective than
placebo in the treatment of patients with chronic TMD.
(lb)  A combination of an SSRI (fluoxetine;Prozac) and a bite guard are more
effective than fluoxetine or bite guard alone in the treatment of chronic TMD.
To be derived from the baseline data of the referral study cohort - Chapter VI
(2)  The demographic and epidemiological features of the study cohort, are consistent 
with the patient population seen within a secondary or tertiary TMJ clinic.
(3)  The duration, character and location of TMD pain described are typical of a patient 
population seen within a secondary or tertiary TMJ clinic.
To be derived from the RCT. secondary outcome measures-Chapter VII
(4a)  A significant improvement in the ‘clinician recorded’ intensity, interference and
frequency of patient TMD pain, is only observed in the dual therapy group.
(4b)  A significant improvement in the ‘self recorded’ impact of TMD pain on daily life;
MPI severity, interference, life control and affective distress is only observed in the 
dual therapy group.
(4c)  There is a significant difference in ‘self recorded’ BDI depression scores between the 
commencement and completion of the study.
(4d)  There is a significant difference in ‘self recorded’ Kellner illness attitude and beliefs 
between commencement and completion of the study.
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(5a)  There is a significant improvement in the signs and symptoms of TMD between the 
commencement and completion of the study.
(5b)  A significant improvement in the signs and symptoms of TMD are only seen in those 
wearing a bite guard.
(5c)  There is a significant difference in the number of co-morbid pain conditions reported
between the commencement and completion of the study.
(5d)  A significant improvement in co-morbid pain conditions are only seen in those taking 
SSRI (fluoxetine).
To be derived from the post hoc subgroup analysis - Chapter VIII
(6a)  A significant and measurable improvement in pain is only seen in those patients 
without depression at baseline
(6b)  A significant and measurable improvement in pain measures are only seen in those 
patients with initially high pain scores
(6c)  Clinical and pain history characteristics at baseline separate the treatment
responders from the non responders.
To be derived from adherence and adverse events data recorded during the RCT- Chapter IX
(7)  The four therapeutic groups were equally adherent to therapy
(8)  There was no significant difference in adverse events between active and placebo 
medication
To be derived from post RCT follow-up analysis- Chapter IX
(9)  The improvement in pain measures at the end of the RCT are maintained 
at six and nine month follow-up.
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6.0.2 Summary of Randomised controlled trial  (Figure 12)
The reporting of the RCT is illustrated by means of a flow diagram, in accordance with 
CONSORT (Consolidated statement of reporting trial) guidelines, figure 12. This 
illustrates the progression of participants through the trial period and subsequent 
follow-up with completion and drop-out. The figure provides an outline of the 
numbers involved in enrolment, allocation, follow-up and post treatment follow-up 
phases, discussed in detail during the course of the results
6.0.3 An overview of the presentation of results
A description of the referral cohort (n=l,038) is first presented with regard to patient 
source of referral, previous consultations and treatments for TMJ/facial pain.
Diagnosis and reasons for exclusion from study participation are reported, with 
alternative treatment or referral provided. (6.1)
The study cohort (n=250) is then examined in detail. Demographic and social 
characteristics, clinical history and examination and self report questionnaires are 
presented. Later, in the discussion, these results are compared with previously reported 
studies, suggesting the data is comparable to a generalised TMD clinic population, 
(6.4). Inter group analysis of the study cohort is undertaken to ensure true 
randomisation, showing an even distribution of characteristics between the four 
treatment groups at baseline,(6.2).
The results of the RCT are presented (7.0), starting with the primary outcome measure, 
(7.1)  NNT analysis, using the VAS, 10cm line, >50% pain improvement. Secondary
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outcome measures are divided into self-reporting verbal rating scales, clinical outcome 
measures and self report pain questionnaire scores (7.2). PPI, frequency and 
interference are next presented in tabular and graphical form,(7.2.1), Clinical outcome 
measures are shown with improvement in signs and symptoms, including interincisal 
mouth opening, TMJ and associated muscular tenderness (7.2.2)
Self report pain questionnaire data is then reported in tabular and graphical format 
illustrating the difference in scores over the three month treatment period,(7.2.3), 
Outcome predictors are investigated using logistic regression analysis, (7.3),
(8.0) Subgroup analysis focuses on three main distinctions: depressed and non 
depressed (8.1), high and low initial pain scores (8.2) and responders and non 
responders to therapy (8.3),
In the final results section, maintenance and withdrawal from therapy and post 
treatment follow up are analysed (9.0) The adherence or compliance to therapy and 
any adverse effects of treatment are reported,(9. l).Follow-up data examines the post 
treatment phase, recorded three and six months from the end of the study phase. An 
analysis of outcome measures; VAS, PPI, frequency, interference, clinical data and 
pain questionnaire scores are presented, (9.2),
Finally, having discussed results, theories and conclusions are drawn (10.0),
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Allocation
Follow up
Figure 12:  Flow chart of participants progress through stages of RCT
Assessed for eligibility ( n = 1,038 ) 
(Referral cohort)
Enrolment Excluded (n = 788)
Randomised ( n =  250 ) 
(Study cohort)
Allocated to Allocated to Allocated to Allocated to
intervention (Gpl) intervention (Gp 2) intervention (Gp 3) intervention (Gp 4)
( n =63 ) (n =63 ) (n =62 ) (n = 62)
Received allocated Received allocated Received allocated Received allocated
intervention Intervention Intervention Intervention
(n =49 ) ( n =53) ( n =51) ( n =48)
Did not receive Did not receive Did not receive Did not receive
allocated allocated allocated allocated
intervention intervention intervention intervention
(n =14 ) ( n =10) ( n =11) ( n = 14)
Follow up (Trial)
1  month  (n =47 )
2 month  (n =43 )
3 month  (n =38 )
Follow up (Trial)
1  month  (n =49 )
2 month  (n =47 )
3 month  (n = 42)
Follow up (Trial)
1  month  (n =47 )
2 month  (n =43 )
3 month  (n =40 )
Follow up (Trial)
1  month  (n =48 )
2 month  (n =45 )
3 month  (n =45 )
Lost to follow up
1  months (n =2)
2 months (n =4)
3 months (n= 5)
Lost to follow up
1  months (n =4)
2 months (n =2)
3 months (n=5)
Lost to follow up 
1  months (n =4) 
2months (n =4)
3 months (n=3)
Lost to follow up
1  months (n =0)
2 months (n =3)
3 months (n=0)
Follow up post trial Follow up post trial Follow up post trial Follow up post trial
6 months (n=33) 6 months (n=36) 6 months (n=36) 6 months (n=38)
9 months (n=33) 9 months (n=36) 9 months (n=34) 9 months (n=35)
Lost to follow up Lost to follow up Lost to follow up Lost to follow up
Post trial Post trial Post trial Post trial
6 months (n=5) 6 months (n=6) 6 months (n=4) 6 months (n=7)
9 months (n=0) 9 months (n=0) 9 months (n=2) 9 months (n=3)
Flow chart according to the CONSORT guidelines
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6.1.0 THE REFERAL COHORT
Referrals to the Eastman Dental Hospital were accepted over a four year period 1995- 
1999. During this time; 1,038 subjects, with a potential diagnosis of Facial 
Arthromyalgia (chronic TMD), were screened and assessed for study eligibility. 
Recruitment was continued until the planned cohort of250 patients was achieved.
6.1.1 Demographic data:
The mean age of subjects in the referral cohort was 37 years (+/-SD13),(range 8-88 
years), with a gender distribution of 1:4 (22% male,78% female).The mean duration of 
pain on presentation was 3 (+/-SD4.4) years,(range one week -32 years).
6.1.2 Referral source:
The predominant source of referral was General Dental Practitioners (GDPs)
950/1038 (92%) as illustrated in figure 13. This was to be expected following the 
targeted GDP letters requesting study participants. Other referral sources, included; 
General Medical Practitioners (GPs) 385/1038 (3%) and Hospital Specialists  58/1038 
(6%) from both the medical and dental fields.
6.1.3 Previous patient consultations regarding TMJ/Facial pain:
Illustrated in figure 14, the majority of patients had previously sought the advice of a 
GDP 962/1038 (93%), consistent with the pattern of referral source. However, 
385/1038 (37%) had consulted their GP, 107/1038 (10%) an Oral Surgeon, 92/1038 
(9%) ENT surgeon, 33/1038 (3%) Neurologist and 18/1038 (2%) Psychiatrist showing 
the diversity in clinicians associated within the domain of facial /TMJ pain.
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6.1.4  Total number of clinicians seen for consultations regarding facial/TMJ pain:
Most  patients had seen either one or two clinicians 546/1038 (53%) and 322/1038 
(31%) respectively, as illustrated in figure 15. The maximum number of clinicians seen 
was 6/1038 (0.1%) whilst 39/1038 (4%) did not recall having previously sought help 
specifically for facial/TMJ pain, the condition only having been discussed as a 
secondary complaint during the course of a consultation appointment.
6.1.5 Previous treatment received for Facial/TMJ pain
The aim of the study was to enrole patients with no previous treatment intervention.
An enquiry into previous treatment received ranged from conservative, self 
administered analgesics to invasive, surgical exploration of the TMJ, as illustrated in 
figure 16.The most popular treatment was the use of analgesics 306/1038 (29%) and 
occlusal appliances 184/1038 (18%).
6.1.6 Total number of previous treatments per patient for Facial/TMJ pain.
Illustrated in figure 17, (483/1038) 53% of patients had received no previous 
treatments. (321/1038) 31% had received one and (150/1038) 14% two previous 
treatments, (83/1038)  8%  three to six previous treatments, whilst (1/1038) 0.1% had 
received over 12 previous treatments.
6.1.7 Diagnoses of referral cohort:
Following history, clinical and radiographic examination not all patients were ascribed 
a diagnosis of chronic TMD (Facial Arthomyalgia), as illustrated in table 6.  131/1038 
(13%) did not have a primary diagnosis of TMD, 907/1038 (87%) did have a diagnosis 
of TMD. However, 59/907 (7%) of this latter group were classified as mixed 
diagnoses. In addition to TMD, this included a diagnosis of other chronic idiopathic
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orofacial pain 34/907 (4%) or concomitant dental pathology affecting teeth or 
periodontium 25/907 (3%). 6/907 (0.7%) had acute TMD but 848/907 (68%) had a 
diagnosis of chronic TMD. Overall, 848/1038 (60%) met the correct diagnostic criteria 
for study inclusion.
6.1.8 Recruitment from referral cohort
During the enrolment procedure for the study, 788/1038 (76%) were excluded from 
participation. This was due either to inappropriate diagnosis 131/1038 (13%), 
indicated above, or due to other exclusion/inclusion criteria as outlined in the methods
6.1.9 Reasons for those diagnosed with TMD not participating in the study.
Reasons for non participation are outlined in table 7. The most commonly occurring 
exclusion criteria for those diagnosed with TMD were: TMD pain not severe enough 
to interfere with life or require treatment 125/848 (14.7%), patient not keen to take 
tablets 124/848 (14.6%), no current TMD pain 78/848 (9.2%) and not enough time to 
participate in the study or travel difficulties in attending for the study 30/1038 (38%)
6.1.10 Treatment received and referrals made for those patients with TMD
Patients with a diagnosis of TMD, who did not participate in the study, received a 
range of treatments, table 8. All patients received informed reassurance; explanation of 
the condition and simple self care management. 274/848 (45.8%) were content with 
informed reassurance alone. The most frequent, additional treatment 147/848 (24.6%) 
was referral back to their GDP for a splint. 53/848 (8.9%) were prescribed medication 
and review arranged, 25/848 (4.2%) were provided with a splint and reviewed. 
Referrals were made to: the GP 17/484 (2.8%), hospital medical and dental consultant 
clinics 15/848 (2.5%) or to studies within the department 26/484 (4.3%) for hypnosis 
and relaxation skills, 4/848 (0.7%) for medical and or cognitive behavioural therapy.
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Figure 13: Referral source
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■  GDP (950/1038)
□  GMP (29/1038)
□ Specialist (58/1038)
Figure 14: Previous patient consultations regarding Facial / TM J pain
■ GDP (962/1038)
□ GMP (385/1038)
■ Oral Surgeon (107/1038)
□ ENT (92/1038)
□ Neurologist (33/1038)
■ Psychiatrist (18/1038)
Figure 15: Total number of clinicians seen for consultations regarding facial / TM J pain
□  0(39/1038)
□  1  (546/1038)
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□ 3(103/1038)
□ 4(22/1038)
□ 5(5/1038)
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Figure 16: Previous treatment received for Facial/TMJ pain
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Table 6: Diagnoses of referral cohort (n=l,038)  % (number of cases)
Chronic idiopathic Facial Pains:
Chronic TMD (Facial Arthromyalgia) 81.7%(848)
Acute TMD 0.6% (6)
Chronic/ Atypical facial pain (AFP) 1.7% (18)
Chronic/ Atypical odontalgia (AO) 0.7% (7)
Oral Dysaesthesia  (OD) 0.3%  (3)
Trigeminal Neuralgia (TN) 0.1%  (1)
Phantom Bite 0.3%  (3)
Migraine 0.3%  (3)
Migranous neuralgia 0.4%  (4)
Tension headache 0.1%  (1)
Mixed diagnosis of Chronic idiopathic Facial Pains:
TMD/AFP 2.1% (22)
TMD/AO 0.3%  (3)
TMD / OD 0.3%  (3)
TMD / TN 0.1%  (1)
TMD / AFP / AO 0.5%  (5)
TMD / Dental 2.4% (25)
AFP/AO 0.1%  (1)
AFP/TN 0.1%  (1)
AFP / AO / TN 0.1%  (1)
Other diagnoses:
Dental caries / Periodontal disease 4.7% (49)
Bruxism 2.2% (23)
Coronoid hyperplasia 0.1%  (1)
Eagles syndrome 0.1%  (1)
Osteoarthrosis / Osteoarthritis 0.6% (6)
Osteoma 0.1% (1)
Osteosarcoma 0.1% (1)
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Table 7: Reasons for those diagnosed with TMD not participating in the study.
Eligible and consented to participate in the study 29.5% (250)
Reasons for non participation
Not severe enough to interfere with life or require treatment 14.7% (125)
Does not want to take tablets 14.6% (124)
No pain at present 9.2%  (78)
Not enough time or travel difficulties 4.5%  (38)
Reassured, self management 3.4%  (29)
Age restriction (<16,>5 5 years) 3.1%  (26)
Already taken or currently taking fluoxetine (Prozac) 3.1%  (26)
Already taken or currently taking other antidepressant medication 2.8%  (24)
Does not want or unsuitable for splint 2.7%  (23)
Not keen on participating in a study 2.6%  (22)
Already has or has had splint 1.9%  (16)
Prefers referral for hypnotherapy and relaxation study,EDH. 1.4%  (12)
Mental health problems 1.1%  (9)
English language difficulties 0.7%  (6)
Medical history exclusion 0.7%  (6)
Substance abuse 0.6%  (5)
Dentistry required 0.6%  (5)
Emigrating or travelling abroad 0.6%  (5)
Pregnant 0.4%  (3)
Does not wish to complete questionnaires 0.4%  (3)
Not keen on the concept of a placebo 0.4%  (3)
Prefers referral for medical and CBT study,EDH. 0.4%  (3)
Prefers to try alternative therapy 0.4%  (3)
To continue with alternative therapy 0.2%  (2)
Referral to consultant clinic due to severity of symptoms 0.2%  (2)
TOTAL 100%  (848)
Table 8: Treatment received and referrals made for those patients with TMD
Randomised TMD study treatment 29.5%  (250)
Treatment and referrals for those not participating in study.
Informed reassurance 45.8%  (274)
Refer to GDP for splint 24.6%  (147)
Medication prescribed and review arranged 8.9%  (53)
Refer to Psychologist, Hypnosis / Relaxation therapy study. 4.3%  (26)
Splint provided and review arranged 4.2%  (25)
Refer to GP 2.8%  (17)
Refer to Hospital Consultant clinics: Maxillofacial and Oral 
Surgery, Dental Specialties, Neurology, Rheumatology, ENT, 
Psychiatry, Clinical Psychology, Interdisciplinary joint pain clinic,
2.5%  (15)
Refer to CBT / Medical therapy study. 0.7%  (4)
TOTAL 100%  (848)
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6.2  THE STUDY COHORT
6.2.1  DEMOGRAPHIC CHARACTERISTICS
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6.2.0  THE RESEARCH STUDY. TREATMENT COHORT
250 patients were eligible and consented to participate in the research study.
The sample characteristics of those patients selected for the study were analysed to 
assess demographic and social details, pain, dental and medical histories, clinical 
findings and patient response to the MPI, MPQ, Kellner and Beck depression indices. 
The demographic and social details (6.2.1), clinical history (6.2.2), clinical examination 
(6.2.3) and self-report questionnaires (6.2.4) are analysed to determine the overall 
characteristics of the study cohort and to ensure true randomisation had been achieved 
amongst all four treatment groups, prior to commencing analysis of the outcome data.
6.2.1  Demographic characteristics of TMD study cohort
Patients within the research study were predominantly female, 76% (191/250), 
compared to male, 24% (59/250), (fig.20). Age was a mean 32.3yrs (SD 9.58) (range 16 
-55), males ,mean 32.2 yrs (SD 9.72), females, mean 32.3yrs (SD 9.55),(fig.l9).
The majority of patients were employed 167/250 (66.8%), (fig.22) in socioeconomic 
group II (semi professional) and group Illi (non professional clerical) 144/250 (57.6%), 
(fig.21). In table 9, gender was compared, showing significant variation in 
socioeconomic status (p=0.002), employment status (p=0.021) and referral source 
(p=0.046).
Treatment categories were then compared to ensure an even distribution of individuals 
between groups. Demographic details of each group are compared in table 10. Age, 
gender, marital status, socio-economic status, employment status, referral source and 
duration of pain were not significantly different between the four treatment groups. 
Subjects within the study cohort were predominantly female (76%), employed (66.8%), 
in the third decade of life, having experienced pain for a mean three years, (fig. 18).
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Figure 18: Duration of TMD pain
>20 years 
10 - 20 years 
9-10 years 
8 -9  years 
7 -8  years 
6 -7  years 
5 -6  years 
4 -5  years 
3 -4  years 
2 -3 years 
1-2 years 
6-12 months 
3 -6  months
0  10  20  30  40  50  60
Patient numbers
Figure 19: Age Distribution
Age (years)
50-55
46-50
41-45
36-40
31-35
26-30
21-25
16-20
0  10  20  30  40  50  60
Patient numbers
L
□  Female 
OMale
1   "  1
r  r  r
208CHAPTER VI  EPIDEMIOLOGY- STUDY COHORT- DEMOGRAPHICS
Figure 20: Gender distribution
■  Male (24%)
□  Female (76%)
Figure 21: Socioeconomic groups
■ Group I (4.4%)
□ Group D (31.2%)
□ Group nii (26.4%)
■ Group Ofii (3.2%)
■ Group IV (2.0%)
□ Group V (0.4%)
■ Group VI (32.4%)
Figure 22: Employment status
B Eirployed (6<v8%)
□ I heirplojed (7.6%)
□ Student (15.6%)
□ Krtiird (0.4%)
□ Housewife (9j6° /c)
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Table 9 : Demographic details of study cohort, comparing gender (n=250)
Recorded at baseline 
assessment
All groups 
(n=250)
Male 
(n  59)
Female
(n=191)
Significance 
between gender
Age (in years) 
Mean (+/- SD) 
Range
32.3 (9.58) 
(16-55)
32.2 (9.72) 
(16-53)
32.3 (9.56) 
(15-55)
ns p=0.948
Duration of pain (in yrs) 
Mean (+/- SD)
Range
3.30 (4.49) 
(0.25-32.0)
3.48 (3.91) 
(0.25,18.00)
3.25 (4.67) 
(0.25,32.00)
ns p=0.734
Referral source
GDP
GP
Specialist
230 (92.0%) 
6 (2.4%) 
14(5.6%)
50 (84.7%) 
2 (3.4%) 
7(11.9%)
180 (94.2%) 
4(2.1%)
7 (3.7%)
* p=0.046
♦ p=0.019 
ns p=0.570 
ns p=0.170
Employment status
Employed
Unemployed
Student
Retired (medical) 
House wife
167 (66.8%) 
19(7.6%) 
39(15.6%) 
1  (0.4%) 
24 (9.6%)
43 (72.9%) 
4 (6.8%) 
11 (18.6%) 
1  (1.7%)
0 (0%)
124 (64.9%) 
15(7.9%) 
28(14.7%) 
0  (0%)
24 (12.6%)
* p=0.021
ns p=0.256 
ns p=0.786 
ns p=0.461 
ns p=0.071
*  p=0.004
Socio-economic status
Professional  I 
Intermmediate  Ili 
Skilled non-manual  llii 
Skilled manual  III 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, retired
11 (4.4%) 
78 (31.2%) 
66 (26.4%) 
8 (3 .2%)
5 (2.0%)
1  (0.4%) 
81 (32.4%)
5 (8.5%) 
22(37.3%) 
10(16.9%) 
5 (8.5%)
3 (5.1%)
0 (0%)
14 (23.7%)
6 (3.2%)
56 (29.3%) 
56 (29.3%) 
3 (1.6%) 
2(1.0%)
1  (0.5%)
67 (35.1%)
** p=0.002
ns p=0.081 
ns p=0.248 
ns p=0.060
*  p=0.008
*  p=0.053 
ns p=0.578 
ns p=0.103
Marital status
Single
Married
Seperated
Divorced
Widowed
147 (58.8%) 
89 (35.6%) 
2 (0.8%)
11 (4.4%)
1  (0.4%)
39 (66.1%) 
15(25.4%) 
1  (1.7%)
4 (6.8%)
0 (0%)
108 (56.5%) 
74 (38.7%)
1  (0.5%)
7 (3.7%)
1  (0.5%)
ns p=0.375
Significance test, Chi-squared (Independent samples t-test for age and duration).
Score test for trend of odds 
was non significant 
p=0.124
Table 9a: Trends in socio-economic groups.
Socio-economic status Male Female Odds ratio 95% Cl
Group I 5 6 1.20 (0.37, 3.93)
Group Hi 22 56 2.55 (1.55, 4.17)
Group llii 10 56 5.60 (2.86, 10.98)
Group III 5 3 0.60 (0.14, 2.51)
Group IV 3 2 0.67 (0.11,3.99)
Group V 0 1 - -
Group VI 14 67 4.79 (2.69, 8.51)
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Table 10: Demographic details of study cohort, comparing treatment groups. (n=250)
Recorded at baseline 
assessment
Group 1 
(n=63)
Group 2 
(n=63)
Group 3 
(n=62)
Group 4 
(n=62)
Significance
between
groups
Age (in years) 
Mean (+/- SD) 
Range
29.8(7.99)
(16-55)
32.8 (10.0) 
(16-54)
32.6 (9.85) 
(17-54)
34.1(9.99)
(16-55)
ns
p=0.076
Duration of pain (in yrs) 
Mean (+/- SD)
Range
3.04 (4.68) 
(0.25-32)
2.99(3.64)
(0.25-22)
3.86(4.65)
(0.25-25)
3.31 (4.96) 
(0.25-30)
ns
p=0.692
Gender M: F 2.4 :7.6 
23.8% (15) 
76.2% (48)
2.4 :7.6
23.8%(15)
76.2%(48)
2.6: 7.4
25.8%(16)
74.2%(46)
2.1 : 7.9 
21.0%( 13) 
79.0%(49)
ns
p=0.938
Referral source
GDP
GP
Specialist
92.1% (58) 
3.2%  (2) 
4.8%  (3)
88.9% (56) 
4.8%  (3) 
6.3%  (4)
93%  (56) 
1.6% (1) 
8.1% (5)
96.8% (60) 
0%  (0) 
3.2%  (2)
ns
p=0.551
Employment status
Employed
Unemployed
Student
Retired (medical) 
House wife
66.7% (42) 
7.9%  (5) 
14.3% (9) 
1.6%  (1) 
9.5%  (6)
69.8%(44) 
6.3%  (4)
11.1%(7) 
0%  (0) 
12.7%(8)
64.5%(40) 
6.5%  (4) 
22.6%(14) 
0%  (0) 
6.5%  (4)
66.1%(41) 
9.7%  (6) 
14.5%(9) 
0%  (0) 
9.7%  (6)
ns
p=0.797
Socio-economic status
Professional  I 
Intermmediate  Ili 
Skilled non-manual  llii 
Skilled manual  III 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, medically 
retired
7.9%  (5) 
27.0% (17) 
23.8% (15) 
6.3%  (4) 
1.6%  (1) 
0%  (0) 
31.7% (20)
4.8%  (3) 
30.2%(19) 
31.7%(20) 
1.6%  (1) 
1.6%  (1) 
0%  (0) 
30.2%(19)
1.6%  (1) 
43.5%(27) 
16.1%(10) 
1.6%  (1) 
1.6%  (1) 
0%  (0) 
35.5%(22)
3.2%  (2) 
24.2%(15) 
33.9%(21) 
3.2%  (2) 
3.2%  (2) 
1.6%  (1) 
30.6%(19)
ns
p=0.398
Marital status
Single
Married
Seperated
Divorced
Widowed
61.9% (39) 
30.2% (19) 
1.6%  (1) 
6.3%  (4) 
0%  (0)
55.6%(35) 
41.3%(26) 
0%  (0) 
3.2%  (2) 
0%  (0)
62.9%(39) 
33.8%(21) 
0%  (0) 
3.2%  (2) 
0%  (0)
54.8%(34) 
37.1%(23) 
1.6%  (1) 
4.8%  (3) 
1.6%  (1)
ns
p=0.511
Group 1  (SSRI), Group 2 (Placebo ), Group 3 (Splint), Group 4 (SSRI and splint)
Significance test, Chi-squared (One way ANOVA for age and duration) all ns.
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6.2.2  CLINICAL HISTORY
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6.2.2  Clinical history
6.2.2.1 TMJ symptoms (Figure 23, Table 11)
TMJ pain was a universal symptom amongst the patient cohort, due to the studies 
specified inclusion criteria. Additionally, commonly reported symptoms included 
muscle pain 100/250 (40%), clicking 192/250 (76.8%) and limitation in mouth 
opening 187/250 (74.8%).
6.2.2.2 Character and location of TMJ pain (Figure 24, Table 11)
Patients generally described their pain as a dull ache 161/250 (64%) and or discomfort 
137/250 (54.8%). A description of sharp pain was also reported by 99/250 (39.6%). 
Location of pain was predominantly unilateral 180/250 (72%) compared to bilateral 
70/250 (28%).
6.2.2.3. Frequency (Table 12)
TMJ pain was recorded as always, often or occasionally present. The majority 
reported pain to be always present 151/250 (60.4%), often 83/250 (33.2%) and 
occasionally 16/250 (6.4%). In some cases, patients in the always and often categories 
gave further clarification to their response. Always dull but occasionally sharp 54/250 
(21.6%) or often dull but occasionally sharp 6/250 (2.4%).
6.2.2.4  Length and frequency of bouts (Table 12)
Bouts of pain length were recorded as constant, weeks, days , hours or minutes in 
duration. The majority of patients reported constant pain 185/250 (74.0%). Frequency 
of occurrence was described as constant 185/250 (74%), daily 43/250 (17.2%), 
weekly 19/250 (7.6%) or monthly 3/250 (1.2%).
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6.2.2.5 Pain free intervals  (Table 12)
Time intervals of pain remission ranged from none for constant pain 185/250 (74%) 
to days 51/250 (20.4%) or weeks 14/250 (5.6%) in duration.
6.2.2.6 Diurnal variation  (Tablel3)
The intensity of pain throughout the day was ascertained. The majority reported pain 
worst in the mornings 113/250 (45.2%). 70/250 (28%) described pain to be worse in 
the evening and 67/250 (26.8%) the same intensity throughout the day.
6.2.2.7 Altered sleep patterns  (Table 13)
Patients reported a range of sleep disorders related to pain, including prevention of 
sleep 113/250 (45.2%) and disturbance of sleep 117/250 (46.8%).
Sleep problems specifically related to current TMJ pain were variable. 98/250 
(39.2%) reported no problems, 34/250 (13.6%) were unable to get to sleep, 58/250 
(23.2%) experienced disturbed sleep whilst 8/250 (3.2%) suffered from early morning 
waking. A combination of sleep disorders occurred in some individuals with difficulty 
getting to sleep and disturbed sleep in 22/250 (8.8%), difficulty getting to sleep and 
early waking in 3/250 (1.2%), disturbed sleep and early waking in 13/250 (5.2%) and 
difficulty getting to sleep, disturbed sleep and early waking in 14/250 (5.6%)
6.2.2.8 Nocturnal bruxism and disturbed occlusal discomfort
Only 49/250 (19.6%) believed they had a nocturnal bruxism habit but 133/250 
(53 .2%) reported a sensation of disturbed occlusal comfort.
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6.2.2.9 Precipitating factors for TMJ pain  (Figure 25, Table 14)
The precipitants were recalled by study participants to be; none 67/250 (26.8%),dental 
in origin 66/250 (26.4%), following an infection 60/250 (24.0%) due to physical 
trauma 39/250 (15.6%) or emotional trauma 7/250 (2.8%).
6.2.2.10 Provocation of TMJ  pain  (Figure 26, Table 14)
These were principally related to jaw movement; chewing 192/250 (76.8%), yawning 
191/250 (76.4%) and biting 164/250 (65.6%). An association with emotional distress 
was however indicated in 134/250 (53.6%) and cold weather 72/250 (28.8%).
6.2.2.11 Relief of TMJ pain  (Figure 27, Table 15)
The use of analgesics, in an attempt to alleviate pain was described by 132/250 
(52.8%). Other commonly reported techniques were resting the jaw 110/250 (44%), 
the application of pressure 96/250 (38.4%) or application of warmth 60/250,(24%).
6.2.2.12 Other chronic pain conditions  (Figure 28, Table 16)
The majority of participants gave an account of other recurrent chronic pain 
conditions. These were most notably headaches 153/250 (61.2%), neckache 125/250 
(50%) and backache 121/250 (48.4%). Nearly a third of patients also reported 
migraine 82/250 (32.8%) and abdominal pain 75/250 (29.6%).
All reported symptoms were not statistically significant between groups.
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Figure 23: TMJ symptoms
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Table 15: Relieving factors for TMJ pain.  A comparison of percentages between groups.
Recorded at baseline 
assessment All groups Group 1 Group 2 Group 3 Group 4
Significance 
between gps.
Relieving factors
Analgesics 52.8% (132) 50.8% (32) 57.1% (36) 48.4% (30) 54.8% (34) ns p=0.761
Rest 44.0% (110) 39.7% (25) 49.2% (31) 45.2% (28) 41.9% (26) ns p=0.727
Pressure 38.4% (  96) 38.1% (24) 39.7% (25) 40.3% (25) 35.5% (22) ns p=0.947
Heat 24.0% (  60) 12.7% (  8) 27.0% (17) 30.6% (19) 25.8% (16) ns p=0.097
Alcohol 6.4% (  16) 7.9% (  5) 3.2% (  2) 4.8% (  3) 9.7% (  6) ns p=0.439
Chewing 3.2% (  8) 3.2% (  2) 3.2% (  2) 3.2% (  2) 3.2% (  2) ns p=0.100
Other 10.0%(  25) 9.5% (  6) 11.1%(  7) 9.7% (  6) 9.7% (  6) ns p=0.990
Table 16: Recurrent chronic pains  A comparison of percentages between groups
Recorded at baseline 
assessment All groups Group 1 Group 2 Group 3 Group 4
Significance 
between gps.
Recurrent chronic pains
Headache 61.2% (153) 58.7% ( 37) 63.5% (40) 59.7% (37) 62.9% (39) ns p=0.932
Migraine 32.8% (  82) 34.9% (22) 39.7% (25) 29.0% (18) 27.4% (17) ns p=0.441
Neck ache 50.0% (125) 36.5% (23) 52.4% (33) 54.8% (34) 56.5% (35) ns p=0.096
Back pain 48.4% (121) 52.4% (33) 50.8% (32) 38.7% (24) 51.6% (32) ns p=0.372
Abdominal pain 29.6% (  74) 30.2% (19) 30.2% (19) 30.6% (19) 27.4% (17) ns p=0.979
Pruritus 22.0% (  55) 23.8% (15) 19.0% ( 12) 19.4% (12) 25.8% (16) ns p=0.749
Chest pain 15.6% (  39) 17.5% ( 11) 12.7% (  8) 14.5% (  9) 17.7% (11) ns p=0.840
Group 1  -  Fluoxetine medication  Group 3 - Splint therapy  Chi squared non significant between groups
Group 2 - Placebo medication  Group 4 -  Fluoxetine and splint therapy
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Table 14: Precipitating  and  provoking factors for TMJ pain.  A comparison of percentages between groups.
Base line record All groups Group 1 Group 2 Group 3 Group 4
Significance 
between groups
Precipitating factors
Dental 26.4% (66) 23.8% (15) 30.2% (19) 21%  (13) 21%  (13) ns p=0.533
Physical trauma 15.6% (39) 25.4% (16) 12.7% (  8) 11.3%(  7) 11.3%(  7) ns p=0.102
Emotional trauma 2.8% (  7) 4.8% (  3) 3.2% (  2) 1.6%  (  1) 1.6%  (  1) ns p=0.186
Infection 24.0% (60) 15.9% (10) 22.2% (14) 32.3%( 20) 32.3%(20) ns p=0.667
None 26.8% (67) 33.3% (21) 31.7% (20) 27.4%( 17) 27.4%(17) ns p=0.074
Provoking factors
Chewing 76.8% (192) 77.8% (49) 73.0% (46) 80.6% (50) 75.8% (47) ns p=0.780
Yawning 76.4% (191) 71.4% (45) 79.4% (50) 75.8% (47) 79.0% (49) ns p=0.701
Biting 65.6% (164) 58.7% (37) 69.8% (44) 66.1% (41) 67.7% (42) ns p=0.582
Emotional tension 53.6% (134) 50.8% (32) 50.8% (32) 58.1% (36) 54.8% (34) ns p=0.817
Talking 31.6% (  79) 33.3% (21) 34.9% (22) 24.2% (15) 33.9% (21) ns p=0.546
Cold weather 28.8% (  72) 23.8% (15) 38.1% (24) 29.0% (18) 24.2% (12) ns p=0.255
Hot weather 2.4% (  6) 3.2% (  2) 1.6% (  1) 4.8% (  3) 0%(  0) ns p=0.329
Hot food/drink 1.6% (  4) 0% (  0) 1.6% (  1) 1.6% (  1) 3.2% (  2) ns p=0.559
Cold food/drink 2.4% (  6) 1.6%(  1) 1.6% (  1) 3.2% (  2) 3.2% (  2) ns p=0.869
Alcohol 3.2% (  8) 6.3%(  4) 1.6% (  1) 1.6% (  1) 3.2% (  2) ns p=0.384
Chocolate 2.0% (  5) 0%(  0)
o
o
N
O
1.6% (  1) 6.5% (  4) ns p=0.031
Cheese 1.6% (  4) o%(  0) 1.6% (  1) 1.6% (  1) 3.2% (  2) ns p=0.559
Other 4.4% (  11) 3.2%(  2) 1.6% (  1) 4.8% (  3) 8.1% (  5) ns p=0.332
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Chi squared non significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
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Table 13: Diurnal variation, sleep and bruxism habits,  A comparison of intergroup percentages. (N=250)
All groups Group 1 Group 2 Group 3 Group 4
Significance 
between groups
Diurnal variation in TMJ pain
Worse in the morning 113(45.2%) 26 (41.3%) 25 (39.7%) 32 (51.6%) 30 (48.4%) ns p=0.484
Worse in the evening 70 (28.0%) 17 (27%) 20 (31.7%) 16(25.8%) 17 (27.4%) ns p=0.890
No variation
Altered sleep patterns
Prevention of sleep 113 (45.2%) 29 (46%) 28 (44.4%) 27 (43.5%) 29 (46.8%) ns p=0.983
Disturbance of sleep 117(46.8%) 29 (46%) 28 (44.4%) 31 (50%) 29 (46.8%) ns p=0.938
No problems 98 (39.4%) 25 (39.7%) 22 (34.9%) 27 (43.5%) 24 (38.7%)
Cannot get to sleep 33 (13.2%) 10(15.9%) 9(14.3%) 4(6.5%)  1 11 (17.7%)
Disturbed sleep 58 (23.2%) 13 (20.6%) 16( 25.4%) 16 (25.8%) 13(21.0%)
Early morning waking 8 (3.2%) 2 (3.2%) 3 (4.8%) 1  (1.6%) 2 (3.2%)
Cannot get to sleep and disturbed 
sleep
22 (8.8%) 5 (7.9%) 5 (7.9%) 7(11.3%) 5(8.1%)
>  ns p=0.919 f  ..................
Cannot get to sleep and early 
waking
3 (1.2%) 2 (3.2%) 1  (1.6%) 0 (0%) 0 (0%)
Disturbed sleep and early waking 13 (5.2%) 3 (4.8%) 3 (4.8%) 5(8.1%) 2 (3.2%)
Cannot get to sleep, disturbed 
sleep and early morning waking
14 (5.6%) 3 (4.8%) 4 (6.3%) 2 (3.2%) 5(8.1%)
J
Bruxism and occlusal comfort
Nocturnal bruxism habit 49 (19.6%) 15 (23.8%) 11 (17.5%) 8  (12.9%) 15 (24.2%) ns p=0.323
Sensation of disturbed occlusal 
comfort
133 (53.2%) 31 (49.2%) 25 (39.7%) 40 (64.5%) 37 (59.7%) ns p=0.026
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Chi squared non significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
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Figure 25: TMJ pain - Precipitating factors
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Figure 27: TMJ pain - Relieving factors
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Figure 28: Other recurrent chronic pain conditions
Headache
Neck pain
Back pain
Abdominal pain
Pruritus
Chest pain
20 40 0 60 80 100 120 140 160
Number of patients (n=250)
2212
2
2
Table 12: Frequency and bouts of TMD pain  An intergroup comparison of percentages. (N=250)
Baseline record All groups Group 1 Group 2 Group 3 Group 4
Significance 
between groups
Frequency of TMJ pain
Always 151 (60.4%) 41 (65.0%) 40 (63.4%) 38(51.6%) 38 (61.4%)
Often 83 (33.2%) 22 (35.0%) 20 (31.8%) 24 (38.7%) 17 (27.4%)
Occasionally 16 (6.4%) 0(  0%) 3  (4.8%) 6 (9.7%) 7(11.3%) I  nsp=0.185
Always dull, occasionally sharp 54 (21.6%) 13 (20.6%) 19(30.1%) 14 (22.6%) 8(13%)
Often dull, occasionally sharp 6 ( 2.4%) 3 (  4.8%) 1  (1.6%) 1  ( 1.6%) 1  (1.6%)
Length of bouts
Constant 185 (74.0%) 43 (68.3%) 43 (68.3%) 48 (77.4%) 51 (82.3%)
Weeks 5 (2.0%) 1(1.6%) 3  (4.8%) 1  (1.6%) 0 ( 0%)
Days 31 (12.4%) 13 (20.6%) 7(11.1%) 7(11.3%) 4 (6.5%) >  ns p=0.092
Hours 22 (8.8%) 6 (9.5 %) 5 (7.9%) 5(8.1%) 6 (9.7%)
Minutes 7 (2.8%) 0 ( 0%) 5 (7.9%) 1  (1.6%) 1  (1.6%) J
Frequency of bouts
Constant 185 (74.0%) 43 (68.3%) 43 (68.3%) 48 (77.4%) 51 (82.3%)
Daily 43 (17.2%) 14 (22.2%) 11 (17.5%) 10(16.1%) 8 (12.9%) ns p=0.431
Weekly 19 (7.6%) 6 (9.5%) 7(11.1%) 3 (  4.8%) 3 (4.8%)
Monthly 3 (1.2%) 0 (0%) 0 (0%) 1(  1.6%) 0(0%) J
Pain free intervals
None 185 (74.0%) 43 (68.3%) 43 (68.3%) 48 (77.4%) 51 (82.3%)
Weeks 14 (5.6%) 14 (22.2%) 17(27.0%) 12 (19.4%) 8 (12.9%) f  ns p=0.329
Days 51 (20.4%) 6 (  9.5%) 3 (  4.8%) 2 (  3.2%) 3 (  4.8%) J
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Chi squared non significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
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Table 11: TMD symptoms  A comparison of percentages between groups.(N=250)
Baseline record prior to 
treatment
All groups (n-250) Group 1 (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62)
Significance 
between groups
TMJ symptoms
TMJ pain 250 (100%) 63 (100%) 63 (100%) 62 (100%) 62 (100%) ns p=1.0
Muscle pain - Temporalis 65 (26%) 12 (19%) 17 (27%) 23 (37.1%) 13 (21%) ns p=0.094
Muscle pain - Masseter 80 (32%) 14 (22.2%) 25 (39.7%) 20 (32.3%) 21 (33.9%) ns p=0.205
Clicking 192 (76.8%) 50 (79.4%) 45 (71.4%) 52 (83.9%) 45 (72.6%) ns p=0.307
Sticking 76 (30.4%) 21 (33.3%) 12(19.0%) 24 (38.7%) 19 (30.6%) ns p=0.106
Locking 19 (7.6%) 4 (6.3%) 5 (7.9%) 6 (9.7%) 4 (6.5%) ns p=0.815
Limitation in mouth opening 187 (74.8%) 51 (81%) 40 (63.5%) 48 (77.4%) 48 (77.4%) ns p=0.112
Ear popping 51 (20.4%) 10(15.9%) 14 (22.2%) 10 (16.2%) 17 (27.4%) ns p=0.451
Ear buzzing 37(14.8%) 6 (9.5%) 12 (19%) 11 (17.8%) 8 (12.9%) ns p=0.673
Ear deafness 37(14.8%) 7(11.1%) 9(14.3%) 7(11.3%) 14 (22.6%) ns p=0.563
Ear fullness 62 (24.8%) 16(25.4%) 20 (31.7%) 12 (19.4%) 14 (22.6%) ns p=0.408
Character and location of 
TMJ pain
Dull ache 161 (64.4%) 43 (68.3%) 33 (52.4%) 45 (72.6%) 40 (64.5%) ns p=0.103
Discomfort 137(54.8%) 35 (55.6%) 37 (58.7%) 33 (53.2%) 32 (51.6%) ns p=0.868
Sharp 99  (39.6%) 27 (42.9%) 30 (47.6%) 17 (27.4%) 25 (40.3%) ns p=0.120
Stabbing 35  (14%) 9(14.3%) 7(11.1%) 14 (22.6%) 5 (  8.1%) ns p=0.109
Throbbing 20  ( 8%) 3 ( 4.8%) 6 (  9.5%) 4 ( 6.5%) 7(11.3%) ns p=0.530
Burning 6  (2.4%) 1  ( 1.6%) 1(  1.6%) 1  ( 1.6%) 3 (  4.8%) ns p=0.553
Unilateral 180 (72%) 45 (71.4%) 47 (74.6%) 43 (69.4%) 45 (72.6%) ns p=0.930
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Chi squared nonsignificant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
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6.2.3  CLINICAL EXAMINATION
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6.2.3 Clinical examination
6.2.3.1 Extra oral examination
6.2.3.1.1 TMJ signs  (Figure 29, Table 17)
On examination all patients had TMJ pain 250/250 (100%), predominantly unilateral 
in nature 168/250 (66%).In addition patients had associated muscle tenderness to 
palpation (57%),TMJ clicking (35%) and limitation in mouth opening exhibited in 
45/250 (18%).
6.2.3.1.2 Interincisal mouth opening  (Figure 30, Table 17)
Interincisal mouth opening was measured from the incisal margin of the maxillary
central incisor to the opposing incisal margin of the mandibular incisor. The mean 
measurement was 38.9mm (SD 9.35) (range 15-60mm). Limitation in mouth opening 
was taken to be less than 30mm.
6.2.3.2 Intra oral examination
6.2.3.2.1 Buccal and lingual soft tissues  (Table 18)
On intra oral examination of the soft tissues evidence of bruxism or clenching was 
noted. Ridging of the buccal mucosa was present in over half the patients 132/250 
(52.8%) and scalloped margin of the lateral border of the tongue in 31/219 (12.4%).
6.2.3.2.2 Occlusion and dentition  (Table 18)
Occlusally the majority of patients were class I malocclusion 98/250 (39.2%) or class 
II division I  malocclusion 95/250 (38%).  158/250 (63.2%) of patients had one wisdom 
tooth removed or missing and 79/250 (31.6%) had four removed or missing posterior 
molar teeth.
6.2.3.3  Intergroup ananlvsis  (Table 17 and 18)
No significant difference was observed between groups in intra and extra oral 
examinations.
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Clinical examination 
Extra oral examination 
Figure 29: TMJ signs
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Table 17: Extra oral examination -TMJ signs,-  intergroup analysis (N=250)
Baseline
recordings
All groups Group 1 Group 2 Group 3 Group 4 Sig.
TMJ pain
Right
Left
162(64.8%)
173(69.2%)
39(61.9%)
41(65.1%)
41(65.1%)
43(68.3%)
39(62.9%)
46(74.2%)
43(69.4%)
43(69.4%)
ns
ns
Unilateral
Bilateral
165(66.0%)
85(34.0%)
46(73.0%)
17(27.0%)
42(66.7%)
21(33.3%)
39(62.9%)
23(37.1%)
38(61.3%)
24(38.7%)
ns
ns
Opening
click
Right
Left
51 (20.4%) 
69 (27.6%)
13(20.6%)
16(25.4%)
13(20.6%)
18(28.6%)
10(16.1%)
14(22.6%)
15(24.2%)
21(33.9%)
ns
ns
Unilateral
Bilateral
73(29.2%)
23(9.2%)
18(28.6%)
5(7.9%)
21(33.3%)
5(7.9%)
16(25.8%)
4(6.5%)
18(29.0%)
9(14.5%)
ns
ns
Closing click
Right
Left
24(9.6%)
36(14.4%)
10(15.9%)
7(11.1%)
2(3.2%)
8(12.7%)
5(8.1%)
10(16.1%)
7(11.3%)
11(7.7%)
ns
Unilateral
Bilateral
34(13.6%)
13(5.2%)
11(17.5%)
3(4.8%)
8(12.7%)
1(1.6%)
9(14.5%)
3(4.8%)
6(9.7%)
6(9.7%)
ns
Deviation on
mouth
opening
Right
Left
10(4%)
10(4%)
0(0%)
2(3.2%)
4(6.3%)
2(3.2%)
2(3.2%)
2(3.2%)
4(6.5%)
4(6.5%)
ns
ns
Sticking
Right
Left
7(2.8%)
6(2.4%)
3(4.8%)
2(3.2%)
1(1.6%)
1(1.6%)
1(1.6%)
1(1.6%)
2(3.2%)
2(3.2%)
ns
ns
Limitation in
mouth
opening
45 (18%) 12(19.1%) 12(19.1%) 10(16.1%) 11(17.7%) ns
Interincisal
mouth
opening
(in mm)
38.29mm 
(20-60) 
(SD 9.58)
38.90mm 
(23-56) 
(SD 8.31)
40.85mm 
(21-60) 
(SD 9.12)
38.66mm 
(15-60) 
(SD 9.87)
ns
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Table 18: Intra oral examination -  inter group analysis (N=250)
Recorded at baseline 
assessment
n=63 
Group 1
(Fluoxetine)
(SSRI)
n=63 
Group 2
(Placebo)
n=62
Group 3
(Splint)
n=62 
Group 4
(Splint and 
Fluoxetine)
Sig
Occlusion
Angles classification
Class I
Class II division i 
Class II division ii 
Class III
20 (31.7%) 
27 (42.9%) 
14 (22.2%) 
2 (3.2%)
22(34.9%)
27(42.9%)
13(20.6%)
1(1.6%)
27(43.5%)
21(33.9%)
14(22.6%)
0(0%)
29(46.8%)
20(32.3%)
13(21.0%)
0(0%)
ns
Overjet  > 6mm
1  (1.6%) 4(6.4%) 1(1.6%) 3(4.8%) ns
Buccal mucosa
Ridging
Frictional keratosis
Abrasion
Ulcer
32 (50.8%) 
3 (4.8%)
2 (3.2%)
0 (0%)
30(47.6%)
3(4.8%)
3(4.8%)
1(1.6%)
41(66.1%)
5(8.1%)
1(1.6%)
0(0%)
29(46.8%)
4(6.5%)
1(1.6%)
0(0%)
ns
Lingual mucosa
Ridging
(scalopped margin)
8(12.7%) 6 (9.5%) 8(12.9%) 9 (14.5%) ns
Missing posterior teeth
None
One
Two
Three
Four
More than five
19 (30.2%) 
2 (3.2%) 
9(14.3%) 
6 (9.5%) 
21 (33.3%) 
6 (9.5%)
19(30.2%)
4(6.3%)
9(14.3%)
3(4.8%)
17(27.0%)
11(17.5%)
21(33.9%)
4(6.5%)
9(14.5%)
6(9.7%)
18(29%)
4(6.5%)
21(33.9%) 
3(4.8%) 
8(12.9%) 
3( 4.8%) 
23(37.1%) 
4(6.5%)
ns
Missing wisdom teeth
None
One
Two
Three
Four
20 (36.8%)
4 (6.3%) 
11 (17.5%)
5 (7.9%) 
23 (36.5%)
22(34.9%)
3(4.8%)
11(17.5%)
5(7.9%)
22(34.9%)
24(38.7%)
4(6.5%)
11(17.7%)
7(11.3%)
16(25.8%)
26(41.9%)
4(6.5%)
6(9.7%)
5(8.1%)
21(33.9%)
ns
Missing maxillary 
canine tooth 2 (3.2%) 1  (1.6%) 2 (3.2%) 2 (3 .2%) ns
Significance test, Chi-squared (One way ANOVA for age and duration) all ns.
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6.2.4  SELF- REPORT PAIN ASSESSMENT QUESTIONNAIRES
BASELINE SCORES
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6.2.4.0 Self-report questionnaires (Table 18a,b)
The MPI, MPQ, BDI and Kellner questionnaires were completed by the patients prior to 
clinical consultations.
6.2.4.1 Multidimensional pain inventory (MPI)  (Table 18a)
The MPI scores ranged from 0-6 and average scores were recorded as median (25th and 75th 
percentiles). Analysing the patient’s perspective of pain and impact on daily life mid-range 
scores were observed by the majority of individuals in M PI: severity mean 3 .00 (1.83,4.00) 
life control 3.25 (1.50,3.87) and affective distress 3.33 (2.33,4.00).
Again mid-range scores were observed for the supportive response 3.33 (2.30,4.66) and 
solicitous response 2.66 (1.50,3.87) of a significant person in the patient’s life.
Frequency of patient participation in common daily activities was slightly above mid-range, 
household chores 4.80 (3.60,5.60), activities away from home 3.50 (2.75,4.25), social 
activites 3.00 (2.30,4.00) and general activity level 3.38 (2.75,3.91).
6.2.4.2 McGill Pain Questionnaire (MPQ)  (Table 18b)
The scores on average were not consistent with severe pain. The median VAS (range 0-10) 
was 2.90 (1.20,5.45), PPI (range 0-5) 2.00 (1.00,2.00), MPQ total % (range 0-100) 31.00 
(20.00,47.00), MPQ sensory % (range 0-100) 33.00 (21.00,45.00) and MPQ affective % 
(range 0-100) 17.00 (3.00,42.00).
6.2.4.3 Beck Depression Index f BDI)  (Table 18b)
The median composite depression score for this cohort of patients was 7.00 (3.00,13.00) 
which would indicate the majority of patients were not suffering from depression, despite 
experiencing chronic pain.
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6.2.4.4 Kellner (Table 18b)
Illness attitude (range 0-30), hypocondriacal beliefs (range 0-15) and disease phobia (range 
0-15) were relatively low and within a normal range with median scores of 8.00 
(6.00,11.00), 3.00 (3.00,6.00) and 3.00 (3.00,5.00) respectively.
6.2.4.5 Intergroup analsis (Table 18a,b)
Results revealed no significant difference between groups suggesting a homogeneity in 
randomisation.
2312
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A comparison of median scores (25th and 75  percentiles) (range 0 •6)
MPI
Baseline recordings
(n=250) 
All groups
(n=63) 
Group 1
(n=63) 
Group 2
(n=62) 
Group 3
(n=62) 
Group 4
Significance 
between groups
Patients perspective of pain and 
impact on daily life
MPI - Severity 3.00(1.83,4.00) 3.33 (2.00,4.33) 3.00 (2.33,4.00) 2.66(1.33,3.40) 2.66 (1.65,4.00) ns  p=0.105
MPI - Interference 1.36 (0.55,2.82) 1.45 (0.55,3.00) 1.63 (0.80,2.90) 1.36 (0.45,2.27) 1.19(0.45,2.65) ns  p=0.427
MPI - Life control 3.25 (2.31,4.00) 3.25 (2.00,4.00) 3.25 (2.25,4.25) 3.25 (2.46,4.00) 3.38 (2.50,4.25) ns  p=0.780
MPI - Affective distress 3.33 (2.33,4.30) 3.33 (2.33,4.30) 3.60(2.65,4.40) 3.00 (2.00,4.00) 3.32 (2.32,4.30) ns  p=0.058
Response of significant other 
person to patient
MPI - Support response 3.33 (2.30,4.66) 3.60 (2.25,4.66) 3.66 (2.32,5.00) 3.00 (2.33,4.33) 3.00 (2.00,4.33) ns  p=0.681
MPI - Punishing response 1.00 (0,2.06) 0.75 (0.25,2.81) 1.25 (0.25,2.56) 0.75 (0,2.00) 0.75 (0,1.75) ns  p=0.201
MPI - Solicitous response 2.66 (1.50,3.87) 2.83 (1.45,3.63) 2.66(1.77,4.37) 2.66 (1.50,3.83) 2.50(1.30,3.83) ns  p=0.929
MPI - Distracting response 1.75 (0.75,2.75) 2.00 (0.75,2.75) 1.50 (0.75,3.00) 2.00 (0.75,2.75) 1.75 (0.50,3.00) ns  p=0.959
Frequency of participation in 
common activities
MPI - Household chores 4.80 (3.60,5.60) 4.80 (3.60,5.60) 4.80 (3.35,5.80) 4.60 (3.40,5.80) 4.80 (3.80,5.40) ns  p^0.961
MPI - Outdoor work 2.00(1.00,3.00) 1.90(1.28,3.00) 1.90(0.81,3.15) 2.00 (0.95,3.00) 2.00 (0.80,3.00) ns  p=0.749
MPI - Activities away from 
home
3.50 (2.75,4.25) 3.50 (2.75,4.25) 3.75 (2.75,4.50) 3.25 (2.25,4.25) 3.50 (2.50,4.50) ns  p=0.714
MPI - Social activities 3.00 (2.30,4.00) 2.75 (2.25,3.75) 3.25 (2.50,4.00) 3.00 (2.33,3.75) 3.38 (2.00,4.01) ns  p=0.655
MPI - General activity level 3.38 (2.75,3.91) 3.40 (2.80,3.88) 3.44 (2.68,3.84) 3.31 (2.50,3.79) 3.34 (2.80,4.05) ns  p=0.901
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Table 18b : McGill pain questionnaire (MPOl. Beck depression index (BDI)  and Kellner illness attitude scale.(Kellner)
A comparison of median  scores (25  and 75  percentiles)Baseline recordings, prior to treatment.
Self report Questionnaire
(n=250) 
All groups
(n=63) 
Group 1
(n=63) 
Group 2
(n=62) 
Group 3
(n=62) 
Group 4
Significance 
between groups
MPQ
Visual analogue scale (VAS) 
(range 0-10)
2.90(1.20,5.45) 2.90(1.20,6.03) 3.30(1.60,5.60) 2.70 (1.23,4.80) 2.75 (0.90,5.38) ns  p=0.881
Present pain intensity (PPI) 
(range 0-5)
2.00 (1.00,2.00) 2.00 (1.00,3.00) 2.00(1.00,2.00) 2.00 (1.00,2.00) 2.00(1.00,2.00) ns  p=0.617
MPQ -  total % 
(range 0-100)
31.00 (20.0,47.00) 35.50 (23.50,47.00) 31.00(19.5,40.0) 30.00 (18.00,39.50) 31.00(18.00,50.00) ns  p=0.384
MPQ- sensory % 
(range 0-100)
33.00(21.0,45.00) 39.00 (26.25,48.00) 31.00(21.00,45.00) 33.00(21.00,42.00) 33.00 (19.50,50.00) ns  p=0.339
MPQ -  affective % 
(range 0-100)
17.00 (3.00,42.00) 25.00 (0, 52.00) 17.00 (8.00,40.50) 17.00 (8.00,25.00) 17.00 (0,50.00) ns  p=0.663
BDI
Composite score 
(range 0-45)
7.00  (3.00,13.00) 7.00 (2.25,13.75) 7.00(3.00,11.00) 6.00(2.00,10.50) 8.00 (4.25,14.75) ns  p=0.344
Kellner
Illness attitude- total 
(range 0-30)
8.00  (6.00,11.00) 8.00(6.00,11.50) 7.00 (6.00,9.50) 7.50 (6.00,11.00) 8.00 (6.00,12.00) ns  p=0.206
Hypochondriacal beliefs 
(range 0-15)
3.00  (3.00,6.00) 4.00 (3.00,6.00) 3.00 (3.0,5.00) 3.00 (3.00,6.00) 3.00 (3.00,6.00) ns  p=0.477
Disease phobia 
(range 0-15)
3.00 (3.00,5.00) 3.00 (3.00,5.50) 3.00 (3.00,4.00) 3.00 (3.00,6.00) 4.00 (3.00,7.00) ns  p=0.112
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
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6.4  Demographics and epidemiological features of the study cohort 
Hypothesis (2)
The demographic and epidemiological features of the study cohort, are 
consistent with the patient population seen within a secondary and tertiary 
TMJ clinic.
It is acknowledged that a clinic environment does not represent the prevalence of 
TMD amongst the overall population,(Drangsholt and Le Resche,1999). However, 
this hypothesis was to investigate this specific TMD clinic sample to ensure the 
cohort studied were representative of a general TMD clinic population.
6.4.1  Age distribution
The mean age 32.3years (range 16-55years) concurs with the age distribution of 
patients previously reported in TMJ clinic populations.
Patients with TMD have frequently been reported to be within the ages of 19-44 
years (Helkimo,1974, Von Korff et al,1988): 25-54 years (Dworkin et al,1990, 
Goulet et al,1995, List et al,1999). Feinmann and Harris 1984a, indicated the 
condition to be most commonly experienced in the third decade of life and this was 
again reiterated in more recent studies (Harrison et al,1997, Madland,2000, Truelove 
et al, 2005).
Interestingly, TMD affects a younger age group than those experiencing other 
chronic idiopathic orofacial pains which normally effects those with a mean age of 
50 years, (Feinmann and Harris, 1984a)
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The age distribution for chronic TMD is also clearly lower than that found in other 
chronic muscular, skeletal or structural pain conditions of the body, which generally 
increase with age,(Anderson et al,1993, Ektor-Anderson et al,1993). It is descrbed as 
a  condition of young  and middle aged  adults rather than children or the elderly, 
notably females of reproductive age,(Le Resche, 1997). The reason for the unusual 
age distribution may become more apparent when the aetiology of the condition has 
become more clearly established.
6.4.2  Gender distribution
The ratio of 24% males to 76% females is again consistent with previous studies. 
This is clearly similar to the 75% of females reported by Bell, 1989.
Overall symptom levels in non patient adults were almost equally distributed 
amongst males and females in early studies but are now believed to be in the ratio of 
2:1 females:males,(Dworkin et al, 1990,Lipton et al,1993, Goulet et 
al,1995,Magnusson et al,2000) Meanwhile, presentation to a clinical environment is 
of the ratio of 3:1, 9:1 females to males (Levitt and McKinney, 1994);3:1,4:1, 
(Dworkin and Le Resch,1993). Females generally seeking treatment for TMD three 
times more frequently than males,(Kultti et al,1998).
It has been suggested the high proportion of females seeking treatment may be due 
to greater health awareness amongst females (Randolph et al, 1990); or that women 
seek health care for pain more frequently than men (Le Resche,2001). Recent 
findings suggest cumulative exposure to females reproductive hormones may also be 
associated with onset of TMD in females,(LeResche et al,2005).
The over representation of female attendance at pain clinics may have a biological 
basis related to oestrogen dependent mediated analgesia, (Mogil et al!993).
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Gender differences in pain response include increased genomic expression of c-fos 
in the hippocampal neurons in response to persistent nociceptive stimulation,
(Aloisi et al,1996). Guilbaud et al, 1996, reported pain threshold variations with time 
in females but not males with decreased responsiveness of females to nonsteroidal 
antiinflamatory drugs over time,(Walker and Carmody, 1996).Where the intensity of 
pain rather than severity of the pathological process relates to treatment need , 
different gender related pain signal processing may therefore result in altered 
perception and reaction to pain (Lavelle,2002, Bradburg,2003).
Interestingly, the small number of men attending clinics were recently found to have 
more difficulty than females in jaw opening and masticatory muscle problems, 
(Johansson, 2003).
6.4.3 Source of referrals
The majority were from GDP’s (84%) following the postal request of patients.
6.4.4 Socio-economic status
The socioeconomic distribution revealed increased involvement of semi- 
professional (Class II) and non-professional clerical (ClassIIIi)  and decreased 
involvement of semi-skilled (Class IV) and unskilled (Class V).This reflects the 
similar clinical findings of Harrison et al,1997 and Truelove et al, 2005. 
Epidemiological studies do not show evidence that TMD is less prevalent in the 
lower social classes (Crook et al,1984). The National Health Service (NHS) ensures 
inclusive access to health care for all social classes. Thomas et al,1997, however, 
suggests there appears to be an unwillingness to attend primary dental care partly 
due to lack of local NHS dentists. This may have consequently restricted the direct
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referral path from the GDP due to possible decreased attendance of lower social 
classes.  However, financial and time constraints may influence participation in 
clinical trials. The cost of travel into central London, time off work for hospital 
attendance or family care commitments may inadvertently exclude social classes IV 
and V. There was no reimbursement of travel expenses or financial incentive for 
taking part in the trial programme.
Length of hospital appointments, completion of questionnaires or poor 
understanding of written English may also have discouraged certain patients from 
trial participation.
Interestingly, Class VI, defined as economically inactive and comprised of the 
unemployed, students and housewives constitutes 32% of those participating in the 
study. This might suggest time is an important factor if one considers these 
individuals may have more time to attend appointments.
6.4.5 Employment status
66.8% of patients were employed, illustrating that a substantial proportion of 
individuals were prepared to take time of work to attend appointments.
6.4.6 Summary of demographics
The demographic features of the clinic population were comparable to previous 
TMD study cohorts. It is hoped results of the RCT will therefore be relevant and 
generalisable to most TMD clinic environments.
Since the randomisation procedure was blocked but unstratified, all demographic 
variables were compared between groups. This demonstrated an even and non­
significant distribution of characteristics between groups.
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6.5  Clinical features of the TMD study group 
Hypothesis (3)
The duration, character and location of TMD pain described are typical of a 
patient population seen within a secondary or tertiary TMJ clinic.
6.5.1 Clinical history -  TMJ symptoms:
These were recorded on a standardised clinical questionnaire (Appendix 8)
6.5.1.1 Pain duration
The mean duration of pain was 3 years (range 3 months -  32 years). Interestingly, 
this is consistent with studies in the TMD clinic environment, (Madland ,2000, 
Truelove et al,2005).However, considering the intention of the study was to focus on 
patients with no previous TMJ treatment, it might have been assumed the length of 
pain experienced may have been considerably less than three years, perhaps nearer 
to the three to six months range that first classifies pain as chronic.
The remitting nature of pain or gradual worsening of symptoms may account for the 
delay in seeking treatment, ( Dworkin and Le Reshe,1999 and Rammelsburg et 
al,2003).
This delay in treatment seeking may however have allowed the establishment of a 
central ‘wind-up’ process, neural plasticity and learned pain behaviour and coping 
mechanism which is already therefore difficult to deconstruct. It makes sense to 
theorise the sooner pain can be ‘tackled’ in its earlier stages the sooner the pain can 
be resolved without the temporal factor allowing for alterations to pain pathways 
and learned psychosocial behaviour.
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6.5.1.2  Character and site of pain
The character of the pain was predominantly described as a dull ache (64%) and or 
discomfort (54.8%), most frequently unilateral (72%).
Location and character of pain were crucial to the diagnostic inclusion for the study. 
TMJ arthralgia with or without myalgia, internal disc derangement or limitation in 
mouth opening were a prerequisite for study inclusion. The majority of referring 
practitioners were aware of inclusion criteria and a diagnosis of TMJ pain had 
already been assigned to the patient but diagnosis had to be reconfirmed or 
established. Care was therefore taken to avoid technical terms or leading questions 
which might effect the patients response to this fundamental inquiry.
The patient was simply requested to describe and show the clinician the exact site of 
pain, asked to point with their finger to indicate the area on their head. The site of 
pain was transcribed by the clinician to a drawing of the face and shown to the 
patient who confirmed the location. The clinician then paraphrased the findings for 
final confirmation. For example, “ a constant, dull ache just in front of the right ear, 
extending into the temple (or side of the head) and down into the jaw muscle”, once 
more pointing to the sites indicated.
A diagram as a useful tool to indicate site of pain has previously been advocated in 
chronic facial and TMD pain (Harris ,1984, Orhbach,1995, Madland,2001). The 
drawing assists in restricting pain description to the head and neck region 
particularly helpful for patients who begin by describing a vague ‘total body pain’.
It can also be useful in deciphering multiple facial pain diagnoses in patients who 
indicate various pains in several sites over the head and neck region.
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6.5.1.3 Frequency of bouts
The majority of patients reported constant pain but to confirm this finding; length, 
frequency of bouts and pain free intervals were also queried. In certain situations, 
patients described severe, sharp episodes of pain superimposed upon a continuous or 
frequent dull ache, a finding previously reported in TMD populations.
6.5.1.4 Diurnal variation
Daily patterns of pain correspond to previous TMD findings in which pain is 
reported to be worst in the morning, 45% (113/250) (Orhbach,1995). Whether this 
relates to a nocturnal bruxism habit remains a controversial issue. Only 20% 
(49/250) of patients believed they had a bruxism habit although 53% (133/250) 
reported a sensation of disturbed occlusal comfort.
6.5.1.5 Altered sleep patterns
Sleep disturbance and prevention were recorded in nearly half the study subjects. 
This may be a consequence of psychological issues, depression, anxiety or worry, 
other chronic pains or medical conditions, young families with babies particularly in 
the age group under investigation and environmental noise pollution in central 
London. Such factors cannot be controlled, but to clarify this issue the patient was 
asked to report sleep problems specifically related to TMJ pain. This still indicated 
prevention and disturbance of sleep with early morning waking, factors frequently 
also associated with depression.
A recent study suggests 65% of adults in the UK are chronically sleep deprived, 
working longer hours and sleeping fewer hours than a decade ago, 
(www.bbc\health,2004).
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The issue of restorative sleep will be re-examined  in more detail during the 
reporting of the three month study results.
6.5.1.6  Precipitating and provoking factors
The identification of initiating and perpetuating factors in aiding diagnosis and 
treatment for TMD, even in the absence of poorly defined biological mechanisms, 
was stressed by Drangsholt and Le Resche,1999. Longtitudinal population based 
studies are obviously more appropriate to gain such information but data from this 
study was nonetheless recorded.
The patient attributed the initiating factor for pain onset to be: unknown cause 
(27%), following dental treatment (restorative, surgical or orthodontic)(26%), 
infection(24%) physical trauma (16%) and emotional trauma (3%). The high 
incidence of reported onset following dental treatment may relate to extensive or 
prolonged mouth opening, but has not as yet been examined in prospective studies. 
Huang et al, 2002, however, does suggest removal of third molars to be a possible 
risk factor for TMD and hypothesise that extensive mouth opening, application of 
force to the mandible whilst removing teeth and general anaesthesia with consequent 
reduction in protective jaw mechanisms may result in trauma to the TMJ and 
musculature. Further prospective research is required to establish whether there is 
indeed a causal link.
The unusual association of onset to infection reported by patients, might either 
suggest they were trying to attribute a physical cause for the pain or that we are 
missing an as yet unidentified pathological, aetiological agent. However, it is 
important to note that the highest number of patients reported no obvious initiating 
factor.
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Movements of the jaw, notably chewing (77%), yawning (76%) and biting (66%) 
were clearly aggravating factors for TMD as expected,(Le Resche et al, 1999, 
Leeson et al,2000). Slightly less frequently reported factors included emotional 
tension (54%), talking (32%) and cold weather (29%).
Interestingly, although patients did not necessarily attribute the initiation of pain to 
emotional trauma, over half were aware of an association between stress and anxiety 
in the aggravation of pain. This may, to some extent result from being confronted by 
a series of pain related psychosocial questionnaires in the waiting area, prior to the 
clinical assessment, causing the patient to reflect on emotional issues.
Talking was affecting pain in a third of individuals, an obvious cause for concern 
amongst patients.
Cold weather was also an important factor to consider since this may have an 
indirect influence on recorded pain levels rising, during the winter months of the 
study. Seasonal variation could therefore be considered a possible confounding 
factor in the study.
6.5.1.7 Relieving factors
Analgesics had been taken for TMD pain by over half the study sample in the past, 
in an attempt to alleviate pain. Other standard techniques employed had included 
resting the jaw (44%), pressure (38%) and application of warmth to the jaw (24%).
6.5.1.8 Recurrent chronic pains
There was a high proportion of concomitant headache (61%),neck ache (50%) and 
backache (48%) reported by the study participants. There were lower reports of 
migraine (33%), abdominal pain (30%), pruritis (22%) and chest pain( 16%).Results
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are consistent with those studying other chronic facial pain and TMD samples where 
a significant percentage of patients report other chronic pains, (Feinmann et al,1984, 
Le Resche et al, 1987,Harrison et al,1997).
Concern arises as to whether co-morbid pain conditions impact on the patients 
reporting of pain, not only clinically but with regard to self report questionnaire 
responses relating to pain behaviour and psychosocial issues. Le Resche and von 
Korff, 2005, address the topic of co-morbidity, indicating the impracticality of 
excluding individuals with co-morbid pain conditions when a significant percentage 
of those with TMD are known to have other chronic pains notably headache and 
backache. The relationship between headache and TMD has led to speculation that 
the two conditions represent a spectrum of related conditions or share associated risk 
factors,(Benoliel and Sharav,1998).
There is clear evidence indicating patients with TMD and multiple co-morbid pain 
conditions are more psychologically distressed,(Le Resche et al 1987, Dworkin et 
al, 1990).In addition there appears to be a greater risk of developing long-term TMD 
pain related disability and persisitent pain in patients with multiple pain sites (John 
et al,2003, Rammelsburg et al,2003)
6.5.2  Clinical examination  TMJ signs:
6.5.2.1 Extra oral examination
6.5.2.1.1  TMJ and associated musculature
Muscle pain and clicking were present in approximately half of individuals with 
limitation in mouth opening noted in 18%.
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6.5.2.1.2  Interincisal mouth opening
The only true parametric measure, the mean score on maximal, non painful, 
unassisted interinciscal mouth opening was 38.9mm (+/-9.35) .Only a small 
percentage of individuals exhibited deviation of the mandible on jaw opening.
6.5.2.2 Intra oral examination
6.5.2.2.1 Soft tissues -  tongue, buccal and lingual mucosa.
On examination, ridging of the buccal mucosa was evident in over half the study 
cohort suggestive of a clenching or bruxism habit. Ridging or a scalloped margin of 
the tongue was less frequently recorded (12%).
6.5.2.2.2 Occlusion
The majority of cases were either Class I (39%) or Class Hi (38%). 32% had no 
missing posterior teeth but 32% had 4 missing posterior teeth and 10% greater than 
5 missing posterior teeth. Interestingly, a large proportion of candidates (63%) had 
one or more missing wisdom teeth.
6.6  Pain and psychosocial self report questionnaires
6.6.1  Pain severity scores
Intensity of pain was measured using several different parameters incorporating both 
current and usual pain. The MPQ, PPI and VAS record current pain whilst MPQ 
reflects upon the usual description of pain.
The MPQ, PPI median scores were  2.00 (1.0,2.0) ,where 0=none, 5=excrutiating, 
most commonly indicating current levels of discomforting pain. The MPQ, VAS 
median scores were 2.9 (1.2,5.45) measured on a 10cm line. Although comparable
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to previous TMD studies this appears relatively low. This is perhaps due to 
measurement of requested ‘current’ pain levels as opposed  to recording levels 
during an episode of severe pain or accessing generalised level of pain. Constant 
pain is hence recorded with more accuracy than intermittent pain or pain of diurnal 
variation since there is no accounting for any temporal variation.
The MPI severity score is a composite score, rating level of pain at the present 
moment and severity over the last week. Perhaps a more versatile scale it therefore 
incorporates both the ‘now’ and ‘recent’ dimensions of pain.
The MPI severity median scores were 3.00 (1.83,4.00) ,scale (0-6), similar to those 
found in other TMD patient cohorts (Turk et al,  1993, Harrison et al,  1997).
6.6.2  Patients’ perspective of nain- 
Interference. life control and affective distress
The level of pain interference was a median 1.36(0.55,2.82) relatively low despite 
reported severity. However, affective distress experienced by the patient was 
calculated to be a median 3.33 (2.33,4.30) with life control 3.25(2.3 l,4.00).Pain was 
clearly causing the patients distress with a sense of lack of control in relation to their 
life and pain as previously reported in other facial pain studies (Harrison et al,1996).
6.6.3 Social support of family, spouse or friends
Supportive and solicitous responses of someone close to the patient, termed  ‘a 
significant other’, had a median score of 3.33 (2.3,4.6) and 2.66(1.5,3.87) 
respectively. Distracting responses were lower at 1.75 (0.75,2.75) and fortunately 
punishing responses lowest at 1.0 (0,2.6). These scores indicate generally positive 
social support. Such findings are not necessarily mirrored in other groups of chronic
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pain patients where longstanding pain may adversely affect social support (Williams 
et al,  1996, Newton-John,2002).
6.6.4 Activity level
Frequency of participation in household chores, activities away from home, social 
activities and general activity levels were recorded with median scores of 4.8 
(3.6,5.6), 3.5 (2.75,4.25), 3.0(2.3,4.0), 3.38(2.75,3.9) respectively suggesting TMD 
patients are not particularly restricted or disabled by their pain. Only outdoor work 
median score 2.00(1.0,3.00) seemed slightly lower which might be related to those 
individuals who found cold weather an aggravating factor. Generally, good activity 
levels may be related to the site of TMD pain in comparison for example to back 
pain patients who report more difficulties in performing daily tasks,(Anderson,1999) 
Level of chronicity and depression may also influence activity levels and these 
patients were generally not clinically depressed.
6.6.5 Depression scores (BDI)
The median BDI depression scores were 7.00 (3.00,13.00) indicating the TMD 
patients studied were generally not depressed but within the normal population 
range. The percentage of patients with scores greater than 20, suggestive of clinical 
depression was only, 11%, (26/237). This is lower compared to other chronic pain 
patient cohorts (Magni et al,1990) In this study, most patients were referred by a 
primary care practitioner, which may indicate patients had been less exposed to 
previous treatment intervention whereas tertiary pain referrals might be regarded as 
atypical in their presentation of high levels of depression and psychosocial 
dysfunction reflecting different clinic populations,(vonKorff and Simon, 1996).
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6.6.6  Illness attitudes (Kellner)
Disease phobia had a median score of 3.0(3.0,6.0) and hypochondriacal beliefs 3.0 
(3.0,5.0) with a total score of 8.00 (6.00,11.00). Results suggest average scores, 
indicating the TMD patients studied generally had a normal range of illness attitude.
Having established the baseline recordings for the study cohort the next chapter 
deals with the treatment phase of the randomised controlled trial.
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VII  RESULTS 
TREATMENT OUTCOME
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7.0  THE RESEARCH STUDY. TREATMENT OUTCOME 
Hypotheses (la) and (lb)
(la) An SSRI (fluoxetine;Prozac) in daily oral doses of 20-40mg is more effective 
than placebo in the treatment of patients with chronic TMD.
(lb) A combination of an SSRI (fluoxetine;Prozac) and a bite guard are equally 
effective  to fluoxetine or bite guard alone in the treatment of chronic TMD.
7.0.1 Outcome measures
Efficacy of treatment, to prove or disprove the above hypotheses, were investigated 
using the primary and secondary outcome measures. These were recorded using the 
clinician recorded amelioration in clinical signs and symptoms, the self report 
numerical and verbal rating scales and the patient recorded pain and psychosocial 
questionnaires.
Recordings at baseline, with repeated measures during the treatment phase and or at 
the end of the trial period of three months were analysed. Both completers of treatment 
intention to treat analyses, for all those originally allocated to treatment and imputation 
analyses for missing data were performed and presented separately in graphical and 
tabular format. The results are presented in the following order:
7.0.2 Primary outcome measures summarised 
Primary outcome measure  (please see section 7.1)
Greater than 50% pain relief, was calculated as the primary outcome measure to 
determine treatment effect size and numbers needed to treat (NNT). These were 
calculated using the visual analogue scale VAS (10cm) of patient reported, current 
pain intensity.
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7.0.3 Summary of  secondary outcome measures 
Secondary outcome measures  (please see section 7.2)
7.0.3.1 Clinician recorded
Self report verbal rating scales  (Non parametric) (section 7.2.1)
Amelioration in scores at four, eight and twelve weeks from baseline.
•  Present pain intensity (Non / mild / moderate / severe)  (section 7.2.1.1)
•  Frequency scores (never / occasionally / often / always)  (section 7.2.1.2)
•  Severity scores  (worse / in pain / improved / pain free)  (section 7.2.1.3)
•  Interference with life  (Yes / No)  (section 7.2.1.4)
Clinical signs and symptoms  ( section 7.2.2)
Amelioration at four, eight and twelve weeks form baseline.
•  Interincisal mouth opening (in mm)  (Parametric)  (section 7.2.2.1)
•  TMD signs and symptoms  (Non parametric)  (section 7.2.2.2)
•  TMD character  (Non parametric)  (section 7.2.2.3)
•  Chronic recurrent pains  (Non parametric)  (section 7.2.2.4)
7.0.3.2  Patient recorded
Pain and nsvcholosocial self report questionnaires  (Non parametric) (see 7.2.3) 
Amelioration in scores at treatment end, three months from baseline.
•  MPI  (section 7.2.3.1)
•  MPQ  (section 7.2.3.2)
•  BDI  (section 7.2.3.3)
•  Kellner  (section 7.2.3.4)
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7.1  PRIMARY OUTCOME MEASURE
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7.1.0 Primary outcome measure
In this study, the definition for target improvement, as specified in the protocol, was 
>25% pain relief. In the medical literature pain relief is frequently quoted as >50%. 
Consequently the power calculation for this trial was undertaken with the higher 
50% percentage, so that both 50% and 25% pain relief could be investigated. The 
measure used to calculate the primary outcome measure was the VAS (visual 
analogue 10cm scale). Scores of >25% and >50% improvement at the end of the 
three months treatment were recorded for each therapeutic group in order to 
calculate the effect size with 95% confidence intervals and the Numbers needed to 
treat (NNT)
7.1.1 Measures used to calculate the effect size and NNT
The treatment effect size and 95% confidence intervals indicate whether the result is 
comparable with a clinically important effect, (Altman et al, 2001).
A favourable outcome in treatment response was recorded for all therapeutic groups. 
Improvement in >50% and >25% pain relief on the 10cm VAS was observed for 
each treatment group but there was no significant difference between groups, (tables 
19, figures 31). A combination of an SSRI (fluoxetine:Prozac) and a bite guard 
therefore appear equally effective to fluoxetine or bite guard alone in the treatment 
of chronic TMD.
However, a significant difference was observed between SSRI and placebo at >50% 
pain relief. An effect size of 2.07 (Cl 1.16-3 .70) for the ITT, (N=201) and 1.84 (Cl 
1.05-3.24)  for the completers analysis, (N=165).
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Tables 19a: Comparison of treatment groups at three months 
>25% improvement in pain (VAS), Intention to treat analysis (N=201)
Group Treatment >25% pain 
reduction VAS
<25% pain 
reduction VAS
Total
1 SSRI 31/49 (63%) 18/49 (37%) 49
2 Placebo 24/53 (45%) 29/53 (55%) 53
3 Splint 27/51 (53%) 24/51 (47%) 51
4 SSRI + Splint 30/48 (63%) 18/48 (37%) 48
Total 112 89 201
Table 19b: Treatment effect size and confidence intervals at three months 
>25% improvement in pain (VAS), Intention to treat analysis (N=201)
Treatment (n/N) Placebo (n/N) Effect size (95% Cl)
SSRI 31/49 24/53 1.40 (0.97-2.01)
Splint 27/51 24/53 1.17(0.80-1.73)
SSRI + Splint 30/48 24/53 1.38(0.96-2.00)
Figure 31a: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months.
SSRI v Placebo ----------0--------------------
Splint v Placebo —0----------------
SSRI + Splint v Placebo
i  i  i  i  7......1
---------0------------------
r-....T " " ....r"   r-----1 -----1 -----1 -----1 —
0  0.2  0.4  0.6  0.8  1.0  1.2  1.4  1.6  1.8  2.0
Favours treatment
Analysing the data for >25% improvement, there is an overall favourable
response to all therapies but confidence intervals, (table 21b) suggest the
improvement is not significant in comparison to placebo treatment.
254C h a p ter v ii  study cohort -  pr im a ry o u tco m e m ea sur e
19c: Comparison of treatment groups at three months,
>50% improvement in pain (VAS), Intention to treat analysis (N=201)
Group Treatment >50% pain 
reduction VAS
<50% pain 
reduction VAS
Total
1 SSRI 23/49  (47%) 26/49  (53%) 49
2 Placebo 12/53  (23%) 41/53 (77%) 53
3 Splint 15/51  (29%) 36/51  (71%) 51
4 SSRI Splint 17/48  (35%) 31/48  (65%) 48
Total 67 134 201
Tables 19d: Treatment effect size and confidence intervals at three months, 
>50% improvement in pain (VAS), Intention to treat analysis (N=201)
Treatment (n/N) Placebo (n/N) Effect size (95% Cl)
SSRI 23/49 12/53 *2.07(1.16-3.70)
Splint 15/51 12/53 1.29 (0.68-2.50)
SSRI + Splint 17/48 12/53 1.56 (0.84-2.93)
Figure 31b: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months.
SSRI v Placebo ------- o --------------------
Splint v Placebo  —— 0-----------
SSRI + Splint v Placebo
■   i  i  i  i  ■   .
-----o------------
0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0 
Favours treatment
Analysing the data for >50% improvement, not only is there an overall 
favourable response amongst all therapeutic groups but confidence intervals, 
(table 21d) suggest the improvement for the SSRI group 2.07 (1.16-3.70) is 
significant in comparison  to placebo. This suggests patients are twice as likely 
to develop > 50% reduction in pain with SSRI therapy compared to placebo.
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Table 19e: Comparison of treatment groups at three months 
>25% improvement in pain (VAS), Completers analysis (N=165)
Group Treatment >25% pain 
reduction VAS
<25% pain 
reduction VAS
Total
1 SSRI 26/38  (68%) 12/38  (32%) 38
2 Placebo 23/42  (55%) 19/42  (45%) 42
3 Bite guard 24/40  (60%) 16/40  (40%) 40
4 SSRI and bite guard 28/45  (62%) 17/45  (38%) 45
Total 101 64 165
Tables 19f: Treatment effect size and confidence intervals at three months, 
>25% improvement in pain (VAS), Completers analysis (N=165)
Treatment (n/N) Placebo (n/N) Odds Ratio (95% Cl)
SSRI 26/38 23/42 1.25 (0.88-1.77)
Splint 24/40 23/42 1.10(0.75-1.60)
SSRI + Splint 28/45 23/42 1.14(0.80-1.62)
Figure 31c: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Completers analysis (N=165), 3 months.
SSRI v Placebo  —------o------------
Splint v Placebo — 0 --------------
SSRI + Splint v Placebo
------1   i-----1 -----1 -----1 -----1 ----
—0------------
1   1 ---- 1   1   ...1 —  ' 1 ' 1 1   1
0  0.2  0.4  0.6  0.8  1.0  1.2  1.4  1.6  1.8  2.0
Favours treatment
Analysing the data for >25% improvement, again there is an overall favourable
response to all therapies but confidence intervals, (table 21e) again suggest the
improvement is not significant in comparison to placebo treatment.
256C h a p ter v ii  study cohort - pr im a r y o u tc o m e m ea sur e
Tables 19g: Comparison of treatment groups at three months, 
>50% improvement in pain (VAS), Completers analysis (N=165)
Group Treatment >50% pain 
reduction VAS
<50% pain 
reduction VAS
Total
1 SSRI 20/38  (53%) 18/38  (47%) 38
2 Placebo 12/42  (29%) 30/42  (71%) 42
3 Bite guard 14/40  (35%) 26/40  (65%) 40
4 SSRI and bite guard 17/45  (38%) 28/45  (62%) 45
Total 63 102 165
Tables 19h: Treatment effect size and confidence intervals at three months, 
>50% improvement in pain (VAS), Completers analysis (N=165)
Treatment (n/N) Placebo (n/N) Odds Ratio (95% Cl)
SSRI 20/38 12/42 *1.84(1.05-3.24)
Splint 14/40 12/42 1.23 (0.65-2.32)
SSRI + Splint 17/45 12/42 1.32 (0.72-2.43)
Figure 31 d: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Completers analysis (N=165), 3 months.
SSRI v Placebo ---------0----------------
Splint v Placebo ~ o-------------
SSRI + Splint v Placebo
— o ------------
i  i  i  i  i  i  1   1   1   1   1   1   1
0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Favours treatment
Once again, analysing the data for >50% improvement, not only is there is an overall 
favourable response amongst all therapeutic groups but confidence intervals, (table 2Id) 
suggest the improvement for the SSRI group 1.84 (1.05-3.24) is  significant in comparison 
to placebo. This suggests patients are almost twice as likely to benefit from > 50% 
reduction in pain with SSRI therapy compared to placebo.
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Table 19i: Comparison of treatment groups at three months 
>25% improvement in pain (VAS), Imputation analysis (N=250)
Group Treatment >25% pain 
reduction VAS
<25% pain 
reduction VAS
Total
1 SSRI 31/63  (49%) 32/63  (51%) 63
2 Placebo 25/63  (40%) 38/63  (60%) 63
3 Bite guard 27/62  (44%) 35/62  (56%) 62
4 SSRI and bite guard 30/62  (48%) 32/62  (52%) 62
Total 68 182 250
Tables 19j: Treatment effect size and confidence intervals at three months, 
>25% improvement in pain (VAS), Imputation analysis (N=250)
Treatment (n/N) Placebo (n/N) Odds Ratio (95% Cl)
SSRI 31/63 25/63 1.24 (0.84-1.84)
Splint 27/62 25/63 1.10(0.72-1.66)
SSRI + Splint 30/62 25/63 1.22 (0.82-1.82)
Figure 31e: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Imputation analysis (N=250), 3 months.
SSRI v Placebo  — ------o--------------
Splint v Placebo — 0-------------
SSRI + Splint v Placebo
-T -----,-----.-----,----- .-----.-----
---------0-----------
1   1   “I---- 1 ---- 1 ---- [-•  1 —
0  0.2  0.4  0.6  0.8  1.0  1.2  1.4  1.6  1.8  2.0
F avours treatment
Even utilising the more rigorous imputation analysis, the data for >25% 
improvement reveals an overall favourable response to all therapies but 
confidence intervals, (table 21e) again suggest the improvement is not significant 
in comparison to placebo treatment.
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Tables 19k: Comparison of treatment groups at three months, 
>50% improvement in pain (VAS), Imputation analysis (N=250)
Group Treatment >50% pain 
reduction VAS
<50% pain 
reduction VAS
Total
1 SSRI 31/63  (49%) 32/63  (51%) 63
2 Placebo 25/63  (40%) 38/63  (60%) 63
3 Bite guard 27/62  (44%) 35/62  (56%) 62
4 SSRI and bite guard 30/62  (48%) 32/62  (52%) 62
Total 68 182 250
Tables 191: Treatment effect size and confidence intervals at three months, 
>50% improvement in pain (VAS), Imputation analysis (N=250)
Treatment (n/N) Placebo (n/N) Odds Ratio (95% Cl)
SSRI 31/63 25/63 1.77 (0.99-3.17)
Splint 27/62 25/63 1.17(0.61-2.26)
SSRI + Splint 30/62 25/63 1.33 (0.71-2.50)
Figure 3If: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Imputation analysis (N-250), 3 months.
SSRI v Placebo    0 -
Splint v Placebo  — -o ------
SSRI + Splint v Placebo  _  .
0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0 
Favours treatment
Analysing the data for >50% improvement, using the imputation analysis suggests an
overall favourable response to therapies but confidence intervals, (table 21e) suggest the
improvement is not significant in comparison to placebo treatment.
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Tables 19m: A comparison of treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 31/49 Splint 27/51 1.53 (0.69-3.41)
SSRI 31/49 SSRI + Splint 30/48 1.03 (0.45-2.36)
SSRI + Splint 30/48 Splint 27/51 1.18(0.84-1.66)
Figure 31g: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months
SSRI v Splint ----o---------------------
SSRI v SSRI + Splint  ------ > --------------
SSRI + Splint v Splint  —— o-----
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Favours treatm ent
Table 19n: A comparison of treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months.
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 23/49 Splint 15/51 2.12(0.93-4.84)
SSRI 23/49 SSRI + Splint 17/48 1.61 (0.71-3.65)
SSRI + Splint 17/48 Splint 15/51 1.20 (0.68-2.13)
Figure 31 h: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Intention to treat analysis (N=201), 3 months.
SSRI v Splint 
SSRI v SSRI + Splint 
SSRI + Splint v Splint
■  i  )  i  .   ■   i  ■ ■  i  i  i  i  i   "   i
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0  4.5  5.0 
Favours treatment
There is no significant difference in treatment effect for >25% or >50% improvement
in pain, between groups.
------------- <F
  0-----
-0---------
260C h a p ter v ii  study cohort -  pr im a ry o u tc o m e m ea sur e
Tables 19o: A comparison of treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Completers analysis (N=165), 3 months
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 26/38 Splint 24/40 1.44 (0.57-3.67)
SSRI 26/38 SSRI + Splint 28/45 1.32 (0.53-3.27)
SSRI + Splint 28/45 Splint 24/40 1.04 (0.74-1.46)
Figure 31 i: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Completers analysis (N=165), 3 months.
SSRI v Splint — o--------------------------------------------------------------------
SSRI v SSRI + Splint — o---------------------------------------------------------
SSRI + Splint v Splint  -
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Favours treatment
Table 19p: A comparison of treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Completers (N=165), 3 months.
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 20/38 Splint 14/40 2.08 (0.83-5.13)
SSRI 20/48 SSRI+Splint 17/45 1.83 (0.76-4.40)
SSRI + Splint 17/45 Splint 14/40 1.08 (0.61-1.90)
Figure 31  j: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Completers analysis (N=165), 3 months.
SSRI v Splint
SSRI v SSRI + Splint
l > oK1 + splint v bplint
i   i   ■   11   i   i
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0  4.5  5.0
There is no significant difference in treatment effect for >25% or >50% improvement
in pain, between groups.
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Tables 19q: A comparison of treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Imputation analysis (N=250), 3 months.
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 31/63 Splint 27/62 1.26 (0.62-2.54)
SSRI 31/63 SSRI + Splint 30/62 1.03 (0.51-2.08)
SSRI + Splint 30/62 Splint 27/62 1.11 (0.76-1.63)
Figure 31k: Diagram illustrating treatment effect size and confidence intervals 
>25% improvement in pain (VAS), Completers analysis (N=250), 3 months.
SSRI v Splint 
SSRI v SSRI + Splint 
SSRI + Splint v Splint
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Table 19r: A comparison of treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Completers (N=250), 3 months.
Treatment (n/N) Treatment (n/N) Odds Ratio (95% Cl)
SSRI 23/63 Splint 15/62 1.80 (0.83-3.91)
SSRI 23/63 SSRI+Splint 17/62 1.52 (0.71-3.25)
SSRI + Splint 17/62 Splint 15/63 1.13 (0.62-2.06)
Figure 311: Diagram illustrating treatment effect size and confidence intervals 
>50% improvement in pain (VAS), Imputation analysis (N=250), 3 months.
SSRI v Splint ---------c--------------------------
SSRI v SSRI + Splint  — — $ ----------------------------------------------
SSRI + Splint v Splint  _
O   0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Favours treatment
Once again, there is no significant difference in treatment effect for >25% or >50%
improvement in pain, between groups.
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7.1.2  Numbers needed to treat analysis (NNT)
Placebo (control) Active treatment
Total number of patients N cont N act
Clinical endpoint, Imp cont Im p a c t
improvement achieved
NNT  = 1 1
(IIT ]Pact^ ^   a ct) ~  (IW iP cont/ N   cont)  A R R
Using the data from tables 19a,b,c,d,e,f the above calculation was used to determine 
the NNT for each form of therapy. The results presented on the following page,
(7.1.1.1),(table 20a,b) are for the ITT analysis,(N=201). These results suggest that 
for every 100 TMD patients, >50% pain relief could be achieved in (100/4.1) 24 
patients with fluoxetine, (100/14.8) 7 patients with a bite guard and (100/7.8) 13 
patients with fluoxetine and biteguard. For every 100 TMD patients >25% pain 
relief could be achieved in (100/5 .6) 18 patients with fluoxetine, (100/13.1) 8 
patients with a bite guard and (100/5.8) 17 patients with both fluoxetine and 
biteguard.
Data from the imputation analysis,(N=250), is illustrated in section (7.1.1.2,(table 
20c,d). These results suggest that for every 100 TMD patients, >50% pain relief 
could be achieved in (100/6.3) 16 patients with fluoxetine, (100/28.1)4 patients with 
a bite guard and (100/14.7) 7 patients with fluoxetine and biteguard. For every 100 
TMD patients >25% pain relief could be achieved in (100/10.5) 9 patients with 
fluoxetine, (100/25.9) 4 patients with a bite guard and (100/11.5) 9 patients with 
both fluoxetine and biteguard.
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A completers analysis,(N=l65), is also illustrated in section (7.1.1.3,(table 20e,f). 
These results suggest that for every 100 TMD patients, >50% pain relief could be 
achieved in (100/4.2) 24 patients with fluoxetine, (100/15.6) 6 patients with a bite 
guard and (100/10.9) 9 patients with fluoxetine and biteguard. For every 100 TMD 
patients >25% pain relief could be achieved in (100/7.3) 14 patients with fluoxetine, 
(100/19.09) 5 patients with a bite guard and (100/13.4) 7 patients with both 
fluoxetine and biteguard.
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7.1.1.1 NNT (Intention to treat analysis)
Table 20a: NNT: Analysing all those who commenced treatment (N=201)
Improvement VAS (10cm line) (pain relief >50%) three months study phase.
Fluoxetine
NNT  = 1
95%CI 
4.1  (2.5-17.2)
(23/49)-(12/53)
Bite guard
NNT  = 1 14.8  (4.3-00)
(15 / 51) - (12 / 53)
Fluoxetine and biteguard
NNT  = 1 7.8  (3.4-20.7)
(17 / 48) -  (12/53)
Table 20b: NNT: Analysing  all those who commenced treatment  (N=201) 
Improvement VAS (10cm line)(pain relief >25%) three month study phase
Fluoxetine
NNT  = 1 =  5.6  (2.8-76.8)
(31/49)-(24/53)
Bite guard
NNT  = 1 =  13.1  (3 .8-00)
(27/51)-(24/53)
Fluoxetine and biteguard
NNT  = 1 =  5.8  (2.9-46.1)
(30/48)-(24/53 )
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7.1.1.2 NNT (Completers analysis) All those who completed treatment
Table 20c: NNT: Analysing all those randomised to the study (N=165)
Improvement VAS (10cm line) (pain relief >50%) three months study phase.
Fluoxetine 95%CI
NNT  = 1 =  4.2  (2.34-38.70)
(20/38)-(12/42)
Bite guard
NNT  = 1 =  15.6  (3.90-oo)
(14/40)-(12/42)
Fluoxetine and biteguard
NNT  = 1 =  10.9  (3.61-00)
(17 / 45) —  (12/42)
Table 20d: NNT: Analysing all those completing treatment (N=165) 
Improvement VAS (10cm line) (pain relief >25%) three months study phase.
Fluoxetine
NNT  = 1
95%CI 
=  7.3  (3.03-13.30)
(26/38)-(23/42)
Bite guard
NNT  = 1 =  19.1  (3.94-00)
(24/40)-(23/42)
Fluoxetine and biteguard
NNT  = 1 =  13.4  (3.71-00)
(28 / 45 ) -  (23 / 42 )
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7.1.1.2 NNT (Imputation analysis) All those randomised to the study
Table 20e: NNT: Analysing all those randomised to the study (N=250)
Improvement VAS (10cm line) (pain relief >50%) three months study phase.
Fluoxetine 95%CI
NNT  = 1 =  6.3  (3.26-00)
(23/63)-(13/63)
Bite guard
NNT  = 1 =  28.1  (5.54-q o)
(15/62)-(13/63)
Fluoxetine and biteguard
NNT  = 1 =  14.7  (4.66-qo)
(17/ 62) - (13/63)
Table 20f: NNT: Analysing all those randomised to the study (N=250)
Improvement VAS (10cm line) (pain relief >25%) three months study phase.
Fluoxetine
NNT  = 1   =  10.5  (3.86-13.08)
(31/63)-(25/63)
Bite guard
NNT  = 1   =  25.9  (4.88-oo)
(27/62)-(25/63)
Fluoxetine and biteguard
NNT  = 1   =  11.5  (3.97-11.78)
(30/62)-(25/63 )
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7.1.3  Visual analogue scale (VAS) summary
VAS a numerical rating scale, used in the analyses of >50% and >25% 
improvement for the NNT, was measured at baseline, four, eight and twelve weeks. 
Detailed in tables 21a, b, c, d, there is clearly a significant reduction in level of pain 
for all treatment groups (p<0.001), as recorded on the 10cm VAS. This was 
observed both in the imputation analysis (N=250) (last score brought forward for 
any missing data values) and in the pragmatic analysis (N=165) (only analysing 
patients with complete data records). Graphically this is illustrated in figures 32 a,b 
as an overall reduction in pain scores. The same response was also observed in the 
intention to treat analysis (N=201), table 21e.
Both parametric and nonparametric analysis was undertaken for completeness and 
both confirmed identical findings.
In the parametric completers analysis using repeated measures ANOVA and the 
Greenhouse-Geisser correction, F(2.37, 383.08)=59.07,P<0.001 showing a 
significantly linear or straight line trend p<0.001 as illustrated in table 21c,fig 32b. 
Similarly in the pragmatic, imputation analysis F(2.17,540.40)=57.85,p<0.001 with 
a significantly linear trend,p<0.001, table 21d, fig 32b.
In the non parametric intra group analysis, Wilcoxon signed rank test showed a 
significant improvement during the course of the studying in the completers and 
imputation analysis, p<0.001, consistent amongst all groups.
In all inter group analyses there was no significant difference overall in outcome 
measures between the four groups.
In the completers analysis VAS improved by 2.5cm from a mean 5.77cm(SD2.29) at 
baseline to 3.25cm(SD 2.41) at 12 weeks a significant reduction in pain for all
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groups (n= 165).Amongst individual groups; group 1  (n=38) showed improvement of 
2.8cm from 5.89cm(SD2.30) to 2.75cm(SD2.48); group 2 (n=42) 2.5cm from 
5.97cm(SD2.33) to 3.42cm(SD2.32); group 3 (n=40),2.4cm from 5.56cm(SD2.18) 
to 3.19cm(SD2.22); group4 (n=45) 2.0cm from 5.68cm(SD2.39) to3.56cm(SD2.61).
Similary this improvement is observed in the imputation analysis. All groups 
combined (n=250) showing a reduction in pain of 1.7cm for 5.77cm(SD2.29) to 
4.06cm (SD2.59), whilst in separate groups;group l(n=63) 2.1cm from 
5.89cm(SD2.30) to 3.80cm(SD2.81); group 2(n=63) 1.7cm from 5.97cm(SD2.33) to 
4.31cm(SD2.46);group 3(n=62) 1.5cm from 5.56cm(SD2.18) to 4.02cm(SD2.39); 
group 4(n=62) 1  6cm from 5.68cm(SD2.39) to 4.1 lcm(SD2.62).
Median scores showed a similar trend, for the completers analysis combined groups 
(n=165) pain scores decreased by 2.7cm, from 5.55(4.68-7.60) to 2.90(0.90-4.90) 
whilst in separate groups;group 1  (n=38) by 3.5cm, from 6.30(500-7.50) to 2.80(0- 
4.90)group 2 (n=42) by 2.7cm, from 6.20(5.00-7.70) to 3.55(0.98-4.93) 
group 3 (n=40) by 2.1cm, from 5.0(3.70-7.60) to 2.90(0.90-4.90) 
group 4 (n=45) by 1.4cm, from 5.20(4.80-7.70) to 3.85(1.05-5.23)
For the imputation analysis median pain scores decreased in the combined groups
(n=250) by 1.1cm, from 5.55(4.68-7.60) to 4.45(2.70-5.83) whilst in the groups;
group 1  (n=63) by 2.7cm, from 6.30(4.90-7.50) to 3.60(0.80-6.30)
group 2 (n=63) by 1.4cm, from 6.20(5.00-7.70) to 4.80(2.80-5.90)
group 3 (n=62) by 1.3cm, from 5.00(3.70-7.60) to 3.75(2.80-5.23)
group 4 (n=62) by 0.5cm, from 5.20(4.75-7.70) to 4.70(2.38-5.45)
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Table 21a: VAS (visual analogue scale, 10cm line)  A comparison of mean scores (+/-SD, standard deviation)
Pragmatic, Completers analysis.(N= 165)
Week All groups Group 1 Group 2 Group 3 Group 4
Significance 
between groups 
(1-way ANOVA)
0
n=250 
5.77 (2.29)
n=63
5.89 (2.30)
n=63
5.97 (2.33)
n=62
5.56 (2.18)
n=62
5.68 (2.39) ns  p=0.74
4
n=191
4.30 (2.20) ***
n=47
4.06 (2.23) **
(p=0.001)
n=49
4.79 (2.34) **
(p=0.002)
n=47
4.22(1.87)***
n=48
4.10(2.30)*** ns  p =0.33
8
n=178
3.88(2.43) ***
n=43
3.99 (2.58)**
(p=0.001)
n=47
4.21 (2.52) ***
n=43
3.62 (2.09)***
n=45
3.68 (2.52) *** ns  p =0.63
12
n=165
3.25 (2.41)***
n=38
2.75 (2.48) ***
n=42
3.43 (2.32) ***
n=40
3.19(2.22)***
n=45
3.56 (2.61)*** ns  p =0.45
***■  * * *   ***■  * * *
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Group 3 - Splint therapy 
Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Repeated measures ANOVA  P<0.0001* 0 0   Paired sample t-test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  One-way ANOVA(not significant)
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eTable 21b: VAS (visual analogue scale, 10cm line). A comparison of mean scores (+/-SD)
Imputation analysis - Last score brought forward  (N=250)
Week All groups  (n=250) Group 1   (n=63) Group 2  (n=63) Group 3  (n=62) Group 4  (n=62)
Significance 
between groups 
(1-way 
ANOVA)
0 5.77 (2.29) 5.89 (2.30) 5.97 (2.33) 5.56 (2.18) 5.68 (2.39) ns  p =0.74
4 4.69(2.23) *** 4.71 (2.46) **
(p=0.001)
4.94(2.18)**
(p=0.002)
4.62 (2.04) *** 4.48 (2.25) *** ns  p =0.70
8 4.39 (2.44) *** 4.58 (2.67) **
(p=0.001)
4.53 (2.33) *** 4.26 (2.24)*** 4.20 (2.54) *** ns  p =0.77
12 4.06 (2.57)*** 3.80 (2.81)*** 4.31 (2.46)*** 4.02 (2.39) *** 4.11 (2.62)*** ns  p=0.74
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Group 3 - Splint therapy 
Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Repeated measures ANOVAP<0.001***  Paired sample t-test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  One-way ANOVA  (not significant)
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Figure 31 : A parametric comparison of completers analysis and imputation (last observation carried forward) analysis
Scores
VAS (visual analogue scale) A comparison of mean scores  VAS (visual analogue scale)  A comparison of mean scores 
Completers analysis  Imputation analysis
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A  Group 3 
“ ■—Group 4
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1
0
0 8 12 4
Weeks
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Group 2 
Group 3 
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Weeks
Group 1  - Fluoxetine medication Group 3 - Splint therapy
Group 2 - placebo medication  Group 4 - Fluoxetine and splint therapy
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Table 21c: VAS (visual analogue scale,10cm line). A comparison of mean scores (+/-SD)
Intention to treat analysis - (N=201)
Week All groups  (n=201) Group 1   (n=49) Group 2  (n=53) Group 3  (n=51) Group 4  (n=48)
Significance 
between groups 
(1-way 
ANOVA)
0 5.71 (2.41) 5.55 (2.40) 6.07 (2.47) 5.62 (2.26) 5.59 (2.56) ns  p =0.67
4 4.40 (2.24) *** 4.03 (2.27) **
(p=0.001)
4.95 (2.24) **
(p=0.003)
4.48 (2.08) *** 4.10(2.30)*** ns  p =0.14
8 4.01 (2.43) *** 3.87 (2.51)**
(p=0.001)
4.42 (2.45) *** 4.04 (2.28) *** 3.67 (2.49)*** ns  p =0.46
12 3.60 (2.51)*** 2.87 (2.36) *** 4.18(2.58)*** 3.75 (2.43) *** 3.56 (2.57)*** ns  p=0.07
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Group 3 -  Splint therapy 
Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Repeated measures ANOVA P<0.001***  Paired sample t-test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  One-way ANOVA  (not significant)
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7.2  SECONDARY OUTCOME MEASURES
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7.2.0 Secondary outcome measures
7.2.1 Self report verbal rating scales
Study participant response, to a series of verbal enquiries, were recorded by the clinician 
at four weekly intervals.
7.2.1.1 Present pain intensity (PPI)
PPI measured the presence of TMJ pain or discomfort: None / Mild / Moderate/ Severe. 
Detailed results are recorded in tables (22) and graphically illustrated in figure (33). 
Analysing all groups together, a significant reduction in PPI (p<0.001) was recorded at 
all time points; four, eight and twelve weeks; in both the pragmatic and imputation 
analyses.
TMJ discomfort and pain was reported by the patient to be non existent or mild in 
104/250 (65%) completers analysis and 154/250 (62%)  in the more conservative 
imputation analysis.
Intra group imputation analysis revealed a significant reduction in PPI at the end of 
treatment (p<0.001) in groups 1,3 and 4, (p<0.005) in group 2.
On treatment completion, nonexistent or mild TMJ discomfort was recorded as 42/63 
(67%) group 1  (SSRI), 33/63 (52%) group 2 (placebo), 44/62 (71%) group 3 (splint) and 
35/62 (57%) group 4 (splint and SSRI).However, intergroup analysis did not reveal a 
significant difference in superiority for any particular treatment group.
7.2.1.2 Frequency scores
Frequency was classified as : Never / Occasionally / Often / Always.
Detailed results are recorded in tables 23 and illustrated in figure 34.
All groups, both together and individually revealed significant improvement in scores at 
each time point; 4,8 and 12 weeks (p<0.001).
276Ch a pter vii STUDY COHORT - SECONDARY OUTCOME MEASURES
On treatment completion, participants reported never or occasional TMJ pain or 
discomfort in: 48% (72/151) in the pragmatic analysis and 35% (87/250) in the 
imputation analysis.
There was no significant difference in reported improvement between groups.
7.2.1.3 Pain response
This was recorded as Worse / In pain / Improved / Pain free
Detailed results are shown in tables 24 and illustrated graphically in figure 35.
Amongst all groups there is a significant improvement in pain response rating (p<0.001). 
Study participants reported pain improvement or complete resolution of pain in 65% 
(104/161). Intra group analysis revealed this to be highest in the splint only group 74% 
(28/38) and fluoxetine only groups 68% (25/37).
However, intergroup analysis did not substantiate any significant difference in 
improvement between scores.
7.2.1.4 Interference with life
The tables of dichotomous Yes / No results are shown in tables 25, figure 36.
There was a highly significant decrease in pain interference in everyday life in all 
individual groups during the course of treatment in both the pragmatic and imputation 
analyses. This was significant at all time points 4,8 and 12 weeks (p<0.001). On 
treatment completion no interference with life was recorded as 72% (114/159) pragmatic 
analysis but slightly lower 53% (130/250) in the imputation analysis although still a 
highly significant reduction (p<0.001). There was no intergroup variation in the 
successful outcome between groups.
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Table 22 a: Secondary outcome measures -  Present pain intensity PPI (Completers analysis) during the study
Week PPI All groups Group 1 Group 2 Group 3 Group 4 Significance 
between groups
0
None
Mild
Moderate
Severe
0 (0%)
106 (42.4%)
97 (38.8%)
47 (18.8%) n=250
0 (0%)
25 (39.7%)
22 (34.9%)
16 (25.4%)n=63
0 (0%)
26 (41.3%)
29 (46.0%) 
8(12.7%)  n=63
0 (0%)
30 (48.4%)
23 (37.1%) 
9(14.5%)  n=62
0 (0%)
25 (40.3%)
23 (37.1%) 
14(22.6%)  n=62
\
ns p=0.490
r
4
None
Mild
Moderate
Severe
16 (8.4%)  *** 
93 (48.7%)
62 (32.5%)
20 (10.5%) n=191
3 (6.7%)  * 
24 (51.1%) 
10(21.3%) 
9(19.1%)  n=47
4 (8.2%)
23 (46.9%)
18 (36.7%)
4 (8.2%)  n=49
6(12.8%)  ** 
23 (48.9%)
16 (34.0%)
2 (4.3%)  n=47
2 (4.2%)  * 
23 (47.9%)
18 (37.5%) 
5(10.4%)  n=48
^  nsp=0.558
<
8
None
Mild
Moderate
Severe
22 (12.4%)  *** 
89 (50.0%)
52 (29.2%) 
15(8.4%)  n=178
5(11.6%)  ** 
18(41.9%)
15 (34.9%) 
5(11.6%)  n=43
7 (14.9%)  ** 
23 (48.9%)
13 (27.7%) 
4(8.5%)  n=47
5(11.6%)  * 
21 (48.8%)
16 (37.2%)
1  (2.3%)  n=43
5(11.1%)  ** 
27 (60.0%) 
8(17.8%) 
5(11.1%)  n=45
y  ns p=0.687
12
None
Mild
Moderate
Severe
30(18.2%)  *** 
77 (46.7%)
45 (27.3%) 
13(7.9%)  n=165
5 (13.2%)  ** 
19(50.0%)
11 (28.9%) 
3(7.9%)  n=38
9(21.4%)  *** 
18 (42.9%) 
13(31.0%)
2 (4.8%)  n=42
9(22.5%)  ** 
21 (52.5%) 
7(17.5%)
3 (7.5%)  n=40
7(15.6%)  * 
19 (42.2%) 
14(31.1%) 
5(11.1%)  n=45
> . ns p=0.305
/
***■  ***■  **•  ***•
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Inter group anaysis :  Kruskall -Wallis  (not significant)
Intra group analysis :  Friedman significance  PO.OOOl***  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
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Table 22 b:  Secondary outcome measures -  Present pain intensity PPI scores (Imputation analysis) during the study.
Week PPI All groups Group 1 Group 2 Group 3 Group 4 Significance 
between groups
0
None
Mild
Moderate
Severe
0 (0%)
106 (42.4%) 
97 (38.8%) 
47(18.8%)
0 (0%)
25 (39.7%) 
23 (36.5%) 
15 (23.8%)
0 (0%)
25 (39.7%) 
29 (46.0%) 
9 (14.3%)
0 (0%)
30 (48.4%) 
22 (35.5%) 
10(16.1%)
0 (0%)
26 (41.9%) 
23 (37.1%) 
13 (21%)
> .  ns p=0.490
4
None
Mild
Moderate
Severe
16 (6.4%)
122 (48.8%)
80 (32%)  *** 
32 (12.8%)
3 (4.8%)
32 (50.8%)
14 (22.2%)  * 
14 (22.2%)
5 (7.9%)
26 (41.3%)
27 (42.9%)  * 
5 (7.9%)
7(11.3%)
33 (53.2%) 
15(24.2%)  ** 
7(11.3%)
1  (1.6%)
31 (50%)
24 (38.7%)  * 
6 (9.7%)
\
ns p=0.431
►
8
None
Mild
Moderate
Severe
22 (8.8%)
127 (50.8%) 
74(29.6%)  *** 
27 (10.8%)
4 (6.3%)
31 (49.2%)
18 (28.6%)  ** 
10(15.9%)
8 (12.7%)
27 (42.9%)
23 (36.5%)  ** 
5 (7.9%)
6 (9.7%)
33 (53.2%)
17 (27.4%)  * 
6 (9.7%)
4 (6.5%) 
36(58.1%)
16 (25.8%)  ** 
6 (9.7%)
..............
ns p=0.793
12
None
Mild
Moderate
Severe
30 (12%)
124 (49.6%)
70 (28%)  *** 
26(10.4%)
5 (7.9%)
37 (58.7%)
13 (20.6%)  *** 
8 (12.7%)
9 (14.3%)
24 (38.1%) 
26(41.3%)  ** 
4 (6.3%)
9 (14.5%)
35 (56.5%) 
10(16.1%)  *** 
8 (12.9%)
7(11.3%)
28 (45.2%)
21 (33.9%)  ** 
6 (9.7%)
< v   ..........  .
ns p=0.384
r
>
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication
Group 3 -  Splint therapy
Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  P<0.0001 *  *  *■   Wilcoxon signed rank test
Inter group anaysis :  Kruskall -Wallis  (not significant)
p<0.05 *  p<0.005 **  p<0.001
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STable 23 a: Secondary outcome measures -  Frequency scores  (Completers analysis)
Week Frequency All groups Group 1 Group 2 Group 3 Group 4 Significance 
between groups
0
Never
Occasionally
Often
Always
0 (0%)
16 (6.4%)
83 (33.2%)
151 (60.4%)  n=250
0 (0%)
0 (0%)
22 (34.9%) 
41(65.1%)  n=63
0 (0%)
3 (4.8%)
20 (31.7%) 
40(63.5%)  n=63
0 (0%)
6 (9.7%)
24 (38.7%) 
32(51.6%)  n=62
0 (0%)
7(11.3%) 
17(27.4%) 
38(61.3%)  n=62.
>   ns p=0.281
4
Never
Occasionally
Often
Always
6(3.6%)  *** 
62 (37.1%)
64 (33.5%) 
59(30.9%)  n=i9l
1(2.1%)  ***
17 (36.2%)
11 (23.4%)
18 (38.3%)  n=47
3(6.1%)  ** 
11 (22.4%)
19 (38.8%)
16 (32.7%)  n=49
2(4.3 %)  ** 
14 (29.8%)
19 (40.4%) 
12(25.5%)  n=47
0(0%)  ***' 
20 (41.7%) 
15(31.3%) 
13(27.1%)  n=48
ns p=0.774
> -
8
Never
Occasionally
Often
Always
16 (9.0%)  *** 
59 (33.1%)
55 (30.9%) 
48(27.0%)  n=178
3 (7.0%)  *** 
18(41.9%) 
5(11.6%) 
17(39.5%)  n=43
4 (8.5%)  *** 
12 (25.5%)
17 (36.2%)
14 (29.8%)  n=47
4(9.3%)  *** 
16 (37.2%) 
17(39.5%) 
6(14.0%)  n=43
5(11.1%)  ***‘ 
13 (28.9%) 
16(35.6%) 
11(24.4%)  n=45
ns p=0.473
r
12
Never
Occasionally
Often
Always
27 (16.4%)  *** 
53 (32.1%)
45 (27.3%) 
40(24.2%)  n=165
5(13.2%)  *** 
14 (36.8%)
9 (23.7%) 
10(26.3%)  n=38
8 (19.0%)  *** 
12 (28.6%)
15 (35.7%) 
7(16.7%)  n=42
6(15.0%)  *** 
17 (42.5%)
9 (22.5%) 
8(20.0%)  n=40
8(17.8%)  ***' 
10 (22.2%)
12 (26.7%) 
15(33.3%)  n=45
ns p=0.547
r
/
* * *   * * *   ***•  **-*•
Group 1  -  Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  PO.OOOl***  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant)
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Table 23 b:  Secondary outcome measures -  Frequency scores (Intention needed to treat analysis)
Week Frequency All groups
n==250
Group 1
n=63
Group 2
n=63
Group 3
n=62
Group 4
n=62
Significance 
between groups
0
Never
Occasionally
Often
Always
0 (0%)
16 (6.4%)
83 (33.2%) 
151 (60.4%)
0 (0%)
0 (0%)
23 (36.5%) 
40 (63.5%)
0 (0%)
3 (4.8%) 
21 (33.3%) 
39 (61.9%)
0 (0%) 
7(11.3%) 
22 (35.5%) 
33 (53.2%)
0 (0%) 
6(9.7%)
17 (27.4 %) 
39 (62.9%)
\
ns p=0.281
r
A
4
Never
Occasionally
Often
Always
6 (2.4%) 
66 (26.4%) 
84 (33.6%) 
94 (37.6%)
*** 1  (1.6%) 
19 (30.2%) 
15 (23.8%) 
28 (44.4%)
*** 3 (4.8 %) 
12 (19.0%) 
24 (38.1%) 
24 (38.1%)
** 2(3.2%) 
14 (22.6%) 
25 (40.3%) 
21 (33.9%)
** 0 (0%)
21 (33.9%)
20 (32.3%)
21 (33.9%)
***
>  ns p=0.565
8
Never
Occasionally
Often
Always
16 (6.4%) 
65 (26.0%) 
85 (34.0%) 
84 (33.6%)
*#* 3 (4.8%) 
19 (30.2%) 
12 (19.0%) 
29 (46.0%)
♦♦♦ 4 (6.3%) 
14 (22.2%) 
25 (39.7%) 
20 (31.7%)
*** 4 (6.5%) 
16 (25.8%) 
28 (45.2%) 
14 (22.6%)
*** 5(8.1%) 
16 (25.8%)
20 (32.3%)
21 (33.9%)
***
y ns p=0.188
12
Never
Occasionally
Often
Always
27(10.8%) 
60 (24.0%) 
77 (30.8%) 
86 (34.4%)
*** 5 (7.9%) 
18 (28.6%) 
16 (25.4%) 
24 (38.0%)
*** 8 (12.7%) 
12 (19.0%) 
24 (38.1%) 
19 (30.2%)
*** 6 (9.7%) 
20 (32.3%) 
20 (32.3%) 
16 (25.8%)
*** 8 (12.9%) 
10(16.1%) 
17 (27.4%) 
27 (43.5%)
***
> . ns p=0.083
/
***•  * * *   ***•
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  P<0.0001***  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant)
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Table 24a: Secondary outcome measure -  Completers analysis
Pain response: Worse / In pain / Improved / Pain free
Week Severity All groups Group 1 Group 2 Group 3 Group 4 Significance 
between groups
4
Worse 
In pain 
Improved 
Pain free
16 (8.4%)
83 (43.5%)
86 (45.0%) 
6(3.1%)
***  n=191
4 (8.5%)
16 (34.0%)
25 (53.2%)
2 (4.3%)
***  n=47
2 (4.1 %)
27 (55.1%)
17 (34.7%) 
3(6.1%)
***  n=49
4 (8.5 %)
23 (48.9%)
19 (40.4%)
1  (2.1%)
***  n=47
6(12.5%)
17(35.4%)
25 (52.1%)
0 (0%)
***  n=48
\
ns p=0.585
r
J
8
Worse 
In pain 
Improved 
Pain free
11 (6.2%)
59 (33.1%)
92 (51.7%)
16 (9.0%)
***  n=178
3 (7.0%) 
17(39.5%)
20 (46.5%)
3 (7.0%)
***  n=43
1  (2.1%)
16 (34%)
24 (51.1%) 
6(12.8%)
**  n=47
5(11.6%)
12 (27.9%)
23 (53.5%)
3 (7.0%)
**  n=43
2 (4.4%) 
14(31.1%)
25 (55.6 %)
4 (8.9%)
***  n=45
\
ns p=0.558
> •
/
12
Worse 
In pain 
Improved 
Pain free
15(9.1%)
44 (26.7%)
76 (46.1%) 
30(18.2%)
***  n=165
4(10.5%)
10 (26.3%)
17 (44.7%) 
7(18.4%)
***  n=38
1  (2.4%)
15 (35.7%)
17 (40.5%) 
9(21.4%)
***  n=42
4 (10.0%) 
6(15.0%)
24 (60.0%) 
6(15.0%)
***  n=40
6(13.3%)
13 (28.9%)
18 (40.0%) 
8(17.8%)
***  n=45
y ns p=0.759
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  PO.OOOHnfr#  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant
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Table 24b: Secondary outcome measure -  Intention needed to treat analysis
Pain response: Worse / In pain / Improved / Pain free
Week Severity All groups
n=250
Group 1
n=63
Group 2
n=63
Group 3
n=62
Group 4
n=62
Significance 
between groups
4
Worse 
In pain 
Improved 
Pain free
16 (6.4%)
142 (56.8%) 
86(34.4%)  *** 
6 (2.4%)
4 (6.3%)
32 (50.8%)
25 (39.7%)  *** 
2 (3.2%)
2 (3.2%)
41 (65.1%) 
17(27.0%)  **
3 (4.8%)
4 (6.5%) 
38(61.3%) 
19(30.6%)  ** 
1  (1.6%)
6 (9.7%)
31 (50.0%)
25 (40.3 %)  *** 
0 (0%)
\
ns p=0.711
> ■
8
Worse 
In pain 
Improved 
Pain free
11 (4.4%)
126 (50.4%) 
97(38.8%)  *** 
16 (6.4%)
3 (4.8%)
35 (55.6%) 
22(34.9%)  *** 
3 (4.8%)
1  (1.6%)
32 (50.8%) 
24(38.1%)  *** 
6 (9.5%)
5(8.1%)
30 (48.4%) 
24(38.7%)  *** 
3 (4.8%)
2 (3.2%)
29 (46.8%) 
27(43.5%)  *** 
4 (6.5%)
'  ....  ....
y  ns p=0.502
/
12
Worse 
In pain 
Improved 
Pain free
15 (6.0%) 
112(47.6%) 
86(34.4%)  *** 
30(12.0%)
4 (6.3%)
29 (46%)
23 (36.5%)  *** 
7(11.1%)
1  (1.6%)
36 (57.1%) 
17(27.0%)  *** 
9(14.3%)
4 (6.5%)
26 (41.9%) 
26(41.9%)  *** 
6 (9.7%)
6 (9.7%)
28 (45.2%)
20 (32.3%)  *** 
8 (12.9%)
ns p=0.950  > ■   r
/
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  PO.OOOHHn*  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant
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Figure 35:
Pain resnnnse at  4 weeks
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Table 25 a:  Secondary outcome measure -  Interference with life (Completers analysis)
Week Interference All groups Group 1 Group 2 Group 3 Group 4
Significance 
between groups
0
Yes
No
250 (100%)
0  (0%) 
n=250
63 (100%)
0  (0%) 
n=63
63 (100%)
0  (0%) 
n=63
62 (100%)
0  (0%) 
n=62
•
62 (100%)
0  (0%) 
n=62
> .  ns  p=1.0
4 Yes
No
72 (37.7%)
119 (62.3%) *** 
n=191
14 (29.8%)
33 (70.2%) *** 
n=47
23 (46.9%)
26 (53.1%)*** 
n=49
12(25.5%)
35 (74.5%) *** 
n=47
•
23 (47.9%)
25 (52.1%) *** 
n=48
V
y  ns  p=0.043
/
8 Yes
No
54 (30.3%)
124 (69.7%) *** 
n=178
15 (34.9%)
28 (65.1%)*** 
n=43
12(25.5%)
35 (74.5%)*** 
n=47
13 (30.2%)
30(69.8%)***
n=43
14(31.1%)
31 (68.9%)*** 
n=45
V
ns  p=0.814
/
12 Yes
No
46 (27.9%)
119(72.1%)***
n=165
12(31.6%)
26(68.4%)  *** 
n=38
11 (26.2%)
31 (73.8%)*** 
n=42
8 (20.0%)
32 (80.0%) *** 
n=40
15(33.3%)
30 (66.7%) *** 
n=45
> *  ns  p=0.528
* * *   * * *   ***•  * * *
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Cochran Test  P<0.001  * * *   McNemarTest  P<0.001 ***
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Table 25 b: Secondary outcome measure -  Interference with life (Intention to treat analysis)
Week Interference All groups  n=250 Group 1   n=63 Group 2  n=63 Group 3  n=62 Group 4  n=62
Significance 
between groups
0
Yes
No
250 (100%) 
0  (0%)
63 (100%) 
0  (0%)
63 (100%) 
0  (0%)
62 (100%) 
0  (0%)
62 (100%) 
0  (0%)
\
> ■  ns  p=1.0
/
4 Yes
No
142 (56.8%)
108 (43.2%)***
32 (50.8%)
31 (49.2%) ***
41 (65.0%)
22 (34.9%) ***
31 (50.0%)
31 (50.0%)***
38(61.3%)
24 (38.7%) ***
V
> -  ns  p=0.144
/
8 Yes
No
127 (50.8%)
123 (49.2%) ***
33 (52.4%)
30 (47.6%) ***
33 (52.4%) 
30(47.6%)***
32 (51.6%)
30 (48.4%) ***
29 (46.8%)
33 (53.2%) ***
ns  p=0.974
12 Yes
No
120 (48.0%)
130 (52.0%) ***
28 (44.4%)
35 (55.6%)  ***
32 (50.8%)
31 (49.2%) ***
31 (50.0%)
31 (50.0%)***
-
29 (46.8%)
33 (53.2%) ***
-
y  ns  p=0.965
Group 1  -  Fluoxetine medication  Group 3 - Splint therapy
Group 2 -  Placebo medication  Group 4 - Fluoxetine and splint therapy
Cochran Test  P<0.001  McNemarTest  P<0.001 ***
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Figure 36:
Interference with life at baseline Interference with life at 4 weeks
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7.2.2  CLINICAL SIGNS AND SYMPTOMS 
AMELIORATION DURING TREATMENT
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7.2.2.0  Clinical signs and symptoms
7.2.2.1  Interincisal mouth opening
Parametric statistics were employed for interincisal mouth opening, an interval 
measure with a true zero and normal distribution curves as illustrated,(figure 37).
7.2.2.1.1  Intra group analysis  ( Table 26a,b. Figure 38)
Analysing all groups together: the within-subjects general linear model, effects of 
change in mouth opening, were significant in both the completers and imputation 
analyses; F(2.3)=6.57,p=0.001 and F(2.4)=3.69 p=0.018 respectively. The multivariate 
tests revealed significant Wilk’s lambda for the completers F(3,162)=3.70, p=0.013, 
with a significant difference  in the measured mouth opening at the 4 time points of a 
significantly linear (straight line) trend F(l)=l 1.00,p=0.001.
Analysing all groups together, mouth opening at three months was 2.81mm higher 
than at baseline for completers (n=165) and 1.38mm higher for imputation analysis 
(n=250). Paired sample t-tests showed this improvement to be significant in the 
completers analysis t(164)=3.31,p=0.001 and imputation analysis t(249)=-2.64, 
p=0.009. The completers analysis also showed significant improvement of 0.18mm 
between baseline and two months t(177)=2.48,p=0.014.
Individual groups showed an overall trend towards increased mouth opening over the 
twelve weeks study period. Within subject effects of mouth opening in placebo were 
significant in both the completers and imputation analyses. F (2.5)=4.65,p=0.007 and 
F(3) =3.79, p=0.017 respectively. Wilk’s lambda F(3,39)=3.9,p=0.016 and 
F(3,60)=3.42,p=0.023, were consistent with the significant linear trend F(l)=9.71, 
p=0.003 and F(l)=8.29,p=0.005. In the splint only, group 3, measurements were just
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significant in the completers analysis F(l)=, p=0.028 but not the imputation analysis
(p=0.182).
Group 1  (SSRI) and Group 4 (SSRI and splint) did not reach a significant level of 
improvement over the 12 weeks p=0.167 and p=0.701 respectively.
Examining individual groups using the completers analysis mouth opening improves in 
both the splint and placebo groups. In group 3 (splint) mouth opening from baseline is 
1.95mm significantly higher at one month t(46)=2.22,p=0.031, 1.95mm significantly 
higher at two months F(42)=2.30,p=0.026 and 2.02mm significantly higher at three 
months F(39)=2.08,p=0.044. Group 2 (placebo) shows a significant improvement from 
baseline to two months of 2.52mm, t(46),2.71,p=0.009 and to three months of 3.99mm, 
t(41)=2.71,p=0.010.In group 2 (placebo) mouth opening from baseline isl.28mm 
significantly higher at two months t(62)=-2.55,p=0.013 and 1.77mm significantly 
higher at three months t(62) =-2.44,p=0.017. From one month it is 1.47mm 
significantly higher at three months t(62) -2.35,p=0.022.Unusually, therefore it would 
appear those patients receiving placebo medication improved most significantly.
7.2.2.1.2.  Inter group analysis (Table 26a,b)
Although it appeared that mouth opening improved most significantly amongst those 
on placebo medication, intergroup analysis showed that there was no difference 
between improvement amongst the four groups.
The one-way ANOVA, for intergroup analysis, was non significant between groups at 
all time points.
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Figure 37: Interincisal mouth opening
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Table 26 a:  Secondary outcome measures  - Interincisal  mouth opening (measured in mm)  Completers analysis
A comparison of mean scores +/- SD
Week All groups Group 1 Group 2 Group 3 Group 4
Significance
between
groups
0
n=250
38.81 (SD 9.36)
n=63
38.21 (SD 9.19)
n=63
38.37 (SD 8.69)
n=62
40.26 (SD 9.62)
n=62
38.42 (SD 9.99) ns p=0.576
4
n=184
39.88 (SD 8.52) 
(p=0.056)
n=47
39.06 (SD 8.05) 
(P=0.81)
n=49
39.37 (SD 8.18)
(p=0.28)
n=47
42.21 (SD8.56) 
*  (p=0.031)
n=48
38.92 (SD 9.09) 
(p=0.45)
ns p= 0.192
8
n=178
40.62 (SD 9.78) 
*  (p=0.014)
n=43
39.79 (SD 12.21) 
(P=0.92)
n=47
40.89 (SD 8.75) 
*  (p=0.009)
n=43
42.21 (SD 8.59)
*  (p=0.026)
n=45
39.62 (SD 9.21) 
(p=0.41)
ns p=0.534
12
n=165
41.62 (SD 9.22)
**  (p=0.001)
n=38
42.66 (SD 9.73)
(p=0.08)
n=42
42.36 (SD 8.71)
*  (p=0.010)
n=40
42.28 (SD 8.32) 
*  (p=0.044)
n=45
39.49 (SD 9.93) 
(p=0.56)
ns p=0.342
p=0.001
ns
p=0.167
*
p=0.007
*
p=0.028
ns
p=0.701
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Group 3 - Splint therapy 
Group 4 - Fluoxetine and splint therapy
Intra group analysis:  Repeated measures ANOVA
**p<0.005 *p<0.05 
Paired samples t-test * p<0.05 **p<0.005 
Intergroup analysis:  One-way ANOVA - not significant
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Table 26 b:  Secondary outcome measures  - Interincisal  mouth opening (measured in mm)  Imputaion analysis
A comparison of mean scores +/- SD
Week All groups 
(n=250)
Group 1  
(n=63)
Group 2 
(n=63)
Group 3 
(n=62)
Group 4 
(n=62)
Significance 
between groups
0 38.90 (SD 9.35) 38.21 (SD 9.19) 38.75 (SD 8.67) 40.26 (SD 9.62) 38.42 (SD 9.99) ns p=0.610
4 39.44 (SD 8.94) 
(p=0.135)
38.02 (SD 8.64) 
(p=0.809)
39.05 (SD 8.68) 
(p=0.545)
41.69 (SD 8.43) 
(p=0.059)
39.05 (SD 9.76) 
(p=0.445)
ns p=0.123
8 39.70 (SD 9.78)
(p=0.101)
37.70 (SD 11.42) 
(p=0.699)
40.03 (SD 9.08) 
*  (p=0.013)
41.66 (SD 8.51) 
(p=0.089)
39.44 (SD 9.68) 
(p=0.340)
ns p=0.155
12 40.28 (SD 9.52) 
*  (p=0.009)
39.67 (SD 10.18)
(p=0.188)
40.52 (SD 9.45) 
*  (p=0.017)
41.60 (SD 8.18) 
(p=0.173)
39.34 (SD 10.17) 
(p=0.488)
ns p=0.555
* ns * ns ns
p=0.018  p=0.219  p=0.017  p=0.182  p=0.708
Group 1  - Fluoxetine medication  Intra group analysis:  GLM repeated measures ANOVA
Group 2 - Placebo medication  *  #p<0.005 #p<0.05
Group 3 - Splint therapy  Paired samples t-test * p<0.05 **p<0.005
Group 4 -  Fluoxetine and splint therapy  Intergroup analysis:  One-way ANOVA - not significant
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Figure 38: Interincisal mouth opening A comparison of mean scores
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7.2.2.2  TMJ signs and symptoms
During the treatment phase symptoms and signs were recorded at four weekly 
intervals.
Despite significant reduction in recorded pain severity, intensity and interference 
scores, as reported in 7.2.2.3, using verbal report and self report pain questionnaires, 
patients were still describing symptoms of TMJ and muscle pain throughout the course 
of the study,(figure 39)
There was however, a significant reduction in reported TMJ pain p<0.001  and in 
muscle discomfort p<0.05 amongst all groups. This is reported in detail in table 27. 
Analysed in separate groups, reduction in TMJ pain was not significant in the SSRI 
group (p=0.080), although this did not reach significance in the between groups 
analysis. Temporalis muscle discomfort decreased significantly only in the splint 
therapy group (p<0.05) but again this did not reach significance in the between groups 
analysis. Reported masseter muscle discomfort only decreased significantly in the 
combined therapy group (p<0.05) and this was significant between groups ( p=0.008).
Fig. 39: Amelioration in TMD symptoms during the three month treatment phase
(All groups n=250)
%
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60 
40 
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7.2.2.3  Character of TMJ pain
The character of pain notably dull and sharp decreased significantly in all groups 
(p<0.001). Individual group analysis showed a significant reduction in dull pain in the 
SSRI (p<0.001), combined therapy (p<0.005) and placebo (p<0.05) groups which was 
significant between groups (p=0.008). The detailed account is depicted in table 28 and 
illustrated in figure 40
7.2.2.4  Chronic recurrent pains
All other reported chronic pains: headache, migraine, neckache, backache and 
abdominal pain decreased significantly (p<0.001) with no overall significant difference 
between groups. This is illustrated in table 29 and figure 41.
7.2.2.5 Other reported head and neck pains
There appears to be an increase in reported facial pain (p=0.003) ear pain (p=0.005) 
and tooth pain (p=0.009) in the splint therapy group and this was significant in the 
between group analysis (p=0.002,p=0.003 and p=0.019 respectively) as illustrated in 
table 30. One could interpret this as an increased awareness of the face, preauricular 
region and teeth in those wearing an occlusal appliance. However, results should be 
interpreted with caution due to the small number of cases with reported symptoms. 
Despite the apparent increase in ear, face and teeth symptoms, one should recall the 
particularly significant reduction in TMJ discomfort (p<0.005) and temporalis muscle 
discomfort (p<0.05) in the splint therapy group and the significant reduction in 
masseter muscle pain (p<0.05) in the combined therapy group which remained 
significant in the between groups analysis (p=0.008). This is illustrated in table 27.
2982
9
9
Table 27: Clinical TMJ symptoms and signs during three month treatment phase (Imputation analysis)
Symptoms Time All groups 
(n=250)
Group 1  
(n=63)
Group 2 
(n=63)
Group 3 
(n=62)
Group 4 
(n=62)
Significance
(between groups)
TMJ discomfort Baseline 
4 weeks 
8 weeks 
12 weeks
250 (100%) 
229 (91.6%) 
224 (89.6%) 
215 (86.0%) 
***
63 (100%) 
60 (95.2%) 
60 (95.2%) 
57 (90.5%) 
ns (p=0.080)
63 (100%) 
60 (95.2%) 
55 (87.3%) 
52 (82.5%) 
**
62 (100%) 
53 (85.5%) 
56 (90.3%) 
52 (83.9%) 
**
62 (100%) 
56 (90.3%)
53 (85.5%)
54 (87.1%) 
*
nsp=0.150 
ns p=0.300 
ns p=0.579
Muscle discomfort - 
Temporalis
Baseline 
4 weeks 
8 week 
12 weeks
65 (26%) 
46 (18.4%) 
53 (21.2%) 
49 (19.6%) 
*
12 (19%)
9 (14.3%)
12 (19%)
9 (14.3%) 
ns (p=0.484)
17 (27%)
16 (25.4%)
17 (27%)
15 (23.8%) 
ns (p=0.827)
23 (37.1%) 
12 (19.4%) 
17 (27.4%) 
16 (25.8%) 
*
13 (21%)
9 (14.5%) 
7(11.3%)
9 (14.5%) 
ns (p=0.191)
ns p=0.094 
ns p=0.331 
ns p=0.089 
ns p=0.224
Muscle discomfort - 
Masseter
Baseline 
4 weeks 
8 weeks 
12 weeks
80 (32%) 
60 (24%) 
60 (24%) 
62 (24.8%) 
*
14 (22.2%) 
11(17.5%) 
12 (19%)
8 (12.7%) 
ns (p=0.379)
25 (39.7%) 
21 (33.3%) 
17 (27.0%) 
19 (30.2%) 
ns (p=0.112)
20 (32.3%)
20 (32.3%)
21 (33.9%) 
23 (37.1%) 
ns (p=0.849)
21 (33.9%) 
8 (12.9%) 
10(16.1%) 
12 (19.4%) 
*
ns p=0.205
* p=0.012
ns p=0.087
* p=0.008
Signs
Right TMJ tender to 
palpate
Baseline 
4 weeks 
8 weeks 
12 weeks
162 (64.8%) 
122 (48.8%) 
128 (51.2%) 
133 (53.2%) 
***
39 (61.9%)
28 (44.4%) 
24 (38.1%)
29 (46.0%) 
**
41 (65.1%) 
30 (47.6%)
38 (60.3%)
39 (61.9%) 
ns (p=0.051)
39 (62.9%)
31 (50.0%) 
33 (53.2%)
32 (51.6%) 
ns (p=0.164)
43 (69.4%) 
33 (53.2%) 
33 (53.2%) 
33 (53.2%) 
*
ns p=0.827 
ns p=0.793 
ns p=0.085 
ns p=0.350
Left TMJ 
tender to palpate
Baseline 
4 weeks 
8 weeks 
12 weeks
173 (69.2%) 
162 (64.8%) 
153 (61.2%) 
148 (59.2%) 
*
41 (65.1%)
42 (66.7%) 
46 (73.0%) 
41 (65.1%) 
ns (p=0.499)
43 (68.3%) 
42 (66.7%) 
33 (52.4%) 
32 (50.8%) 
*
46 (74.2%) 
41 (66.1%)
38 (61.3%)
39 (62.9%) 
ns (p=0.143)
43 (69.4%) 
37 (59.7%) 
36 (58.1%) 
36 (58.1%) 
ns (p=0.303)
ns p=0.740 
ns p=0.812 
ns p=0.110 
nsp=0.372
Muscle discomfort only decreased significantly between groups in the combined therapy group.
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Table 28: Character of pain reported during three month treatment phase (Imputation analysis)
Character Time All groups 
(n=250)
Group 1  
(n=63)
Group 2 
(n=63)
Group 3 
(n=62)
Group 4 
(n=62)
Significance 
(between groups)
Dull ache Baseline 
4 weeks 
8 weeks 
12  weeks
161 (64.4%)
134 (53.6%)** 
121 (48.4%)*** 
111 (44.4%)*** 
***
43 (68.3%)
29 (46.0%)*
28 (44.4%)** 
23 (36.5%)***
33 (52.4%)
34 (54.0%) 
27 (42.9%) 
23 (36.5%) 
*
45 (72.6%)
39 (62.9%)
40 (64.5%)* 
39 (62.9%)** 
ns (p=0.382)
40 (64.5%) 
32 (51.6%) 
26 (41.9%) 
26 (41.9%) 
*#
ns  (p=0.103) 
ns  (p=0.294)
* p=0.034
* p=0.008
Discomfort Baseline 
4 weeks 
8 weeks 
12  weeks
137 (54.8%) 
152 (60.8%) 
154 (61.6%) 
140 (56.0%) 
ns (p=0.089)
35 (55.6%) 
40 (63.5%) 
34 (54.0%) 
33 (52.4%)
37 (58.7%) 
36 (57.1%)
38 (60.3%) 
35 (55.6%)
33 (53.2%) 
39 (62.9%) 
43 (69.4%) 
36 (58.1%)
32 (51.6%) 
37 (59.7%) 
39 (62.9%) 
36 (58.1%)
ns (p=0.868) 
ns (p=0.875) 
ns (p=0.360) 
ns (p=0.907)
Sharp Baseline 
4 weeks 
8 weeks 
12  weeks
99 (39.6%)
67 (26.8%)*** 
62 (24.8%)*** 
64 (25.6%)*** 
***
27 (42.9%) 
16 (25.4%)* 
18 (28.6%) 
16 (25.4%)* 
*
30 (47.6%)
19 (30.2%)*
16 (25.4%)*
13 (20.6%)*** 
***
17 (27.4%)
14 (22.6%)
15 (24.2%)
16 (25.8%) 
ns (p=0.774)
25 (40.3%)
18 (29.0%)
13 (21.0%)**
19 (30.6%)
*
ns (p=0.120) 
ns (p=0.766) 
ns (p=0.803) 
ns (p=0.649)
Stabbing Baseline 
4 weeks 
8 weeks 
12  weeks
35 (14.0%) 
32 (12.8%) 
25 (10%)
31 (12.4%) 
ns (p=0.258)
9 (14.3%) 
9 (14.3%) 
7(11.1%) 
4 (6.3%) 
ns(p=0.179)
7(11.1%) 
8 (12.7%) 
4 (6.3%)
8 (12.7%) 
ns (p=0.347)
14 (22.6%) 
11 (17.7%) 
11 (17.7%) 
10(16.1%) 
ns (p=0.417)
5 (8.1%)
4 (6.5%)
3 (4.8%)
9 (14.5%) 
ns (p=0.094)
ns (0.190) 
ns (p=0.293) 
ns (p=0.072) 
ns (p=0.365)
Throbbing Baseline 
4 weeks 
8 weeks 
12  weeks
20 (8%)
23 (9.2%) 
21 (8.4%) 
26 (10.4%) 
ns (p=0.552)
3 (4.8%)
4 (6.3%)
4 (6.3%)
4 (6.3%)
ns (p=0.925)
6 (9.5%) 
2 (3.2%)
2 (3.2%)
3 (4.8%) 
*
4(6.5%) 
7(11.3%) 
9 (14.5%) 
8 (12.9%) 
ns(p=0.219)
7(11.3%) 
10(16.1%) 
6(9.7%) 
11(17.7%) 
ns (p=0.094)
ns (p=0.530) 
ns (p=0.065) 
ns (p=0.126) 
ns (p=0.064)
Burning Baseline 
4 weeks 
8 weeks 
12weeks
6  (2.4%)
7  (2.8%)
4  (1.6%)
6  (2.4%) 
ns (p=0.479)
1  (1.6%)
2 (3.2%)
1  (1.6%)
1  (1.6%) 
ns (p=0.392)
1  (1.6%)
1  (1.6%)
1  (1.6%)
1  (1.6%) 
ns(p=1.00)
1  (1.6%)
1  (1.6%)
2 (4.8%)
3 (4.8%) 
ns (p=0.194)
3 (4.8%)
3 (4.8%)
0 (0%)
1  (1.6%) 
ns (p=0.101)
ns (p=0.553) 
ns (p=0.650) 
ns (p=0.562) 
ns (p=0.553)
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Figure 40: Character of pain described 
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Table 29: Other chronic pains reported during three month treatment phase (Imputation analysis)
Chronic pains Time All groups
(n=250)
Group 1 (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62)
Significance 
between groups
Headache Baseline 
4 weeks 
8 weeks 
12weeks
153 (61.2%)
120 (48.0%)*** 
126 (50.4%)** 
114 (45.6%)*** 
***
37 (58.7%)
31 (49.2%)
27 (42.9%)*
27 (42.9%)*** 
*
40 (63.5%)
33 (52 4%)
35 (55.6%)
31 (49.2%)*** 
ns (p=0.079)
37 (59.7%)
28 (45.2%)
31 (50.0%)
29 (46.8%)*** 
ns (p=0.055)
39 (62.9%)
28 (45.2%)*
33 (53.2%)
27 (43.5%)*** 
*
ns p=0.932 
ns p=0.820 
ns p=0.511 
ns p=0.882
Migraine Baseline 
4 weeks 
8 weeks 
12  weeks
82  (32.8%)
49 (19.6%)*** 
48 (19.2%)*** 
45 (18.0%)*** 
***
22 (34.9%) 
15 (23.8%) 
15 (23.8%) 
11(17.5%)* 
***
25 (39.7%)
13 (20.6%)*** 
12 (19.0%)*** 
12 (19.0%)*** 
***
18 (29.0%) 
12 (19.4%) 
12 (19.4%) 
12 (19.4%) 
ns (p=0.145)
17 (27.4%)
9 (14.5%)*
9 (14.5%)* 
10(16.1%)* 
*
ns p=0.441 
ns p=0.621 
ns p=0.628 
ns p=0.963
Neck ache Baseline 
4 weeks 
8 weeks 
12  weeks
125 (50.0%)
89 (35.6%)*** 
93 (37.2%)*** 
77 (30.8%)*** 
***
23 (36.5%)
20 (31.7%)
21 (33.3%) 
15 (23.8%)* 
ns (p=0.062)
33 (52.4%)
21 (33.3%)*
22 (34.9%)*
18 (28.6%)*** 
***
34 (54.8%)
24 (38.7%)* 
24 (38.7%)* 
20 (32.3%)** 
***
35 (56.5%)
24 (38.7%)** 
24 (38.7%)* 
24 (38.7%)* 
*
ns p=0.096 
ns p=0.784 
ns p=0.753 
ns p=0.324
Back pain Baseline 
4 weeks 
8 weeks 
12  weeks
121 (48.4%)
74 (29.6%)***
75 (30.0%)*** 
73 (29.2%)*** 
***
33 (52.4%)
19 (30.2%)** 
19 (30.2%)** 
19 (30.2%)** 
***
32 (50.8%)
22 (34.9%)*
22 (34.9%)*
19 (30.2%)*** 
***
24 (38.7%) 
16 (25.8%) 
15 (24.2%) 
13 (21.0%)* 
*
32 (51.6%)
17 (27.4%)*** 
19 (30.6%)** 
22 (35.5%)* 
***
ns p=0.372 
ns p=0.697 
ns  p=0.629 
ns p=0.351
Abdominal
pain
Baseline 
4 weeks 
8 weeks 
12 weeks
74 (29.6%)
37 (14.8%)*** 
39 (15.6%)*** 
41 (16.4%)*** 
***
19 (30.2%)
9 (14.3%)* 
11 (17.5%)* 
11 (17.5%)* 
**
19 (30.2%)
8 (12.7%)**
9 (14.3%)*
9 (14.3%)* 
***
19 (30.6%)
9 (14.5%)** 
9 (14.5%)* 
12 (19.4%)
17 (27.4%) 
11(17.7%) 
10(16.1%)
9 (14.5%) 
ns (p=0.067)
ns p=0.979 
ns p=0.882 
ns p=0.957 
ns p=0.847
Pruritis Baseline 
4 weeks 
8 weeks 
12 weeks
55 (22%)
44 (17.6%)
44 (17.6%)
45 (18.0%) 
ns (p=0.153)
15 (23.8%) 
13 (20.6%) 
8 (12.7%) 
10(15.9%) 
ns (p=0.082)
12 (19.0%) 
15 (23.8%) 
14 (22.2%) 
14 (22.2%) 
ns (p=0.737)
12 (19.4%) 
8(12.9%) 
10(16.1%) 
9 (14.5%) 
ns (p=0.576)
16 (25.8%)
8 (12.9%)* 
12 (19.4%) 
12 (19.4%) 
*
ns p=0.749 
ns p=0.266 
ns p=0.533 
ns p=0.673
Chi squared inter group comparisons for each of the chronic pains was not significant between groups
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Figure 41: Amelioration in reported chronic pains during the three month treatment phase (All groups n=250)
%
70 
60 
50 
40 
30 
20 
10 T j
0   *   i-J— 1   .  ■   — I?  ,  ™   — — tsLT _ * _ i — —   ,  H   — LL^
Headache Migraine Neck ache Back ache  Abdominal pain
□ Baseline
□ 4 weeks
□ 8 weeks
□ 12 weeks
There was a significant decrease in all reported chronic pains during the three month treatment phase p<0.001 at all three 
time  ponts. However, analysis between groups was not significant.
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Table 30: Other reported head and neck pain during the three month treatment phase (Imputation analysis)
Other head and 
neck pain
Time All groups
(n=250)
Group 1 (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62)
Significance 
between groups
Face Baseline 
4 weeks 
8 weeks 
12  weeks
16 (6.4%)
33 (13.2%)
36 (14.4%)
27 (10.8%)
* *  (p=0.002)
1  (1.6%)
2 (3.2%)
2 (3.2%)
0 (0%) 
ns (p=0.468)
6 (9.5%)
5 (7.9%)
5 (7.9%)
6 (9.5%)
ns (p=0.881)
5 (8.1%)
17 (27.4%)
18 (29.0%)
13 (21.0%) 
**(p=0.003)
4 (6.5%)
9 (14.5%)
11 (17.7%)
8 (12.9%) 
ns (p=0.193)
ns  p=0.290
***p<0.001 
***p<0.001 
** p=0.002
Ears Baseline 
4 weeks 
8 weeks 
12  weeks
21 (8.4%) 
28(11.2%) 
29(11.6%) 
28(11.2%) 
ns (p=0.338)
5 (7.9%)
3 (4.8%)
2 (3.2%)
2 (3.2%) 
ns (p=0.112)
4 (6.3%)
3 (4.8%)
3 (4.8%)
4 (6.3%)
ns (p=0.881)
5 (8.1%)
15 (24.2%) 
15 (24.2%) 
14 (22.6%) 
* (p=0.005)
7(11.3%)
7(11.3%)
9 (14.5%)
8 (12.9%) 
ns (p=0.886)
ns  p=0.791
**p=0.001
**p=0.001
*  p=0.003
Teeth Baseline 
4 weeks 
8 weeks 
12  weeks
8 (3.2%)
16 (6.4%)
14 (5.6%)
17 (6.8%) 
ns (p=0.087)
0 (0%)
0 (0%)
0 (0%)
1  (1.6%) 
ns (p=0.392)
3 (4.8%)
2 (3.2%)
2 (3.2%)
2 (3.2%) 
ns (p=0.392)
2 (3.2%) 
10(16.1%) 
11 (17.7%)
9 (14.5%)
*  (p=0.009)
3 (4.8%)
4 (6.5%)
1  (1.6%)
5 (8.1%)
ns (p=0.336)
ns  p=0.344
***p<0.001
*  p=0.019
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7.2.3  PAIN AND PSYCHOSOCIAL SELF-REPORT PAIN
QUESTIONNAIRES 
Outcome scores at three months
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7.2.3.1  Multidimensional pain inventory (MPD
The patient’s perspective of pain; severity, interference, life control and affective 
distress; had significantly improved during the three months treatment phase amongst 
the combined groups (p<0.001), as illustrated graphically by the box plots (figure 
42).The improvement was evident both in the imputation and completers analysis as 
shown in tables 31a,b.
Analysing all groups, severity (p<0.001), interference (p<0.001) and affective distress 
(p<0.001) had clearly decreased which consequently resulted in an increase in the 
patient’s perspective of their level of control in life (p<0.001).
Intra group analysis suggested severity appeared to reduce most markedly in the splint 
only and placebo only groups (p<0.001), compared to SSRI (p<0.005) and combined 
therapy (p<0.05).Improvement in interference was again more marked in the placebo 
(p<0.001) and splint (p<0.05) groups with no significant change in SSRI and combined 
therapy groups. Nevertheless, affective distress was not significantly decreased in the 
splint only group but was significant in medical therapy groups: SSRI (p<0.05), 
placebo (p<0.005) and combined therapy (p<0.05).Meanwhile, life control only 
seemed to improve in the SSRI only group (p<0.005) with no significant change in the 
other three groups, in the imputation analysis.
As an incidental finding, level of support by family and friends appeared to decrease in 
the splint only group (p<0.05).
However, all these findings were not substantiated by the inter group analysis which 
did not reveal any significant difference in change in scores between the four treatment 
groups.
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7.2.3.2  McGill pain questionnaire (MPOI
Analysing groups together, all scores significantly improved during the three month 
treatment phase both in the imputation and completers analysis VAS (p<0.001), PPI 
(p<0.001), total % (p<0.001), sensory % (p<0.001) and affective % (p<0.001).
Detailed results are reported in table 27a,b and illustrated in figure 31. Intra group 
analysis suggests VAS pain severity significantly decreased only in the placebo and 
splint only groups (p<0.005).However, inter group analysis revealed no significant 
difference in improvement in all scores between groups.
7.2.3.3  Beck Depression index f BDU
Analysing combined groups, there appeared to be a significant reduction in composite 
score (p<0.005).However, this indicates a reduction from a median score of 7.00 to 
6.00 which indicates the majority of patients were not depressed, either at baseline or 
follow up. Despite this minimal reduction in score in each group, intra group analysis 
suggests only placebo (p<0.05) and splint (p<0.05) show a significant reduction in 
score. However, this finding was not substantiated by intergroup analysis which as 
expected showed a non significant difference in score reduction between the 4 groups.
7.2.3.4  Kellner illness attitude
Kellner disease phobia did not significantly decrease during the course of treatment. 
Hypochondriacal beliefs and illness attitude reduced in the completers analysis of all 
groups (p<0.05).Intra group analysis suggests the SSRI group in both completers and 
imputation analysis had a significant reduction in hypochondriacal beliefs (p<0.05) but 
this was not confirmed as significant in the between groups analysis.
Results are shown in tables 32a,b and illustrated by box plots in figures 43.
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Table 31 a:
Multidimensional pain inventory (MPD A comparison of median scores (25th , 75th  percentiles) between the start and finish of the three months.
(Completers analysis)
MPI Study All groups Group 1 Group 2 Group 3 Group 4 significance
Patients perspective of pain
MPI - Severity Start
Finish
3.00(1.92,4.00) 
2.00(1.00,3.33)  ***
3.33 (2.00,4.33)
2.33 (1.11,3.50)  **
3.00 (2.33,4.00) 
2.00(1.00,3.66)  ***
2.66(1.33,3.40) 
2.00(0.60,2.92)  ***
2.66 (1.65,4.00) 
2.00(1.32,3.63)  *
ns p=0.105 
ns p=0.380
MPI - Interference Start
Finish
1.45 (0.65,2.88) 
0.90(0.30,2.36)  ***
1.90(0.82,3.36) 
0.86 (0.20,2.36) ***
1.63 (0.80,2.90) 
1.00(0.45,2.18)  ***
1.36 (0.45,2.27) 
0.65(0.18,2.46)  *
1.24 (0.52,2.65) 
0.90 (0.41,2.55)
ns P=0.103
ns p=0.808
MPI -  Life control Start
Finish
3.25 (2.31,4.00)
3.75 (2.75,4.25)  ***
3.25 (2.00,4.00) 
3.75(3.00,4.50)  **
3.25 (2.25,4.25) 
3.75 (3.25,4.50)  *
3.25 (2.46,4.00) 
3.50(2.75,4.25)  *
3.38 (2.50,4.25) 
3.25 (2.50,4.25)
ns p=0.780 
ns p=0.544
MPI - Affective distress Start
Finish
3.33 (2.33,4.30) 
3.00(1.66,3.66)  ***
3.33 (2.33,4.30) 
3.00(1.53,4.00)  *
3.60 (2.65,4.40) 
3.00(1.50,3.47)  **
3.00 (2.00,4.00) 
3.00(1.66,3.92)
3.32 (2.32,4.30) 
3.00(2.00,4.00)  *
ns p=0.235 
ns p=0.960
Response of significant other
MPI -  Support response Start
Finish
3.33 (2.30,4.66) 
3.60 (2.33,4.33)
3.60 (2.25,4.66)
3.60 (2.66,4.32)
3.66 (2.32,5.00) 
3.15 (2.33,4.66)
3.00 (2.33,4.33) 
3.66(2.60,4.00)  *
3.00 (2.00,4.33) 
3.60 (2.33,4.53)
ns p=0.681
nsp=0.961
MPI -  Punishing response Start
Finish
1.00(0,2.06) 
0.75 (0,1.75)
0.75 (0.25,2.81) 
0.75(0,1.25)
1.25 (0.25,2.56) 
0.75 (0.06,1.75)
0.75 (0,2.00) 
1.00 (0,2.00)
0.75 (0,1.75) 
0.75 (0,2.00)
ns P=0.201 
ns p=0.874
MPI -  Solicitous response Start
Finish
2.66 (1.50,3.87) 
2.83 (1.50,3.83)
2.83 (1.45,3.63) 
2.50(1.16,4.20)
2.66 (1.77,4.37) 
2.58(1.41,3.92)
2.66 (1.50,3.83) 
3.16(2.00,4.16)
2.50(1.30,3.83) 
2.83 (1.00,3.50)
ns p=0.929 
nsp=0.487
MPI -  Distracting response Start
Finish
1.75 (0.75,2.75) 
2.00 (0.88,3.00)
2.00 (0.75,2.75) 
2.25 (1.00,3.50)
1.50 (0.75,3.00) 
1.75(0.75,2.94)
2.00 (0.75,2.75)
2.00 (0.75,3.00)
1.75 (0.50,3.00) 
2.00 (1.00,3.00)
ns p=0.959 
ns p=0.975
Frequency of participation in
MPI -  Household chores Start
Finish
4.80 (3.60,5.60) 
4.40 (3.60,5.20)
4.80 (3.60,5.60) 
4.60 (4.05,5.20)
4.80 (3.35,5.80) 
4.40 (3.00,5.25)
4.60 (3.40,5.80) 
4.40 (3.65,5.24)
4.80 (3.80,5.40) 
4.60 (3.60,5.50)
ns p=0.961 
ns p=0.756
MPI - Outdoor work Start
Finish
2.00 (1.00,3.00) 
2.00(1.00,3.00)
1.90 (1.28,3.00) 
1.68(1.26,3.15)
1.90(0.81,3.15)
2.00(1.00,2.70)
2.00 (0.95,3.00)
2.00 (0.75,3.00)
2.00 (0.80,3.00) 
2.33 (1.00,3.31)
ns p=0.731  
nsp=0.736
MPI - Activities away from 
home
Start
Finish
3.50 (2.75,4.25) 
3.75 (2.75,4.25)
3.50 (2.75,4.25) 
3.75 (3.00,4.25)
3.75 (2.75,4.50)
3.75 (2.94,4.31)
3.25 (2.25,4.25) 
3.50 (2.75,4.25)
3.50 (2.50,4.50) 
3.25 (2.63,4.50)
ns p=0.714 
ns p=0.707
MPI -  Social activities Start
Finish
3.00 (2.30,4.00) 
3.25 (2.25,4.00)
2.75 (2.25,3.75) 
3.25 (2.27,4.00)
3.25 (2.50,4.00)
3.25 (2.44,4.00)
3.00 (2.33,3.75) 
3.13 (2.27,3.62)
3.38 (2.00,4.06) 
3.25 (1.88,3.88)
ns p=0.655 
ns p=0.793
MPI -  General activity level Start
Finish
3.38(2.75,3.91) 
3.23 (2.74,3.90)
3.40 (2.80,3.88) 
3.30 (2.68,4.01)
3.44 (2.68,3.84) 
3.20 (2.76,4.01)
3.31 (2.50,3.79) 
3.20 (2.47,3.68)
3.34 (2.80,4.05) 
3.24 (2.89,3.77)
ns P=0.901 
nsp=0.830
Group 1 - Fluoxetine medication  Group 3 -  Splint therapy  Kruskall Wallice not significant between groups
Group 2 -  Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *, p<0.005 **, p< 0.001***
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Table 31 b:
tli  fU
Multidimensional pain inventory (MPD A comparison of median scores (25  ,75  percentiles) (Imputation analysis)
MPI Study All groups Group 1 Group 2 Group 3 Group 4 Sig.
Patients perspective of pain
MPI - Severity Start
Finish
3.00(1.92,4.00)
2.33 (1.30,3.66)  ***
3.33 (2.00,4.33) 
2.60(1.30,4.00)  **
3.00 (2.33,4.00)
2.33 (1.33,3.66)  ***
2.66(1.33,3.40) 
2.00(0.66,3.00)  ***
2.66 (1.65,4.00) 
2.33 (1.33,3.75)  *
nsp=0.105 
ns p=0.298
MPI - Interference Start
Finish
1.45 (0.65,2.88)
1.05 (0.36,2.38)  ***
1.90 (0.82,3.36) 
1.30 (0.36,2.72) ***
1.63 (0.80,2.90) 
1.16(0.54,2.54)  ***
1.36 (0.45,2.27) 
0.90(0.29,2.27)  *
1.24 (0.52,2.65) 
1.00 (0.43,2.40)
ns P=0.103 
ns p=0.684
MPI - Life control Start
Finish
3.25 (2.31,4.00) 
3.50(2.50,4.25)  ***
3.25 (2.00,4.00) 
3.50(2.75,4.50)  **
3.25 (2.25,4.25) 
3.50 (2.50,4.00)
3.25 (2.46,4.00) 
3.50 (2.50,4.25)
3.38 (2.50,4.25) 
3.50 (2.50,4.25)
ns p=0.780 
nsp=0.952
MPI - Affective distress Start
Finish
3.33 (2.33,4.30) 
3.00(2.00,4.00)  ***
3.60 (2.60,4.33) 
3.30(2.00,4.00)  **
3.60 (2.65,4.40) 
3.33 (2.00,4.00)  **
3.00 (2.00,4.00)
3.00 (1.92,4.00)
3.32 (2.32,4.30) 
2.83 (2.00,3.62)  *
nsp=0.063 
ns p=0.590
Response of significant other
MPI - Support response Start
Finish
3.33 (2.30,4.66)
3.33 (2.32,4.33)
3.60 (2.25,4.66) 
3.33 (2.33,4.33)
3.66 (2.32,5.00) 
3.33 (2.33,5.00)
3.00(2.33,4.33) 
3.00(1.70,4.00)  **
3.00 (2.00,4.33) 
3.60 (2.17,4.47)
ns p=0.681
ns p=0.300
MPI -  Punishing response Start
Finish
1.00 (0,2.06) 
1.00 (0,2.00)
0.75 (0.25,2.81) 
1.00(0,2.5)
1.25 (0.25,2.56) 
1.25(0.25,2.00)
0.75 (0,2.00) 
1.00(0,2.00)
0.75(0,1.75)
1.00(0,1.75)
ns P=0.201 
ns p=0.394
MPI -  Solicitous response Start
Finish
2.66 (1.50,3.87)
2.66 (1.33,3.83)
2.83 (1.45,3.63) 
2.50 (1.30,4.00)
2.66 (1.77,4.37)
2.66 (1.33,4.50)
2.66(1.50,3.83) 
2.66 (1.50,4.08)
2.50 (1.30,3.83) 
2.50(1.08,3.50)
nsp=0.929 
ns p=0.798
MPI - Distracting response Start
Finish
1.75 (0.75,2.75)
1.75 (0.75,3.00)
2.00 (0.75,2.75)
2.00 (0.75,2.75)
1.50 (0.75,3.00)
1.50 (0.75,2.75)
2.00 (0.75,2.75) 
1.75 (0.75,2.88)
1.75 (0.50,3.00)
1.75 (0.63,3.00)
ns p=0.959 
ns p=0.927
Frequency of participation in
MPI -  Household chores Start
Finish
4.80 (3.60,5.60) 
4.60 (3.60,5.60)
4.80 (3.60,5.60) 
4.60 (4.20,5.40)
4.80 (3.35,5.80) 
4.40 (3.40,5.60)
4.60 (3.40,5.80)
4.60 (3.80,5.55)
4.80 (3.80,5.40) 
4.60 (3.60,5.60)
nsp=0.961 
ns p=0.903
MPI -  Outdoor work Start
Finish
2.00(1.00,3.00) 
2.00 (1.00,3.00)
2.00 (1.30,3.00) 
1.78(1.29,3.00)
2.00(0.88,3.10) 
2.00 (1.00,3.00)
2.00 (0.95,3.00) 
1.80(0.85,2.60)
2.00 (0.85,3.00)
2.00 (0.95,3.05)
nsp=0.749 
ns p=0.687
MPI -  Activities away from 
home
Start
Finish
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.75 (2.75,4.50) 
3.50 (2.75,4.25)
3.25 (2.25,4.25) 
3.50 (2.75,4.25)
3.50 (2.50,4.50) 
3.38(2.50,4.31)
ns p=0.714 
ns p=0.891
MPI -  Social activities Start
Finish
3.00 (2.30,4.00) 
3.25 (2.30,3.75)
2.75 (2.25,3.75) 
3.00(2.25,4.00)
3.25 (2.50,4.00)
3.25 (2.50,4.00)
3.00 (2.33,3.75) 
3.13 (2.33,3.75)
3.38 (2.00,4.06) 
3.29 (2.19,4.00)
nsp=0.655 
ns p=0.498
MPI - General activity level Start
Finish
3.38(2.75,3.91) 
3.30 (2.76,3.81)
3.40 (2.80,3.88) 
3.38 (2.69,3.89)
3.44 (2.68,3.84) 
3.34(2.84,3.83)
3.31 (2.50,3.79) 
3.30 (2.72,3.71)
3.34 (2.80,4.05) 
3.25 (2.83,3.81)
ns P=0.901 
ns p=0.969
Group 1 - Fluoxetine medication  Group 3 -  Splint therapy  Kruskall Wallice not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *, p<0.005 **, p< 0.001
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Figure 42:  Patient’s perspective of pain 
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Table 32 a:  McGill pain questionnaire (MPQ). Beck depression index (BDD  and Kellner illness attitude scale.(Kellner)
A comparison of median scores (25  and 75  percentiles) (Completers analysis)
Self report Questions Study All groups Group 1 Group 2 Group 3 Group 4 Sig.
MPQ
Visual analogue scale 
(VAS)(range 0-10)
Start
Finish
2.90 (1.20,5.45)
2.10 (0.75,4.30) ***
2.90 (1.20,6.03) 
2.55 (0.83,5.05)
3.30 (1.60,5.60) 
2.20 (0.60,5.43)**
2.70 (1.23,4.80) 
1.55 (0.48,3.05) **
2.75 (0.90,5.38) 
2.00 (1.00,5.20)
nsp=0.881 
ns p=0.564
Present pain intensity 
(PPI)(range 0-5)
Start
Finish
2.00 (1.00,2.00)
1.00 (1.00,2.00) ***
2.00 (1.00,3.00)
1.00 (1.00,2.00) **
2.00 (1.00,2.00) 
1.00 (1.00,2.00)*
2.00 (1.00,2.00) 
1.00(1.00,2.00) **
2.00 (1.00,2.00) 
1.00 (1.00,2.00)*
nsp=0.617
nsp=0.439
MPQ - total % 
(range 0-100)
Start
Finish
31.00 (20.00,47.00)
20.00 (12.00,36.00)***
35.50 (23.50,47.00) 
24.00 (13.00,40.50) *
31.00(19.5,40.0) 
27.00 (13.0,38.0)*
30.00 (18.00,39.50) 
15.50 (9.50,31.00)***
31.00(18.00,50.00)
18.00(11.00,36.00)*
nsp=0.398 
ns p=0.342
MPQ- sensory % 
(range 0-100)
Start
Finish
33.00 (21.00,45.00)
24.00 (15.0,42.00) ***
39.00 (26.25,48.00) 
31.50(17.25,45.00)*
31.00(21.00,45.00) 
33.00 (18.00,45.00)
33.00(21.00,42.00) 
18.00 (12.50,33.00)*
33.00 (19.50,50.00) 
21.00(15.00,42.00)
nsp=0.342 
ns p=0.278
MPQ - affective % 
(range 0-100)
Start
Finish
17.00 (3.00,42.00)
8.00 (0, 25.00) ***
25.00 (0, 52.00)
8.00 (0,27.00) *
17.00 (8.00,40.50)
8.00 (0,25.00) **
17.00 (8.00,25.00)
8.00 (0,25.00) *
17.00 (0,50.00) 
8.50 (0,25.00)
ns p=0.639 
ns p=0.972
BDI
Composite score 
(range 0-45)
Start
Finish
7.00  (3.00,13.00)
5.00  (2.00,12.00)**
7.00 (2.25,13.75) 
5.00(1.25,11.75)
7.00 (3.00,11.00)
5.00 (2.75,10.00)*
6.00 (2.00,10.50) 
4.00(0.75,10.50)*
8.00 (4.25,14.75)
7.00 (3.00,14.00)
ns p=0.344 
ns p=0.088
Kellner
Illness attitude- 
total (range 0-30)
Start
Finish
8.00  (6.00,11.00) 
7.00  (6.00,10.00)*
8.00 (6.00,11.50)
7.00 (6.00,12.00)
7.00 (6.00,9.50)
7.00 (6.00,9.00)
7.50 (6.00,11.00) 
7.00 (6.00,10.00)
8.00 (6.00,12.00) 
8.50 (6.00,12.00)
ns p=0.206 
nsp=0.147
Hypochondriacal 
beliefs (range 0-15)
Start
Finish
3.00  (3.00,6.00)
3.00  (3.00,5.00) *
4.00 (3.00,6.00)
3.00 (3.00,5.00) *
3.00 (3.0,5.00)
3.00 (3.00,4.75)
3.00 (3.00,6.00)
3.00 (3.00,5.00)
3.00 (3.00,6.00) 
3.50 (3.00,5.00)
ns p=0.477 
ns p=0.919
Disease phobia 
(range 0-15)
Start
Finish
3.00 (3.00,5.00)
3.00 (3.00,5.00)
3.00 (3.00,5.50)
3.00 (3.00,6.00)
3.00 (3.00,4.00)
3.00 (3.00,4.00)
3.00 (3.00,6.00)
3.00 (3.00,6.00)
4.00 (3.00,7.00) 
4.50 (3.00,6.00)
ns p=0.112 
ns p=0.085
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Kruskall-Wallis not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001 ***
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eTable 32 b:  McGill pain questionnaire (MPQ). Beck depression index (BDD  and Kellner illness attitude scale.(Kellner)
A comparison of median scores (25  and 75  percentiles) (Imputation analysis)
Self report Questions Study All groups Group 1 Group 2 Group 3 Group 4 Sig.
MPQ
Visual analogue scale 
(VAS) (range 0-10)
Start
Finish
2.90 (1.20,5.45)
2.20 (0.80,4.95) ***
2.90 (1.20,6.03) 
2.40 (0.63,4.90)
3.30 (1.60,5.60) 
2.50 (0.95,5.35) *♦
2.70(1.23,4.80)
2.10(0.7,4.50)**
2.75 (0.90,5.38) 
2.20 (0.95,5.95)
ns p=0.881 
ns p=0.682
Present pain intensity 
(PPI) (range 0-5)
Start
Finish
2.00(1.00,2.00)
1.00 (1.00,2.00) ***
2.00(1.00,3.00) 
2.00 (1.00,2.00) **
2.00 (1.00,2.00) 
2.00 (1.00,2.00) *
2.00 (1.00,2.00) 
1.00(1.00,2.00) **
2.00 (1.00,2.00) 
1.00(1.00,2.00)*
ns p=0.617 
ns p=0.627
MPQ - total % 
(range 0-100)
Start
Finish
31.00 (20.00,47.00)
27.00 (13.00,40.00)***
35.50 (23.50,47.00) 
29.00 (17.00,45.50) *
31.00(19.5,40.0) 
29.00 (14.5,37.0)**
30.00 (18.00,39.50) 
24.00(13.00,31.00)***
30.00 (17.50,49.50) 
20.00(11.00,42.00)*
ns p=0.384 
ns p=0.423
MPQ- sensory % 
(range 0-100)
Start
Finish
33.00 (21.00,45.00)
30.00 (15.00,42.00) ***
39.00 (26.25,48.00)
33.00 (18.00,45.00) *
31.00 (21.00,45.00) 
30.00(17.50,41.00)*
33.00 (21.00,42.00)
24.00 (15.00,37.50) **
31.50(18.00,49.00) 
21.00 (12.00,45.00) *
nsp=0.339
nsp=0.558
MPQ - affective % 
(range 0-100)
Start
Finish
17.00 (0,42.00)
17.00 (0, 25.00) ***
25.00 (0, 52.00)
17.00 (0, 46.00) ♦
17.00 (8.00,40.50)
17.00 (0,25.00) **
17.00 (8.00,25.00)
17.00 (0,25.00) *
17.00 (0,50.00)
9.00 (0,33.00)
ns p=0.663 
ns p=0.905
BDI
Composite score 
(range 0-45)
Start
Finish
7.00  (3.00,13.00)
6.00  (3.00,12.00)**
7.00 (2.25,13.75)
6.00 (2.00.12.50)
7.00 (3.00,11.00)
7.00 (3.00,11.00)*
6.00(2.00,10.50)
5.00 (1.00,10.00)  *
8.00 (4.25,14.75) 
7.00(3.00,13.00)
nsp=0.344 
ns p=0.106
Kellner
Illness attitude 
total (range 0-30)
Start
Finish
8.00  (6.00,11.00) 
7.00  (6.00,11.00)
8.00(6.00,11.50) 
7.00 (6.00,11.50)
7.00 (6.00,9.50)
7.00 (6.00,10.00)
7.50 (6.00,11.00) 
7.00 (6.00,10.00)
8.00 (6.00,12.00) 
9.00 (6.00,12.00)
ns p=0.206 
ns p=0.101
Hypochondriacal 
beliefs (range 0-15)
Start
Finish
3.00  (3.00,6.00)
3.00  (3.00,5.00) *
4.00 (3.00,6.00) 
3.00(3.00,5.00)*
3.00 (3.00,5.00)
3.00 (3.00,5.00)
3.00(3.00,6.00) 
3.00 (3.00,5.00)
3.00 (3.00,6.00) 
3.50 (3.00,6.00)
ns p=0.477 
ns p=0.546
Disease phobia 
(range 0-15)
Start
Finish
3.00 (3.00,5.00)
3.00 (3.00,5.00)
3.00 (3.00,5.50)
3.00 (3.00,5.50)
3.00 (3.00,4.00)
3.00 (3.00,5.00)
3.00 (3.00,6.00)
3.00 (3.00,5.25)
4.00 (3.00,7.00)
5.00 (3.00,6.75)
nsp=0.112 
ns p=0.068
Group 1  -  Fluoxetine medication  Group 3 - Splint therapy  Kruskall-Wallis not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001 ***
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Change in MPQ (VAS)
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eFigure 43 continued : 
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7.3  Outcome Predictors
Bivariate analysis, using the nonparametric Spearman’s Rho, identified associations 
between >25% and >50% pain severity improvement at the end of the trail period of 
three months and several initial MPI,MPQ,BDI and Kellner self reported scores. 
Logistic regression analysis was then used to examine a number of these variables to 
see if they predict an explanatory outcome. The enter method in addition to forward 
and backward stepwise techniques were employed. A number of factors did remain 
evident in the regression analysis.
7.3.1  Summary of the Loeisitic regression Analysis
Table 33:  Summary of logistic regression analysis >25% improvement at 3/12
Enter method P value Regression
coefficient
SE
(standard error)
OR
(Odds ratio)
95% Cl
(Confidence
interval)
MPI
(support)
0.049 * 0.233 0.118 1.262 (1.001-1.591)
MPI
(outdoor work)
0.043  * 0.337 0.166 1.401 (1.011-1.941)
MPI
(punishing )
0.60 -0.276 0.147 0.759 (0.569-1.011)
MPI
(social activity)
0.170 0.342 0.249 1.408 (0.864-2.294)
MPI
(general
activity)
0.101 -0.654 0.399 0.520 (0.238-1.136)
*p<0.05
The above model accounts for 70.4% prediction of results,( x2 =14.710 df 5, p=0.012). 
In this particular study, only initially reported MPI support  by significant family or 
friends and outdoor activity were significant predictors of improvement in pain of at 
least 25%..
MPI support (OR=1.26,95%CI 1.00-1.59, P=0.049), suggests that the chances of, at 
least 25% pain improvement, increase for every 1.26 unit increase in recorded level of
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support. Similarly MPI outdoor activity (OR=1.40,95%CI 1.01-1.94, P=0.043), 
indicates that the chances of at least 25% pain improvement, increases for every 1.40 
unit increase in recorded outdoor activities.
Conversely, increased recorded MPI punishing response by significant family and 
friends and general activity level has a negative response and social activity a positive 
response but this did not reach a significant level.
Table 34: Logistic regression analysis >50% pain improvement at three months
Enter method OR
(Odds ratio)
95% Cl
(Confidence
interval)
P value Regression
coefficient
SE
(standard error)
Duration 
(TMJ pain)
0.838 0.707-0.994 0.043* -0.176 0.087
Backache 0.359 0.38-0.935 0.036* -1.025 0.489
Abdominal pain 3.662 1.219-11.00 0.021* 1.298 0.561
Temporal pain 0.362 0.118-1.113 0.076 -1.016 0.573
VAS (clinical) 1.410 1.122-1.773 0.003* 0.344 0.117
VAS(MPQ) 0.820 0.667-1.007 0.059 -0.198 0.105
Kellner total 
(Illness attitude)
1.270 0.988-1.632 0.062 0.239 0.128
Kellner
(Disease phobia)
0.636 0.407-0.992 0.046* -0.453 0.227
MPI
(punished response)
0.625 0.408-0.958 0.031* -0.469 0.218
MPI
(household chores)
0.635 0.383-1.052 0.078 -0.454 0.257
MPI
(social activity)
0.368 0.178-0.759 0.007* -1.001 0.370
MPI
(generalactivity)
3.434 1.099-10.73 0.034* 1.234 0.581
*p<0.05
This model accounts for 78.5% of the 50% pain reduction x2 =38.177(12) P<0.001.
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Several factors were found to decrease the chances of a successful 50% pain 
improvement at three months. These included the longer the duration of TMJ pain on 
initial presentation to the clinic (OR=0.84,95%CI  0.71,0.99, p=0.043), the presence of 
backache (OR=0.36,95%CI 0.38,0.94,p=0.036). The reporting of temporal muscle pain 
on presentation was again seen to decrease the chances of success but this did not 
reach a significant level (OR=0.362, 95%CI 0.12,1. ll,p=0.07).Conversely, those 
reporting abdominal pain at initial presentation appeared 3 times more likely to have a 
50% reduction in pain, (OR=3.66,95%CI 1.22,11.0,p= 0.021).
With regards to the self report pain questionnaires, a decreased chance of a successful 
outcome at three months was associated with initially reported higher score ratings in 
the Kellner (disease phobia) (OR=0.64, 95%CI 0.41,0.99, p=0.046), MPI (punishing 
response by significant family and friends) (OR=0.63, 95%CI 0.41,0.96, p=0.031),
MPI (social activities) (OR=0.37,95% Cl 0.18,0.76, p=0.007). Raised scores in Kellner 
illness attitude, MPI (household chores) and VAS (MPQ) were also negatively 
associated with improvement but did not reach a significant level. Conversely, pain 
improvement was associated with a 1.4 unit increase in initial, clinically recorded VAS 
(OR=l 41,95%CI 1.12,1 77,p=0.003).
MPI (general activity level) at baseline increased the chances of successful outcome 
for every 3.4 unit increase in initially recorded scores (OR=3.43, 95%CI 1.09,10.73, 
p=0.034).
An attempt was made to determine what specific factors might influence a successful 
therapeutic outcome in physical or medical therapy groups. Using a split file analysis 
no clear predictors of outcome appeared to exist solely amongst the individual groups, 
medical therapy versus occlusal therapy, combined therapy or indeed placebo.
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7.4  The randomised controlled study three month treatment phase 
Hypothesis (la):
An SSRI (fluoxetine;Prozac) in daily oral doses of 20-40mg is more effective 
than placebo in the treatment of patients with chronic TMD.
Hypothesis (lb):
A combination of an SSRI (fluoxetine; Prozac) and a bite guard are equally 
effective to fluoxetine or bite guard alone in the treatment of chronic TMD.
7.4.0.1 The randomised placebo controlled trial
Randomised, placebo controlled trials are often viewed as the research ‘gold 
standard’ in the development of new treatment; measuring effect size in a 
scientifically consistent manner; establishing clinical sensitivity and internal 
validity, (Adam et al, 2005,Hauschke and Pigeot,2005, Rohmel,2005). The aim of a 
placebo is to control for the non-specific effects of therapy which include: statistical 
regression towards the mean, the natural history of the condition being treated, 
methodological or measurement anomalies and improvement due to psychological 
elements of therapy, (Kienle and Kiene,1997, Kirsch,1997, McDonald and 
McCabe, 1989).
In recent years, since the commencement of this RCT, the role of placebo has come 
under close scrutiny; considered by some inappropriate or unacceptable, (Farr,2000, 
Weijer, 2002).Consequently, the ethical issues surrounding placebo treatment have 
been the topic of much discussion,(Linde et al,2003, Emanuel and Miller,2001). The 
5th revised version of the declaration of Helsinki, 2000, states that “the placebo 
controlled clinical trials are only acceptable when no proven treatment exists for the 
studied disease”. Therefore, trial enrolment with a placebo is only considered
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legitimate when a state of‘clinical equipoise’ exists; uncertainty or disagreement 
amongst the professional community of expert clinicians as to the preferred 
treatment, (Freedman, 1987, Reynolds,2000).
The Note of Clarification of the Declaration of Helsinki, 2001, aimed to elucidate 
when trials are scientifically necessary and ethically justifiable, even when proven 
therapy already exists. An example would be ‘to determine the efficacy or safety of 
therapeutic, diagnostic or prophylactic methods for a minor condition where use of a 
placebo will not subject the patient to additional risk, serious or irreversible harm’, 
(WMA,2001). Clearly, no research patient should be exposed to unnecessary harm 
or risks of pain or suffering (Reynolds, 2000, Simon, 2000).The controversy centres 
around studies of non-life threatening conditions, when a delay in effective 
treatment is unlikely to cause harm, (Ready,2000, Vastag,2000). Placebo controlled 
trials are considered by some to arise from a misplaced emphasis on statistical 
significance testing,(Simon, 2000). However, in order for clinical research to be 
ethical, it must be considered scientifically valid; nevertheless, moral considerations 
must always take priority over the quest for scientific knowledge,(Simon,2000). 
Inadequate trial design is unethical since it may lead to the reporting of erroneous, 
inconclusive results and misleading recommendations of inconsistent or minimally 
effective treatment, (Weijer,2002, Power,2005).
An active control is not necessarily an alternative to an inactive placebo control, 
since study population inter and intra individual variation prevents direct 
comparison or equivalence with historical controls,(Linde et al,2003).Use of an 
active -control, where a new agent and an active control are shown to have similar 
efficacy, is a non inferiority response and is therefore a less scientifically reliable 
design than superiority trials with either an active or in-active comparator, (Emanuel
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and Miller,2001, Reynolds,2000).However, a similar response with an active control 
but no placebo does not necessarily prove efficacy in a particular population or 
experimental group beyond the natural course of the condition, (Emanuel and 
Miller,2001). Where the effectiveness of available active treatment is mild or 
variable compared to new treatment, superiority over placebo is the only scientific 
way to establish efficacy, (Reynolds, 2000, Vickers, 2000).Therefore, incorporating a 
placebo group clearly increases scientific credence of the study population. Placebo 
controlled trials are considered to have a sound scientific rationale when, the studied 
population has a high placebo response rate; the condition is typically characterised 
by a remitting course with frequent spontaneous remissions and existing therapies 
are only partially effective,(Emanuel and Miller,2001). All these specified criteria are 
fulfilled within the study of TMD.
Ideally a new drug should be tested against both placebo and active control, in a 
three armed study design,(Temple and Ellenberg, 2000). This particular research 
study was in fact a four armed design which provides scientifically valid information 
on the two treatments under investigation drug and splint alone and in combination 
versus placebo. Would a trial of this design be prohibited in the future? Within 
TMD, placebo groups may be considered unethical because simple treatments have 
proven beneficial for many TMD patients; however, placebo controlled trials are 
useful for determining the most appropriate treatment for the varied TMD subgroups 
who do not respond to standard treatment (Dworkin et al, 2002c).
When considering TMD, although a range of therapies are currently employed, a 
state of‘clinical equipoise’ does exist with regards to the most appropriate form of 
treatment for this condition and its subgroups; hence justifying the need for RCT’s 
in this particular field, (Dworkin and Drangsholt,2005).
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7.4.0.2 Study participation and informed consent
Informed consent was obtained from all patients prior to enrolment in treatment.
The motivation for patients entering trials is predominantly personal benefit rather 
than altruistic or scientific in origin (Edwards et al,1998, Farr,2000). Patients usually 
trust and depend on the clinician for advice and treatment; an equipoised RCT may 
therefore seem contrary to their expectations of care,(Linde et al,2003). 
‘Randomisation’ and ‘double-blinding’ can be difficult concepts for the patient to 
grasp,(Corbett et al,1996, Stead et al,2005). Therapy, within a RCT, is no longer the 
informed decision of the patient guided by the clinician but instead a chance 
allocation not directly under the clinicians control,(Tumey,1996, Joffe et al,2001). 
This could lead to a lack of confidence in care and difficulty in acceptance of 
treatment within the trial,(Corbett et al,1996, Edwards et al,1998). To allay this fear 
requires a certain level of communication; the quality of communication between the 
patient and the clinician obtaining consent is fundamental in gauging the patients 
level of understanding and acceptance of treatment,(Stead et al,2005). National 
guidelines on written information for trial participants now exist which should be 
pre-tested to ensure readability,(Adam et al,2005). The written information sheet 
must provide a realistic view of the study without being over optimistic or 
provoking undue concern,(Stead et al,2005). Qualitative studies of the patients 
understanding and perspective of clinical trial information showed that what may 
appear objective and unambiguous to the clinician can still be misinterpreted by a 
patient with limited scientific knowledge and variable levels of understanding, often 
compounded by emotional stress associated with the decision of whether to 
participate in an experimental trial (Edwards et al,1998, Stead et al,2005). Clinicians 
sometimes underestimate the patients need for detailed information, yet conversely
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too much information can increase anxiety and reduce willingness to participate in a 
study, (Edwards et al,1998, Emanuel and Miller,2001). This in part is perhaps 
explained by the patients’ internal or external health locus of control.
The role of the clinician within a trial is, first and foremost, to protect the welfare of 
the patient; the task of physician and healer taking precedence over the role of 
researcher and scientist,(WMA,2000). Therefore, informed consent is essential, in 
all realms of treatment but particularly in clinical studies, to ensure the subject 
understands the implications of participation as an individual and as a ‘co­
adventurer’ in the prospective research,(Thornton, 1995,Linde et al, 2005). Patients, 
before embarking on treatment and when participating in the clinical trial were 
clearly informed they were under no obligation to complete the study but could 
withdraw at any stage, a standard pre-requisite for clinical research, (Linde et 
al,2003). This obviously results in the potential for individual deviation from the 
study protocol, leading to non-adherence, withdrawal from study participation and 
drop-out, which will be discussed in Chapter IX.
7.4.1  Treatment outcome
Treatment outcome was assessed when possible using the recommended intention to 
treat analysis (ITT), Altman et al,2001. This is a means whereby all randomised 
subjects are analysed according to their original treatment group, whether or not they 
completed the treatment intervention. ITT analysis provides a conservative measure 
of treatment effect and prevents potential bias by maintaining all subjects with 
baseline equivalence at random allocation,(Altman et al, 2001).
In contrast, analysis of only complete cases is problematic since the decreased 
sample size causes loss of power. Therefore, analysing data only from patients
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adherent to the assigned treatment regimes is unreliable and may be misleading, 
(Knatterand,2002,). The literature suggests this type of assessment only gives a 
clinical indicator for the possible success in an individual compliant patient. 
Therefore, when data is missing an imputation analysis is required in order to 
account for the missing variables.
Last-observation-carried-forward (LOCF), a form of imputation analysis, is 
frequently employed,(Altman et al,2001). However, it has disadvantages of bias due 
to imputed values having no variability and perfect correlation hence actually 
underestimating variability in the data set and reducing the chances of observing a 
marked effect, (Peduzzi et al, 2002).
An imputation analysis, last score brought forward, was undertaken but compared to 
the pragmatic, completers analysis. As a sensitivity analysis both sets of results were 
compared but did not show any remarkable differences or variation in outcome and 
significance.
7.4.1.1  Primary outcome measures
A favourable outcome in treatment response was recorded for all therapeutic groups. 
Improvement in >50% and >25% pain relief on the 10cm VAS was observed for 
each treatment group but there was no significant difference between groups, (tables 
19, figures 31). A combination of an SSRI (fluoxetine:Prozac) and a bite guard 
therefore appear equally effective to fluoxetine or bite guard alone in the treatment 
of chronic TMD.
However, a significant difference was observed between SSRI and placebo at >50% 
pain relief in the ITT and completers analysis. An effect size of 2.07 (Cl 1.16-3 .70) 
for the ITT, (N=201) and  1.84 (Cl 1.05-3.24)  for the completers analysis, (N=165).
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These results suggest approximately twice as many patients improve with SSRI 
compared to placebo, indicating that an SSRI (fluoxetine:Proazac) in daily oral 
doses of 20-40mg may be more effective than placebo in the treatment of patients 
with chronic TMD.
This finding was only observed at >50% improvement in pain scores. The more 
generalised improvement of >25%, perhaps more readily attainable by study 
subjects, was not statistically significant between SSRI and placebo. This might 
suggest the SSRI was effective in producing a marked reduction in pain levels for a 
particular subgroup of the population and therefore merits further investigation.
7.4.1.1.1  Numbers needed to treat analysis
The results suggest that for every 100 TMD patients who commenced treatment, 
>50% pain relief could be achieved in (100/4.1) 24 with fluoxetine,(100/14.8) 7 with 
a bite guard and (100/7.8) 13 with fluoxetine and biteguard. For every 100 TMD 
patients >25% pain relief could be achieved in (100/5 .6) 18 with fluoxetine,
(100/13.1) 8 with a bite guard and (100/5.8) 17 with both fluoxetine and biteguard. 
One might have hoped that results would indicate a synergistic therapeutic effect 
with the dual treatment but this was not apparent. The NNT was most favourable for 
the SSRI medical therapy group. Although the NNT values are not within the ideal 
range of 2-4, an NNT of 4.1  for >50% pain relief or 5 .6 for >25% pain relief, 
compares very favourably to previous studies of S SRI’s in chronic pain suggesting 
an NNT of 6.7,(Chang,2005).
Moore, 1999, suggests that in acute pain trials in order to achieve a ‘clinically 
credible’ NNT result in terms o f‘magnitude’of analgesic efficacy, 500 patients per 
group are required not the more conventional 40 patients per group, since NNT
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values between 1-9 may otherwise occur by chance. Although this study deals with 
chronic pain, random chance may still be an issue.
Another error to consider in the trial methodology is whether the initial (VAS) pain 
severity was of a significant level to enable assessment of analgesic efficacy. 
Including patients with only moderate to severe pain intensity at baseline and 
excluding those with mild or no pain optimises trial sensitivity but cannot allow for 
natural fluctuation in levels of pain intensity over time and regression towards the 
mean. What is considered moderate pain on a VAS? Collins et al,1997, suggest that 
when patients record a baseline severity score in excess of 3 cm, on a VAS, this 
probably relates to at least a moderate level on a categorical scale. The VAS severity 
recordings, used to calculate the NNT, complied with this recommendation. At 
baseline clinical consultation, patients asked to indicate on a VAS the severity of 
their pain consistently recorded a mean 5-6.3cm.
However, on examining the patient self-reported MPQ VAS in the baseline McGill 
pain questionnaire, completed prior to consultation, median pain scores are recorded 
below the mandatory 3 cm in all groups. If patients were in fact experiencing levels 
of current pain below 3 cm, suggesting mild pain, the actual measurement of pain at 
baseline and description of treatment efficacy becomes problematic. Indeed, 
repeating the NNT with the MPQ  VAS, as opposed to the VAS severity used in the 
earlier calculations, produces no meaningful results. Guidance was given by the 
clinician on completing the VAS severity. In contrast, although instructions were 
provided for completing the VAS on the MPQ, these recordings were completed 
without supervision which may give rise to initial erroneous reporting (Scott and 
Hutchinson, 1979). It has been noted that a VAS may be difficult for patients to 
complete when first encountered, (Downie,1978).
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Another issue to consider, is whether patients should be shown their initial pain 
rating when reassessing pain at review appointments,(McDowell and Newell,  1987). 
The accuracy with which an individual can recall an original pain score from 
memory varies according to the placement of the original mark at the centre or the 
extremety of the line, (Dixon, 1981).
Patients in this RCT completed the VASMPQ after a three month gap without 
visible knowledge of the original scores. Scott and Hutchinson, 1979, suggest 
patients should be shown their previous scores when the length of time between 
assessments may lead to the patients having difficulty in recalling their initial scores 
hence reducing the validity of comparing scores before and after treatment. 
Nevertheless, the VAS is a standard tool for the assessment of pain. The recordings 
taken at the regular monthly intervals on the VAS severity scale, as opposed to the 
VASMPQ,  were therefore considered the most valid for the measurement of effect 
size and NNT.
7.4.1.2  Secondary outcome measures
Hypothesis (4a): A significant improvement in the ‘clinician recorded’ 
intensity, interference and frequency of patient TMD pain, is only observed in 
the dual therapy group.
7.4.1.2.1  Pain severity and intensity
Pain severity was measured using the VAS (l-10cm line). General severity scores 
showed a significant and consistent reduction regardless of therapeutic intervention 
p<0.001. This was similarly seen in pain intensity.
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7.4.1.2.2 Frequency and interference with life
Frequency and interference with life again showed significant improvement over the 
time course of the study independent of the treatment provided. This would be 
consistent with the observed reduction in pain severity and intensity.
Hypothesis (4b): A significant improvement in the ‘self recorded’ impact of 
TMD pain on daily life; MPI severity, interference, life control and affective 
distress is only observed in the dual therapy group.
7.4.1.2.3 Mutidemensional pain inventory (MPI)
MPI results showed no significant differences between groups at three months. 
Examining the entire cohort as a single group analysis showed overall improvement 
in the patients perspective of pain p<0.001 in severity, interference, life control and 
affective distress.
Examining each group individually intra group analysis reveals reduced pain 
severity, greatest amongst group 2 and group 3  p<0.001, group 1  p<0.005 and group 
4 p <0.05.
Interference was reduced in group 2 p<0.001 and group 1  and group 3 p<0.05.
Life control was improved in group 1  p<0.005, group2 and group 3 p<0.05 whilst 
affective distress was reduced in group 2 p<0.001 and group 1  and group  4 p<0.05.
7.4.1.2.4 MPQ
Results were significantly reduced when examining all groups p<0.001. In intra 
group analysis MPQ and PPI was significantly reduced in group 1  and group 3 whilst 
VAS was significantly reduced in group 2 and group3. However, there was no 
significant difference between the four groups.
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Hypothesis (4c): There is a significant difference in ‘self recorded9  BDI 
depression scores between the commencement and completion of the study.
7.4.1.2.5 Depression
Interestingly it is the placebo and splint alone groups who showed significant 
reduction in depression scores p<0.05. However, this must be considered, in the 
light of the fact, that median scores are already below those indicative of mild 
depression.
Hypothesis (4d): There is a significant difference in ‘self recorded9  Kellner 
illness attitude and beliefs between commencement and completion of the 
study.
7.4.1.2.4  Dlness attitude
Hypochondriacal beliefs alone were seen to reduce in the Fluoxetine only group 
p<0.05 which might be related to the effect this type of drug has on the individuals 
affect.
7.5 Clinical outcome measures
7.5.1  Interincisal mouth opening
The measurement of mouth opening and range of movement is limited by the 
patient’s subjective interpretation and awareness of associated pain. However, 
maximal assisted jaw opening reduces the patients subjective component and is 
therefore considered an objective measure, (Stegenga et al,1993).Parametric 
statistics were therefore employed and revealed a statistically significant linear 
improvement in mouth opening at all four time points for both completers and 
imputation analysis, F(2.3)=6.57,p=0.001 and F(2.4)=3.69,p=0.018 respectively.
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An improvement of 2.81mm was observed in the completers analysis (n=165) and 
1.38mm for the imputation analysis (n=250). Although statistically significant this 
may not be a clinically meaningful change.
Interestingly, intra group analysis suggested the SSRI group and SSRI with splint 
groups did not appear to improve significantly over 12 weeks in the completers 
analysis p=0.167 and p=0.701 respectively, whilst improvement was noted in 
placebo and splint only groups p=0.007 and p=0.028 respectively. However, inter 
group analysis was not significant so no assumptions can be drawn from these 
findings.
Hypothesis (5a): There is a significant improvement in the signs and symptoms 
of TMD between the commencement and completion of the study.
Hypothesis (5b): A significant improvement in the signs and symptoms of TMD 
are only seen in those wearing a bite guard.
7.5.2  TMJ signs and symptoms
A significant reduction in reported TMJ pain p<0.001 and muscle discomfort p<0.05 
were recorded for all groups. Inter group analysis showed a significant reduction in 
masseter muscle pain, (p<0.05) in the splint therapy group which remained 
significant in the between group analysis (p=0.008).This concurs with previous 
studies showing a significant reduction in tender masticatory muscles with the use of 
stabilization appliances (p=0.018),(Ekberg et al, 2003).This may indicate a true 
reduction in muscle pain as a result of the splint therapy. Conversely it may relate to 
an increase in muscle pain related to the medical therapy group due to the possibility 
that SSRIs may increase the level of bruxism and insomnia so aggravating TMD.
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The character of pain notably dull ache and sharp episodes also decreased 
significantly in all groups, (p<0.001).However, patients continued to describe 
symptoms of TMJ and muscle pain throughout the course of the study which 
reinforces the concept of whether results can be considered clinically meaningful. 
Perhaps patients although aware of symptoms, no longer experienced a 
‘dyfunctionaT TMJ but could now be classified as ‘functional’, having reached a 
point of symptom tolerance where, despite mild symptoms, there was less 
significant interference with daily activities of social functioning notably eating, 
chewing, talking and yawning.
7.5.3 Orofacial pain
In contrast, increased pain was related to the face,(p=0.002), ears,(p=0.003) and 
teeth,(p=0.019) were noted in the splint therapy group which remained significant 
between groups. This might relate to an increased focus on the occlusion and an 
awareness of the face, preauricular region of the ear and teeth whilst wearing an 
occlusal appliance.
Hypothesis (5c): There is a significant difference in the number of co>morbid 
pain conditions reported between commencement and completion of the study. 
Hypothesis (5d): A significant improvement in co-morbid pain conditions is 
only seen in those taking SSRI (fluoxetine).
7.5.4 Chronic recurrent pains
Headache, migraine, neck ache, backache and abdominal pain all decreased 
significantly during the course of treatment, (p<0.001). In chapter VI, comment was
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made of the high level of concomitant headache (61%), neck ache (50%) and 
backache (48%) amongst study participants. There is evidence to suggest patients 
with TMD and multiple chronic pain conditions are more psychologically distressed, 
(LeResche et al,1987, Dworkin et al,1990). Such patients may also be more prone to 
develop long term TMD with pain related disability and persistent pain, (John et 
al,2003, Rammelsburg,2003).This may indicate that patients with multiple co- 
morbid pain conditions would have been more recalcitrant to therapy particularly a 
simple physical occlusal appliance. However, the patients in this RCT appear to 
have responded favourably to a decrease in co-morbid pain conditions regardless of 
therapeutic intervention. It would be interesting to observe long-term, whether the 
decrease in co-morbid pain conditions was simply a transitory phenomena, for the 
duration of study participation.
7.6  Overall outcome
In relation to hypothesis la; An SSRI (fluoxetine; Prozac) in daily oral doses of 20- 
40mg has been found to be more effective than placebo in the treatment of patients 
with TMD.
In relation to hypothesis lb; A combination of an SSRI (fluoxetine;Prozac) and a 
bite guard have been found to be equally effective to fluoxetine and bite guard alone 
in the treatment of chronic TMD.
Initially it had been proposed that group 4, the splint and drug combination, would 
provide the most comprehensive treatment. Increased therapeutic content provided 
by two clinicians could theoretically have resulted in higher levels of improvement, 
There was no difference between groups in the majority of primary and secondary 
outcome measures. The placebo often appeared equally effective to the dual therapy.
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In TMD, it has been shown that conservative advice and reassurance is responsible 
for improvement or resolution of symptoms in 40% of the population, (Wright and 
Schiffman, 1995).The results of this study may therefore simply reflect a generalised 
improvement following informed  and explanatory reassurance of the nature of the 
pain condition at the initial consultation. If reassurance alone was responsible for 
improvement, one might wonder why patients would have entered into the 
inconvenience of attending a study. The patients who entered treatment may have 
sought reinforcement of the therapeutic alliance with regular clinical appointments 
within a hospital environment, which in itself could be viewed as a therapeutic 
intervention or an element of the placebo phenomena. Improvement in pain may also 
reflect a general improvement due to the satisfactory completion of the treatment 
intervention. It may not necessarily be the prescribed treatment that is important but 
unknown confounding factors, the manner, environment or mere provision of 
treatment that is important, reinforcing the concept that treatment approaches may 
be variable provided they remain reversible and non-invasive.
Overall, regardless of therapeutic intervention, there was a significant reduction in 
pain scores, primary and secondary outcome measures, over the trial period. This 
may imply that all patients improve regardless of therapy and may simply reflect a 
natural regression towards the mean, (Whitney and Von Korff,  1992). If this were 
the case, then one might consider whether the therapeutic intervention plays any 
active role in the improvement observed or could the patients simply have been 
observed over the study period. In order to confirm this hypothesis a group receiving 
no therapeutic intervention, a waiting list group, could have been included.
However, such an approach was not thought appropriate and could be deemed 
unethical when considering the evidence suggesting that the sooner chronic pain is
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treated , the greater the chances of a successful therapeutic outcome. However, the 
high level of placebo response observed in this RCT is not unusual.
7.7  The placebo effect
The placebo response is often observed but varies considerably between clinical 
trials; the high correlation of medication and placebo response frequently causes 
difficulty in proving superior efficacy of the study drug, (Walach et al, 2005). One 
third of published trials of antidepressants in the treatment of depression fail to 
demonstrate efficacy,(Thane, 1999).
The placebo response in relief of chronic pain is reliant on the phenomena of 
regression towards the mean, the natural history of remitting and fluctuating 
symptom levels together with the sensitivity of patients to the encouragement and 
nurturing received during treatment,(Kienle and Kiene,1997, Kirsch,1997,
McDonald and McCabe, 1989).
Kaptchuk et al, 2006, suggests not all placebos have equivalent effect but vary 
depending upon the clinical environment and ‘behaviours embedded in the medical 
ritual’. Neurobiological, psychosocial and psychodynamic mechanisms of the 
placebo effect are gradually being unravelled,(Colloca and Benedetti,2005, Wager et 
al,2004, Pariente et al,2005, Mayberg et al,2002).The diverse range of empirical 
factors are too numerous to list but tangibly may include: appearance, attitude and 
seniority of the clinician together with the placebo treatment received; colour of 
tablets, expected side effects, use of sham needles, technical equipment or surgical 
intervention,(Kaptchuk  et al,2006).
The use of the placebo controlled trial was also considered to be the major influence 
on drop-out in antipsychotic drug trials prompting consideration of alternative
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designs, (Kemmler et al,2005). To reduce the placebo effect in depression and 
increase the power of trials it is suggested recruiting only subjects with moderate 
and severe illness and incorporating a four week lead in phase with patient education 
on depression to reduce the placebo response once the trial begins. A pre­
randomisation placebo run-in period has been used in an attempt to exclude poor 
adherents,(Davis et al,1995). The participants for the potential clinical trial were 
considered poor adherents if they took less than 80% of their medication and were 
mainly identified amongst the less educated population. However, placebo run-in 
had a negative effect on recruitment with little effect on outcome and was not 
recommended for highly educated participants.(Davis et al 1995).
Improvement during placebo treatment appears to be attributed to the non-specific 
factors of clinical trial participation rather than taking medication as recorded in a 
study evaluating the effect of placebo versus no treatment during a hypnosis trial 
(McCall et al, 2005). A three arm clinical study including an active control group is 
recommended to demonstrate superiority of active reference and experimental 
treatment over placebo,(Hauschke and Pigeot,2005).
Desbiens,2002, suggests more effort should be made in studies to ensure placebo 
treatment cannot be distinguished form active treatment. Walter et al, 2005 
undertook pre-trial evaluation of potential un-blinding of medication by determining 
if tablets could be differentiated by taste and appearance. Taste was not significant 
but texture, colour and shape of tablets showed borderline significance although 
tablets were compared simultaneously side by side which is unlikely to occur in a 
parallel group drugs trial. The placebo treatment in this study was identical in 
appearance, colour and texture to the active drug treatment.
Ernst and Resch,1995, indicates that within clinical trials a mixture of true and false
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placebo responses exist. The true placebo effects may be due to ‘the meaning of an 
intervention’ for a particular patient and the resultant therapeutic effect, (Moreman 
and Jonas,2002). Therapeutic effects of treatment may be considered a ‘meaning 
effect’ when complex interactions occur within an individual to induce healing, 
(Moreman, 2002). The individual attempts to construct meaning out of their medical 
condition, therapeutic intervention and accompanying psychological state with 
observed alteration in brain function (Wagner et al,2004, Pariente et al,2005). 
Hrobjartsson, 2002, indicate that the true placebo response rate of a RCT can not be 
measured when a natural control group is absent. Incorporating a third component: 
treatment, placebo and natural history control group found no significant difference 
for dichotomous variables but a significant effect size for continuous measures 
reflecting the placebo effect in pain, (Hrobjartsson and Gotzche,2001). Although a 
waiting list group is sometimes recommended this was not employed in this study 
since withholding any form of treatment seemed unethical.
The components of the placebo effect have only been analysed in a few clinical 
trials (Amarzio et al,2001, Vase et al,2003). Indirect secondary analysis of published 
trials was undertaken to investigate the study characteristics which contribute to 
placebo response rate in RCT’s,(Walach et al,2005). Walach and Maighof,1999, 
analysed 26 RCT’s of treatment duration of 12 weeks or greater and found a 
significant correlation between placebo response rate(r=0.59). In studies of 
antidepressants there was an even higher correlation between treatment and placebo 
group (r=0.9),(Kirsch and Sapirstein,1998 cited in Walach, et al,2005). These 
findings were replicated in an analysis of SSRI’s, using licsensing data, which found 
that 82% of the drug effect was in fact replicated by placebo, (Kirsch et al,2002, 
cited in Walach et al,2005).
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Expectations and cognitions of the clinician and patient may influence response rate 
in addition to the investment of time, effort and involvement of staff within the 
study and direct patient contact. Walach et al 2005, conducted a systematic review 
of published data to determine if the placebo rate in RCT’s was dependant not only 
on quality and length of study but also a range of further characteristics including 
organisational aspects, methodology including unblinding, time and intensity of 
patient contact and attitude of investigators towards the study. The duration of the 
studies were all chosen to encompass an appropriate time period of natural 
fluctuation. Placebo improvement rates were significantly correlated to improvement 
rates in treatment groups r=0.78 , in duration of study r=0.41 and in preventative 
trials r=0.59. Methodological quality including unblinding did not appear to be 
correlated. The non-specific effects of treatment were therefore found to be more 
important than the specific effects of treatment as also noted in previous studies, 
(McQuay,1996, Vase et al,2003, Walach and Jonas,2004).Walach ,2005 found that 
non specific effects of treatment accounted for 60% of the variance in treatment 
effects; natural history of the condition under study or general cohort effects perhaps 
explaining the high correlation. In a subsidiary analysis an even higher placebo 
response rate was noted in studies of antidepressants and anxyolitics.
Clearly from the literature, a wide variability in placebo response is 
frequently a feature of pain studies, (Ware, 1993). Kirsch and Sapirstein,1998, in a 
meta analysis of 19 trials using fluoxetine, calculated that the placebo affect 
accounted for 50% of the observable improvement. Earlier, in the 1980’s a series of 
meta analyses for a quality assurance programme of antidepressants in mental 
disorders found that placebo accounts for 60% improvement in depression, 53% in 
anxiety disorder, 23% in agoraphobia and 21% in obsessive compulsive disorder,
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(Andrews,2001). Walach et al, 2005, suggests the placebo response rate reflects a 
genuine improvement and accounts for nearly 60% of the variance of all treatment 
effects. They found study characteristics notably methodological anomalies and 
diagnoses treated partly explain the placebo response but significant positive 
predictors of the placebo response include: preventive trials, duration and quality of 
study, (Walach et al,2005). It appears the placebo response increases for longer 
studies and those of better methodological quality whereas a decreased response is 
seen when dropouts and additional treatment have not been documented,(Walach et 
al,2005)
The large placebo response is clearly a major confounding factor for research drug 
trials (Enserink, 1999). The extent of the placebo response although perhaps 
problematic in research could be beneficial for general treatment. When analysing 
studies that maximise the placebo effect there was a much greater effect size 
(d=0.95) compared to those using placebo merely as a control measure (d=0.15), 
(Vase et al, 2002). Rather than being viewed as a hindrance, potentiation of the 
placebo effect, by simple psychological strategies, could be utilized in the clinical 
setting to optimise patient care,(Andrews,2001).
7.8  Sleep
Sleep is an essential element to an individuals feeling of well being with disturbance 
of sleep patterns causing fatigue, worsening pain and aggravating depression, 
(Brousseau et al, 2003, Araow et al, 2006).
From animal studies it has been noted that Fluoxetine suppressed REM (rapid eye 
movement) sleep; cats became irritable and hostile during REM sleep after several 
days of receiving fluoxetine, decreasing with continued treatment and disappearing
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on cessation of the drug, (Slater et al, 1978). In human clinical trials, sleep again 
appeared to be the only symptom where improvement with Fluoxetine was not 
significantly superior to placebo at the end of the study. Meanwhile, the tricyclic 
antidepressants, such as imipramine, were significantly superior in relation to sleep 
patterns compared to fluoxetine, (Cohn and Wilcox, 1985). The effect on sleep 
clearly varies between antidepressant classes, (Mayes and Baldwin, 2005, Lam, 
2006). The lack of sedative action in relation to fluoxetine, causing an alerting or 
insomniac effect, is well known although equivocally some patients do report 
tiredness, (BNF, 2006).
However, one could suggest that perhaps the key factor with regards to sleep 
disturbance in the use of fluoxetine, is the alteration of the sleep pattern. From EMG 
studies of the TMJ masticatory function it is clear that nocturnal bruxism occurs 
during sleep, (Dahlstrom,1989, Lavigne et al,  1999). Any agitation during this time, 
could hypothetically, therefore, increase the level of grinding and tooth clenching, in 
fact exacerbating the TMJ condition. This could therefore begin to explain the 
observed and unexpected lack of clear improvement in the SSRI and SSRI and splint 
groups. It is feasible that the drug was inadvertently aggravating the neuromuscular 
grinding habit during sleep especially during the initial stages of usage. Such 
supposition would require controlled sleep studies with Fluoxetine or SSRIs, TCA’s 
and placebo to monitor masticatory muscle activity during sleep.
7.9  Outcome predictors
Performing a logistic regression analysis of outcome predictors it was hoped to 
establish a model to account for pain improvement >25% and >50% at three months 
(table 68,69). Pain improvement of 25%, was related to MPI support by significant
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family or friends OR=1.26 (Cl 1.00,1.59) p=0.049 and outdoor activity OR =1.4 (Cl 
1.01-1.94) p=0.043. Support by others is clearly an important facet of pain 
management as found in previous studies (Newton-John, 2004).Outdoor activity is 
an interesting finding suggesting fresh air exposure and exercise. This will no doubt 
to some extent be seasonally dependant on the weather and may, therefore, 
additionally act as a confounding factor in the course of the study.
Pain improvement of greater than 50%, was associated with a more comprehensive 
model of factors. A decrease in successful outcome was related to several factors 
including: the duration of TMJ pain at presentation to the clinic; the presence of 
additional chronic recurrent pains (backache, abdominal pain and temporal pain); 
high scored ratings in Kellner (disease phobia) and  MPI (punishing response and 
social activity level). Increase in VAS and general activity level at baseline 
improved the chances of a successful outcome OR=3.43 (Cl 1.09,10.73) p=0.034.
In an attempt to analyse the study cohort in more depth, in the following chapter, 
subgroup analysis will be explored. Groups will be examined in relation to the 
initially depressed and non-depressed, initially high and low pain scores and 
responders and non-responders to therapy to see if patterns of improvement were 
evident or established between particular groups.
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8.0  SUB-GROUP  ANALYSIS
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Hypothesis (6a), (6b), (6c)
(6a)  A significant and measurable improvement in pain  is only seen in those
patients without depression at baseline.
(6b)  A significant and measurable improvement in pain  measures are only seen
in those patients with initially high pain scores
(6c)  Clinical and pain history characteristics at baseline separate the treatment
responders from the non responders
8.0  Subgroup analysis
Subgroup analysis was performed to investigate whether there was any difference 
between the initial demographics, clinical history, examination and pain questionnaire 
scores in responders(>50% pain improvement) and nonresponders to therapy, (<50% 
pain improvement).
Demographics and outcome response in those who initially had high depression scores 
(BDI score >9.00) and high pain scores (MPI severity scores >3.00) were examined to 
determine if this influenced outcome measures.
The three subgroups to be analysed:
The effect of depression on outcome measures  (section 8.1)
The effect of initially high pain scores on outcome  (section 8.2)
The difference between responders and non-responders  (section 8.3)
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8.1  THE EFFECT OF DEPRESSION 
ON OUTCOME MEASURES
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8.1.0 The effect of depression on outcome measures
Hypothesis (6a) A  significant and measurable improvement in pain is only seen in 
those patients without depression at baseline.
8.1.1  BDI scores at baseline
The baseline BDI scores of depression were non parametric, with the distribution 
curve skewed to the left,(figure 44). The majority of patients were clinically non­
depressed with a median score of 7.00 (25th and 75th percentiles 3.00-13.00).
Using non-parametric bivariate correlation, significance was established at the 0.01 
level, with a number of variables. Unexpectedly, the duration of pain did not correlate 
with depression (p=0.535).
A positive correlation at the 0.01 level was observed at baseline between: age, r =0.189 
(p=0.003), MPQ:  VAS (r = 0.228 p=0.001), PPI (r =0.228 p =0.001), total% (r =
0.402 p <0.001), sensory % (r = 0.355 p<0.001), affective % (r = 0.426 p<0.001), 
Kellner: illness attitude (r = 0.364 p<0.001), hypochondriacal beliefs (r=0.314 
p<0.001), disease phobia  (r = 0.317 p<0.001), M PI: pain severity (r = 0.313 p<0.001), 
interference (r = 0.467 p<0.001),affective distress (r =0.533 p<0.001) and punishing 
response (r =0.320 p<0.001)
A negative correlation at baseline was observed between BDI score and MPI activities 
away from home (r = -0.262,p<0.001), social activities (r = -0.197, p=0.003) and life 
control (r = -0.491 p<0.001).
8.1.2 BDI scores at three months
After treatment at three months again a positive correlation was observed between BDI 
score at baseline and the MPI scores at three months: severity  (r=0.271, p<0.001),
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interference (r=0.426,p<0.001), affective distress (r=0.446,p<0.001), punishing 
response (r=0.352,p,0.001), household chores (r=0.128,p<0.05), outdoor work 
(r=0.148,p=0.03) with a negative correlation between BDI score at three months and 
MPI activities away from home (r=-0.185,p=0.004).
A positive correlation was found with MPQ:  VAS (r=0.256,p<0.001),PPI 
(r=0.025,p<0.001), total (r=0.314,p<0.001), sensory (r=0.261,p<0.001), affective 
(r=0.428,p<0.001), Kellner: total (r=0.425,p<0.001),hypochondriacal beliefs 
(r=0.377,p<0.001), disease phobia (r=342,p<0.001).Similar correlations were also 
found with the BDI scores recorded at three months.
8.1.3  BDI categorised into depressed and non depressed subgroups
Although there is a significant (p<0.005) amelioration in BDI rating at three months, 
there are clearly a number of outliers,(figure 45). To examine this broad variation, BDI 
scores at baseline were first categorised into levels of depression (scores 0-9 none, 10- 
14, borderline, 15-20, mild, 21 or above severe),(figure 46).There was no significance 
in the distribution between therapeutic groups x2 =1.272(3),p=0.736,(table35).
This was further dichotomised into depressed (n=84) and non depressed (n=153), with 
no significant difference between groups x2 = = 2.313(3),p=0.510,(figure 47).
These two categories were then analysed to determine the significance of depression in 
relation to a series of reported variables. These included; demographic details, sleep 
disturbance and prevention, emotional factors influencing pain, reporting of chronic 
pains and treatment, outcome variables, self reporting scales and pain questionnaires.
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Figure 44: BDI scores at  baseline
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Figure 45: Amelioration in BDI scores at three months
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Figure 46: BDI levels
Not depressed (0-9), borderline (10-14), mild (15-20),  severe (21 and above).
I
not depressed
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I   1 SSR1 mild depression
|Splint severe depression
|  |SSRI and splint
O 10 20 30 40 50
Count
Table 35: Depression at baseline
Depression at baseline SSRI Placebo Splint SSRI and 
Splint
Total
No depression 36 40 41 36 153
Borderline 10 6 5 9 30
Mild 10 6 4 8 28
Severe 4 7 8 7 26
Total 60 59 58 60 237
Figure 47: BDI dichotomised into depressed and non depressed categories
not depressed
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8.1.4 Demographic details (Table 36)
Demographic details between depressed and non depressed categories were non 
significant apart from age, p=0.041 .The depressed patients were slightly older with an 
average mean age of 34 (SD 10), compared to the non depressed who had an average 
age of 31 (SD 9).
8.1.5 Alteration in sleep patterns (Table 37, Figure 48)
There was a significant difference in reported sleep alteration. The depressed group 
suffering significantly increased sleep prevention and disturbance (p<0.001).
8.1.6 Emotional factors influencing pain (Table 36, Figure 49)
Emotional factors reported as an initiating factor for pain was just significantly raised 
in the depressed group (p=0.049). Emotional distress, identified by patients as a 
provoking factor for the pain, was significantly higher in the depressed group
(p<0.001).
8.1.7 Recurrent chronic pains (Table 39)
Table 30, indicates there was a significant decrease in headaches (p=0.001), abdominal 
pain (p=0.001), neckache (p=0.01) and backache (p=0.01) in non depressed compared 
to depressed groups.
Logistic regression is then used to analyse these results in more detail and is presented 
with tables 40a and 40b.
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Table 36: Demographic details for depressed and non-depressed groups ( N=237)
Recorded at baseline 
assessment
All groups 
(n=237)
Depressed
(n=84)
Nondepressed
(n=153)
Significance
Age (in years) 
Mean (+/- SD) 
Range
32.7
(16-55)
34.06 (10.08) 
(18-55)
31.37(9.37)
(16-53)
*
(p=0.041)
Duration of pain (inyrs) 
Mean (+/- SD)
Range
3.31(4.55)
(0.25-32.0)
3.91 (5.73) 
(0.25-32.0)
2.98 (3.73) 
(0.25-22.00)
ns
(p=0.131)
Gender M: F 54:183
22.8%:77.2%
18 : 66
21.4%: 78.6%
36 :  117 
23.5%:76.5%
ns
(p=0.712)
Referral source
GDP
GP
Specialist
219 (92.4%) 
5(2.1%) 
13 (5.5%)
75 (89.3%) 
2 (2.4%)
7 (8.3%)
144 (94.1%) 
3 (2.0%)
6 (3.9%)
ns
(p=0.349)
Employment status
Employed
Unemployed
Student
Retired (medical) 
House wife
158 (66.7%) 
18 (7.6%) 
36(15.2%) 
1   (0.4%) 
24(10.1%)
62 (73.8%)
4 (4.8%) 
12 (14.3%)
1  (1.2%)
5 (5.9%)
96 (62.7%) 
14 (9.2%) 
24 (15.7%) 
0 (0%)
19 (12.4%)
ns
(p=0.165)
Socio-economic status
Professional  I 
Intermmediate  Hi 
Skilled non-manual  Ilii 
Skilled manual  III 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, retired
10 (4.2%) 
75 (31.6%) 
61 (25.7%) 
8 (3.4%)
5 (3.3%)
1 (0.4%) 
77 (32.5%)
4 (4.8%) 
30 (35.7%) 
24 (28.6%) 
2 (2.4%)
1  (1.2%)
1  (1.2%) 
22 (26.2%)
6 (3.9%) 
45 (29.4%) 
37 (24.2%) 
6 (3.9%)
4 (2.6%)
0 (0%)
55 (36.0%)
ns
(p=0.355)
Marital status
Single
Married
Seperated
Divorced
Widowed
139(58.6%) 
85 (35.9%) 
2 (0.84%) 
10 (4.2%)
1  (0.4%)
51 (60.7%) 
30 (35.7%) 
1  (1.2%)
2 (2.4%)
0 (0%)
88 (57.5%) 
55 (35.9%) 
1  (0.7%)
8 (5.2%)
1  (0.7%)
ns
(p=0.702)
Significance test, Chi-squared (Independent samples t-test for age and duration) all ns.
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Figure 48:
Sleep prevention and disturbance in depressed and non depressed groups
Sleep prevention (n=237)  Sleep disturbance (n=237)
Prevents sleep
□   No 
m   Yes
Disturbs sleep 
□   No 
m  Yes
not depressed not depressed depressed
depression base line  depression base fine
Table 37: Sleep alteration in depressed and non depressed groups
Sleep alteration Non depressed (n=153) Depressed (n=84) Significance
Prevention 54 (35%) 55 (66%) p<0.001
Disturbance 57 (37%) 56 (67%) p<0.001
Figure 49:
Emotional factors influencing onset and provocation of pain
Emotional upset (initiating factor)  Emotional upset (provoking factor)
Emotional tension 
□   No 
0   Yes
Emotional upset
□   No
■   Yes
not depressed  depressed  not depressed  depressed
depression base line  depression base line
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Table 38: Emotional distress in depressed and non depressed groups
Emotional distress Non depressed
(n=153)
Depressed
(n=84)
Significance
Emotional upset 
(pain initiating factor)
30 (20%) 26 (31%) p=0.049
Emotional upset 
(pain provoking factor)
66 (43%) 60 (71%) p<0.001
Table 39:
Recurrent chronic pains for depressed and non depressed groups (n=237)
Chronic pains Non depressed
(n=153)
Depressed
(n=84)
Significance 
(between groups)
Headache Baseline 
4 weeks 
8weeks 
12 weeks
86 (56.2%)
68 (44.4%)*
68 (44.4%)** 
58 (37.9%)*** 
* * *
60 (71.4%) 
44 (52.4%)** 
51 (60.7%)
51 (60.7%) 
* *
*  p=0.021
ns p=0.261
*  p=0.017
** p=0.001
Migraine Baseline 
4 weeks 
8weeks 
12 weeks
43 (28.1%)
28 (18.3%)** 
27 (17.6%)*
23 (15.0%)*** 
* * *
33 (39.3%) 
18(21.4%)** 
17 (20.2%)*** 
19 (22.6%)** 
* * *
ns p=0.078 
ns p=0.389 
ns p=0.624 
ns p=0.143
Neckache Baseline 
4 weeks 
8weeks 
12 weeks
65 (42.5%)
43 (28.1%)** 
52 (34.0%)*
38 (24.8%)*** 
* * *
51 (60.7%)
40 (47.6%)*
36 (42.9%)** 
34 (40.5%)*** 
* * *
*  p-0.007 
ns p=0.119 
ns p=0.176
* p=0.012
Backache Baseline 
4 weeks 
8weeks 
12 weeks
67 (43.8%)
40 (26.1%)***
41 (26.8%)*** 
37 (24.2%)*** 
* * *
48 (57.1%)
29 (34.5%)*** 
29 (34.5%)** 
31 (36.9%)*** 
* * *
* p=0.049 
ns p=0.490 
ns p=0.212
*  p=0.038
Abdominal pain Baseline 
4 weeks 
8weeks 
12 weeks
36 (23.5%) 
16(10.5%)*** 
18(11.8%)*** 
16 (10.5%)*** 
* * *
33 (39,3%) 
18(21.4%)* 
18(21.4%) 
23 (27.4%) 
* * *
*  p=0.011
ns p=0.512
*  p=0.047
**p=0.001
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8.1.7.1  logistic regression analysis of chronic pains in relation to depression 
Table 40a:
Logistic regression analysis of chronic pains in relation to depression at baseline
Enter method OR
(Odds ratio)
95% Cl
(Confidence
interval)
P value Regression
coefficient
SE
(standard error)
Temporal (scalp) 
pain
2.67 1.45-4.93 0.002** 0.984 0.312
Abdominal pain 2.06 1.33-3.76 0.018* 0.725 0.306
Teeth pain 7.18 1.32-39.05 0.023* 1.97 0.864
* p<0.05, **p<0.005.
This model 69.6% correctly predicts depression at baseline, x2  =21.57 (3),p<0.001. 
There is an almost 3 fold increase in likelihood of depression amongst those with 
reported temporal (scalp) muscle pain at baseline (OR=2.67,95% Cl 
1.45,4.93,p=0.002). There is a two fold increase amongst those with reported 
abdominal pain (OR=2.06,95%CI 1.33,3.76,p=0.018) and a remarkable seven fold 
increase in those with reported concomitant dental pain from clenching, bruxism or 
biting (OR=7.18 95%CI 1.32,39.05,p=0.023)
Analysing chronic pain report at three months again several factors predict depression. 
Table 40b:
Logistic regression analysis of chronic pains in relation to depression at 3 months
Enter method OR
(Odds
ratio)
95% Cl
(Confidence
interval)
P value Regression
coefficient
SE
(standard error)
Headache (3 months) 2.13 1.20-3.76 0.009* 0.76 0.38
Abdominal pain 
(3 months)
2.78 1.33-5.81 0.006* 1.02 0.56
Teeth pain (3 months)  3.49 1.18-10.40 0.024* 1.25 0.22
* p<0.05, **p<0.005
This model 71.3% correctly predicts depression at baseline, x2  =23.51 (3),p<0.001.
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Headache at three months indicates a two fold increase in depression at baseline 
(OR=2.13,95%CI 1.20-3.76,p=0.009), abdominal pain nearly a three fold increase in 
likelihood of depression (OR=2 78,95%CI 1.33,5.8 l,p=0.006) and dental pain also a 
three fold increase (OR=3 .49,95%CI 1.18,10.40,p=0.024).
8.1.8  Verbal reported pain rating scales
8.1.8.1  VAS  (depressed and non depressed categories! (Table 41, figure 50)
8.1.8.1.1 Parametric analysis
Analysing the whole study cohort there is an observable and significant improvement 
in both depressed and non depressed categories at all three time points, p<0.001.
For individual groups, group 1  significantly improved in both depressed and non 
depressed categories p=0.001 by three months. This improvement was not significantly 
perceptible at four weeks in the non depressed group, but both categories showed 
significant improvement during the eight and twelve week follow-up.
Interestingly, placebo group 2, showed no overall significant improvement amongst 
depressed subjects but significant improvement amongst the non depressed category 
p<0.001. With splint usage, group 3, again significant improvement was observed 
amongst the nondepressed  subjects p<0.001 but to a lesser ,yet significant extent in 
the  depressed category p=0.003. In group 4, again both depressed and nondepressed 
categories improved p<0.005 and p<0.019 respectively. Having observed the slight 
variation in pattern of improvement, there was nonetheless no significant differences in 
the improvement amongst depressed and non depressed categories between the four 
groups. Again, inter group analysis revealed no significant difference between groups.
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8.1.8.1.2 Non parametric analysis
Analysing all groups together there was a significant improvement in both depressed 
and non depressed categories (p<0.001). Examining individual groups, this dual 
pattern was mirrored in group 4 combined therapy , depressed p=0.001 and non 
depressed  p=0.003. Meanwhile, groups 1,2 and 3 only showed significant 
improvement in the non depressed groups (p<0.001) but less marked, although 
significant improvement in depressed categories for group 1 and 3 p=0.004 and 
p=0.003 respectively. However, group 2 placebo did not show overall improvement 
amongst the depressed individuals. Inter group analysis revealed no significant 
difference between groups.
8.1.8.2  PPI f  depressed and non depressed categories! (Table 43)
Once again, analysing all groups synchronously there was a significant improvement 
in both the depressed and non depressed categories (p<0.001).
Intra group analysis did not reflect this pattern. Group 2 (placebo) showed no 
significant improvement over the three month course of therapy regardless of 
depression state. In group 4 (combined therapy) both depressed and non depressed 
groups reached the minimal level of significance p=0.023 and p=0.006 respectively. In 
group 3 (splint) the non depressed group significantly improved (p=0.001) with less 
marked, yet still significant improvement in the depressed category p=0.024!n group 1  
(fluoxetine) the observation was reversed. It was the depressed group that significantly 
improved p<0.001 with no significant improvement in the non depressed category 
p=0.066.0verall, there was statistically no significant difference between groups.
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8.1.8.3  Frequency (depressed and non depressed categories! (Table 44)
Improvement was observed in both depressed and non depressed categories. In 
combined groups for depressed and non depressed categories p<0.001. On closer 
inspection of the intra group analysis notably in groups 1,2 and 3 it was clearly the non 
depressed categories who exhibit the most significant improvement over the three time 
points,p<0.001, whilst the depressed categories are less significant p=0.013 (groupl), 
p=0.002 (group2), p=0.011 (group3). In group 4 the depressed and non depressed 
categories both improved p=0.003 and p=0.008 respectively. Inter group analysis 
revealed no significant difference in improvement between the four groups.
8.1.8.4 Pain severity (depressed and non depressed categories) (Table 45)
A significant improvement was observed, amongst all groups together, in both 
depressed and non depressed categories, p<0.001. Analysing the intra group analysis it 
was clearly the non depressed categories who exhibit the most significant 
improvement over the three time points p<0.001. In groups 1,2 and 4 the improvement 
in depressed categories also reached significance, p=0.006 (group 1) p=0.005 (group 2) 
and p=0.002 (group 4). However, in group 3 the depressed category did not 
significantly improve p=0.123. Intergroup analysis was non significant.
8.1.8.5  Interference (depressed and non depressed categories) (Table 461
Improvement was seen in both categories when analysisng all patients together 
p<0.001. This finding was also reflected in both groups 1  and 4  (p<0.001).However, 
only non depressed patients showed similar improvement (p<0.001) in groups 2 and 3. 
Depressed patients showed less significant improvement in group 2 (p<0.005) and 
group 3 (p<0.05).However, once again there was no inter group statistical significance.
3563
5
7
Table 41: A comparison of Depressed / Non depressed categories - Imputation analysis (last score brought forward!
Week All groups 
(n=237)
Group 1  
(n=60)
Group 2 
(n=59)
Group 3 
(n=58)
Group 4 
(n=60)
Significance 
between groups. 
One-way ANOVA
Depressed Non
depressed
Depressed Non
Depressed
Depressed Non
Depressed
Depressed Non
Depressed
Depressed Non
Depressed
Depressed Non
Depressed
0 6.15
(2.43)
5.60
(2.17)
6.60
(2.42)
5.62
(1.94)
5.33
(2.71)
6.25
(2.09)
5.89
(2.01)
5.40
(2.27)
6.54
(2.44)
5.11
(2.28)
ns
p=0.286
ns
p=0.126
4 4.97
(2.21)
***
4.62
(2.19)
***
5.01
(2.46)
* p=0.008
4.67
(2.31)
p=0.05
4.52
(2.21)
p=0.274
5.14
(2.12)
**p=0.004
5.41
0.75)
p=0.166
4.48
(2.08)
* p=0.003
4.98
(2.30)
** p=0.003
4.18
(2.24)
* p=0.022
ns
p=0.702
ns
p=0.275
8 4.70
(2.53)
***
4.21
(2.39)
***
4.93
(2.93)
* p=0.015
4.34
(2.46)
* p=0.014
4.29
(2.10)
p=0.117
4.59
(2.42)
***
4.48
(1.81)
* p=0.004
4.15
(2.46)
**p=0.001
4.95
(2.91)
* p=0.009
3.72
(2.23)
** p=0.004
ns
p=0.791
ns
p=0.447
12 4.31
(2.54)
***
3.90
(2.51)
***
4.17
(2.87)
**p=0.001
3.64
(2.69)
** p=0.001
4.03
(2.04)
* p=0.025
4.21
(2.52)
***
4.70
(2.10)
* p=0.010
3.78
(2.42)
***
4.39
(2.91)
* p=0.005
3.94
(2.50)
* p=0.019
ns
p=0.872
ns
p=0.787
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Group 3 - Splint therapy
p=0.001  p=0.001  p=0.11 p=0.003 p=0.005  p=0.019
Intra group analysis :  Repeated measures ANOVA  P<0.00014*4*4*  P<0.0054*4* P<0.054* 
Paired sample t-tests  p<0.05 *  p<0.005 **  p<0.001***
Group 4 - Fluoxetine and splint therapy  Inter group analysis :  One -way ANOVA - not significant.
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Figure 50 : VAS (visual analogue scale) A comparison of mean scores
Depressed  (n=84)  Non depressed  (n=153)
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Table 42: Outcome measures -  Present pain intensity scores - Depressed / Non Depressed - Intention needed to treat analysis
Week Present
pain
All groups (n=237) Group 1  (n=60) Group 2 (n=59) Group 3 (n=58) Group 4 (n=60)
Depressed
(n=84)
Non
Depressed
(n=153)
Depressed
(n=24)
Non
Depressed
(n=36)
Depressed
(n=19)
Non
Depressed
(n=40)
Depressed
(n=17)
Non
Depressed
(n=41)
Depressed
(n=24)
Non
Depressed
(n=36)
0 None
Mild
Moderate
Severe
0 (0%)
25 (29.8%) 
34 (40,5%) 
25 (29.8%)
0 (0%)
73 (47.7%) 
61 (39.9%) 
19(12.4%)
0 (0%)
6 (25.0%) 
10(41.7%) 
8 (33.3%)
0 (0%)
17 (47.2%) 
12(33.3%) 
7(19.4%)
0 (0%) 
6(31.6%) 
9 (47.4%) 
4(21.1%)
0 (0%)
17 (42.5%) 
20 (50.0%) 
3 (7.5%)
0 (0%)
6 (35.3%) 
6(35.3%) 
5 (29.4%)
0 (0%)
22 (53.7%) 
16(39.0%) 
3 (7.3%)
0 (0%)
7 (29.2%) 
9 (37.5%)
8 (33.3%)
0 (0%)
17 (47.2%) 
13(36.1%) 
6(16.7%)
4
None
Mild
Moderate
Severe
6(7.1%)
30 (35.7%)
31 (36.9%) 
17(20.2%)
**  (p=0.002)
9 (5.9%) 
84 (54.9%) 
46 (30.1%) 
14(9.2%) 
* * *
2 (8.3%) 
11 (45.8%) 
4(16.7%) 
7 (29.2%)
*  (p=0.020)
2 (5.6%) 
19(52.8%) 
8 (22.2%) 
7(19.4%)
ns  (p-0.186)
3(15.8%) 
4(21.1%) 
10 (52.6%) 
2(10.5%)
ns  (p— o. 141)
1  (2.5%) 
20 (50.0%) 
16 (40.0%) 
3 (7.5%)
ns (p-0.251)
1  (5.9%) 
6(35.3%) 
7(41.2%) 
3(17.6%)
ns (p-0.317)
4 (9.8%) 
27 (65.9%) 
8 (19.5%) 
2(4.9%)
**  (p=0.001)
0 (0%)
9 (37.5%) 
10 (24.4%) 
5 (20.8%)
ns (p=0.212)
2 (5.6%) 
18 (75.0%) 
14 (38.9%) 
2 (5.6%)
ns  (p-0.079)
8
None
Mild
Moderate
Severe
8 (9.5%)
36 (42.9%)
28 (33.3%)
12(14.3%)
***
13 (8.5%) 
84 (54.9%) 
42 (27.5%)
14 (9.2%) 
***
3 (12.5%) 
10(41.7%) 
6 (25.0%) 
5 (20.8%)
* (p— 0.012)
2 (5.6%) 
19(52.8%) 
10 (27.8%) 
5 (13.9%)
ns (p=0.059)
3(15.8%)
6(31.6%)
8(42.1%)
2(10.5%)
*  (p-0.070)
4(10.0%) 
19 (47.5%) 
14 (35.0%) 
3 (7.5%)
*  (p=0.032)
1  (5.9%) 
7(41.2%) 
8(47.1%) 
1  (5.9%)
ns (p-0.083)
3 (7.3%) 
26 (63.4%) 
9 (22.0%) 
3 (7.3%)
ns (p=0.072)
1  (4.2%) 
13 (54.2%) 
6(25.0%) 
4(16.7%)
*  (p-0.020)
4(11.1%) 
20 (55.6%) 
9 (25.0%) 
3 (8.3%)
*  (p~0.016)
12
None
Mild
Moderate
Severe
8 (9.5%)
35(41.7%)
30 (35.7%)
11 (13.1%) 
***
20(13.1%)
81 (52.9%)
39 (25.5%)
13 (8.5%) 
***
2 (8.3%) 
12 (50.0%)
7 (29.2%)
3 (12.5%)
*  (p=0.017)
2(5.6%) 
22 (61.1%) 
7(19.4%) 
5(13.9%)
*  (p=0.006)
2(10.5%) 
7 (36.8%) 
9 (47.4%) 
1  (5.3%)
*  (p=0.046)
7(17.5%)
15 (37.5%)
16 (40.0%) 
2 (5.0%)
*  (p=0.026)
2(11.8%) 
9(53.0%) 
3(17.6%) 
3 (17.6%)
*  (p=0.007)
6(14.6%) 
26 (63.4%) 
6 (14.6%) 
3 (7.3%)
* (p=0.006)
2 (8.3%)
7 (29.2%) 
11 (45.8%) 
4(16.7%)
I1S (p=0.070)
5(13.9%) 
18 (50.0%) 
10(27.8%) 
3 (8.3%)
** (p=0.003)
* * *   ***  ***  ns (p=0.066)  ns (p=0.187)  ns (p=0.099)  *p=0.024  **(p=0.001)  #p~0.023  *p-0.006
Group 1  -  Fluoxetine medication  Intra group analysis:  Friedman significance  PO.OOOl * * *
Group 2 -  Placebo medication  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Group 3 -  Splint therapy
Group 4 -  Fluoxetine and splint therapy  Inter group anaysis:  Kruskall -Wallis  (not significant)
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Table 43: Outcome measures -  Frequency scores - Depressed / Non Depressed - Intention needed to treat analysis
Week
All groups :n=237) Group 1  (n=60) Group 2  (n=59) Group 3  (n=58) Group 4  (n=60)
Depressed
(n=84)
Non
Depressed
(n=153)
Depressed
(n=24)
Non
Depressed
(n=36)
Depressed
(n=19)
Non
Depressed
(n=36)
Depressed
(n=17)
Non
Depressed
(n=41)
Depressed
(n=24)
Non
Depressed
(n=36)
0 Never
Occasional
Often
Always
0 (0%)
5 (6%)
28 (33.3%) 
51 (60.7%)
0 (0%)
11 (7.2%) 
50 (32.7%) 
92 (60.1%)
0 (0%)
0 (0%)
9 (37.5%) 
15 (62.5%)
0 (0%)
0 (0%)
12 (33.3%) 
24 (66.7%)
0 (0%)
1  (5.3%) 
8(42.1%) 
10 (52.6%)
0 (0%)
2 (5.6%)
11 (30.6%) 
27 (75.0%)
0 (0%)
1  (5.9%)
6 (35.3%) 
10(58.8%)
0 (0%)
5 (12.2%) 
15 (36.6%) 
21 (51.2%)
0 (0%)
3 (12.5%) 
5 (20.8%) 
16 (66.7%)
0 (0%) 
4(11.1%) 
12 (33.3%) 
20 (55.6%)
4
Never
Occasional
Often
Always
3 (3.6%)
19 (22.6%)
29 (34.5%)
33 (39.3%) 
***
2(1.3%)
46 (30.1%)
51 (33.3%)
54 (35.3%) 
***
0 (0%)
6 (25.0%) 
5 (20.8%) 
13 (54.2%)
ns (p=0.074)
0 (0%)
11 (30.6%) 
11 (30.6%) 
14 (38.9%) 
***
2 (10.5%) 
2(10.5%) 
9 (47.4%) 
6(31.6%)
*  (p=0.030)
1  (2.8%)
9 (25.0%) 
14 (38.9%) 
16 (44.4%)
**  (p=0.004)
1  (5.9%) 
2(11.8%) 
9 (52.9%) 
5 (29.4%)
*  (p=0.023)
1  (2.4%) 
14(34.1%) 
15 (36.6%) 
11(26.8%)
**  (p=0.004)
0 (0%)
9 (37.5%) 
6 (25.0%) 
9 (37.5%)
*  (p=0.010)
0 (0%)
12 (33.3%) 
11 (30.6%) 
13(36.1%)
*  (p=0.031)
8
Never
Occasional
Often
Always
4 (4.8%)
22 (26.2%)
30 (35.7%)
28 (33.3%) 
** *
12 (7.8%)
42 (27.5%)
50 (32.7%)
49 (32%) 
***
1  (4.2%)
8 (33.3%) 
4 (16.7%) 
11(45.8%)
*  (p=0.008)
2 (5.6%) 
10 (27.8%) 
8 (22.2%) 
16 (44.4%)
**  (p=0.001)
2(10.5%) 
2 (10.5%) 
9 (25.0%) 
6(31.6%)
*  (p=0.030)
2 (5.6%)
10 (27.8%)
15(41.7%)
13(36.1%)
***
0 (0%)
3 (17.6%) 
11 (64.7%) 
3 (17.6%)
*  (p=0.007)
4 (9.8%)
15 (36.6%)
14(34.1%)
8 (19.5%) 
***
1  (4.2%)
9 (37.5%) 
6 (25.0%) 
8 (33.3%)
**  (p=0.004)
4(11.1%) 
7(19.4%) 
13(36.1%) 
12 (33.3%)
*  (p=0.007)
12
Never
Occasional
Often
Always
8 (9.5%) 
14 (16.7%) 
31 (36.9%) 
31 (36.9%) 
***
18(11.8%) 
44 (28.8%) 
43 (28.1%) 
48 (31.4%) 
***
2 (8.3%)
6 (25.0%) 
5 (20.8%) 
11 (45.8%)
*  (p=0.014)
3 (8.3%)
9 (25.0%) 
11 (30.6%) 
13 (36.1%) 
***
2 (10.5%)
3 (15.8%) 
9 (47.4%) 
5 (26.3%)
*  (p=0.015)
6(16.7%)
10 (27.8%) 
13(36.1%)
11 (30.6%)
1  (5.9%)
1  (5.9%)
9 (52.9%) 
6(35.3%)
ns (p=0.096)
4 (9.8%) 
20 (48.8%) 
10 (24.4%) 
7(17.1%) 
***
3 (12.5%)
4 (16.7%)
8 (33.3%)
9 (37.5%)
*  (p=0.012)
5 (13.9%) 
5 (13.9%) 
9 (25.0%) 
17 (47.2%)
ns (p=0.053)
Group 1  -  Fluoxetine medication 
Group 2 -  Placebo medication 
Group 3 -  Splint therapy 
Group 4 -  Fluoxetine and splint therapy
Intra group analysis:  Friedman significance  P<0.0001
Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant)
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Table 44: Primary outcome measure -  Pain response Depressed / Non Depressed - Intention needed to treat analysis
Week Severity All groups (n=237) Group 1   (n=60) Group 2 (n=59) Group 3 (n=58) Group 4 (n=60)
Depressed
(n=84)
Non
Depressed
(n=153)
Depressed
(n=24)
Non
Depressed
(n=36)
Depressed
(n=19)
Non
Depressed
(n=40)
Depressed
(n=17)
Non
Depressed
(n=41)
Depressed
(n=24)
Non
Depressed
(n=36)
4
Worse 
In pain 
Improved 
Pain free
5 (6%) 
48(57.1%) 
28 (33.3%) 
3(3.6%)
♦ ♦♦
11 (7.2%) 
86 (56.2%) 
53 (34.6%) 
3 (2%) 
***
2 (8.3%) 
13 (54.2%) 
8 (33.3%) 
1  (4.2%)
*
(p=0.033)
2 (5.6%) 
17(47.2%) 
16 (44.4%) 
1  (2.8%) 
**
(p=0.001)
0 (0%)
13 (68.4%) 
4(21.1%) 
2 (10.5%)
*
(p=0.023)
2 (5.0%) 
26 (65.0%) 
11 (27.5%) 
1(2.5%)
*
(p=0.008)
1  (5.9%) 
13 (76.5%) 
3 (17.6%) 
0 (0%) 
ns
(p=0.317)
3 (7.3%) 
22 (53.7%) 
15 (36.6%) 
1  (2.4%) 
**
(p=0.003)
2 (8.3%)
9 (37.5%) 
13 (54.2%) 
0 (0%)
*
(p=0.005)
4(11.1%) 
21(58.3%) 
11 (30.6%) 
0 (0%) 
ns
(p=0.071)
8
Worse 
In pain 
Improved 
Pain free
6 (7.1%)
39 (46.4%) 
34 (40.5%) 
5 (6%) 
***
5 (3.3%) 
80 (52.3%) 
57 (37.3%) 
11(7.2%)
2 (8.3%) 
11 (45.8%) 
10 (41.7%) 
1(4.2%)
*
(p=0.012)
1  (2.8%) 
22 (61.1%) 
11 (30.6%) 
2(5.6%) 
**
(p=0.002)
0 (0%)
12 (63.2%) 
4(21.1%) 
3(15.8%)
*
(p=0.015)
1  (2.5%) 
19 (47.5%) 
17 (42.5%) 
3 (7.5%) 
***
3 (17.6%) 
6 (35.3%) 
8(47.1%) 
0 (0%) 
ns
(p=0.132)
2 (4.9%) 
21 (51.2%) 
15 (36.6%)
3 (7.3%)
1  (4.2%) 
10 (41.7%) 
12 (50.0%) 
1(4.2%) 
**
(p=0.002)
1  (2.8%) 
18 (50.0%) 
14 (38.9%) 
3 (8.3%) 
***
12
Worse 
In pain 
Improved 
Pain free
7 (8.3%) 
41 (48.8%) 
28 (33.3%)
8 (9.5%) 
***
8 (5.2%) 
71(46.4%) 
54 (35.3%) 
20(13.1%)
2 (8.3%) 
10 (41.7%) 
10 (41.7%) 
2 (8.3%)
*
(p=0.007)
2 (5.6%) 
17 (47.2%) 
13(36.1%) 
4(11.1%) 
**
(p=0.001)
0 (0%)
13 (68.4%) 
4(21.1%) 
2 (10.5%)
*
(p=0.023)
1  (2.5%) 
20 (50.0%) 
12 (30.0%) 
7(17.5%) 
***
2(11.8%) 
7 (41.2%) 
7 (41.2%) 
1  (5.9%) 
ns
(p=0.052)
2 (4.9%) 
18 (43.9%) 
17 (41.5%) 
4 (9.8%) 
*#*
3 (12.5%) 
11 (45.8%) 
7 (29.2%) 
3 (12.5%)
*
(p=0.032)
3 (8.3%) 
16 (44.4%) 
12 (33.3%) 
5 (13.9%) 
**
(p=0.001)
Group 1   -  Fluoxetine medication  Intragroup analysis:  Friedman significance  P<0.00014*4*4*
Group 2  -  Placebo medication  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Group 3  -  Splint therapy
Group 4  -  Fluoxetine and splint therapy  Inter group anaysis:  Kruskall -Wallis  (not significant)
C
h
a
p
t
e
r
 
v
i
i
i
 
s
t
u
y
 
c
o
h
o
r
t
 
-
s
u
b
 
g
r
o
u
p
 
a
n
a
l
y
s
i
s3
6
2
Table 45: Primary outcome measure -  Depressed / Non depressed groups -  Interference with life (Intention to treat analysis)
Week IjBtsrifeffe& ce All groups (n=237) Group 1  (n=60) Group 2 (n=59) Group 3 (n=60) Group 4 (n=60)
Depressed
(n=84)
Non
Depressed
(n=153)
Depressed
(n=24)
Non
Depressed
(n=36)
Depressed
(n=19)
Non
Depressed
(n=40)
Depressed
(n=17)
Non
Depressed
(n=41)
Depressed
(n=24)
Non
depressed
(n=36)
0
Yes 84(100%) 153(100%) 24(100%) 36 (100%) 19(100%) 40 (100%) 17 (100%) 41(100%) 24(100%) 36(100%)
No 0 (0%) 0 (0%) 0  (0%) 0 (0%) 0 (0%) 0 (0%) 0  (0%) 0 (0%) 0 (0%) 0 (0%)
4 Yes 51(60.7%) 85 (55.6%) 14(58.3%) 16 (44.4%) 14(73.7%) 25(62.5%) 10 (58.8%) 19(46.3%) 13(54.2%) 25(69.4%)
No 33(39.3%) 68(44.4%)
***
10(41.7%)
** (p=0.002)
20(55.6%)
***
5 (26.3%)
ns (p=0.063)
15(37.5%)
***
7  (41.2%)
* (p=0.016)
22(53.7%)
***
11(45.8%)
** (p=0.001)
11(30.6%)
** (p=0.001)
8 Yes 46(54.8%) 75 (49%) 12 (50.0%) 17 (47.2%) 12(63.2%) 20(50.0%) 11 (64.7%) 20(48.8%) 11(45.8%) 18 (50%)
No 38(45.2%)
***
78(51%)
***
12(50.0%)
** (p=0.001)
19(52.8%)
***
7(36.8%)
* (p=0.016)
20(50.0%)
***
6(35.3%) 
* (p=0.031)
21(51.2%)
***
13(54.2%)
***
18 (50%) 
***
12 Yes 48(57.1%) 66 (43.1%) 13 (54.2%) 15 (41.7%) 11(57.9%) 19(47.5%) 10(58.8%) 18(43.9%) 14 (58.3%) 14(38.9%)
No 36(42.9%)
***
87(56.9%)
***
11(45.8%)
***
21(58.3%)
***
8  (42.1%)
* (p=0.008)
21(52.5%)
***
7 (41.2%)
* (p=0.016)
23(56.1%)
***
10(41.7%)
** (p=0.002)
22(61.1%)
***
* * *   * * *   * * *   **(p=0.002)  * * *   **(p=0.004)  * * *   * * *   * * *
Group 1  -  Fluoxetine medication
Group 2 -  Placebo medication  Cochran Test  PO.OOl  *  *  *
Group 3 -  Splint therapy  McNemar Test  PO.OOl ***
Group 4 - Fluoxetine and splint therapy  Chi squared not significant between groups
C
h
a
p
t
e
r
 
v
i
i
i
 
s
t
u
y
 
c
o
h
o
r
t
 
-
s
u
b
 
g
r
o
u
p
 
a
n
a
l
y
s
i
sCHAPTER  VIII STUY COHORT -  SUB GROUP ANALYSIS
8.1.9 Self-report pain questionnaires outcome measures in depression
8.1.9.1  MPI (Depressed and non depressed categories! (Table 47, figure 51)
Analysing all groups together, the patient’s perspective of pain improved, during the 
three months treatment phase, in severity, interference and affective distress amongst 
both depressed and non depressed categories. MPI severity improved significantly 
regardless of depression p<0.001. Similarly, MPI interference: depressed p<0.001, non 
depressed  p=0.001, MPI affective distress: depressed p=0.001 and to a lesser extent in 
the non depressed p=0.003.
In group 1  the depressed category appeared to improve most significantly. MPI 
severity p=0.010, interference p=0.004, life control p=0.015 and affective distress 
p=0.023, whilst only interference improved in the non depressed p=0.030. Conversely, 
in group 3, the non depressed category appeared to improve most significantly; MPI 
severity p=0.008, interference p=0.002 in the non depressed. Only severity in the 
depressed significantly improved p=0.027. Severity, interference and affective distress 
improved in depressed and non depressed cateogories of group 2 but not life control. 
MPI life control only appeared to have improved amongst groups 1  and 4 with 
depression p=0.015 and p=0.04 respectively. As an incidental finding the MPI level of 
support from others appeared to decrease in the non depressed group 3, p=0.010.
Once again all these apparent variations between groups were not substantiated by 
rigorous inter group analysis.
8.1.9.2  MPO (Depressed and non depressed categories) (Table 48, Figure 52)
Together, the groups showed significant improvement amongst both the depressed and 
non depressed categories, PPI (p<0.001) and MPQ sensory % (p<0.005). In non
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depressed categories VAS and MPQ total % were significantly reduced p<0.001.This 
was reflected to a lesser extent in the depressed category VAS p<0.05 and MPQ total% 
p<0.005. MPQ affective % showed significant improvement in the depressed category
p<0.05.
Within groups analysis was variable. A significant improvement in PPI was noted 
amongst depressed categories in groups 1  and 2 (p<0.05) but conversely non depressed 
categories in groups 3 and 4 (p<0.05). Only non depressed patients appeared to 
improve significantly in group 3, PPI p<0.05, MPQ: sensory % p<0.05 and affective % 
p<0.05 and total % p<0.005. Inter group analysis revealed no significant difference.
8.1.9.3 BPI (Depressed and non depressed categories)
Composite scores decreased significantly in the depressed category in all groups 
p<0.005. This was reiterated in group 1, p<0.05 and group 2 ,p<0.005, yet statistically 
there was no significant difference between groups.
8.1.9.4 Kellner (Depressed and non depressed categories!
Hypochondriacal beliefs reduced in the non depressed category in the analysis of all 
groups p<0.05. Intra and inter group analysis revealed no significant differences.
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8.1.9.5  Logistic regression analysis of questionnaire scores in depression
Following the earlier bivariate correlations for the self report pain questionnaires, a 
logistic regression analysis was also performed for pain rating scores as predictors of 
depression. Only a small number of variables remained as significant predictors.
Table 46: Logistic regression analysis of questionnaire scores in depression
Enter method OR
(Odds
ratio)
95% Cl
(Confidence
interval)
P value Regression
coefficient
SE
(standard error)
MPI (life control) 0.45 0.30-0.67 <0.001
***
-0.81 0.21
MPI (punishing 
response)
1.50 1.10-2.04 0.010
*
0.41 0.16
MPI (activities away 
from home)
0.68 0.47-1.00 0.047
*
-0.38 0.19
MPQ (sensory) 1.02 1.00-1.04 0.063 0.02 0.01
Kellner (total) 1.24 1.12-1.38 <0.001
***
0.22 0.05
* p<0.05, **p<0.005,***p<0.001
The model 82.4% correctly predicts depression at baseline, x2 =79.55 (5),p<0.001.
As expected, decrease in MPI (life control) score indicates an increase in depression, 
(OR=0.45,95% Cl 0.30,0.67,p<0.001) whilst an increase in Kellner illness attitude 
(hypochondriacal beliefs and disease phobia) indicates an increased  prediction of 
depression,(OR=l .24,95%CI 1.12,1.3 8,p<0.001). An increase in MPI (punishing 
response of others) increases the chances of depression(OR=1.50,95% Cl 
1.10,2.04,p<0.01) whilst an increased score of MPI (activities away from home) 
decreases the chances of depression (OR=0.68,95% Cl 0.47,1.00,p=0.047).
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Table 47: Multidimensional pain inventory (MPI) A comparison of median scores (25th,75th  percentiles) between the start and finish of the three months.
(Depressed and Non depressed groups)
MPI Study All groups Group 1 Group 2 Group 3 Group 4
Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
Depressed Depressed
Non
Depressed
Patients perspective of‘pain
MPI - 
Severity
Start
Finish
3.47
(2.60,4.65)
2.66
(1.60,4.00)
***
2.66
(1.66.3.66)
2.00
(1.30,3.33) 
♦ ♦♦
3.60
(2.15.4.32)
2.67
(1.04,4.00)
*(p-0.010)
3.17
(2.00,4.25)
2.60
(1.62,4.00)
3.00
(2.60.4.00) 
2.60
(1.60.3.00)
* (p=0.012)
3.15
(2.33,4.00)
2.33
(1.08,3.92)
**(p=0.002)
3.00
(2.47,4.48)
3.00
(2.17,4.30) 
*  (p-0.027)
2.33
(1.30.3.00) 
1.60 
(0.66,2.66) 
* (p=0.008)
4.00
(2.57,5.00)
4.00
(2.00,5.00)
2.17
(1.30-3.00)
2.00
(1.30,3.00)
MPI -
Interference
Start
Finish
2.77
(1.29,4.10)
2.33
(0.90,3.72)
***
1.14
(0.46,1.90)
0.73
(0.30,1.73)
**(p-0.001)
2.90
(1.29,3.90)
2.54
(0.33,3.58)
**(p=0.004)
1.39
(0.62,2.53)
0.86
(0.32,2.00) 
* (p=0.030)
1.91
(0.82,3.54)
1.16
(0.73,3.36)
*(p=0.008)
1.45
(0.68,2.27)
1.09
(0.47,2.20)
*(p~0.030)
2.30
(1.85,4.37)
2.50
(2.14,4.27)
0.95
(0.41,1.55)
0.54
(0.23,1.41)
**(p~0.002)
3.19
(1.26,4.25)
2.50
(1.00,4.16)
0.77
(0.28,1.30)
0.59
(0.26,1.30)
MPI-Life 
control
Start
Finish
2.38
(1.50,3.25)
2.75
(1.81.3.75)
**(p=0.002)
3.75
(3.00,4.25)
3.75
(3.00,4.50)
*(p=0.066)
2.38
(1.06,2.94)
2.88
(2.00,3.94)
*(p=0.015)
3.71
(3.00,4.25)
3.75
(3.25,4.50)
2.25
(1.25.3.25)
2.75
(1.50,3.75)
3.75
(2.75.4.50)
3.75
(3.06.4.50)
2.25
(2.13,3.25)
2.50
(2.00,3.38)
3.50
(2.75,4.13)
3.60
(2.75,4.25)
2.63
(2.00,3.44)
2.75
(1.75,4.19)
* (p=0.040)
3.75
(3.06,4.50)
3.75
(3.0,4.25)
MPI -
Affective
distress
Start
Finish
4.00
(3.33,4.92)
3.66
(3.00,4.33)
**(p=0.001)
3.00
(2.00.3.66)
2.66
(1.60,3.63)
**(p=0.003)
4.00
(3.08,5.00)
3.50
(2.60,4.23)
*(p=0.023)
3.30
(2.40.3.92) 
3.00
(1.33.3.92) 
ns (p=0.053)
4.00
(3.60,5.33)
3.66
(3.33,5.30)
*(p=0.028)
3.00
(2.00,4.00)
2.66
(1.33,3.58)
*(p-0.041)
3.66
(3.15,4.47)
3.66
(2.83,4.32)
2.60
(1.66.3.47)
2.66
(1.63,3.66)
4.00
(2.83,4.83)
3.33
(2.70,4.58)
2.66
(2.0,3.65)
2.33
(1.66,3.0)
Response of significant other
MPI -
Support
response
Start
Finish
3.00
(1.83,4.47)
3.42
(1.92,4.33)
3.60
(2.60.4.66) 
3.33
(2.33.4.66)
3.25
(1.32,5.08)
3.42
(1.00,4.75)
3.60
(2.47,4.66)
3.47
(2.53,4.33)
2.60
(0.9,4.75)
2.80
(0.9,4.62)
4.00
(3.00,5.00)
4.00
(3.00,5.30)
3.15
(2.41,4.33)
3.30
(2.33,4.00)
3.17
(2.40,4.66) 
3.00
(1.60,4.33)
*(p=0.010)
3.00
(1.83,4.33)
3.66
(2.00,4.47)
3.30
(2.6,4.47)
3.47
(2.53,4.62)
MPI
Punishing
response
Start
Finish
1.50
(0.50,2.75)
1.75
(0.94,3.00)
0.66
(0.00,1.50)
0.50
(0,1.25)
1.13
(0.31,2.94)
1.38
(0.75,2.81)
0.71
(0.63,1.75)
0.75
(0,2.00)
2.00
(1.00,3.75)
1.75
(1.25,2.75)
1.00
(0,2.00)
0.63
(0,2.13)
1.38
(0.50,2.94)
1.38 
(1.00,2.81)
0.50
(0,1.94)
0.50
(0,1.81)
1.75
(0.63,2.31)
2.25
(0.75,3.00)
0.50
(0,1.0)
0.38
(0,1.0)
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MPI Study All groups Group 1 Group 2 Group3 Group 4
Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
Depressed Depressed
Non
Depressed
MPI
Solicitous
response
Start
Finish
2.66
(1.30,3.67)
2.63
(1.00,3.83)
2.66
(1.50.4.00) 
2.60
(1.33.4.00)
3.23
(2.20,4.45)
3.08
(1.43,4.42)
2.13
(1.30,3.46)
2.00
(1.16,3.42)
2.66
(1.72.3.25) 
2.50
(1.33.3.25)
2.83
(1.71.4.53) 
2.92
(1.29.4.53)
2.58
(1.13,3.91)
2.63
(1.13,3.88)
2.66
(1.53,3.83)
2.63
(1.50,4.37)
1.80
(0.66,3.75)
2.83
(0.92,3.50)
3.0
(1.72,4.16)
2.50
(1.48,3.58)
MPI
Distracting
response
Start
Finish
1.75
(0.63,3.00)
2.00
(0.75,3.00)
1.75
(0.75.2.75)
1.50
(0.75,2.75)
2.00
(0.75,2.88)
2.38
(0.75,3.38)
1.88
(0.81,2.50)
1.50
(0.88,2.38)
1.50
(0.38,2.63)
1.25
(0.63,1.88)
1.63
(0.94,3.25)
1.63
(0.69,3.00)
2.38
(0.56,2.94)
2.38
(0.88,3.19)
1.63
(0.56,2.75)
1.63
(0.44,2.75)
1.63
(0.56,3.00)
2.00
(1.13,3.00)
1.75
(0.25,2.88
1.63
(0.19,3.0)
Frequency of participation
MPI -
Household
chores
Start
Finish
5.00
(3.65.5.60)
5.00
(3.80.5.60)
4.80
(3.55.5.60) 
4.40
(3.60.5.60)
5.00
(3.60.5.75) 
4.70
(4.20.5.75)
4.70
(3.30,5.55)
4.60
(3.70,5.24)
4.00
(3.40.5.20) 
4.60
(3.40.5.20)
5.20
(3.25,5.95)
4.40
(3.60,5.80)
5.20
(3.40,5.90)
5.00
(3.80,5.70)
4.50
(3.50.5.40) 
4.40
(3.60.5.40)
5.00
(3.90,5.75)
5.20
(3.85,5.60)
4.80
(3.85,5.20)
4.40
(3.25,5,51)
MPI -
Outdoor
work
Start
Finish
2.00
(0.95,3.00)
2.20
(1.00,3.60)
2.00
(1.10,3.00)
1.75
(1.00,2.60)
2.00
(1.43,2.94)
2.35
(1.38,3.35)
1.75
(1.20,2.75)
1,50
(1.00,2.50)
2.45
(1.20,3.55)
2.28
(1.20,3.90)
1.78
(0.73,3.05)
1.90
(0.94,2.70)
2.00
(0.90,3.13)
1.90
(0.79,3.20)
2.00
(1.00,2.60)
1.90
(1.00,2.60)
1.40
(0.68,3.00)
1.60
(0.80,3.20)
2.00
(1.2,3.28)
2.10
(1.0,3.05)
MPI - 
Activities 
away from 
home
Start
Finish
3.00
(2.25.4.00)
3.00
(2.25.4.00)
3.75
(3.25,4.50)
3.75
(3.00,4.50)
3.13
(2.50,4.19)
3.13
(2.31,3.94)
3.75
(2.81,4.63)
3.75
(3.00,4.25)
3.50
(2.25.4.25)
3.50
(2.50.4.25)
4.00
(3.00,4.50)
3.75
(3.00,4.50)
2.25
(1.63,3.88)
2.75
(1.75,4.0)
3.50
(3.25,4.25)
3.75
(3.25,4.50)
3.13
(2.06,3.94)
3.00
(2.50,3.88)
4.00
(3.25,4.94)
3.75
(2.81,4.75
MPI - 
Social 
activities
Start
Finish
2.75
(2.00,3.75)
3.00
(2.00,3.75)
3.25
(2.50.4.00) 
3.42
(2.58.4.00)
2.50
(2,0,3.63)
2.63
(2.00,3.90)
3.00
(2.50,4.25)
3.25
(2.33,4.00)
2.75
(2.30.4.00) 
3.00
(2.33.4.00)
3.50
(2.50.4.00) 
3.58
(2.81.4.00)
3.00
(1.75,3.63)
3.00
(2.00,3.75)
3.00
(2.50.3.75) 
3.25
(2.50.3.75)
3.13
(2.00,4.13)
3.13
(1.56,3.69)
3.50
(2.31.4.19)
3.50
(2.75.4.19)
MPI - 
General 
activity 
level
Start
Finish
3.30
(2.71.3.74) 
3.26
(2.69.3.75)
3.49
(2.81,4.02)
3.36
(2.90,3.88)
3.36
(2.76,3.73)
3.31
(2.59,3.76)
3.50
(2.83,2.97)
3.48
(2.78,3.91)
3.23
(2.68,3.81)
3.11
(2.88,3.99)
3.54
(2.82,4.01)
3.42
(2.86,3.98)
3.39
(2.16,3.90)
3.39
(2.38,3.79)
3.33
(2.77,3.76)
3.30
(2.96,3.64)
3.24
(2.78,3.63)
3.21
(2.78,3.57)
3.57
(2.82,4.10)
3.30
(3.03,3.90
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Wilcoxon significance p<0.05 *, p<0.005 **, p< 0.001
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Kruskall Wallice not significant between groups
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Table 48: McGill pain questionnaire (MPQ). Beck depression index (BDI)  and Kellner illness attitude scale.(Kellner)
tli  tV i A comparison of median scores (25  and 75  percentiles) Intention to treat analysis (Depressed and non depressed groups
Self report 
Questionnaire
Study All groups (n=237) Group 1 (n=60) Group 2 (n=59) Group 3 (n=58) Group 4=(n=60)
Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
depressed Depressed
Non
depressed
MPQ
Visual analogue 
scale (VAS) 
(range 0-10)
Start
Finish
4.2
(1.6.6.7)
3.2
(1.2.5.7) 
*
2.6
(1.03,4.6)
2.0
(0.63,4.0)
***
3.5
(1.15,6.63)
4.15
(0.5,6.03)
2.8
(1.23,5.25)
2.3
(0.83,3.68)
3.05
(1.23.5.68)
2.5
(1.38.4.68)
3.3
(1.48,5.33)
2.5
(0.5,5.6)
♦
4.5
(2.5,5.8) 
3.35
(0.93,5.08)
2 2
(1,4.05)
1.5
(0.7,3.2) 
p=0.05
4.7
(2.1,7.4) 
4.5
(1.3,7.6)
2.2
(0.5,3.95)
1.85
(0.5,3.63)
Present pain 
intensity (PPI) 
(range 0-5)
Start
Finish
2.0
(1.0,3.0)
2.0
(1.0,2.0) 
♦♦♦
2.0
(1.0,2.0)
1.0
(1.0,2.0) 
***
2.0
(1.25,3.0) 
2.0 
(1.0,2.0)
*
2.0 
(1.0,2.0) 
1.0 
(1.0,2.0)
2.0 
(1.0,2.0) 
2.0 
(1.0,2.0) 
*
2.0 
(1.0,2.0) 
1.0 
(1.0,2.0)
2.0
(1.0,3.0) 
2.0 
(1.0,2.0)
1.0
(1.0,2.0)
1.0
(1.0,2.0) 
*
2.0
(1.0,3.0) 
2.0
(1.0,3.0)
2.0 
(1.0,2.0) 
1.0
(1.0,2.0) 
*
MPQ -  total % 
(range 0-100)
Start
Finish
42
(29,53)
33
(18,51)
**
27.0
(17.5.37.0)
22.0
(11.5.36.0) 
***
44.0
(29.0,51.0)
42.0 
(22,53)
31.0 
(20,44)
27.0 
(18,40)
36.0
(31,51)
31
(18,38)
*
24
(18,37)
26.5
(9,36)
38
(31.51.5) 
33
(28.5.56.5)
27
(17,36)
19
(13,31)
**
50
(25.25,68.25
31
(16,64)
22
(11,33.5)
16.5
(7.75,36)
MPQ- sensory % 
(range 0-100)
Start
Finish
42
(30,58)
33
(18,55)
*♦
30.0
(18,40.5)
25.5
(15,39)
*♦
39.0
(24,51.5)
33.0 
(15,52)
39.0
(27,48)
34.5
(21,42)
45.0
(30,54)
33
(21,45)
*
30
(17.5,37.5)
28.5
(12,39)
45
(31.5,63.5)
39
(25.5,64.75
30
(18,39)
21
(15,35.25)
*
45
(29.25,70.75
36
(15,67)
24
(14.25,39.75
21
(10.5,42)
MPQ -  affective 
%
(range 0-100)
Start
Finish
42
(17.58) 
25
(9.58) 
**
17.0 
(0,25)
8.0 
(0,25)
42.0 
(25,67)
33.0
(17,58)
*
8.0
(0,42)
7.0
(0,25)
17
(17,42)
17
(8,33)
*
17
(0,29)
8
(0,25)
*
25
(17,46)
25
(14.75,67)
17
(0,25)
8
(0,25)
*
54
(14.75,75.75
42
(8,58)
8.0
(0,25)
0
(0,17)
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Self report 
questionnaire
Study
All groups (n=237) Group 1 (n=60) Group 2 (n=59) Group 3 (n=58) Group 4 (n=60)
Depressed
Non
Depressed Depressed
Non
Depressed Depressed
Non
Depressed Depressed
Non
Depressed Depressed
Non
Depressed
BDI
Composite
score
(range 0-45)
Start
Finish
16.5 (11.3,21.8)
14  (11,21)
**
4.0 (1,7) 
4.0(2,7)
16(11,19)
13 (10,16.8) 
*
4.0(1,6) 
4.0(1,6)
17(11,24)
12(11,20)
♦
5.0(2,7.8) 
5.0(1,7)
18(12,26.5)
18(12,25.8)
3.0(1,7)
3.0(0.5,5.
5)
16.5(11.3,21))
14.0(11.0,22)
5.0 (3,8)
4.0 (3,7)
Kellner
Illness
attitude-
total
(range 0-30)
Start
Finish
10 (7,14) 
10(7,13.5)
7.0 (6,9)
7.0 (6,9)
11.0(6,15) 
11.0 (6,14)
7.0 (6,9)
7.0 (6,9)
9.0 (7,13)
9.0 (7,12)
6 (6,8) 
6(6,8)
10(6,14)
10(6,13.75)
7.0(6,9.5) 
7.0 (6,9)
11.0(6.8,15.3) 
12.0 (9,16)
7.5(6,10.8) 
7.0(6,9)
Hypochondria 
cal beliefs 
(range 0-15)
Start
Finish
5 (3,7) 
5 (3,7)
3.0 (3,5)
3.0 (3,4) 
*
5.0 (3,7.75)
5.0 (3,8)
3.0 (3,4.8)
3.0 (3,4)
5.0 (3,7)
5.0 (3,7)
3.0 (3,3.8)
3.0 (3,3.8)
5.0 (3,7)
5.0 (3,7)
3.0 (3,5)
3.0 (3,5)
6.0 (3,7)
6.0 (3,7)
3.0 (3,4)
3.0 (3,4)
Disease phobia 
(range 0-15)
Start
Finish
4(3,7) 
5 (3,7)
3.0 (3,5)
3.0 (3,5)
5.0 (3,8)
5.0 (3,8)
3.0 (3,4)
3.0 (3,4)
4.0 (3,5)
4.0 (3,5)
3.0 (3,4)
3.0 (3,4)
4.5 (3,7)
4.5 (3,7)
3.0 (3,5)
3.0 (3,4)
5.0 (3,9)
5.0 (4,9)
3.5 (3,6.75) 
3.0 (3,5.75)
Group 1 -  Fluoxetine medication  Group 2 -  Placebo medication 
Group 3 -  Splint therapy  Group 4 -  Fluoxetine and splint therapy
Kruskall-Wallis not significant between groups 
Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001***
There was no statistically significant difference between  groups in 
the recorded pain questionnaire scores, although there was an 
observable decrease, illustrated graphically between groups, in MPQ- 
VAS (figure52)  MPI severity and MPI affective distress (figures 51).
1 3 6
not depressed depressed
Change in N1PQ VAS at three months
Figure 52
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8.2  THE EFFECT OF INITIALLY HIGH PAIN SCORES
ON OUTCOME
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8.2.0  The effect of high Initial pain scores on outcome measures
Hypothesis (6b) A significant and measurable improvement in pain measures are 
only seen in those patients with initially high pain scores.
8.2.1 Baseline pain severity scores
Figure 53 shows the MPI pain severity scores at baseline and VAS scores were 
normally distributed. Bivariate,  nonparametric, correlations of initial VAS severity 
scores and initial MPI severity scores revealed significant correlations at the 0.01 level 
on a range of variables.
VAS was positively correlated with baseline BDI (r=0.186,p=0.004), MPI scores of: 
pain severity (r=0.313,p<0.001),interference (r=0.386,p<0.001),affective distress 
(r=0.241,p<0.001), support (r=0.163,p=0.014),MPQ scores of: PPI (r=0.267,p<0.001), 
total (r=0.418,p<0.001),sensory (r=0.315,p<0.001) and affective (r=0.407,p<0.001). 
There was a negative correlation with MPI level of life control (r=-0.213,p=0.001). 
MPI severity scores were positively correlated with baseline BDI (r=0.313,p<0.001), 
VAS (r=0.498,p<0.001),MPl scores of: interference (r=0.668,p<0.001),affective 
distress (r=0.354,p<0.001), support (r=0.286,p<0.001),solicitous (r=0.191,p=0.005), 
distracting response (r=0.138,p=0.046), MPQ: PPI (r=0.600,p<0.001),total 
(r=0.589,p<0.001), sensory (r=0.522,p<0.001),affective (r=0.520,p<0.001),Kellner 
illness attitude (r=0.151,p=0.019) and hypochondriacal beliefs (r=0.154,p=0.017). MPI 
life control was negatively correlated (r=-0.282,p<0.001).
8.2.2 MPI severity gauge for low and high initial pain scores
MPI severity scores at baseline was normally distributed and more closely correlated 
to a broader range of outcome variables. It was therefore decided to use this measure to
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demarcate individuals into high and low initial pain categories.
High category were classified as those with scores greater than 3 whilst the low 
category were scores of 0-3. Although a rather arbitrary division, this successfully 
classified patients into two dichotomous groups, high (n=78) and low (n= 171),(fig 54). 
These was no significant difference in the two categories between the four treatment 
groups, )?=6 87 (3),p=0.08,(fig  55, table 49).
Figure 53: Baseline pain scores (MPI seventy and VAS)
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Figure 54: MPI severity gauge (all groups n=249)
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Table 49: MPI severity gauge
High
MPI pain severity 
guage
SSR1 Placebo Splint SSRI and 
Splint
Total
Low 32 (51%) 42 (67%) 49 (80%) 43 (69%) 171
High 26 (41%) 21 (33%) 12 (20%) 19(31%) 78
Total 63 63 61 62 249
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8.2.3 Demographic details {initial high and low pain score patients)  (Table 50) 
Demographic details suggest there was no difference in age, gender, duration of pain, 
referral source, employment, socio-economic or marital status between high and low 
initial pain categories.
8.2.4 Other reported chronic pains  (Table 51)
Only headaches (p=0.008) significantly decreased in the low compared to the high 
pain scorers.
8.2.5 Verbal reported pain scores
8.2.5.1 VAS (High and low initial pain categories)  (Table 52)
8.2.5.1.1 Parametric analysis
Collectively all groups showed a significant reduction in VAS in both high and low 
categories p<0.001. With medication only, groups 1  and 2, both high and low 
categories were all significantly improved in the repeated measures ANOVA p=0.001. 
However, using paired sample t-tests, there was a more significant improvement at 
three months amongst the low pain scorers p<0.001 in both group 1  and 2. In the splint 
only group, repeated measures ANOVA revealed a significant reduction in score 
amongst the low as opposed to high scorers p<0.001 and p=0.011  respectively. This 
was not mirrored in group 4 where there was a slightly more significant improvement 
amongst the high compared to low scorers, p=0.003 compared to p=0.005.
Overall, there was no significant difference between groups in high and low scores at 
any time point.
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8.2.5.1.2  Non parametric analysis
Analysing all groups together, a highly significant reduction in scores were seen 
amongst both high and low initial pain categories, p<0.001. At three months this was 
reflected in group2 and group4. In group 1 the high pain group showed a significant 
reduction p<0.001, low pain p<0.005. Conversely, in group 3 it was the low pain group 
which showed the most significant reduction p<0.005, the high group p<0.05.
Inter group analysis revealed no significant difference in improvement between groups.
8.2.5.2 Interference (High and low pain categories)  (Table 53)
This was significantly reduced amongst both high and low initial pain score categories 
p<0.001.This did not appear to be reflected amongst individual groups. In group 2, 3,4 
low pain scorers improved significantly at all three time points p<0.001.High pain 
scorers decreased but to a lesser extent at three months group 3 and group 4 p<0.005.In 
group 1 both categories had improved p<0.001 at three months although at the earlier 
time points of four and eight weeks the high pain group decreased to a lesser extent 
p<0.005 compared to the low pain category p<0.001.
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Table 50: Demographic details for Initial high and low pain score patients
(MPI severity g u a g e ) _____________ _____________________________
Recorded at baseline 
assessment
All groups 
(n=250)
High pain 
scores (n=78)
Low pain 
scores (n=171)
Significance
Age (in years) 
Mean (+/- SD) 
(Range)
32.3 (9.58) 
(16-55)
31.73 (8.99) 
(16-54)
32.51 (9.86) 
(16-55)
ns
(p=0.550)
Duration of pain (in yrs) 
Mean (+/- SD)
Range
3.30 (4.49) 
(0.25-32.0)
2.53 (2.72) 
(0.25-16.0)
3.64 (5.08) 
(0.25-32.0)
ns
(p=0.070)
Gender M: F 59:191 
23.6%:76.4%
17:  61
21.8%: 78.2%
42:129
24.6%: 75.4%
ns
(p=0.634)
Referral source
GDP
GP
Specialist
230 (92.0%) 
6 (2.4%) 
14 (5.6%)
72 (92.3%) 
2 (2.6%) 
4(5.1%)
157 (91.8%) 
4 (2.3%) 
10 (5.8%)
ns
(p=0.969)
Employment status
Employed
Unemployed
Student
Retired(medical) 
House wife
167 (66.8%) 
19 (7.6%) 
39(15.6%) 
1  (0.4%) 
24 (9.6%)
56 (71.8%)
6 (7.7%) 
9(11.5%) 
0 (0%)
7 (9.0%)
111 (64.9%) 
12 (7.0%) 
30(17.5%) 
1 (0.6%) 
17 (9.9%)
ns
(p=0.708)
Socio-economic status
Professional  I 
Intermmediate  Hi 
Skilled non-manual  Uii 
Skilled manual  III 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, retired
11 (4.4%) 
78 (31.2%) 
66 (26.4%) 
8 (3.2%)
5 (2.0%)
1  (0.4%) 
81 (32.4%)
4(5.1%) 
25 (32.1%) 
20 (25.6%) 
4(5.1%)
2 (2.6%)
1  (1.3%) 
22 (28.2%)
7(4.1%) 
53 (31.0%) 
46 (26.9%) 
4 (2.3%)
3 (1.8%)
0 (0%)
58 (33.9%)
ns
(p=0.691)
Marital status
Single
Married
Seperated
Divorced
Widowed
147 (58.8%) 
89 (35.6%) 
2 (0.8%) 
11 (4.4%)
1 (0.4%)
51 (65.4%) 
25 (32.1%) 
1  (1.3%)
1 (1.3%)
0 (0%)
96 (56.1%) 
63 (36.8%) 
1  (0.6%) 
10 (5.8%)
1  (0.6%)
ns
(p=0.439)
Significance test, Chi-squared (Independent samples t-test for age and duration) 
** p<0.005, * p<0.05, ns=not significant.
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Table 51: Other reported chronic pains (MPI severity gauge)
Chronic pains Low initial pain
(n=171)
High initial pain
(n=78)
Significance
(between
groups)
Headache Baseline 
4 weeks 
8weeks 
12 weeks
98 (57.3%)
78 (45.6%) *
75 (43.9%) ** 
68 (39.8%) *** 
* * *
54 (69.2%)
42 (53.8%) ** 
51 (65.4%)
45 (57.7%) * 
*
ns p=0.228
**p=0.002 
*  p=0.008
Migraine Baseline 
4 weeks 
8weeks 
12 weeks
51 (29.8%)
31 (18.1%)*** 
31 (18.1%)*** 
28 (16.4%)*** 
* * *
31 (39.7%) 
18(23.1%)** 
17(21.8%)** 
17(21.8%)**
ns p=0.362 
ns p=0.496 
ns p=0.303
Neckache Baseline 
4 weeks 
8weeks 
12 weeks
85 (49.7%)
56 (32.7%)*** 
62 (36.3%)*** 
49 (28.7%)*** 
* * *
40 (51.3%) 
33 (42.3%) 
31 (29.7%) 
28 (35.9%)* 
*
ns p=0.144 
ns p==0.598 
ns p=0.251
Backache Baseline 
4 weeks 
8weeks 
12 weeks
77 (45.0%)
48 (28.1%)*** 
47 (27.5%)*** 
47 (27.5%)*** 
* * *
43 (55.1%)
26 (33.3%)*** 
28 (35.9%)*** 
26 (33.3%)*** 
* * *
ns p=0.399 
ns p=0.180 
ns p=0.347
Abdominal pain Baseline 
4 weeks 
8weeks 
12 weeks
52 (30.4%)
24 (14.0%)***
25 (14.6%)** 
24 (14.0%)*** 
* * *
21 (26.9%)
13 (16.7%)**
14 (17.9%)** 
17(21.8%)* 
ns p=0.095
ns p=0.588 
ns p=0.503 
ns p=0.126
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Table 52 : High and low pain scores  - Imputation analysis
Pain response: VAS (visual analogue scale),(10cm line). A comparison of mean scores (+/- SD)
Week All groups (n= 249) Group 1  (n=63) Group 2 (n=63) 
Low
Group 3 (n=61) Group 4 (n=62) Significance 
between groups
High Low High Low High Low High Low High Low High Low
0 7.26
(1.95)
5.08
(2.11)
6.87
(2.29)
5.19
(2.07)
7.19
(1.71)
5.36
(2.37)
7.33
(2.20)
5.07
(1.92)
7.83
(1.46)
4.73
(2.09)
ns
p=0.451
ns
p=0.565
4 5.61
(2.51)
**♦
4.27
(1.97)
#**
5.44
(2.79)
* p=0.028
4.19
(2.09)
* p=0.014
5.64
(2.02)
** p=0.003
4.59
(2.19)
p=0.07
5.76
(3.05)
* p=0.044
4.34
(1.66)
* p=0.006
5.72
(2.43)
***
3.93
(1.95)
* p=0.029
ns
p=0.979
ns
p=0.464
8
5.38
(2.67)
***
3.94
(2.20)
♦**
5.14
(2.98)
* p=0.017
4.19
(2.39)
* p=0.028
5.52
(2.14)
**p=0.001
4.03
(2.28)
* p=0.005
4.86
(2.87)
** p=0.001
4.09
(2.09)
** p=0.001
5.88
(2.73)
** p=0.003
3.45
(2.08)
** p=0.004
ns
p=0.714
ns
p=0.409
12 5.02
(2.82)
3.64
(2.33)
***
4.27
(3.08)
** p=0.001
3.47
(2.59)
***
5.34
(2.66)
* p=0.005
3.80
(2.22)
5.35
(3.06)
* p=0.029
3.74
(2.12)
***
5.47
(2.45)
* p=0.005
3.51
(2.49)
* p=0.011
ns
p=0.438
ns
p=0.893
p=0.001  p=0.001  p=0.001  p=0.001  p=0.011  p=0.003  p=0.005
Group 1  - Fluoxetine medication
Group 2 - Placebo medication  Intra group analysis  :  Repeated measures ANOVA  ^  4nfrP<0.0001 4* 4*P<0.005 4*P<0.05
Group 3 - Splint therapy  Paired sample t-test  p<0.05 *  p<0.005 **  pO.OOl***
Group 4 - Fluoxetine and splint therapy  Inter group analysis:  One-way ANOVA  not significant
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sFigure 56:  VAS (visual analogue scale) A comparison of mean scores
High and low pain scorers  (High n=171, low  n=78)
Scores
9 n
Group 1 (High) 
HI>»Group 2 (High) 
^ ^ “ Group 3 (High) 
■  •  1  Group 4 (High) 
Group 1 (Low) 
□  Group 2 (Low) 
"Tfc"’ Group 3 (Low) 
■ • “ Group 4 (Low)
Group 1  -  Fluoxetine medication 
Group 2 -  Placebo medication 
Group 3 -  Splint therapy 
Group 4 -  Fluoxetine and splint
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Table 53: Severity guaeeanitial high and low pain scores -  Interference with life (Imputation analysis)
Week Interference All groups (n=249) Group 1  (n=63) Group 2 (n=63) Group 3 (n=61) Group 4 (n=62)
High
(n=78)
Low
(n=171)
High
(n=26)
Low
(n=37)
High
(n=21)
Low
(n=42)
High
(n=12)
Low
(n=49)
High
(n=19)
Low
(n=43)
0 Yes 78  (100%) 171  (100%) 26  (100%) 37  (100%) 21  (100%) 42  (100%) 12  (100%) 49  (100%) 19  (100%) 43  (100%)
No 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%) 0  (0%)
4 Yes 49  (20%) 93  (37%) 15  (58%) 17  (46%) 15  (71%) 26  (62%) 5  (42%) 25  (51%) 14  (74%) 25  (58%)
No 29  (12%) 
***
78  (31%) 
***
11  (42%)
**(p=0.001)
20  (54%) 
***
6  (29%) 
*(p=0.031)
16  (38%) 
***
7  (58%)
*(p=0.016)
24  (49%) 
***
5  (26%) 
ns (p=0.063)
18  (42%) 
***
8 Yes 48  (19%) 78  (31%) 15  (58%) 17 (46%) 15  (71%) 18  (43%) 6  (50%) 25  (51%) 12  (63%) 18  (42%)
No 30  (12%) 
***
93  (37%) 
***
11  (42%)
**(p=0.001)
20  (54%) 
***
6  (29%) 
*(p=0.031)
24  (57%) 
***
6  (50%) 
*(p=0.031)
24  (49%) 
***
7  (37%)
*(p=0.016)
25  (58%) 
***
12 Yes 48  (19%) 72  (29%) 14 (54%) 16  (43%) 15  (71%) 17  (41%) 7  (58%) 22  (45%) 12  (63%) 17  (40%)
No 30  (12%) 
***
99  (40%) 
***
12  (46%) 
***
21  (57%) 
***
6  (29%) 
*(p=0.031)
25  (59%) 
***
5  (42%) 
ns (p=0.063)
27  (55%) 
***
7  (37%)
*(p=0.016)
26  (60%) 
***
* * *   * * *   * * *   * * *   *(p=0.023)  * * *   **(p=0.001)  * * *   *(p=0.005)  * * *
Group 1  -  Fluoxetine medication  Intra group analysis :  Cochran Test  PO.OOl
Group 2 -  Placebo medication  McNemar Test  PO.OOl  ***
Group 3 -  Splint therapy
Group 4 -  Fluoxetine and splint therapy  Intergroup analysis :  Chi squared test
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8.2.6 Self Report Pain questionnaires (high and low pain severity gauge)
8.2.6.1  MPI (High and low pain severity gauge at baseline) (Table 54)
The patient’s perspective of pain had significantly improved during the three months 
treatment phase in severity, interference, life control and affective distress, amongst all 
those with initially high pain scores p<0.001. Low initial pain scores also improved but 
to a lesser extent in some fields; severity p<0.001, interference  p=0.001 and affective 
distress p=0.006.
This pattern was reflected in the significant improvement of initial high scorers in 
group 1  severity p=0.003, interference p=0.002, life control p=0.012 and affective 
distress p=0.011  with no significant change in low scorers. In group 2 and 3 the 
severity improvement was significant in both groups. In group 2 high (p=0.002), low 
(p=0.012), group 3 high (p=0.043), low (p=0.007). However, interference only 
improved in low scorers in group 3, p=0.033 and high scorers in group 2, p=0.002.
The response of significant others revealed support response improved in low severity 
group 3, p=0.009, punishing response increased in high severity group 1, p=0.010. 
These differences, amongst therapeutic groups, were not statistically confirmed in 
rigorous inter group analysis.
8.2.6.2  MPO (High and low pain severity gauge) (Table 55)
Together the groups showed significant improvement amongst the low pain scorers in 
VAS,(p<0.001) and PPI, (p<0.001). This was reflected to a lesser extent in high pain 
scorers VAS, (p=0.017) and PPI, (p=0.004). MPQ total % decreased with comparable 
significance amongst both high and low pain scorers, (p<0.001). MPQ sensory % and 
affective % although significantly reduced in both groups showed slightly increased
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improvement amongst the high category p=0.001 and p<0.001 compared to p=0.005 
and p=0.005 in the low category respectively.
Within group analysis  revealed an interesting observation. Amongst groups 1 and 2 it 
was only the high initial scorers who showed significant improvement whilst groups 3 
and 4 only showed significant improvement in the low pain scorers. In group 1, high 
pain scorers revealed reduced values in PPI, p=0.017, MPQ tota 1%, p=0.015, MPQ 
sensory %, p=0.025 and MPQ affective %, p=0.036. In group 2, high pain scorers had 
reduced values in VAS, p=0.01, MPQ total %, p=0.005, MPQ sensory %, p=0.012 and 
MPQ affective %, p=0.018.Conversely in group 3 it was the low scorers who showed 
significant improvement in VAS, p=0.009, PPI, p=0.005, MPQ total%, p=0.003 and 
MPQ sensory %, p=0.009. In group 4 the low scorers only showed significant 
improvement in PPI, p=0.024.
8.2.63  BDI (High and low pain severity scores) Table 55
The composite scores amongst all groups decreased significantly amongst the low
scorers, p=0.001, reflected to a lesser extent in group 3, p=0.025.
8.2.6.4  Kellner (High and low pain severity scores) Table 55
Illness attitude and hypochondriacal beliefs only significantly decreased amongst the 
high scorers, p=0.026 and p=0.024 respectively. Intra group analysis revealed no 
significant differences.
8.2.6.5  Intergroup analysis
In the intergroup analysis, despite the interesting trends in the MPI and MPQ scores 
there was no significant difference observed in MPI, MPQ, BDI or Kellner to clearly 
distinguish between the four groups.
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Table 54: Multidimensional pain inventory (MPI)  (Pain severity gauge, high and low initial pain scores)
A comparison of median scores (25  ,75  percentiles) between the start and finish of the three months._______
MPI Study All groups (n=249) Group 1  (n=63) Group 2 (n=63) Group 3 (n=61) Group 4 (n=62)
High Low High Low High Low High Low High Low
Patients perspective of pain
MPI - Severity Start
Finish
4.60
(4.00,5.00)
4.00
(2.66,4.66)
2.33
(1.33,3.00)
2.00
(1.00,2.66)
***
4.6
(4.0,5.0)
4.0
(2.45,4.66)
**(p=0.003)
2.00
(1.47,3.0)
1.66
(1.0,3.0) 
ns(p=0.248)
4.33
(4.00,4.66)
4.00
(2.50,4.33)
**(p=0.002)
2.60
(1.66,3.00)
2.16
(1.00,2.75)
* (p=0.012)
4.50
(4.00,5.75)
4.32
(3.25,4.66)
*(p=0.043)
2.33
(1.15,3.00) 
2.00 
(0.66,2.66) 
* (p=0.007)
5.00
(4.00,5.33)
4.00
(3.60,5.30)
2.00
(1.30,3.00)
2.00
(1.30,2.33)
MPI - Interference Start
Finish
3.18
(2.09,4.18)
2.59
(1.07,4.00)
***
1.0
(0.45,1.63)
0.80
(0.30,1.73)
** (p=0.001)
3.10
(2.47,4.05)
2.540
(0.54,3.89)
** (p=0.002)
1.09
(0.55,1.62)
0.82
(0.25,1.81)
ns(p=0.086)
3.27
(1.78,4.14)
2.54
(1.09,3.86)
**(p=0.002)
1.09
(0.52,1.90)
0.81
(0.36,1.75) 
ns (p=0.070)
3.09
(1.90,4.55)
2.23
(0.91,4.05) 
ns (p=0.273)
1.00
(0.38,1.99)
0.70
(0.27,2.14) 
* (p=0.033)
3.81
(1.36,4.36)
3.09
(1.09,4.27)
0.90
(0.30,1.45)
0.64
(0.36,1.33)
MPI - Life control Start
Finish
2.50
(1.50,3.50)
3.00
(1.75,3.75)
**(p=0.003)
3.50
(2.75.4.25) 
3.66
(2.75.4.25)
*  (p=0.023)
2.63
(1.44,3.56)
3.50
(1.50,4.06)
* (p=0.012)
3.50
(2.75,4.50)
3.75
(2.88,4.75)
ns(p=0.055)
2.75
(1.50,3.88)
3.25
(2.40,4.68)
3.38
(2.50,4.25)
3.75
(2.69,4.06)
2.29
(2.00,3.13)
2.38
(2.00,3.63)
3.50
(2.75,4.13)
3.50
(2.75,4.25)
2.50
(1.75.3.50)
2.50
(1.50.3.50)
3.75
(3.00,4.50)
3.75
(3.00,4.50)
MPI -Affective 
distress
Start
Finish
4.00
(3.32,5.00)
3.66
(2.60,4.62)
***
3.00
(2.23,4.00)
3.00
(2.00,3.66)
**(p=0.006)
4.00
(3.25,5.08)
3.63
(2.37,4.15)
* (p=0.011)
3.30
(2.32,4.30)
3.00
(1.83,4.00)
ns(p=0.070)
4.00
(3.15,4.83)
3.60
(2.15,4.48) 
* (p=0.023)
3.33
(2.17,4.00)
3.30
(2.00,3.66) 
ns (p=0.064)
3.83
(3.33,5.00)
3.83
(2.87,4.83)
3.00
(2.00,3.66)
3.00
(1.66,3.83)
4.00
(3.30.5.33) 
3.33
(2.33.5.33)
2.66
(2.30,4.00)
2.60
(1.66,3.33)
Response of significant other
MPI - Support 
response
Start
Finish
4.00
(3.00,5.15)
4.00
(3.00,4.66)
3.00
(2.00,4.33)
3.00
(2.00,4.00)
4.33
(3.0,5.15)
4.00
(3.33,4.66)
2.60
(1.15,4.00)
2.83
(1.00,4.00)
4.60
(3.15,6.00)
4.60
(3.15,5.65)
3.00
(2.00,4.25)
3.00
(1.66,4.33)
3.33
(2.13,4.50)
3.66
(2.66,4.33) 
ns (p=0.655)
3.00
(2.25,4.41)
3.00
(1.60,4.00) 
* (p=0.009)
3.33
(1.57,5.08)
3.66
(1.92,4.75)
3.00
(2.32,4.33)
3.33
(2.33,4.00)
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MPI All groups (n=249) Group 1  (n= 63) Group 2 (n= 63) Group 3 (n=61) Group 4 (n= 62)
Study High Low High Low High Low High Low High Low
MPI Punishing 
response
Start
Finish
1.00
(0.25,2.25)
1.25
(0.25,2.25)
1.00
(0,2.0)
1.00
(0,2.00)
0.50 (0,2.63) 
1.25
(0.38,2.75)
* (p=0.010)
1.0(0.5,3.13) 
0.88 
(0,2.56) 
ns (p=0.072)
1.38
(0.50,2.75)
1.25
(0.50,2.00)
1.25
(0.06,2.44)
1.25
(0.06,2.38)
0.25
(0,1.44)
0.75
(0.19,1.44)
0.88
(0.63,2.25)
1.00
(0,2.06)
1.50
(0.19,2.37)
1.50
(0.19,2.50)
0.75
(0,1.25)
0.75
(0,1.25)
MPI Solicitous 
response
Start
Finish
3.00
(1.33,4.83)
3.00
(1.60,4.50)
ns(p=0.791)
2.63
(1.5,3.53)
2.50
(1.16,3.50)
*(p=0.039)
3.00
(1.45,4.58)
3.00
(1.72,4.75)
2.33
(1.40,3.42)
2.33
(1.16,3.37)
3.38
(2.62,5.20)
3.16
(2.00,5.16)
2.63
(1.08,3.46)
2.50
(1.00,3.53)
3.08
(1.53,4.36)
3.08
(1.42,4.16)
2.66
(1.50,3.42)
2.63
(1.50,3.50)
1.97
(0.77,3.95)
2.33
(0.83,3.83)
2.55
(1.55,4.00)
2.50
(1.50,3.50)
MPI Distracting 
response
Start
Finish
2.00
(1.00,3.00)
2.25
(1.00,3.00)
1.75
(0.75,2.75)
1.50
(0.75,2.75)
1.75
(0.63,2.75)
2.25
(0.63,3.25)
2.00
(1.00,2.63)
1.75
(1.00,2.56)
2.13
(1.00,3.56)
2.25
(1.00,3.50)
1.50
(0.75,2.63)
1.38
(0.50,2.44)
2.63
(0.94,3.06)
2.63
(0.69,3.06)
1.63
(0.50,2.75)
1.75
(0.75,2.75)
1.88
(0.44,3.06)
1.88
(0.88,3.00)
1.75
(0.38,2.88)
1.75
(0.50,3.00)
Freauencv of participation
MPI - Household 
chores
Start
Finish
4.80
(3.60,5.90)
4.70
(3.60,5.40)
4.80
(3.40.5.60) 
4.60
(3.60.5.60)
4.50
(3.15,5.55)
4.60
(3.45,5.65)
5.00
(4.00,5.60)
4.80
(4.20,5.40)
4.50
(3.60,5.95)
4.60
(3.30,5.70)
4.80
(3.20,5.65)
4.30
(3.40,5.60)
5.00
(3.65,5.85)
4.90
(3.95,5.40)
4.50
(3.35,5.80)
4.40
(3.60,5.60)
5.00
(4.20,6.00)
4.8
(3.8,5.4) *
4.80
(3.40,5.25)
4.60
(3.40,5.60)
MPI - Outdoor 
work
Start
Finish
1.66
(1.00,3.00)
2.00
(1.00,3.40)
2.00
(1.00,3.00)
1.80
(1.00,2.79)
1.75
(1.20,3.40)
2.20
(1.30,4.00)
2.00
(1.40,2.850)
1.75
(1.25,2.75)
2.60
(1.23,3.40)
2.29
(1.35,3.70)
1.90
(0.62,2.95)
1.90
(0.81,2.46)
1.40
(1.00,2.50)
1.90
(0.95,2.15)
2.0
(0.85,3.00)
1.60
(0.68,2.80)
0.80
(0.25,3.00)
1.67
(0.48,3.35)
2.00
(1.23,3.15)
2.0
(1.00,3.00)
MPI - Activities 
away from home
Start
Finish
3.75
(2.50,4.25)
3.50
(2.50,4.00)
3.50
(2.75,4.25)
3.50
(2.75,4.50)
3.63
(2.25,4.31)
3.50
(2.44,4.00)
3.50
(2.75,4.38)
3.66
(2.75,4.63)
4.00
(2.50,4.81)
3.75
(2.50,4.50)
3.63
(2.94,4,50)
3.42
(2.75,4.31)
3.75
(2.06.4.00) 
3.63
(2.63.4.00)
3.25
(2.44.4.25) 
3.50
(2.75.4.25)
3.25
(2.50,4.00)
3.25
(2.25,3.75)
3.75
(2.50,4.75)
3.75
(2.75,4.50)
MPI - Social 
activities
Start
Finish
3.25
(2.13,3.75)
3.25
(2.00,4.00)
3.00
(2.33,4.00)
3.25
(2.37,3.75)
3.00
(2.25,3.56)
3.00
(2.19,4.06)
2.71
(2.27,4.25)
2.88
(2.33,3.75)
3.38
(2.35,4.29)
3.25
(2.53,4.25)
3.25
(2.50.4.00) 
3.50
(2.50.4.00)
3.50
(1.69,3.94)
3.50
(1.44,4.00)
3.00
(2.31,3.75)
3.00
(2.33,3.50)
3.25
(2.00,3.50)
3.25
(1.60,3.75)
3.50
(2.25.4.25)
3.50
(2.50.4.25)
MPI - General 
activity level
Start
Finish
3.44
(2.66,3.91)
3.30
(2.70,3.93)
3.34
(2.74,3.90)
3.30
(2.79,3.76)
3.49
(2.52,3.90)
3.36
(2.53,3.93)
3.38
(2.84,3.88)
3.38
(2.74,3.87)
3.61
(2.52,4.29)
3.53
(2.62,4.55)
3.31
(2.68,3.70)
3.20
(2.93,3.60)
3.51
(2.56,3.81)
3.44
(2.87,3.78)
3.28
(2.49,3.73)
3.24
(2.53,3.68)
3.29
(2.75,3.64)
3.13
(2.75,3.36)
3.36
(2.81,4.06)
3.36
(2.85,3.88)
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Table 55: McGill pain questionnaire (MPQ), Beck depression index (BDI)  and Kellner illness attitude scale.(Kellner)
A comparison of median scores (25th and 75  percentiles) Intention to treat analysis (High and low initial pain scores)
Self report 
Questionnaire
Study All groups Group 1 Group 2 Group 3 Group 4
High  Low High Low High Low .JM ........... Low High Low
MPQ
Visual analogue 
scale (VAS) 
(range 0-10)
Start
Finish
5.8
(3.3,7.5) 
5.1
(2.25,6.9)
*  p=0.012
2.1
(0.8,3.7) 
1.6
(0.5,3.28)
♦♦♦
5.05
(1.73,6.68)
4.0
(2.13,6.13)
1.95
(0.65,3.65)
1.4
(0.5,3.38)
5.65
(3.60,7.5)
5.0
(1.83,6.08)
* p=0.011
2.5
(0.93,4.15)
1.9
(0.6,4.0)
6.5
(2.8,8)
5.45
(2.63,7.68)
2.2
(1.1,3.85)
1.4
(0.58,3.2) 
* p=0.009
6.8
(4.18,7.95)
6.75
(2.5,8.25)
1.65
(0.5,3.65)
1.5
(0.5,2.7)
Present pain 
intensity (PPI) 
(range 0-5)
Start
Finish
2.0
(2.0,3.0) 
2.0
(1.0,3.0)
** p=0.004
1.0 
(1.0,2.0) 
1.0 
(1.0,2.0) 
♦♦♦
2.0
(1.75,3.0)
2.0
(1.0,2.25) 
* p=0.017
2.0 
(1.0,2.0) 
1.0 
(1.0,2.0)
2.0
(1.5.2.5) 
2.0
(1.5.2.5)
1.0 
(1.0,2.0) 
1.0 
(1.0,2.0) 
p=0.052
3.0
(2,3.75)
2.5
(1.25,3.0)
1.0 
(1.0,2.0) 
1.0 
(1.0,2.0)
* p=0.005
3.0
(2.0,3.0)
2.0
(2.0,3.0)
1.0 
(1.0,2.0) 
1.0 
(1.0,2.0)
* p=0.024
MPQ - total % 
(range 0-100)
Start
Finish
44
(29,60)
36
(22,53.75)
♦♦♦
27.0
(16.36) 
20
(11.36) 
♦♦♦
(27,51)
33
(22.5,50.5) 
* p=0.015
31
(20,47)
24
(12,42)
40
(31,58)
33.5
(19,38)
* p=0.005
27
(18,36)
26
(12,34.5)
40
(29,56)
38.5
(27.5,59)
(17,36)
20
(12,32)
** p=0.003
57
(39.8.72.3) 
46.5
(17.5.71.3)
22
(13.8,34.5)
18
(10,32)
MPQ- sensory % 
(range 0-100)
Start
Finish
42
(32,67)
36
(21,56.5)
** p=0.001
30.0 
(18,39)
24.0
(13.3,38.5) 
** p=0.005
39.0 
(30,50)
36.0
(24.8,46.5) 
* p=0.025
36
(24,48)
30
(13.5,45)
42
(32,57)
34.5
(21,45)
* p=0.012
30
(17,36)
27
(12,38)
42
(30,63)
45.5
(27.75,72)
30
(18,39)
21
(14.5,33) 
* p=0.009
62.5
(32.3,74.5)
53.5
(14.3,73.8)
24
(15.8,39)
21
(12,40.5)
MPQ - affective % 
(range 0-100)
Start
Finish
42
(17,67)
25
(8,58)
♦♦♦
17.0 
(0,25)
8.0 
(0,25)
** p=0.005
42
(8,75)
25
(6.5,67)
** p=0.036
17
(0,42)
8
(0,25)
33
(25,58)
21
(10.25,33)
* p=0.018
17
(0,25)
17
(0,25)
25
(17.42) 
17
(17.42)
17
(0,25)
8
(0,25)
58
(42,83)
42
(7,75.75)
8.0
(0,25)
8.0
(0,17)
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Self report questionnaire 
Study
All groups (n=249) Group 1  (n=63) Group 2 (n=63) Group 3 (n=61) Group 4 (n=62)
High Low High Low High Low High Low High Low
BDI
Composite score 
(range 045)
Start
Finish
10
(6,19)
9.5
(5,17)
6.0
(2.75,10.0) 
5.0 
(2.0,10.0) 
** p=0.001
8.0
(3.5,15)
7.0
(3.75,12.5)
6.00
(2.13) 
5.00
(1.13)
7.0 
(5,16)
7.0
(3.5,10.5)
7.5
(3.11) 
6.0
(2.11)
10
(7,21)
11
(5.25,20.8)
5.0
(1.75,9.25)
3.0
(0.75,8.25) 
* p=0.025
16
(11,21)
15
(11,23)
6.0
(3.0,9.0) 
5.5
(3,10.25)
Kellner
Illness attitude- total 
(range 0-30)
Start
Finish
9.00 
(6,14)
9.00 
(6,12)
* p=0.026
7.00 
(6,10)
7.00 
(6,10)
9.0
(7.14)
9.0
(6.14)
7.0
(6.0,10.75)
6.5
(6,11)
7.0 
(6.0,10.0)
7.0 
(6.0,10.0)
7.0
(6.0,9.0)
7.0
(6.0,9.25)
8.0
(6,10)
6.0
(6,8.75)
7.5
(6,12)
7.0
(6,11)
12
(9.5,17)
12
(9,16)
7.0
(6.0,10.25)
8.0
(6.0,10.25)
Hypochondriacal 
beliefs 
(range 0-15)
Start
Finish
4.5
(3.0,7.0) 
4.0
(3.0,6.5)
* p=0.024
3.0
(3.0,5.0)
3.0
(3.0,5.0)
4.0
(3.0,7.0)
4.0
(3.0,7.0)
3.0
(3.0,5.75)
3.0
(3.0,4.75)
3.0
(3.0,5.75)
3.0
(3.0,5.0)
3.0
(3.0,5.0)
3.0
(3.0,5.0)
3.0
(3.0,7.0)
3.0
(3.0,3.75)
3.0
(3.0,6.0)
3.0
(3.0,5.0)
7.0
(4.5,9.0) 
6.5
(3.75,7.5)
3.0
(3.0,5.0)
3.0
(3.0,5.0)
Disease phobia 
(range 0-15)
Start
Finish
4.0
(3.0,6.25)
4.0 
(3,6)
3.0
(3.0,5.0)
3.0
(3.0,5.0)
4.0
(3.0,6.5)
3.0
(3.0.7.0)
3.0
(3.0,4.75)
3.0
(3.0,4.75)
3.5
(3.0,4.0) 
3.0
(3.0,4.5)
3.0
(3.0,4.0)
3.0
(3.0,4.0)
3.0
(3.0.5.0)
3.0
(3.0.4.75)
3.0
(3.0,6.0)
3.0
(3.0,6.0)
5.5
(3.0,9.25)
5.0
(3.0,9.25)
3.5
(3.0,5.0)
3.5
(3.0,6.0)
Group 1  - Fluoxetine medication  Kruskall-Wallis not significant between groups
Group 2 - Placebo medication  Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001 ***
Group 3 - Splint therapy
Group 4 - Fluoxetine and splint therapy
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8.3  THE CHARACTERISTICS OF RESPONDERS AND 
NONRESPONDERS TO TREATMENT
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8.3.0  Responders and non responders to therapy (>25% pain improvement) 
Hypothesis (6c) Clinical and pain history characteristics at baseline separate the 
treatment responders from the non responders
Treatment responders and non responders were categorised using the primary outcome 
measure of >25% pain improvement at the end of the three months treatment phase, 
from the clinical visual analogue scale, using the completers analysis (N=165), (fig. 56, 
table 57), followed by the more rigorous ITT analysis (N=201),(fig57a, table 
56a).Demographic, initial self reported pain questionnaires, clinical history and 
examination findings were analysed to assess differences in those responding 
positively to therapy, using the ITT analysis.
Table 56: > 25% improvement  at three months (Completers ) (VAS (clinical)
>25% improvement in 
VAS (clinical) at 3/12
SSRI Placebo Splint SSRI and 
Splint
Total
Non Responder 12 (32%) 19 (45%) 16 (40%) 17 (38%) 64
Responder 26 (68%) 23 (55%) 24 (60%) 28 (62%) 101
Total 38 42 40 45 165
Figure 57: > 25% improvement at three months (Completers)
~ \ Placebo
Splint
I   ISSRI+sp lint
Responder : (n= 101) 
Non Responder: (n=64)
N on R esonder  R esponder
25% pain reduction at treatment end  3/12 (VAS)
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Table 56a: > 25% improvement  at three months (ITT analysis) VAS (clinical)
>50% improvement in 
VAS (clinical) at 3/12
SSRI Placebo Splint SSRI and 
Splint
Total
Non Responder 18 (37%) 29 (55%) 24 (47%) 18 (38%) 89
Responder 31 (63%) 24 (45%) 27 (53%) 30 (63%) 112
Total 49 53 51 48 201
Figure 57b: > 25% improvement at three months (ITT analysis)
Responder : (n= 112)
Non Responder: (n=89)
Group
Splint
N on R esponders  R esponders
25%pain reduction at treatment end 3/12  VAS)
8.3.1  Demographics, summary of responders (table 57)
Between category comparisons suggest no significant difference in age, gender, 
referral source, pain duration, employment, marital and socioeconomic status.
8.3.2  Self-report pain questionnaire, summary of responders (table 58)
The table illustrates there was no significant difference in initial scores of patient’s 
perspective of pain, impact on daily life. The attitude and actions of significant family 
or friends suggest a punishing response was higher amongst non responders to 
therapy,(p=0.017). Frequency of participation in social activities seemed to be higher 
amongst non responders p=0.011  and so was the general activity level p=0.047.
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Tabic 57:
Demographic details for responders and non responders to treatment ( N=201)
Recorded at baseline 
assessment
All groups 
(n=201)
Responders
(n=112)
Nonresponders
(n=89)
Significance
Age (in years) 
Mean (+/- SD) 
(Range)
32.4 (9.78) 
(16-55)
33.0 (10.28) 
(16-55)
31.6(9.13)
(16-55)
ns
(p=0.322)
Duration of pain (in yrs) 
Mean (+/- SD)
Range
3.38 (4.40) 
(0.25-32.0)
3.19(4.17)
(0.25-25.0)
3.61 (4.70) 
(0.25-32.0)
ns
(p=0.510)
Gender M: F
48:153 
23.9%:76.1%
26:  86 
23.2%:76.8%
22: 67
24.7%:75.3%
ns
(p=0.804)
Referral source
GDP
GP
Specialist
182 (90.5%) 
6 (3.0%) 
13 (6.5%)
99 (88.4%) 
5 (4.5%) 
8(7.1%)
83 (93.3%) 
1  (1.1%)
5 (5.6%)
ns
(p=0.339)
Employment status
Employed
Unemployed
Student
Retired (medical) 
House wife
138 (68.7%) 
17 (8.5%) 
31 (15.4%) 
1  (0.5%) 
14 (7.0%)
79 (70.5%) 
10 (8.9%) 
15(13.4%) 
0 (0%) 
8(7.1%)
59 (66.3%) 
7 (7.9%) 
16(18.0%) 
1  (1.1%)
6 (6.7%)
ns
(p=0.710)
Socio-economic status
Professional  I 
Intermmediate  Ili 
Skilled non-manual  Ilii 
Skilled manual  III 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, retired
7 (3.5%) 
66 (32.8%) 
56 (27.9%) 
7(3.5%)
3 (1.5%)
1  (0.5%) 
61 (30.4%)
6 (5.4%) 
33 (29.5%) 
33 (29.5%) 
6 (5.4%) 
2(1.8%)
0 (0%)
32 (28.6%)
1  (1.1%) 
33 (37.1%) 
23 (25.8%) 
1  (1.1%)
1  (1.1%)
1  (1.1%) 
29 (32.6%)
ns
(p=0.252)
Marital status
Single
Married
Seperated
Divorced
Widowed
123 (61.2%) 
69 (34.3%) 
1  (0.5%)
7 (3.5%)
1  (0.5%)
68 (60.7%) 
37 (33.1%) 
1 (0.9%)
0 (4.5%)
0 (0.9%)
55 (61.8%) 
32 (36.0%) 
0 (0%)
2 (2.2%)
0 (0%)
ns
(p=0.519)
Significance test, Chi-squared (Independent samples t-test for age and duration)
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Table 58: Self -Report Pain Questionnaires at baseline (Responders and Non responders)
MPI
(n=201) 
All groups
(n=112)
Responders
(n=89)
Non responders Significance
Patients perspective of pain 
and impact on daily life
MPI - Severity 3.00 (2.00,4.00) 3.00 (2.00, 4.23) 3.00 (1.66, 3.83) ns
(p=0.285)
MPI - Interference 1.45 (0.64,2.90) 1.50(0.82,3.19) 1.40 (0.50, 2.41) ns
(p=0.121)
MPI -  Life control 3.25 (2.50,4.00) 3.25 (2.50, 4.00) 3.25 (2.29, 4.00) ns
(p=0.810)
MPI -  Affective distress 3.33 (2.33,4.30) 3.33(2.31,4.30) 3.33 (2.60, 4.30) ns
(p=0.775)
Response of significant 
other person to patient
MPI - Support response 3.60 (2.30,4.66) 3.66 (2.60, 4.66) 3.00 (2.00, 4.33) ns
(p=0.198)
MPI -  Punishing response 0.75 (0,2.00) 0.50 (0.00, 1.94) 1.25 (0.25, 2.75) *
(p=0.017)
MPI -  Solicitous response 2.66 (1.50,3.83) 2.83 (1.50, 4.00) 2.66 (1.60, 3.60) ns
(p=0.617)
MPI -  Distracting response 2.00 (0.75,3.00) 2.00 (0.75,3.00) 1.75 (0.75, 2.75) ns
(p=0.689)
Frequency of participation 
in common activities
MPI - Household chores 4.80 (3.40,5.60) 4.80 (3.20, 5.40) 5.00 (3.65, 5.80) ns
(p=0.112)
MPI -  Outdoor work 2.00(1.00,3.00) 2.00(1.10,3.00) 2.00 (1.00, 2.80) ns
(p=0.349)
MPI -  Activities away from 
home
3.50 (2.75,4.50) 3.50 (2.69, 4.25) 3.75 (3.00, 4.69) ns
(p=0.172)
MPI -  Social activities 3.25 (2.28,4.00) 3.00 (2.19,3.75) 3.50 (2.50, 4.25) *
(p=0.011)
MPI -  General activity level 3.40(2.75,3.98) 3.30 (2.71,3.77) 3.57 (2.83,4.06) *
(p=0.047)
MPQ
Visual analogue scale 
(VAS) (range 0-10)
3.00(1.40,5.60) 3.00 (1.48, 5.20) 3.00(1.10, 5.90) ns
(p=0.835)
Present pain intensity 
(PPI) (range 0-5)
2.00 (1.00,2.00) 2.00 (1.00, 2.00) 2.00 (1.00, 2.00) ns
(p=0.779)
MPQ -  total % 
(range 0-100)
29.0(18.0,42.5) 29.0(18.00,41.00) 29.0 (20.00,44.00) ns
(p=0.941)
MPQ- sensory %  
(range 0-100)
33.0 (21.0,45.0) 33.0 (21.0,45.00) 33.0(21.00,45.00) ns
(p=0.771)
MPQ - affective % 
(range 0-100)
17.0 (0,42.0) 17.0 (0.0, 42.00) 17.0 (8.00, 37.50) ns
(p=0.618)
BDI
Composite score 
(range 0-45)
7.0  (3.00,12.0) 7.0 (3.00, 15.00) 7.0 (3.00, 11.00) ns
(p=0.653)
Kellner
Illness attitude- total 
(range 0-30)
7.0  (6.0,11.0) 7.5 (6.00, 10.75) 7.0(6.00, 11.00) ns
(p=0.581)
Hypochondriacal beliefs 
(range 0-15)
3.0 (3.00,6.00) 3.0 (3.00,6.00) 3.0 (3.00,6.00) ns
(p=0.264)
Disease phobia 
(range 0-15)
3.0 (3.00,6.00) 3.0 (3.00,5.00) 3.0 (3.00, 5.00) ns
(p=0.878)
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Table  59a: TMJ symptoms
Baseline record prior to 
treatment
All groups
(n=201)
Responders
(n=112)
NonResponders
(n=89) Significance
TMJ symptoms
TMJ pain 201 (100%) 112(100%) 89 (100%) -
Muscle pain -  
Temporalis
52 (26%) 29 (27.9%) 23 (25.8%) ns (p=0.994)
Muscle pain - 
Masseter
64 (32%) 31 (26.8%) 33 (37.1%) ns (p=0.155)
Clicking 152 (76.8%) 90 (83.8%) 62 (69.7%) ns (p=0.079)
Sticking 59 (30.4%) 37 (26.5%) 22 (24.7%) ns (p=0.198)
Limitation in mouth 
opening
35 (74.8%) 20 (67.6%) 15(16.9%) ns (p=0.852)
Ear popping 36 (20.4%) 21 (20.6%) 15(16.8%) ns (p=0.798)
Ear buzzing 27(14.8%) 14 (20.6%) 13 (14.6%) ns (p=0.757)
Ear deafness 30 (14.8%) 18(19.1%) 12 (13.5%) * (p=0.045)
Ear fullness 47 (24.8%) 26 (22.1%) 21 (23.6%) ns (p=0.890)
Character of TMJ pain
Dull ache 132 (65.7%) 71 (63.4%) 61 (68.5%) ns (p=0.445)
Discomfort 109 (54.2%) 59 (52.7%) 50 (56.2%) ns (p=0.621)
Sharp 82 (40.8%) 44 (39.3%) 38 (42.7%) ns (p=0.625)
Stabbing 31 (15.4%) 15(13.4%) 16(18.0%) ns (p=0.371)
Throbbing 11 (5.5%) 6 (5.4%) 5 (5.6%) ns (p=0.936)
Burning 3(1.5%) 3 (2.7%) 0 (0%) ns (p=0.120)
Unilateral 140 (69.7%) 83 (74.1%) 57 (64.0%) ns (p=0.123)
Table 59b: Other reported chronic pains
R ecorded at b aselin e 
assessm ent
(n=201) 
All groups
(n=112)
Responders
(n=89)
Non responders Significance
R ecu rren t ch ron ic 
pains
Headache 121 (60.2%) 61 (54.5%) 60 (67.4%) ns (p=0.062)
Migraine 65 (32.3%) 36(32.1%) 29 (32.6%) ns  (p=0.947)
Neck ache 100 (49.8%) 50 (44.6%) 50 (56.2%) ns(p=o.i04)
Back pain 94 (46.8%) 57 (50.9%) 37(41.6%) ns(p=0.188)
Abdominal pain 61 (30.3%) 37 (33.0%) 24 (27.0%) ns (p=0.353)
Pruritus 44 (21.9%) 26 (23.2%) 18 (20.2%) ns (p=o.6ii)
Chest pain 29 (14.4%) 16 (14.3%) 13 (14.6%) ns (p=0.949)
393Ch a pter  v i i i   stu y  c o h o r t - s u b  g r o u p  a n a ly s is
Table 59c: Onset,exacerbation and relief of TMJ pain
Base line record All groups 
(n=201)
Responders
(n=112)
Non Responders 
(n=89) Significance
Precipitating factors
Dental 58 (28.9%) 34 (30.4%) 24 (27.0%) ns (p=0.60)
Physical trauma 31 (15.4%) 16 (14.3%) 15(16.9%) ns (p=0.62)
Emotional trauma 49 (24.4%) 31 (27.7%) 18 (20.2%) ns (p=0.22)
Infection 5 (2.5%) 3 (2.7%) 2 (2.2%) ns (p=0.85)
None 54 (26.9%) 29 (25.9%) 25 (28.1%) ns (p=0.73)
Provoking factors
Chewing 152 (75.6%) 83 (74.1%) 69 (77.5%) ns (p=0.58)
Yawning 153 (76.1%) 85 (75.9%) 68 (76.4%) ns (p=0.93)
Biting 129 (64.2%) 70 (62.5%) 59 (66.3%) ns (p=0.58)
Emotional tension 108 (53.7%) 54 (48.2%) 54 (60.7%) ns (p=0.08)
Talking 62 (30.8%) 34 (30.4%) 28 (31.5%) ns (p=0.87)
Cold weather 57 (28.4%) 33 (29.5%) 24 (27.0%) ns (p=0.70)
Hot weather 4 (2.0%) 2(1.8%) 2 (2.2%) ns (p=0.82)
Hot food/drink 2(1.0%) 1  (0.9%) 1 (1.1%) ns (p=0.87)
Cold food/drink 4 (2.0%) 2(1.8%) 2 (2.2%) ns (p=0.82)
Alcohol 7 (3.5%) 4 (3.6%) 3 (3.4%) ns (p=0.94)
Chocolate 5 (2.5%) 5 (4.5%) 0 (0%) *  (p=0.04)
Cheese 4 (2.0%) 3 (2.7%) 1(1.1%) ns (p=0.43)
Relieving factors
Analgesics 105 (52.2%) 54 (48.2%) 51 (57.3%) ns (p=0.20)
Rest 85 (42.3%) 48 (42.9%) 37(41.6%) ns (p=0.86)
Pressure 77 (38.3%) 38 (33.9%) 39 (43.8%) ns (p=0.15)
Heat 50 (24.9%) 29 (25.9%) 21 (23.6%) ns (p=0.71)
Alcohol 11 (5.5%) 7 (6.3%) 4 (4.5%) ns (p=0.59)
Chewing 8 (4.0%) 6 (5.4%) 2 (2.2%) ns (p=0.26)
8.3.3  TMD signs and symptoms, summary of responders, (table 59a,59b)
There are no significant differences in TMJ symptoms or character of pain described 
apart (table 59a) or the reporting of other chronic recurrent pains (table 59b). 
Frequency, diurnal variation, bruxism and occlusal habits were not significantly 
different between categories (table 59c). TMJ signs recorded at initial examination 
were also comparable and non significant (table 59d).
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Table 59d: Frequency, diurnal variation, bruxism and occlusal discomfort in TMJ pain
Frequency of TMJ pain All groups 
(n=201)
Responders
(n=112)
Non Responders 
(n=89)
significance
Always 78 (38.8%) 49 (43.8%) 29 (32.6%) ns (p=o.08i)
Often 60 (29.9%) 38 (33.9%) 22 (24.7%)
Occasionally 13 ( 6.5%) 8(7.1%) 5 (5.6%)
Always dull, occasionally sharp 46 (21.6%) 15 (13.4%) 31 (34.9%)
Often dull, occasionally sharp 4 ( 2.0%) 2(1.8%) 2 (2.2%)
Length of bouts
Constant 150 (74.6%) 87 (77.7%) 63 (73.6%) ns (p=0.521)
Weeks 3 (1.5%) 2(1.8%) 1(1.1%)
Days 22 (10.9%) 12 (10.7%) 10(11.2%)
Hours 19 (9.5%) 7 (6.3%) 12(13.5%)
Minutes 7 (3.5%) 4 (3 .6%) 3 (3 .4%)
Frequency of bouts
Constant 150 (74.6%) 87 (77.7%) 63 (70.8%) ns (p=0.470)
Daily 36(17.9%) 18(16.1%) 18 (20.2%)
Weekly 14 (7.0%) 6 (5 .4%) 8 (9.0%)
Monthly 1  (0.5%) 1  (0.9%) 0 (0%)
Pain free intervals
None 150 (74.6%) 87 (77.7%) 63 (70.8%) ns (p=0.341)
Weeks 11 (5.5%) 4 (3 .6%) 7 (7.9%)
Days 40 (19.9%) 21 (18.8%) 19 (21.3%)
Diurnal variation in TMJ 
pain
Worse in the morning 96 (47.8%) 60 (53.6%) 36 (40.4%) ns (p=0.064)
Worse in the evening 54 (26.9%) 28 (25.0%) 26 (29.2%) ns (p=0.503)
Altered sleep patterns
Prevention of sleep 93 (46.3%) 50 (44.6%) 43 (48.3%) ns (p=0.604)
Disturbance of sleep 94 (46.8%) 51 (45.5%) 43 (48.3%) ns (p=0.695)
Sleep alterations
No problems 83 (41.3%) 43 (38.4%) 40 (44.9%) ns (p=0.482)
Cannot get to sleep 25 (12.4%) 13 (11.6%) 12 (13.5%)
Disturbed sleep 43 (21.4%) 28 (25.0%) 15 (16.9%)
Early morning waking 8 (4.0%) 5 (4.5%) 3 (3.4%)
Cannot get to sleep and 
disturbed sleep
19 (9.5%) 9 (8.0%) 10(11.2%)
Cannot get to sleep and 
early waking
2(1.0%) 0 (0%) 2 (2.2%)
Disturbed sleep and early 
waking
10 (5.0%) 7 (6.3%) 3 (3.4%)
Cannot get to sleep, disturbed 
sleep and early morning waking
11 (5.5%) 7 (6.3%) 4 (4.5%)
Bruxism and occlusal comfort
Nocturnal bruxism habit 39(19.4%) 23 (20.5%) 16(18.0%) ns (p=0.649)
Sensation of disturbed 
occlusal comfort
110(54.7%) 68 (60.7%) 42 (47.2%) ns (p=0.056)
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Table 59e: TMJ signs
TMJ signs All groups
(n=201)
Responders
(n=112)
Non Responders
(n=89) Significance
TMJ pain
Tenderness
Right
Left
201(100%)
135(67.2%)
137(68.2%)
112(100%)
75 (67.0%)
76 (67.9%)
89 (100%)
60 (67.4%)
61 (68.5%)
ns (p=0.946) 
ns (p=0.918)
Opening click
Right
Left
40 (19.9%) 
55 (27.4%)
23 (20.5%) 
25 (22.3%)
17(19.1%) 
30 (33.7%)
ns (p=0.800) 
ns (p=0.072)
Closing click
Right
Left
16 (8.0%) 
26 (12.9%)
10 (8.9%) 
10 (8.9%)
6 (6.7%) 
16 (18.0%)
ns (p=0.569) 
ns (p=0.058)
Deviation on 
mouth opening
Right
Left
5 (2.5%) 
8 (4.0%)
1 (0.9%) 
2(1.8%)
4 (4.5%) 
6 (6.7%)
ns (p=0.103) 
ns (p=0.074)
Sticking
Right
Left
4 (2.0%)
5 (2.5%)
3 (2.7%) 
3 (2.7%)
1  (1.1%) 
2 (2.2%)
ns (p=0.433) 
ns (p=0.845)
Recorded at baseline assessment
All groups
(n=201)
Responders
(n=112)
Non
Responders
(n=89)
Significance
Occlusion
Angles classification
Class I
Class II division i 
Class II division ii 
Class HI
81 (40.3%) 
78 (38.8%) 
40 (19.9%) 
2 (1.0%)
47 (42.0%) 
44 (39.3%) 
19 (17.0%) 
2 (1.8%)
34 (38.2%) 
34 (38.2%) 
21 (23.6%) 
0 (0%)
ns (p=0.411)
Overjet  > 6mm 11 (5.5%) 4 (3.6%) 7 (7.9%) ns (p=0.184)
Buccal mucosa
Ridging
Frictional keratosis 
Abrasion
109 (54.2%) 
10 (5.0%)
6 (3.0%)
59 (52.7%) 
6 (5.4%)
2 (1.8%)
50 (56.2%) 
4 (4.5%) 
4 (4.5%)
ns (p=0.621) 
ns (p=0.780) 
ns (p=0.262)
Lingual mucosa
Ridging (scalopped margin) 24(11.9%) 14 (12.5%) 10(11.2%) ns (p=0.784)
Missing posterior teeth
Greater than five 
Greater than six
24(11.9%) 
11 (5.5%)
17 (15.2%) 
8(7.1%)
7 (7.9%) 
3 (3.4%)
ns (p=0.112) 
ns (p=0.243)
Missing wisdom teeth
None
One
Two
Three
Four
70 (34.8%) 
13 (6.5%) 
32 (15.9%) 
19 (9.5%) 
67 (33.3%)
41 (36.6%) 
9 (8.0%) 
17 (15.2%) 
10 (8.9%) 
35 (31.3%)
29 (32.6%) 
4 (4.5%) 
15 (16.9%) 
9(10.1%) 
32 (36.0%)
ns (p=0.794)
Missing maxillary canine tooth 6 (3.0%) 2 (1.8%) 4 (4.5%) ns (p=0.432)
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8.3.4  Responders and non responders to therapy f>50% improvement in pain)
Treatment responders and non responders were categorised using the primary outcome 
measure of >50% pain improvement at the end of the three months treatment phase, 
from the clinical visual analogue scale, using the rigorous imputation analysis (n=250) 
(,table 56).Demographic, initial self reported pain questionnaires, clinical history and 
examination findings were analysed to assess differences in those responding 
positively to therapy.
Table 60: Greater than 50% improvement  at three months VAS (clinical)
>50% improvement in 
VAS (clinical) at 3/12
SSRI Placebo Splint SSRI and 
Splint
Total
Non Responder 40 (63.5%) 50 (79.3%) 47 (75.8%) 45 (72.6%) 182
Responder 23 (36.5%) 13 (20.6%) 15 (24.2%) 17 (27.4%) 68
Total 63 63 62 62 250
8.3.5  Demographics, summary of responders (table 57)
Between category comparisons suggest no significant difference in age, gender, 
employment, socioeconomic status or pain duration.
Examining the referral source, the majority of all referrals were from GDP’s , 
responders 63/68 (92.6%) and non responders 167/182 (91.8%).However, a higher 
percentage of non responders were tertiary referrals from Consultant specialists 13/182 
(7.1%) as opposed to 1/68 (1.5%), p=0.023.
Marital status also varied. In both categories, the majority of patients were single, 
although slightly higher in responders 45/68 (66.2%) than non responders 102/182 
(56%). A similar proportion of patients were married 22/68 (32.3%) in responders and 
67/182 (36.8%) in non responders but a significantly higher proportion of patients 
were divorced 11/182 (6%) in the non responders compared to zero in the responders, 
p=0.035.
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8.3.6 Self-report pain questionnaire, summary of responders (table 58)
The table illustrates there was no significant difference in initial scores of patient’s 
perspective of pain and impact on daily life. The attitude and actions of significant 
family or friends suggests a punishing response was just significantly higher amongst 
non responders p=0.036. Frequency of participation in social activities again seemed to 
be higher amongst non responders p=0.036.
8.3.7 TMD signs and symptoms, summary of responders, (table 59,60)
There are no significant differences in TMJ symptoms or character of pain described 
(table 59) or the reporting of other chronic recurrent pains (table 60).
8.3.8 TMD description, summary of responders, (table 61,62,63)
Onset, exacerbation or relief of pain (table 61) only suggests a slight increase in the 
amount of analgesia usually taken to relieve pain in non responders 103/182 (56.6%) 
compared to 29/68 (42.6%) in responders to therapy p=0.049.
Frequency, diurnal variation, bruxism and occlusal habits were not significantly 
different between categories (table 62). TMJ signs recorded at initial examination were 
also comparable and non significant (table 63).
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Table 61:
Demoaraphic details for responders and non responders to treatment ( N=250)
Recorded at baseline 
assessment
All groups 
(n=250)
Responders
(n=68)
Nonresponders
(n=182)
Significance
Age (in years) 
Mean (+/- SD) 
Range
32.3 (9.58) 
(16-55)
32.9 (10.49) 
(16-55)
32.1 (9.23) 
(16-54)
ns
(p=0.560)
Duration of pain (in yrs) 
Mean (+/- SD)
Range
3.30 (4.49) 
(0.25-32.0)
3.08(4.11)
(0.25-32.0)
3.38 (4.64) 
(0.25-32.0)
ns
(p=0.639)
Gender M: F
59. 191 
23.6%:76.4%
16.  52
23.5%:76.5%
43:139 
23.6%:76.4%
ns
(p=0.987)
Referral source
GDP
GP
Specialist
230 (92%) 
6 (2.4%) 
14 (5.6%)
63 (92.6%) 
4 (5.9%)
1  (1.5%)
167(91.8%) 
2(1.1%) 
13 (7.1%)
*
(p=0.023)
Employment status
Employed
Unemployed
Student
Retired (medical) 
House wife
167 (66.8%) 
19 (7.6%) 
39(15.6%) 
1 (0.4%) 
24 (9.6%)
43 (63.2%) 
10 (14.7%) 
10 (14.7%) 
0 (0%)
5 (7.4%)
124 (68.1%) 
9 (4.9%) 
29(15.9%) 
1 (0.5%) 
19 (10.4%)
ns
(p=0.121)
Socio-economic status
Professional  I 
Intermmediate  Hi 
Skilled non-manual  Ilii 
Skilled manual  HI 
Semi skilled  IV 
Unskilled  V 
Unemployed, house  VI 
wife, student, retired
11 (4.4%) 
78 (31.2%) 
66 (26.4%) 
8 (3.2%)
5 (2.0%)
1 (0.4%) 
81 (32.4%)
2 (2.9%) 
23 (33.8%) 
18 (26.5%) 
0 (0%)
0 (0%)
0 (0%)
25 (36.8%)
9 (4.9%)
55 (30.2%) 
48 (26.4%)
8 (4.4%)
5 (2.7%)
1  (0.5%)
56 (30.7%)
ns
(p=0.437)
Marital status
Single
Married
Seperated
Divorced
Widowed
147 (58.8%) 
89 (35.6%) 
2 (0.8%) 
11 (4.4%)
1  (0.4%)
45 (66.2%) 
22 (32.3%) 
1  (1.5%)
0 (0%)
0 (0%)
102 (56.0%) 
67 (36.8%) 
1 (0.5%) 
11 (6.0%)
1  (0.5%)
*
p=0.035
Significance test, Chi-squared (Independent samples t-test for age and duration).
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Table 62: Self -Report Pain Questionnaires at baseline (Responders and Non responders)
MPI
(n=250) 
All groups
(n=68)
Responders
(n=182)
Non responders Significance
Patients perspective of pain 
and impact on daily life
MPI - Severity 3.00 (1.92,4.00) 2.60 (1.66, 4.00) 3.00 (2.00, 4.00) ns
(p=0.299)
MPI - Interference 1.45 (0.65,2.88) 1.39(0.73,3.02) 1.45 (0.60, 2.82) ns
(p=0.895)
MPI -  Life control 3.25 (2.31,4.00) 3.25 (2.56, 4.00) 3.25 (2.25, 4.25) ns
(p=0.876)
MPI - Affective distress 3.33 (2.33,4.30) 3.00 (2.08, 4.23) 3.33 (2.60, 4.30) ns
(p=0.277)
Response of significant 
other person to patient
MPI -  Support response 3.33 (2.30,4.66) 4.00 (2.66, 4.66) 3.00 (2.00, 4.47) ns
(p=0.233)
MPI - Punishing response 1.00(0,2.06) 0.58 (0.00, 1.75) 1.00 (0.25, 2.50) *
(p=0.036)
MPI -  Solicitous response 2.66(1.50,3.87) 2.50 (1.04, 3.83) 2.66 (1.60, 4.00) ns
(p=0.542)
MPI - Distracting response 1.75(0.75,2.75) 1.75 (0.50,2.75) 1.75 (0.75, 2.81) ns
(p=0.555)
Frequency of participation 
in common activities
MPI - Household chores 4.80 (3.60,5.60) 4.80 (3.40, 5.40) 4.80 (3.60, 5.80) ns
(p=0.429)
MPI -  Outdoor work 2.00(1.00,3.00) 2.00(1.30, 3.30) 1.75 (1.00, 2.80) ns
(p=0.104)
MPI -  Activities away from 
home
3.50 (2.75,4.25) 3.50 (2.50, 4.25) 3.50 (2.75, 4.50) ns
(p=0.476)
MPI - Social activities 3.00 (2.30,4.00) 2.75 (2.25, 3.66) 3.25 (2.32, 4.00) *
(p=0.036)
MPI - General activity level 3.38 (2.75,3.91) 3.33 (2.77, 3.79) 3.44 (2.71, 3.98) ns
(p=0.409)
MPQ
Visual analogue scale 
(VAS) (range 0-10)
2.90(1.20,5.45) 2.30 (1.20, 4.60) 3.00 (1.25, 5.65) ns
(p=0.223)
Present pain intensity 
(PPI) (range 0-5)
2.00(1.00,2.00) 2.00 (1.00, 2.00) 2.00 (1.00, 2.00) ns
(p=0.195)
MPQ-total % 
(range 0-100)
31.0 (20.0,47.0) 29.0(18.00,40.00) 31.0 (20.5,47.00) ns
(p=0.182)
MPQ- sensory % 
(range 0-100)
33.0 (21.0,45.0) 31.5(20.25,42.25) 34.5(21.00,47.75) ns
(p=0.435)
MPQ -  affective %  
(range 0-100)
17.0 (3.0,42.0) 17.0 (0.0,42.00) 25.0 (8.00, 42.0) ns
(p=0.097)
BDI
Composite score 
(range 0^15)
7.0  (3.00,13.0) 7.0 (2.00, 13.00) 7.0 (3.00, 12.75) ns
(p=0.326)
Kellner
Illness attitude' total 
(range 0-30)
8.0  (6.0,11.0) 7.0 (6.00, 10.00) 8.0 (6.00, 12.00) ns
(p=0.336)
Hypochondriacal beliefs 
(range 0-15)
3.00(3.00,6.00) 3.00 (3.00,5.75) 3.00 (3.00,6.00) ns
(p=0.870)
Disease phobia 
(range 0-15)
3.00 (3.00,5.00) 3.00 (3.00,5.00) 3.00 (3.00, 5.75) ns
(p=0.200)
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Table  63a: TMJ symptoms
Baseline record prior to 
treatment
All groups
(n=250)
Responders
(n=68)
NonResponders
(n=182) Significance
TMJ symptoms
TMJ pain 250 (100%) 68 (100%) 182 (100%) -
Muscle pain -  
Temporalis
65 (26%) 19 (27.9%) 46 (25.3%) ns (p=0.669)
Muscle pain - 
Masseter
80 (32%) 25 (26.8%) 55 (30.2%) ns (p=0.324)
Clicking 192 (76.8%) 57 (83.8%) 135 (74.2%) ns (p=0.108)
Sticking 76 (30.4%) 18 (26.5%) 58(31.9%) ns (p=0.409)
Limitation in mouth 
opening
187 (74.8%) 46  (67.6%) 141 (77.5%) ns (p=0.111)
Ear popping 51 (20.4%) 14 (20.6%) 37 (20.3%) ns (p=0.964)
Ear buzzing 37 (14.8%) 14 (20.6%) 23 (12.6%) ns (p=0.115)
Ear deafness 37 (14.8%) 13 (19.1%) 24 (13.2%) ns (p=0.240)
Ear fullness 62 (24.8%) 15 (22.1%) 47 (25.8%) ns (p=0.540)
Character of TMJ pain
Dull ache 161 (64.4%) 45 (66.2%) 116(63.7%) ns (p=0.720)
Discomfort 137(54.8%) 43 (63.2%) 94 (51.6%) ns (p=0.101)
Sharp 99  (39.6%) 31 (45.6%) 68 (37.4%) ns (p=0.237)
Stabbing 35  (14%) 10(14.7%) 25 (13.7%) ns (p=0.844)
Throbbing 20  (8%) 5 (7.4%) 15 (8.2%) ns (p=0.818)
Burning 6  (2.4%) 1  (1.5%) 5 (2.7%) ns (p=0.557)
Unilateral 180 (72%) 45 (66.2%) 135 (74.2%) ns (p=0.210)
Table 63b: Other reported chronic pains
R ecorded at baselin e 
assessm ent
(n=250) 
All groups
(n=68)
Responders
(n=182)
Non responders Significance
R ecurrent ch ron ic 
pains
Headache 61.2% (153) 54.4% (37) 63.7% (116) ns (p=0.178)
Migraine 32.8% (  82) 39.7% (27) 30.2% (55) ns  (p=0.155)
Neck ache 50.0% (125) 42.6% (29) 52.7% (96) ns(p=0.155)
Back pain 48.4% (121) 41.2% (28) 51.1% (93) ns(p=0.162)
Abdominal pain 29.6% (  74) 27.9% (19) 30.2% (55) ns (p=0.725)
Pruritus 22.0% (  55) 14.7% (10) 24.7% (45) ns (p=0.089)
Chest pain 15.6% (  39) 16.2% (11) 15.4% (28) ns (p=0.878)
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Table 63c: Onset,exacerbation and relief of TMJ pain
Base line record
(n=250) 
All groups
(n=68)
Responders
(n=182)
Non Responders Significance
Precipitating factors
Dental 26.4% (66) 30.9% (21) 24.7% (45) ns (p=0.326)
Physical trauma 15.6% (39) 11.8%  (8) 17.0% (31) ns (p=0.307)
Emotional trauma 2.8% (  7) 19.1% (13) 25.8% (47) ns (p=0.269)
Infection 24.0% (60) 1.5%  (1) 3.3%  (  1) ns (p=0.436)
None 26.8% (67) 23.5% (16) 28.0% (51) ns (p=0.475)
Provoking factors
Chewing 76.8% (192) 82.4% (56) 74.7% (136) ns (p=0.204)
Yawning 76.4% (191) 82.4% (56) 74.2% (135) ns (p=0.175)
Biting 65.6% (164) 66.2% (45) 65.4% (119) ns (p=0.907)
Emotional tension 53.6% (134) 57.4% (39) 52.2% (95) ns (p=0.467)
Talking 31.6% (  79) 29.4% (20) 32.4% (59) ns (p=0.649)
Cold weather 28.8% (  72) 30.9% (21) 28.0% (51) ns (p=0.657)
Hot weather 2.4% (  6) 2.7%  (5) 1.5%  (1) ns (p=0.557)
Hot food/drink 1.6% (  4) 0%  (  0) 2.2% (  4) ns (p=0.218)
Cold food/drink 2.4% (  6) 1.5% (  1) 2.7% (  5) ns (p=0.557)
Alcohol 3.2% (  8) 2.9% (  2) 3.3% (  6) ns (p=0.887)
Chocolate 2.0% (  5) 4.4% (  3) 1.1% (  2) ns (p=0.096)
Cheese 1.6% (  4) 2.9% (  2) 1.1% (  2) ns (p=0.302)
Relieving factors
Analgesics 52.8% (132) 42.6% (29) 56.6% (103) * p=0.049
Rest 44.0% (110) 52.9% (36) 40.7% (74) ns p=0.082
Pressure 38.4% (  96) 42.6% (29) 36.8% (67) ns p=0.339
Heat 24.0% (  60) 25.0% (17) 23.6% (43) nsp=0.821
Alcohol 6.4% (  16) 8.8%  (6) 5.5%  (10) ns p=0.339
Chewing 3.2% (  8) 2.9%  (2) 3.3%  (6) ns p=0.887
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Table 63d: Frequency, diurnal variation, bruxism and occlusal discomfort in TMJ pain
Frequency of TMJ pain All groups 
(n=250)
Responders
(n=68)
Non Responders 
(n=182)
significance
Always 151 (60.4%) 25 (36.8%) 72 (39.6%) ns (p=0.763)
Often 83 (33.2%) 18 (26.5%) 59 (32.4%)
Occasionally 16 ( 6.4%) 4 (5 .9%) 12 (6.6%)
Always dull, occasionally sharp 54 (21.6%) 19 (28.0%) 35 (19.2%)
Often dull, occasionally sharp 6 (2.4%) 2 (2.9%) 4 (2.2%)
Length of bouts
Constant 185 (74.0%) 51 (75.0%) 134 (73.6%) ns (p=0.996)
Weeks 5 (2.0%) 1   (1.5%) 4  (2.2%)
Days 31 (12.4%) 8  (11.8%) 23  (12.6%)
Hours 22 (8.8%) 6  (8.8%) 16  (8.8%)
Minutes 7 (2.8%) 2  (2.9%) 5  (2.7%)
Frequency of bouts
Constant 185 (74.0%) 51 (75.0%) 134 (73.6%) ns (p=0.931)
Daily 43 (17.2%) 12 (17.6%) 31 (17.0%)
Weekly 19 (7.6%) 4 (5.9%) 15 (8.2%)
Monthly 3 (1.2%) 1  (1.5%) 2(1.1%)
Pain free intervals
None 185 (74.0%) 51 (75.0%) 134 (73.6%) ns (p=0.883)
Weeks 14 ( 5.6%) 3 (4.4%) 11 (6.0%)
Days 51 (20.4%) 14 (20.6%) 37 (20.3%)
Diurnal variation in TMJ 
pain
Worse in the morning 113 (45.2%) 33 (48.5%) 80 (44.0%) ns (p=0.5l8)
Worse in the evening 70 (28.0%) 20 (29.4%) 50 (27.5%) ns (p=0.761)
Altered sleep patterns
Prevention of sleep 113 (45.2%) 35(51.5%) 78 (42.9%) ns (p=0.223)
Disturbance of sleep 117(46.8%) 32(47.1%) 85 (46.7%) ns (p=0.960)
Sleep alterations
No problems 98 (39.4%) 26 (38.2%) 72 (39.6%) ns (p=0.422)
Cannot get to sleep 33 (13.2%) 12 (17.6%) 22(12.1%)
Disturbed sleep 58 (23.2%) 16 (23.5%) 42 (23 .1%)
Early morning waking 8 (3.2%) 0 (0%) 8 (4.4%)
Cannot get to sleep and 
disturbed sleep
22 (8.8%) 5 (7.4%) 17 (9.3%)
Cannot get to sleep and 
early waking
3 (1.2%) 1  (1.5%) 2(1.1%)
Disturbed sleep and early 
waking
13 (5.2%) 2 (2.9%) 11 (6.0%)
Cannot get to sleep, disturbed 
sleep and early morning waking
14 (5.6%) 6 (8.8%) 8 (4.4%)
Bruxism and occlusal comfort
Nocturnal bruxism habit 49 (19.6%) 10 (14.7%) 39 (21.4%) ns (p=0.233)
Sensation of disturbed 
occlusal comfort
133 (53.2%) 36 (52.9%) 97 (53.3%) ns (p=0.960)
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Table 63e: TMJ signs
TMJ signs All groups Responders Non
Responders Significance
TMJ pain
Tenderness 250 (100%) 68 (100%) 182 (100%) -
Right 162(64.8%) 44 (64.7%) 118(64.8%) ns (p=0.985)
Left 173(69.2%) 48 (70.6%) 125 (68.7%) ns (p— U. / /1)
Opening click
Right 51 (20.4%) 15 (22.1%) 36 (19.8%) ns (p=0.691)
Left 69 (27.6%) 19 (27.9%) 50 (27.5%) ns (p=0.941)
Closing click
Right 24(9.6%) 6 (8.8%) 18 (9.9%) ns (p=0.799)
Left 36(14.4%) 8(11.8%) 28 (15.4%) ns (p=0.468)
Deviation on
mouth opening
Right 10(4%) 1  (1.5%) 9 (4.9%) ns (p=0.212)
Left 10(4%) 1  (1.5%) 9 (4.9%) ns (p=0.212)
Sticking
Right 7(2.8%) 1  (1.5%) 6 (3.3%) ns (p=0.436)
Left 6(2.4%) 1  (1.5%) 5 (2.7%) ns (p=0.557)
Recorded at baseline assessment
n=68
Responders
n=182 
Non Responders Significance
Occlusion
Angles classification
Class I
Class II division i 
Class II division ii 
Class III
25 (36.8%) 
24 (35.3%) 
17 (25.0%) 
2 (2.9%)
73 (40.1%) 
71 (39.0%) 
37 (20.3%) 
1 (0.5%)
ns (p=0.365)
Overjet  > 6mm 4 (5.9%) 9 (4.9%) ns (p=0.766)
Buccal mucosa
Ridging
Frictional keratosis 
Abrasion
37 (54.4%) 
2 (2.9%)
2 (2.9%)
95 (52.2%) 
13 (7.1%)
5 (2.7%)
ns (p=0.537) 
ns (p=0.213) 
ns (p=0.934)
Lingual mucosa
Ridging (scalopped margin) 7 (10.3%) 24 (13.2%) ns (p=0.537)
Missing posterior teeth
Greater than five 
Greater than six
10 (14.7%) 
4 (5.9%)
15 (8.2%) 
8 (4.4%)
ns (p=0.130) 
ns (p=0.625)
Missing wisdom teeth
None
One
Two
Three
Four
21 (30.9%) 
5 (7.4%)
9 (13.2%) 
7 (10.3%) 
26 (38.2%)
71 (39.0%) 
10 (5.5%) 
30 (16.5%) 
15 (8.2%) 
56 (30.8%)
ns (p=0.629)
Missing maxillary canine tooth 3 (4.4%) 4 (2.2%) ns (p=0.565)
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8.4  Subgroup analysis 
Hypothesis (6a), (6b), (6c)
(6a)  A significant and measurable improvement in pain is only seen in  those 
patients without depression 
(6b)  A significant and measurable improvement in pain measures are only 
seen in those patients with initially high pain scores 
(6c)  Clinical and pain history characteristics at baseline separate the 
treatment responders from the non responders
Subgroup analysis allows examination of treatment effect and observation of 
qualitative interaction in subjects with particular characteristics; an important 
clinical consideration when caring for individual patients, (Peduzzi,2002).
However, caution should be taken in interpretation due to the poor reliability of 
subgroup analysis arising from multiplicity, as previously discussed, and small 
sample sizes compared to the entire group analysis. Results of subgroup analysis are 
therefore not definitive but exploratory for formulating further research hypotheses, 
(Peduzzi, 2002).
8.4.1  Depressed and non depressed patients
Depression warranted investigation as it is an important component in the 
management of pain conditions, (Amow et al, 2006).
TMJ pain causing disturbance and prevention of sleep was significantly higher 
amongst the depressed category p<0.001. This finding concurs with the concept of 
alteration in sleep patterns and depression, (Taylor et al, 2005, Rosen et al, 2006, 
Lam, 2006). It is now well recognised that depression is a consequence of chronic
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pain, (Amow et al, 2006). However, speculation as to whether depression and 
problematic sleep lead to the TMJ symptoms or whether the TMJ symptoms lead to 
sleep deprivation and depression is an interesting concept. This comorbidity of 
reported sleep disturbance and psychological distress in patients with chronic TMD 
has also been shown by others (Yatani et al, 2002, Lavigne, 2006).
Interestingly, chronic sleep restriction has recently been shown to cause a gradual 
and prolonged desensitisation of the (5-HT)l A receptor system, suggesting a link 
between chronic sleep loss and sensitivity disorders associated with altered 
serotonergic neurotransmission, (Roman et al, 2005).
An interesting finding was the patient’s association of emotional factors to onset of 
TMJ pain p=0.049 and provocation of TMJ pain p<0.001, highest in depressed 
groups. This perhaps suggests either a greater awareness of the psychological 
aspects of pain or an increased psychological component to the pain in these 
individuals. Other recurrent chronic pains: headache p=0.021, neck ache p=0.007, 
backache p=0.049 and abdominal pain p=0.01 are higher in the depressed group at 
baseline. Despite significant reduction in reported pains during the course of therapy 
this was more pronounced in the non depressed groups; headaches p<0.001, 
abdominal pain p<0.001, neck ache p<0.001 and backache p=0.01. Risk factors for 
depression were related to temporal muscle pain at baseline OR=2.67 (Cl 
1.45,4.93)p<0.001; abdominal pain OR =2.06 (Cl 1.33,3.76) p<0.018 and dental 
pain OR=7.18 (Cl 1.32,39.05)p<0.023. With regards to temporal muscle pain, 
previous studies have similarly reported an association between myalgic pain and 
depression, (Kight,Gatchel and Wesley, 1999). As might be expected the self report 
pain questionnaires revealed an increased risk of depression with decreased MPI life
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control OR=0.45; increased Kellner illness attitude (hypochondriacal beliefs and 
disease phobia) OR=1.24 and MPI punishing response of others OR=1.50. 
Decreased depression was observed in increased MPI activities away from home 
OR=0.68.
8.4.1.1  Analysing reduction in pain severity (Tables 41 >48)
Before making any assumptions regarding the effect of depression on therapeutic 
outcome it should be noted that statistically there was no clearly significant 
difference between groups. Frequency improvement again appeared more successful 
in the non-depressed category for groups 1,2 and 3 p<0.001 compared to p<0.05. 
However, although interference improved more significantly in non depressed 
categories in groups 2 (p<0.005) and 3 (p<0.05), both groups improved equally in 
groups 1  and 4 (p<0.001). PPI again improved almost equally in group 4, group 3 
non depressed improved more significantly p<0.001 compared to depressed p=0.045 
whilst group 1  the observation was reversed and the depressed group improved more 
significantly p,0.001 than the non depressed.
MPI perspective of pain revealed equal improvement in severity p,0.001 and 
interference p<0.005 in both depressed and non depressed categories, whereas life 
control p<0.05 and effective distress p<0.005 improved to a lesser extent in the non 
depressed categories. The reverse was once again seen in groups 2 and 3 where more 
significant improvements were seen in the non depressed groups. MPQ scores 
significantly improved amongst the non depressed group VAS total % (p<0.001) and 
sensory % (p<0.005) but to a lesser extent in depressed ,VAS (p<0.05) total% 
(p<0.005) whilst affective % was successfully improved (p<0.005) and PPI 
(P<0.001). Intra group analysis showed improvement in PPI amongst the depressed
408CHAPTER VIII DISCUSSION
in groups 1  and 2 (p<0.05) but non depressed in groups 3 and 4 (p<0.05). Only non 
depressed patients appear to improve significantly in group 3 PPI p<0.05 MPQ 
sensory % and affective % p<0.05 and total % p<0.05.
Broadly, results would imply that non depressed patients respond more favourably 
to physical therapy whilst the depressed react to medical therapy but this was not a 
significant finding. Depression in relation to medical therapeutic intervention might 
warrant further investigation with additional use of more sensitive psychological 
rating scales.
The logistic regression analysis suggesting other concurrent chronic pains, a myalgic 
and dental TMJ pain component, social environmental interaction with others, 
altered sleep patterns, emotional factors and the level of life control over pain do 
have a significant effect on the level of depression in these individuals with TMJ 
pain.
Depressed patients were slightly older with a mean age of 34 years (18-55) 
compared to the non depressed group 31years (16-53) p<0.05. The primary outcome 
measure of the VAS did appear to show a significant improvement in the non 
depressed group p<0.001 compared with improvement in the depressed group 
p<0.05. However, this difference was not significant. For the secondary outcome 
measures; pain improvement, responders and frequency again appeared more 
successful in the non depressed group.
For PPI; an interesting pattern emerges where depressed patients report greater 
improvement in scores in group 1  taking antidepressants, whilst nondepressed 
patients report greater improvement in scores in group 3 the physical therapy group. 
However, findings are still non-significant between groups.
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Interference with life improved significantly in the non depressed groups but in 
depressed groups was more pronounced in those who received medication, group 1  
and group 4. Again, intergroup significance was not achieved.
8.4.2  Responders and non responders to therapy
Greater than 50% improvement in pain, taken as a conservative measure of 
treatment response, did not reveal any remarkable differences in the demographic 
and initial baseline recordings. There was no significant difference in age, gender, 
employment, socioeconomic status or pain duration. A higher percentage of non 
responders were tertiary referrals from consultant specialists 131/161 (7.1%) 
p=0.023 which could imply such referrals relate to pain not of longer duration but of 
a more complex, intractable nature. In relation to marital status there was a higher 
number of divorcees 11/182 (6%) in the non responders compared to zero in the 
responders p=0.035 which, one could speculate, might relate to increased levels of 
previous marital conflict and distress.
Self-report pain questionnaires indicate no difference in initial scores for patient’s 
perspective of pain and impact on daily life. However, the attitude and action of 
significant family or friends suggest a punishing response was significantly higher 
amongst non responders p=0.036. One could envisage a negative and unkind 
response from others could impact on the individuals self esteem. A lack of 
encouragement and negativity from others might affect their capability in 
responding to therapy since previous studies suggest a solicitous response by others 
can be beneficial to pain patients,(Newton-John,2003). Increased frequency of 
participation in social activities seemed higher amongst non responders p=0.036, in 
contrast to the finding that increased social activity seemed to reduce the level of
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depression. One could hypothesis, that aggravating factors for the pain might 
therefore relate to stressful social situations, noise, fatigue and alcohol consumption 
in certain individuals.
The amount of analgesia consumed at baseline was also higher amongst non 
responders 103/182 (56.6%) compared to 29/68 (42.6%) p=0.049. This may indicate 
a range of factors which might include a lower pain threshold requiring more 
frequent medication, an inflammatory element to the pain, more frequent temporal 
headaches or even an alteration in pain and biochemical receptor response from 
increased analgesic consumption.
Greater than 25% improvement in pain, did not reveal any differences in age, 
gender, referral source, pain duration, marital, employment or socioeconomic status. 
The frequency of participation in social activities was again higher amongst non 
responders, p=0.030 for completers analysis and p=0.011  for ITT analysis.
8.4.3  Low and high initial pain scores
There was no discemable difference in the demographic baseline recordings. In 
relation to other pains there was a significant reduction in headaches in the low 
compared to the high pain category (p=0.008) and an observable yet not significant 
reduction in neckache and abdominal pain. VAS reduction was observed in both 
high and low pain categories p<0.001 as reflected in groups 2 and 4. In groupl the 
high category showed significant reduction p<0.001, low category p<0.005. 
Conversely, in group 3 it was the low group which showed more significant 
reduction p<0.005 compared to the high group p<0.05. Interference although 
significantly reduced amongst high and low initial pain categories, was more
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significantly reduced in intra group analysis within low categories, particularly 
groups 2, 3 and 4.
MPI patient’s perspective of pain, significantly improved in both pain categories but 
to a greater extent in high pain scores p<0.001. This pattern was observed in group 1  
but in group 2 and 3 severity improved in both groups but interference and life 
control only improved in low scorers.
Amongst all groups MPQ: VAS, PPI and total% decreased significantly in the low 
compared to high categories p<0.001 compared to p=0.012, p=0.004 and p<0.001 
respectively. A similar trend was observed in group 3 although this was again 
reversed in group 1  a more favourable outcome in the high category.
BDI decreased significantly in the low category p=0.001 amongst all groups which 
was mirrored by group 3 (p=0.025).
Observable findings might lead one to suppose that low pain categories responded 
favourably to physical therapy whilst high pain categories appeared to respond to 
medical therapy but such clear cut theory is not substantiated by statistical 
intergroup analysis which revealed no significant difference between groups for any 
pain rating scores.
These patients differed slightly in their employment p<0.005, socioeconomic p<0.05 
and marital status p<0.005. There was significantly less improvement in primary and 
secondary outcome measures amongst high pain score patients but once again this 
was not statistically significant between treatment groups.
In the next chapter maintenance and adherence to therapy are examined together 
with an analysis of the follow-up data.
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9.0  MAINTENANCE AND WITHDRAWAL OF THERAPY
AND
POST TREATMENT FOLLOW UP
413CHAPTER IX STUDY COHORT -  ADHERENCE TO THERAPY
9.1  MAINTENANCE AND WITHDRAWAL OF THERAPY, 
ADHERENCE AND ADVERSE EVENTS.
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9.1.1 Maintenance and withdrawal of participants within the study and follow up.
9.1.1.1 Maintenance (Figures 58, 59,60 and 12)
250 patients were randomised to participate in the study. 49/250 (19.6%) of patients, 
although allocated to a therapeutic intervention at baseline, did not commence 
treatment but withdrew before starting the three month study phase. The remaining 
201/250 (80.4%) of patients actually commenced treatment.
When feasible, the recommended intention-to treat (ITT) analysis was conducted on all 
250 cases. Where this was not possible due to inadequate or unavailable data an 
imputation analysis, last-score-brought-forward (LSBF) was conducted. An analysis of 
complete data records, a pragmatic or completers analysis, was also undertaken to 
provide a sensitivity analysis.
Overall, 165/201 (82%) of patients who actually commenced treatment successfully 
completed treatment, constituting a withdrawl rate of36/201 (18%) from the treatment 
phase. 138/165 (84%) of patients were successfully maintained throughout the post 
therapy follow-up phase. This was 138/201 (69%) of the patients who initially 
commenced therapy, which is a withdrawl rate of63/201 (31%).
No one group appeared to have a higher erosive rate than another. Between the four 
therapeutic interventions, there was no significant difference between the numbers 
who were maintained within the treatment and follow-up phase jf=0.34 (3) p=0.95.
9.1.1.2 Withdrawal (Tables 64,65 and Figure 61)
The time and reason for withdrawal from the study were recorded. Results were 
analysed to determine any variability between the different therapeutic interventions
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9.1.1.3 Time of withdrawal (Table 64)
Time scale of withdrawal was recorded for each group participant. Pearson Chi 
squared test revealed no significant difference between the four groups at any of the 
time points for numbers leaving treatment or indeed for those completing treatment 
and follow-up.
9.1.1.4 Reasons for withdrawal (Table 65)
Reasons for withdrawal were not significantly different between the four groups, apart 
from the reasons associated specifically with the therapy provided. The term ‘splint 
and run7  was applied to patients who, after attending the appointment for the fitting of 
their occlusal appliance, took their newly acquired item home but did not return for 
further appointments. Amongst the four groups this was a significant overall reason for 
withdrawal, p<0.001. It totalled eleven patients, one in group 4 but a significantly 
increased frequency of 10 patients in group 3, OR=l 1.7(CI 1.45,94.7) p=0.004. This is 
nearly a twelve fold likelihood of disappearing with the occlusal appliance if it were 
the sole form of treatment as opposed to those receiving combined therapy.
Following randomisation at baseline, eight patients withdrew from treatment because 
they decided they did not want a splint. This was a significant overall reason between 
groups for withdrawal p=0.006. Seven patients also withdrew from treatment because 
they decided against taking medication, although this did not reach overall significance 
between groups p=0.43
Other reasons for non adherence were not significant between groups but most 
commonly included : resolution of pain 22/250 (8.8%),no reason given 18/250 (7.2%), 
time and travel difficulties 14/250 (5.6%) and moved away from locality 8/250 (3.2%). 
The less frequently reported reasons for non-adherence included: changing to
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alternative therapy 4/250 (1.6%), work related problems 4/250 (1.6%) and family 
health problems 1/250 (0.4%).
With regards to medical therapy reasons for withdrawal at baseline included the 
disclosure of previously unreported concomitant mental health problems 3/250 (1.2%) 
or medical history complicating factors which were incompatible with the study 
inclusion criteria 5/250 (2.0%). During the course of medical therapy two subjects 
became pregnant and treatment was discontinued 2/250 (0.8%). Both individuals were 
followed up pre and post partum. During pregnancy TMD resolved in one individual 
and an occlusal appliance was made for the second individual. Both gave birth to 
healthy babies with no adverse events.
Five subjects developed side effects to the medical therapy which resulted in 
discontinuation of treatment, two in group 1, two in group 2 and one in group 4. Three 
patients discontinued therapy due to gastrointestinal complaints of nausea, vomiting 
and diarrhoea and one patient developed a rash on the face and torso.
Amongst the four groups the most common reasons for non adherence were in 
group 1 and 2 ‘resolution of pain’, 8/63  (12.7%) and 6/63 (9.5%) respectively, group 3 
‘splint and run’ 10/62 ( 16.1%) and group 4 ‘reason unknown’ 5/62 (8.1%).
9.1.2  Adherence (Compliance! (Figure 62) (Tables 66,67)
Adherence previously termed compliance to the therapy was recorded for each group 
of patients. Adherence measures relied upon patients’ self report and additionally, in 
the case of medication returned bottles and capsule counts. There was no significant 
difference between the adherence to medication in the three medical therapy groups 
(1,2 and 4),(table 66).However, there was a significant difference between adherence 
to splint wear between the two groups (3 and 4) (table 67).This was evident at four
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weeks ^=(1)3.92,p=0.048 and twelve weeks x?=(l)4.78,p=0.029, reflecting a 
decreased level of adherence in group 3 , occlusal appliance only group.
9.1.3  Adverse events (Side effects)
9.1.3.1 Adverse events to medical therapy  (Table 69,70)
The most commonly reported adverse events associated with the fluoxetine groups and 
not seen at an equivalent incidence among the placebo group were the gastrointestinal 
symptom of nausea and the nervous system symptoms of insomnia and conversely 
drowsiness. All adverse events are however non significant between groups apart from 
the generalised gastrointestinal complaint of nausea. Group 4 the combined splint and 
SSRI group appeared to have a ten times higher likelihood of nausea compared to the 
placebo group OR=10.4 (Cl 1.2-86) (Table 70).
Overall, there was a significant difference between medical and placebo groups in 
adverse events reported following the initial treatment phase at four weeks in both 
groupl OR=2.8 (1.0-7.7) and group 4 OR=2.7 (1.0-7.5) indicating nearly a three fold 
increase in side effects to medication compared to placebo. However, there was no 
significant difference in adverse events reported during the subsequent eight and 
twelve weeks of therapy, (Table 69)
9.1.3.2 Adverse events to physical therapy  (Table 68)
Adverse events whilst wearing an occlusal bite guard were recorded throughout 
treatment. The most commonly reported problems were related to leaving the 
appliance at home on the day of the appointment. Two patients lost their bite guard and 
two broke their bite guard. Discomfort in splint wear and poor oral hygiene were not 
statistically significant between groups.
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Figure 61  : Reasons for non adherence or withdrawl form treatment and follow-up
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Table 64 :  Time scale of withdrawal from treatment phase or follow up
Time scale: All groups 
(n=250)
Group 1  
(n=63)
Group 2 
(n=63)
Group 3 
(n=62)
Group 4 
(n=62)
Significance 
between groups
Baseline, before treatment 49  (19.6%) 14 (22.2%) 10(15.9%) 11(17.7%) 14 (22.6%) ns p=0.73
Baseline to one month 10  (4.0%) 2 (3.2%) 4 (6.3%) 4 (6.5%) 0 (0%) ns p=0.21
One to two months 13  (5.2%) 4 (6.3%) 2 (3.2%) 4 (6.5%) 3 (4.8%)) ns p=0.82
Two to three months 13  (5.2%) 5 (7.9%) 5 (3.2%) 3 (4.8%) 0 (0%) ns p=0.15
Three to six months 22  (8.8%) 5 (7.9%) 6 (9.5%) 4 (6.5%) 7(11.3%) ns p=0.80
Six to nine months 5  (2.0%) 0 (0%) 0 (0%) 2 (3.2%) 3 (4.8%) ns p=0.13
Complete treatment and follow-up 138 (55.2%) 33 (52.4%) 36 (57.1%) 34 (54.8%) 35 (56.5%) ns p=0.95
Group 1  -  Fluoxetine medication  Group 3 -  Splint therapy
Group 2 -  Placebo medication  Group 4 - Fluoxetine and splint therapy
Pearson Chi squared test  between groups P<0.0001
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Table 65: Reasons for non adherence or withdrawl from treatment and follow up
Reasons All groups
(n=250)
Group 1
(n=63)
Group 2
(n=63)
Group 3
(n=62)
Group 4
(n=62)
Significance 
between groups
Pain gone 22 (8.8%) 8 (12.7%) 6 (9.5%) 4 (6.5%) 4 (6.5%) ns p= 0.56
Time / travel problems 14 (5.6%) 3 (4.8%) 4 (6.3%) 3 (4.8%) 4 (6.5%) ns p= 0.%
Moved away 8 (3.2%) 3 (4.8%) 2 (3.2%) 1  (1.6%) 2 (3.2%) ns p= 0.80
Splint and run! 11 (4.4%) 0 (0%) 0 (0%) 10(16.1%) 1  (1.8%) p< 0.001
Does not want splint 8 (3.2%) 0 (0%) 0 (0%) 6 (9.7%) 2 (3.2%) * p= 0.006
Does not want medication 7 (2.8%) 3 (4.8%) 2 (3.2%) 0 (0%) 2 (3.2%) ns p= 0.43
Medical complications 5 (2.0%) 1  (1.6%) 1  (1.6%) 0 (0%) 3 (4.8%) ns p= 0.27
Side effects 5 (2.0%) 2 (3.2%) 2 (3.2%) 0 (0%) 1  (1.6%) ns p= 0.53
Other treatment 4 (1.6%) 0 (0%) 1  (1.6%) 1  (1.6%) 2 (3.2%) ns p= 0.56
Work problems 4 (1.6%) 2 (3.2%) 2 (3.2%) 0 (0%) 0 (0%) ns p= 0.26
Mental health problems 3 (1.2%) 1  (1.6%) 1  (1.6%) 0 (0%) 1  (1.6%) ns p= 0.80
Pregnant 2 (0.8%) 1  (1.6%) 1  (1.6%) 0 (0%) 0 (0%) ns p= 0.58
Family problems 1  (0.4%) 0 (0%) 1  (1.6%) 0 (0%) 0 (0%) ns p= 0.40
Reason unknown 17 (6.8%%) 6 (9.5%) 4 (6.3%) 2 (3.2%) 5 (8.1%) ns p= 0.54
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Table 66 :Adherence to medication
Time in 
weeks
Groupl Group 2 Group 4 Significance between 
groups
0 No  0 
Yes  49
No  0 
Yes  53
No  0 
Yes  48
-
4 No  2 
Yes  47
No  4 
Yes  49
No  0 
Yes  48 ns p=0.154
8 No  6 
Yes  43
No  6 
Yes  47
No  3 
Yes  45 ns p=0.569
12 No  11 
Yes  38
No  11 
Yes  42
No  3 
Yes  45 ns p=0.062
Table 67 : Adherence to occlusal appliance therapy
Time in 
weeks
Group 3 Group 4 Significance between 
groups
0 No  0 No  0
Yes  51 Yes  48 -
4 No  4 No  0
Yes  47 Yes  48 * p=0.048
8 No  8 No  3
Yes  43 Yes  45 ns p=0.135
12 No  11 No  3
Yes  40 Yes  45 * p=0.029
Table 68 : Adverse events recorded during physical therapy (splint wear)
Adverse event
Group 3 (n=51) 
Splint
Group 4 (n=48) 
Splint and fluoxetine
Weeks 4 8 12 4 8 12
Splint lost 0 (0%) 0 (0%) 2 (3.9%) 0 (0%) 0 (0%) 0 (0%)
Splint broken 0 (0%) 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 1 (2.1%)
Splint at home 1 (2.0%) 1 (2.0%) 2 (3.9%) 3 (6.3%) 1 (2.1%) 4 (8.3%)
Splint uncomfortable 4 (7.8%) 0 (0%) 4 (7.8%) 4 (8.3%) 0 (0%) 2 (4.2%)
Poor oral hygiene 
(Gross plaque deposits)
1 (2.0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (6.3%)
Gingival inflammation 1 (2.0%) 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%)
Gingival swelling 0 (0%) 0 (0%) 0 (0%) 0  (0%) 0 (0%) 0 (0%)
Gingival bleeding 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Gingival ulceration 0 (0%) 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%)
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Table 69 : Adverse events reported during medical treatment phase
Weeks
Group 1 
(SSRI)
Group 2 
(Placebo)
Group 4 
(SSRI + splint)
Groupl 
versus 
Group 2
OR (Cl)
Group 4 
versus 
Group 2
OR (Cl)
4 15/47
(31.9%)
7/49
(14.3%)
15/48
(31.3%)
*2.8 
(1.0-7.7)
*2.7 
(1.0-7.5)
8 13/43
(30.2%)
8/47
(17.0%)
10/45
(22.2%)
2.1 
(0.8-5.8)
2.0 
(0.7-5.5)
12 12/38
(31.6%)
8/42
(19.0%)
12/45
(26.7%)
2.0 
(0.7-5.5)
1.5
(0.6-4.3)
Table 70 : Adverse experience recorded during medical therapy
Adverse event
Group 1
SSRI
(n=49)
Group 2 
Placebo 
(n=53)
Group 4 
SSRI+splint 
(n=48)
Groupl
versus
Group2
Group4
versus
Group2
Digestive system OR (Cl) OR (Cl)
General gastric 
complaints 6 (12.2%) 3 (5.7%) 1  (2.1%) 2.3(0.5,99) 0.4(0.04,4)
Nausea 5 (10.2%) 1  (1.9%) 8 (16.7%) 5.9(0.7,52) *10.4(1.2,86)
Diarrhoea 3 (6.1%) 1  (1.9%) 3 (6.3%) 3.4(0.3-33) 3.5(0.4,35)
Vomitting 0 (0%) 1 (1.9%) 2 (4.2%) - -
Anorexia 1  (2.0%) 0 (0%) 0 (0%) - -
Dry mouth 1  (2.0%) 2 (3 .8%) 3 (6.3%) 0.5(0.1,5.9) 1.7(0.3,11)
Nervous system
Headache 3 (6.1%) 3 (5.7%) 4 (8.3%) 1.1(0.2,5.7) 1.5(03,7.1)
Insomnia 5 (10.2%) 1  (1.9%) 4 (8.3%) 5.9(0.7,52) 4.7(0.5,44)
Drowsiness 6 (12.2%) 1  (1.9%) 3 (6.3%) 7.3(0.8,62) 3.5(0.35,35)
Dizzieness 0 (0%) 1 (1.9%) 3 (6.3%) - -
Skin
Rash 3 (6.1%) 3 (5.7%) 6 (12.5%) 1.1(0.2,5.7) 2.4(0.6,10)
Sweating 1  (2.0%) 0 (0%) 2 (4.2%) - -
Urogenital
system
Sexual
dysfunction 0 (0%) 0 (0%) 1  (2.1%)
Other adverse 
event
URTI ( cold, 
cough) flu-like 
symptoms, malaise 
musculoskeletal 
pain, fatigue,.
7(14.3%) 3 (5.7%) 4 (8.3%) 2.8(0.7,11) 1.5(0.32,7.2)
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9. 2  FOLLOW -  UP  PHASE
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9.2.0 Follow u p  phase
9.2.1 Maintenance and amelioration in overall nain severity and intensity (Fig. 63)
Illustrated graphically, it is clear a significant reduction in pain severity (MPI severity) 
(figure 63 a) occurs at the end of the three month trial programme which, after 
discontinuation of treatment, is then sustained during the follow-up phase within all 
four treatment groups. Similar findings were found in MPQ present pain intensity, 
MPQ,total %(fig. 63b), VAS (clinical report) (fig. 63c), VAS (self-report) (fig. 63d)
9.2.2 Verbal rating scales  9.2.2.1 Visual analogue scale VAS (clinical renortl
9.2.2.1.1  VAS (Imputation analvsisl  (Table 71, Figure 64)
Analysing all groups together, using the repeated measures ANOVA, there was a 
clearly significant improvement in VAS even during the follow-up phase F(2) 8.93, 
p<0.001. Multivariate tests Wilk’s lambda F(2,248) =7.60,p=0.001, suggested a 
significant improvement in the mean recorded VAS during the follow-up phase of a 
significantly linear trend F(l)=14.30,p<0.001. Paired sample t-tests of all groups 
together showed the mean VAS had been maintained three months post therapy, 
having minimally decreased from 4.06 (2.57) to 3.91 (2.66) a non significant 
improvement. However, six months post therapy the mean VAS scale was recorded as 
3.56 (2.68), a small but nonetheless significant improvement of 0.5mm,p<0.001. 
Amongst each group, all scores were maintained and even appeared to improve post 
therapy but only groups 2 and 3 showed a significant improvement of 0.5mm, 
F(2)3.74,p=0.026 and 0.7mm F(2) 8.84,p=0.001 respectively. Such small changes in 
score would not be considered clinically relevant.
Inter group analysis, using the parametric one-way ANOVA, revealed no significant 
difference in VAS improvement during the follow-up phase.
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9.2.2.1.2 VAS (Completers analysis!  (Table 72, figure 65)
Analysing all groups together, the repeated measures ANOVA for within-subjects 
effect, revaled a significant maintenance and improvement in VAS F(2) =8.1,p<0.001, 
as were the multivariate tests Wilk’s lambda F(2,248)=5.04,p=0.001 suggesting 
significant difference in measurement during the follow-up phase of a significantly 
linear trend F(l) 13.98,p<0.001. Paired sample t-tests for all groups were only 
significant between the end of treatment and end of follow-up with an improvement of 
0.3mm, from 3.25(2.41) to 3.58(2.68) at treatment end, p<0.001.
Within groups only group 3 showed a significant improvement of 1.2mm from 3.19 
(2.22) at treatment end to 1.99 (1.78) at end of follow-up, F(2) 9.76,p=0.001. This was 
a significantly linear trend F(l) 15.08,p=0.001. Again such minimal changes of mm’s 
in VAS scores do not serve any clinical relevance and inter group analysis showed no 
significant difference in improvement between groups.
9.2.2.1.3 Relapse in VAS  (Table 73)
Relapse in scores were not significant either within or between groups, using 
McNemar tests for intra group analysis and x2 for intergroup analysis.
9.2.2.2  PPI  (Non/mild/moderate/severe) (Table 74, Figure 66)
PPI was maintained and significantly improved during follow up amongst all the study 
participants, ^=(2)16.17,  p<0.001. Those with none or mild pain increased from 
154/250 (61.6%) at the end of treatment to 168/250 (67.2%) at the end of follow up. 
This remained significant in intra group analysis in group 2 y?=(2) 8.72, p=0.013 and 
group 3 5^=(2) 6.60, p=0.037 but inter group analysis showed no significant difference 
between groups.
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9.2.2.3 Pain response (Worse / In pain / Improved / Pain free) (Table75,Figure 67)
Results indicate slight improvement in scores with no significant relapse during the 
follow up phase amongst the combined study participants % ={2)1.92, p=0.019. There 
was no significant difference between the four groups.
9.2.2.4 Frequency (Never / Occasionally / Often / Always) (Table 76, Figure 68)
Frequency of pain actually improved during follow up with 87/250 (35%) with never 
or occasional pain at the end of treatment increasing to 117/250 (47%) by the end of 
follow up x2=(2)14.48,p=0.001. This remained significant in group 4 analysis 
X?=(2)7.10, p=0.029 but there was no proven significance between groups.
9.2.2.5 Interference (Yes / no) (Table 77, Figure 69)
There was significant reduction in pain interference of 120/250 (48%) at three months 
which was maintained and further reduced during follow up 104/250 (42%) Cochrane 
Q=(2) 7.42, p=0.024 . Interference appeared to decrease most significantly in group 3 
from 29/62 (46.8%) to 22/62 (35.5%), Cochrane Q=(2)7.17, p=0.028. However, this 
was not found to be significant between groups.
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Figure 63a:  Pain severity —  MPI severity (median scores)
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Figure 63c: VAS (clinical report)  median scores
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Figure 63b:  MPQ —  total'Vb (median scores)
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Figure 63d: VAS (self report) median scores
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Table 71: VAS (10cm scale) mean (+/- SD)  Imputation analysis
Time All
groups
Groupl Group2 Group3 Group4 One-way
ANOVA
End
treatment
3/12
4.06
(2.57)
3.80
(2.81)
4.31
(2.46)
4.02
(2.39)
4.11
(2.62)
ns
p=0.74
Follow-up 1  
6/12 (FU1)
3.91
(2.66)
ns
p=0.164
3.50
(2.97)
ns
p=0.167
4.06
(2.44)
ns
p=0.20
3.76
(2.37)
ns
p=0.117
4.31
(2.82)
ns
p=0.487
ns
p=0.35
Follow-up 2 
9/12 (FU2)
3.58
(2.68)
***
p<0.001
3.33
(3.30)
ns
p=0.072
3.78
(2.69)
*
p=0.013
3.37
(2.42)
**
p=0.001
3.85
(2.57)
ns
p=0.449
ns
p=0.59
* * *   ns  *   * *   ns
p<0.001  p=0.129  p=0.026  pF=0.001  p=0.342
Table 72 : VAS (10cm scale) mean (+/- SD)  Completers analysis
Time All
groups...
Groupl Group2 Group3 Group4 One-way
ANOVA
End
treatment
3/12
n=165
3.25
(2-41)
n=38
2.75
(248)
n=42
3.43
(2.32)
n=40
3.19
(2.22)
n=45
3.56
(2.61)
ns
p=0.453
Follow-up 1  
6/12 (FU1)
n=138
3.03
(2.52)
ns
p=0.265
n=35
2.37
(2.61)
ns
p=0.168
n=34
2.90
(2.07)
ns
p=0.203
n=35
2.93
(2.11)
ns
p=0.183
n=34
3.95
(3.01)
ns
p=0.291
ns
p=0.066
Follow-up 2 
9/12 (FU2)
n=135
3.58
(2.68)
***
p<0.001
n=35
2.06
(2.58)
ns
p— 0.072
n=35
2.41
(2.29)
ns
p=0.012
n=31
1.99
(1.78)
**
p=0.001
n=34
3.12
(2.35)
ns
p=0.406
ns
p=0.165
* * *   ns  ns  **   ns
p<0.001  p=0.129  p=0.062  p=0.001  p=0.427
Table 73 : Relapse in VAS score during follow-up  numbers (%) N=250
Time All groups Group 1 Group2 Group3 Group4 Significance
FU1 46 (18.4%) 10(15.9%) 10(15.9%) 9 (14.5%) 17 (27.4%) ns
p=0.211
FU2 43 (17.2%) 12 (19%) 9 (14.3%) 6 (9.7%) 16 (25.8%) ns
p=0.102
ns (p=0.735)  ns (p=0.754)  ns (p=1.0)  ns(p=0.375)  ns (p=1.0)
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Figure 64: VAS (visual analogue scaled
A comparison of mean scores showing maintenance and continued improvement in scores during follow-up.
Imputation analysis showing three month (week 12 ) treatment and follow-up at six months ( week 24) and nine months (week36).
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Figure 65: VAS (visual analogue scale)
A comparison of mean scores showing maintenance and continued improvement in scores during follow-up.
Completers analysis showing three month (week 12 ) treatment and follow-up at six months ( week 24) and nine months (week36).
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Table 74:  Present pain intensity scores (PPD (Intention to treat, imputation analysis) during follow-up.
Time PPI All groups (n=250) Group 1  (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Significance
End of 
treatment 
(3 months)
None
Mild
Moderate
Severe
30 (12%) 
124 (49.6%) 
70 (28%)
26 (10.4%)
5 (7.9%) 
36(57.1%) 
14 (22.2%) 
8 (12.7%)
9 (14.3%) 
25 (39.7%) 
25 (39.7%) 
4 (6.3%)
9 (14.5%) 
36 (58.1%) 
10(16.1%) 
7(11.3%)
7(11.3%) 
27 (43.5%) 
21 (33.9%) 
7(11.3%)
ns
p=0.384
Follow-up 1  
(6 months)
None
Mild
Moderate
Severe
39(15.6%) 
121 (48.9%) 
68 (27.2%) 
22 (8.8%) 
ns (p=0.083)
10(15.9%) 
35 (55.6%) 
11 (17.5%) 
7(11.1%)
9 (14.3%) 
28 (44.4%) 
24 (38.1%) 
2 (3.2%)
10(16.1%) 
35 (56.5%) 
13(21.0%) 
4 (6.5%)
10(16.1%) 
23 (37.1%) 
20 (32.3%) 
9 (14.5%)
ns
p=0.255
Follow-up 2 
(9 months)
None
Mild
Moderate
Severe
55 (22%)
113 (45.2%) 
59 (23.6%) 
23 (9.2%)
** (p=0.001)
13 (20.6%) 
29 (46%) 
12 (19%)
9 (14.3%)
13 (20.6%) 
26 (41.3%) 
22 (34.9%) 
2 (3.2%)
16 (25.8%) 
34 (54.8%) 
8 (12.9%)
4 (6.5%)
13 (21%) 
24 (38.7%) 
17 (27.4%) 
8 (12.9%)
ns
p=0.189
* * *   ns (p=0.199)  *(p=0.013)  *(p=0.037)  ns(p=0.325)
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 -  Placebo medication  Group 4 -  Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  P<0.000mmn*  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant)
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Figure 66  :  Pain intensity at baseline
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Table 75: Pain severity: Worse / In pain / Improved / Pain free- (Intention needed to treat, imputation analysis) during follow-up
Time Severity All groups (n=250) Group 1   (n=63) Group 2  (n=63) Group 3  (n=62) Group 4  (n=62) Significance
End of treatment 
(3 months)
Worse 
In pain 
Improved 
Pain free
15 (9.3%) 
119(47.6%) 
86 (34.4%) 
30 (12.0%)
4 (6.3%) 
29 (46.0%) 
23 (36.5%) 
7(18.9%)
1  (1.6%) 
36(57.1%) 
17(39.5%) 
9 (20.9%)
4 (6.5%) 
26(41.9%) 
26 (41.9%) 
6(15.8%)
6(13.9%) 
28 (45.2%) 
18 (32.3%) 
8 (12.9%)
ns
p=0.950
Follow-up 1  
(6 months)
Worse 
In pain 
Improved 
Pain free
10 (4%) 
117(46.8%) 
89 (35.6%) 
34(13.6%) 
ns (p=0.154)
1  (1.6%)
28 (44.4%) 
25 (39.7%) 
9 (14.3%)
2 (3.2%)
34 (54%) 
18 (28.6%) 
9 (14.3%)
1  (1.6%)
29 (46.8%) 
24 (38.7%) 
8 (12.9%)
6 (9.7%) 
26(41.9%) 
22 (35.5%) 
8 (12.9%)
ns
p=0.655
Follow-up 2 
(9 months)
Worse 
In pain 
Improved 
Pain free
11 (4.4%) 
113 (45.2%) 
80 (32%)
46 (18.4%)
* (p=0.015)
2 (3.2%)
29 (46%) 
19 (30.2%) 
13 (20.6%)
0 (0%)
33 (52.4%) 
18 (28.6%) 
12 (19%)
1  (1.6%) 
26(41.9%) 
25 (40.3%) 
10(16.1%)
8 (12.9%) 
25 (40.3%) 
18 (29%)
11 (17.7%)
ns
p=0.624
*(p=0.019)  ns(p=0.152)  ns(p=0.135)  ns(p=0.262)  ns(p=0.839)
Group 1  -  Fluoxetine medication  Group 3 -  Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :  Friedman significance  PO.OOOl***  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis :  Kruskall -Wallis  (not significant)
C
h
a
p
t
e
r
 
i
x
 
s
t
u
d
y
 
c
o
h
o
r
t
 
-
 
f
o
l
l
o
w
 
-
 
u
p
 
p
h
a
s
e4
3
7
Figure 67:  Pain response at 12 weeks (Treatment end)
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Table 76:  Frequency scores  (Intention needed to treat, imputation analysis) during follow-up
Time Frequency All groups (n=250) Group 1   (n=63) Group 2  (n=63) Group 3  (n=62) Group 4  (n=62) Significance
End of treatment 
(3 months)
Never
Occasionally
Often
Always
27 (10.8%) 
60 (24.0%) 
77 (30.8%) 
86 (34.4%)
5 (7.9%) 
16 (25.4%) 
16 (25.4%) 
26 (41.3%)
8(12.7%) 
13 (20.6%) 
24 (38.1%) 
18 (28.6%)
6 (9.7%) 
22 (35.5%) 
20 (32.3%) 
14 (22.6%)
8 (12.9%) 
9(14.5%) 
17 (27.4%) 
28 (45.2%)
ns
p=0.083
Follow-up 1  
(6 months)
Never
Occasionally
Often
Always
27 (10.8%) 
70 (28%)
68 (27.2%) 
85 (34%) 
ns (p=0.297)
8 (12.7%) 
14 (22.2%) 
19 (30.2%) 
22 (34.9%)
7(11.1%) 
17 (27%) 
15 (23.8%) 
24 (38.1%)
5 (8.1%)
25 (40.3%) 
21 (33.9%) 
11 (17.7%)
7(11.3%)
14 (22.6%) 
13 (21%)
28 (45.2%) 
ns (p=0.590)
ns
p=0.108
Follow-up 2 
(9 months)
Never
Occasionally
Often
Always
36 (14.4%) 
81 (32.4%) 
55 (22%)
78 (31.2%)
** (p=0.001)
9 (14.3%) 
16 (25.4%) 
11 (17.5%) 
27 (42.9%)
9 (14.3%) 
23 (36.5%) 
13 (20.6%) 
18 (28.6%)
8 (12.9%) 
25 (40.3%) 
19 (30.6%) 
10(16.1%)
10(16.1%) 
17 (27.4%) 
12 (19.4%) 
23 (37.1%) 
* (p=0.014)
ns
p=0.169
(p=0.001)  ns(p=0.412)  ns(p=0.065)  ns(p=0.185)  *(p=0.029)
Group 1  - Fluoxetine medication  Group 3 -  Splint therapy
Group 2 - Placebo medication  Group 4 -  Fluoxetine and splint therapy
Intra group analysis:  Friedman significance  PO.OOOl***  Wilcoxon signed rank test  p<0.05 *  p<0.005 **  p<0.001***
Inter group anaysis:  Kruskall -Wallis  (not significant)
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Figure  68:  Frequency at baseline
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Table 77:  Secondary outcome measure —  Interference with life (Intention to treat, imputation analysis) during follow-up.
Time Interference All groups (n=250) Group 1  (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Significance
End of 
treatment 
(3 months)
Yes 120 (48.0%) 30 (47.6%) 32 (50.8%) 29 (46.8%) 29 (46.8%) ns
p=0.965
Follow-up 1  
(6 months)
Yes 111 (44.4%) 
ns (p=0.188)
28 (44.4%) 28 (44.4%) 28 (45.2%) 
ns (p=1.0)
27 (43.5%) ns
p=0.998
Follow-up 2 
(9 months)
Yes 104 (41.6%)
* (p=0.012)
26 (41.3%) 28 (44.4%) 22 (35.5%)
* (p=0.016)
28 (45.2%) ns
p=0.684
*  (p=0.024)  ns(p=0.424)  ns(p=0.202)  *(p=0.028)  ns(p=0.829)
Group 1  - Fluoxetine medication 
Group 2 - Placebo medication 
Cochran Test  PO.OOl
Group 3 -  Splint therapy
Group 4 - Fluoxetine and splint therapy
McNemarTest  PO.OOl ***
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9.2.3 Self-Report pain questionnaires
9.2.3.1 MPI - Follow up summary  (Illustrated in figure 70)
9.2.3.1.1 Comparison to baseline recordings (shown in Tables 78)
Analysing treatment from baseline recordings to the end of the final follow up phase 
there is clearly a significant improvement in several elements of the patient’s perspective 
of pain, despite the discontinuation of treatment at the end of the three month treatment 
phase.In the combined group cohort, significant improvement was observed in pain 
severity (p<0.001), pain interference with life (p<0.001) and affective distress (p<0.001) 
with consequent increase in patients perceived level of life control (p<0.001)
9.2.3.1.1.1 Pain severity
In intra group anlayis, pain severity was significantly reduced amongst all individual 
groups, 1,2,3,and 4 (p<0.001).
9.2.3.1.1.2 Pain interference
Pain interference with life improved significantly in groups 1, 2 and 3, (p<0.001) but not 
group 4 (p=0.276).
9.2.3.1.1.3 Life control
Meanwhile, life control having improved only in the SSRI (group 1) at the end of the 
treatment phase was also maintained during follow up p=0.007. However, an additional 
improvement was seen in group 3, (p=0.006) by the end of follow up.
9.2.3.1.1.4 Affective distress
Affective distress had significantly improved in medical therapy groups 1,2 and 4 at the
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end of treatment and this was clearly maintained in group 1  during follow up p<0.001. 
However, there was no between group significance.
9.2.3.1.1.5 Response of significant other -  support
The anomaly of reduced support by significant family and friends, seen in group 3 at the 
end of treatment, was also reiterated during follow up with significance in group 3,
p=0.002.
9.2.3.1.1.6 Inter group analysis
Despite all the above observations, intergroup analysis revealed no significant difference 
between groups amongst any of the variables.
9.2.3.1.2 Comparison to end of treatment recordings (Table 79)
Analysing improvement since treatment completion, we see there is only a significant 
improvement in severity and interference, p<0.001. This was mirrored by the results for 
group 3 p<0.001 but only interference reached significant improvement in group 1  
p=0.047 and group 2 p=0.033. The median change in all MPI scores during follow up is 
zero, indicating a generalised maintenance of treatment effect.
9.2.3.2 MPQ. BDI. Kellner -  Follow-up summary  (shown in Figure 71)
9.2.3.2.1  Comparison to baseline recordings  (shown in Table 80)
Analysing treatment from baseline to end of final follow up, there is a significant 
difference amongst  combined groups in VAS, PPI, total %, sensory %, affective %,
BDI, Kellner illness attitude and hypochondriacal beliefs, p<0.001. PPI improved 
similarly in groups 1,2 and 3 p<0.001 and to a lesser extent in group 4 p=0.005.
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MPQ VAS improved most significantly in group 3 p<0.001 and to a lesser extent in 
group 2 p=0.005 and group 4 p=0.006. MPQ total% improved significantly amongst all 
individual groups p<0.001.MPQ sensory% improved significantly in groups 3 and 4 
p<0.001 and to a slightly lesser extent in group 1, p=0.002 and group 2, p=0.001.MPQ 
affective % improved significantly in group 1  p=0.002, group 2 p<0.001 and group 3 
p=0.002. BDI however, improved most significantly in group 1, p<0.001, group2, 
p=0.001 and group 3, p=0.032 and group 4, p=0.028. Kellner illness attitude and 
hypochondriacal beliefs were only improved in group 1 p=0.002 and p=0.006 
respectively.
The median change in score during follow up is zero, again indicating an overall 
maintenance of improvement since treatment end. Within groups this varies but is not 
significant between groups.
9.2.3.2.2  Comparison to end of treatment recordings  (Table 81)
Improvement since treatment completion and final follow up is significant amongst 
combined groups in VAS, MPQ: total %, sensory %, affective, BDI, Kellner illness 
attitude and hypochondriacal beliefs, p<0.001.Differences occurred within groups with 
PPI most significantly improved in groupl,2 and 3, p<0.001 and to a lesser extent in 
group 4,p=0.005. MPQ VAS was significantly reduced in group 3 p<0.001 and to a 
lesser extent in group 2, p=0.005 and group 4, p=0.006. MPQ total % was significantly 
improved in each individual group p<0.001.MPQ sensory % was reduced in groups 3 
and 4, p<0.001, group 1, p=0.002 and group 2, p=0.001. MPQ affective % was reduced 
in groups 1  and 3, p=0.002 and group 2, p<0.001.BDI composite scores were most 
significantly reduced during follow-up in group 1, p<0.001, group 2, p=0.001 and to a 
lesser extent in group 3, p=0.032 and group 4 p=0.028. Kellner illness attitude and
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hypochondriacal beliefs was only significantly reduced in group 1, p=0.002 and p=0.006 
respectively.
9.2.3.3  Relapse in MPL MPQ. BDI and Kellner scores since end of treatment
(Table 821 and figures 72 and 73).
Maintenance and improvement in post treatment scores were 80-90% without 
significance between groups. For example maintenance and improvement in scores for 
MPI severity averaged zero at follow up 1 and 0.33 at follow up 2.1n other words, an 
overall maintenance of score but no further improvement at the three month post 
treatment follow-up was recorded  and an actual improvement in score at the six month 
post treatment follow up. The relapse in score which occurred was approximately 18% 
three months post treatment at FU1, and 16%, six months post treatment at FU2.
4454
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Table 78: Multidimensional Pain inventory (MPD A comparison of median scores (25th,75th  percentiles) (Imputation analysis)
MPI Study All groups (n=250) Group 1 (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Sig.
Patients perspective of pain
MPI - Severity Start
Finish
FU1
FU2
3.00 (1.92,4.00)
2.33 (1.30,3.66) ***
2.33 (1.30,3.37) ***
2.00 (1.00,3.66) *** 
* * *
3.33 (2.00,4.33) 
2.60(1.30,4.00)**
2.33 (1.33,4.00)*** 
2.00(1.00,4.00)*** 
* * *
3.00 (2.33,4.00)
2.33 (1.33,3.66) ***
2.33 (1.33,3.33) ***
2.33 (1.00,3.60) *** 
* * *
2.66(1.33,3.40) 
2.00 (0.66,3.00) *** 
2.00(0.66,3.00) *** 
1.63 (0.58,2.66) ***
2.66 (1.65,4.00)
2.33 (1.33,3.75) *
2.33 (1.00,4.00) * 
2.15 (0.92,3.75) ** 
* * *
ns p=0.105 
ns p=0.298 
ns p=0.406 
ns p=0.130
MPI - Interference Start
Finish
FU1
FU2
1.45 (0.65,2.88) 
1.05(0.36,2.38)*** 
1.00(0.36,2.32) *** 
0.95(0.27,2.21) *** 
* * *
1.90(0.82,3.36) 
1.30(0.36,2.72) 
1.09 (0.55,2.73)* 
0.90 (0.30,2.72) **
1.63 (0.80,2.90) 
1.16(0.54,2.54) *** 
0.82 (0.36,2.54) *** 
0.90 (0.36,2.00) ***
1.36 (0.45,2.27) 
0.90(0.29,2.27)  * 
0.85(0.18,2.18) *** 
0.58 (0.90,2.19) *** 
* * *
1.24 (0.52,2.65) 
1.00 (0.43,2.40) 
1.00(0.43,2.50) 
1.09 (0.27,2.40) 
ns (p=0.276)
nsp=0.103 
ns p=0.684 
nsp=0.350 
ns p=0.532
MPI - Life control Start
Finish
FU1
FU2
3.25 (2.31,4.00)
3.50 (2.50,4.25) ***
3.50 (2.50,4.25) ***
3.50 (2.75,4.50) ***
3.25 (2.00,4.00)
3.50 (2.75,4.50) **
3.50 (2.50,4.50) *
3.50 (2.75,4.50) ** 
* (p=0.007)
3.25 (2.25,4.25) 
3.50 (2.50,4.00)
3.75 (2.75,4.25)
3.75 (3.00,4.25) 
ns(p=0.173)
3.25 (2.46,4.00)
3.50 (2.50,4.25)
3.25 (2.50,4.25) *
3.50 (2.75,4.25) **
* (p=0.006)
3.38 (2.50,4.25)
3.50 (2.50,4.25)
3.50 (2.50,4.56)
3.50 (2.50,4.75)* 
ns (p=0.206)
ns p=0.780 
nsp=0.952 
ns p=0.746 
nsp=0.909
MPI - Affective distress Start
Finish
FU1
FU2
3.33 (2.33,4.30)
3.00 (2.00,4.00) ***
3.00 (2.00,3.66) ***
3.00 (1.92,4.00) *** 
* * *
3.60 (2.60,4.33) 
3.30 (2.00,4.00) ** 
3.00 (1.66,4.00)*** 
3.00(1.66,4.00)*** 
* * *
3.60 (2.65,4.40)
3.33 (2.00,4.00) ** 
3.00 (2.00,4.00) *
3.33 (2.30,4.00)
* (p=0.012)
3.00 (2.00,4.00)
3.00 (1.92,4.00)
3.00 (1.65,4.00)
3.00 (1.60,4.00) 
ns (p=0.059)
3.32 (2.32,4.30) 
2.83 (2.00,3.62) * 
3.00 (1.66,3.60) * 
2.66 (1.60,3.40) * 
ns (p=0.054)
ns p=0.063 
ns p=0.590 
nsp=0.551 
ns p=0.257
Response significant other
MPI - Support response Start
Finish
FU1
FU2
3.33 (2.30,4.66)
3.33 (2.32,4.33)
3.33 (2.00,4.33) * 
3.00 (2.00,4.33) ** 
*(p=0.013)
3.60 (2.25,4.66)
3.33 (2.33,4.33)
3.33 (2.00,4.33) 
3.00 (2.00,4.33)
3.66 (2.32,5.00)
3.33 (2.33,5.00)
3.33 (1.83,4.66)
3.66 (2.32,4.66)
3.00(2.33,4.33) 
3.00(1.70,4.00)  ** 
3.00(1.83,4.00)* 
3.00 (1.60,4.00) *
**(p=0.002)
3.00 (2.00,4.33) 
3.60 (2.17,4.47) 
3.33 (2.33,4.00) 
3.15 (2.00,4.31)
ns p=0.681 
ns p=0.300 
nsp=0.491 
nsp=0.103
MPI - Punishing response Start
Finish
FU1
FU2
1.00 (0,2.06) 
1.00 (0,2.00) 
1.00 (0.25,2.00) 
1.00(0.19,2.00)
0.75 (0.25,2.81) 
1.00 (0,2.5) 
1.00(0.38,2.50) 
1.00)0.25,2.75)
1.25 (0.25,2.56)
1.25 (0.25,2.00)
1.25 (0.25,2.75)
1.25 (0.25,2.25)
0.75 (0,2.00) 
1.00(0,2.00) 
0.75(0.25,1.75) 
0.75 (0,1.75)
0.75(0,1.75)
1.00(0,1.75)
0.75(0,1.75)
1.00(0,1.88)
nsp=0.201 
nsp=0.394 
ns p=0.164 
nsp=0.511
MPI - Solicitous response Start
Finish
FU1
FU2
2.66 (1.50,3.87)
2.66 (1.33,3.83)
2.66 (1.50,4.00)
2.66 (1.50,4.00)
2.83 (1.45,3.63)
2.50 (1.30,4.00)
2.50 (1.66,4.08) 
2.42 (1.50,3.50)
2.66 (1.77,4.37) 
2.66(1.33,4.50) 
2.83 (1.66,4.50)
2.66 (1.66,4.50)
2.66 (1.50,3.83)
2.66 (1.50,4.08) 
2.66(1.33,4.00)
2.66 (1.50,4.00)
2.50 (1.30,3.83)
2.50 (1.08,3.50) 
2.66 (1.50,3.83)
2.50 (1.50,3.75)
ns p=0.929 
ns p=0.798 
ns p=0.798 
ns p=0.704
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MPI Study All groups Group 1 Group 2 Group 3 Group 4 siS-  ___
MPI - Distracting response Start
Finish
FU1
FU2
1.75 (0.75,2.75) 
1.75(0.75,3.00) 
1.75(0.75,2.75) 
1.75(0.75,3.00)
2.00 (0.75,2.75)
2.00 (0.75,2.75)
1.75 (1.00,2.75)
1.75 (0.75,2.56)
1.50(0.75,3.00)
1.50(0.75,2.75)
1.50(0.75,3.25)
1.50(0.81,2.75)
2.00 (0.75,2.75)
1.75 (0.75,2.88)
1.75 (0.50,2.75)
1.75 (0.75,3.00)
1.75 (0.50,3.00) 
1.75(0.63,3.00)
2.00 (0.88,3.00)
2.00 (0.75,3.25)
ns p=0.959 
nsp=0.927 
ns p=0.938 
nsp=0.984
Frequency of participation 
in
MPI - Household chores Start
Finish
FU1
FU2
4.80 (3.60,5.60) 
4.60 (3.60,5.60)
4.80 (3.60,5.60)
4.80 (3.60,5.60)
4.80 (3.60,5.60)
4.60 (4.20,5.40) 
5.00 (4.00,5.60)
4.60 (3.40,5.60)
4.80 (3.35,5.80) 
4.40 (3.40,5.60) 
5.00 (3.40,5.60) 
4.60 (3.40,5.40)
4.60 (3.40,5.55)
4.60 (3.80,5.55)
4.80 (3.65,5.60)
4.80 (3.80,5.70)
4.80 (3.80,5.40) 
4.60 (3.60,5.60)
4.80 (3.80,5.40)
4.80 (3.60,5.60)
nsp=0.961 
ns p=0.903 
nsp=0.852 
ns p=0.806
MPI - Outdoor work Start
Finish
FU1
FU2
2.00 (1.00,3.00) 
2.00(1.00,3.00)
2.00 (1.00,3.00)
2.00 (1.20,3.00)
2.00 (1.30,3.00) 
1.78(1.29,3.00)
2.00 (1.24,2.76)
2.00 (1.40,3.25)
2.00(0.88,3.10)
2.00 (1.00,3.00)
2.00 (1.00,3.20)
2.00 (1.00,3.00)
2.00 (0.95,3.00) 
1.80(0.85,2.60)
2.00 (0.78,3.00)
2.00 (1.00,2.80)
2.00 (0.85,3.00)
2.00 (0.95,3.05) 
2.00(1.15,3.00) 
2.00(1.15,3.20)
ns p=0.749 
ns p=0.687 
ns p=0.898 
ns p=0.496
MPI - Activities away 
from home
Start
Finish
FU1
FU2
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.50,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.50)
3.50 (2.75,4.50)
3.75 (2.75,4.50)
3.50 (2.75,4.25)
3.50 (2.75,4.00)
3.50 (2.50,4.25)
3.25 (2.25,4.25) 
3.50 (2.75,4.25) 
3.38(2.81,4.19) 
3.25(2.63,4.13)
3.50 (2.50,4.50) 
3.38 (2.50,4.31)
3.50 (2.44,4.25) 
3.25 (2.25,4.50)
nsp=0.714 
ns p=0.891 
ns p=0.913 
ns p=0.923
MPI - Social activities Start
Finish
FU1
FU2
3.00 (2.30,4.00) 
3.25 (2.30,3.75) 
3.00(2.33,3.75)
3.00 (2.32,3.75)
2.75 (2.25,3.75)
3.00 (2.25,4.00) 
3.00(2.33,3.66)
3.00 (2.25,3.75)
3.25 (2.50,4.00)
3.25 (2.50,4.00) 
3.00(2.50,3.75)
3.25 (2.75,3.75)
3.00 (2.33,3.75) 
3.13 (2.33,3.75) 
3.00(2.25,3.75) 
3.00(2.13,3.75)
3.38 (2.00,4.06) 
3.29 (2.19,4.00) 
3.00(2.25,3.81) 
3.00 (2.19,4.00)
ns p=0.655 
ns p=0.498 
nsp=0.740 
nsp=0.362
MPI - General activity 
level
Start
Finish
FU1
FU2
3.38 (2.75,3.91) 
3.31(2.76,3.81) 
3.37(2.80,3.80) 
3.34 (2.73,3.87)
3.40 (2.80,3.88)
3.38 (2.69,3.89) 
3.39(2.88,3.87)
3.38 (2.80,3.98)
3.44 (2.68,3.84) 
3.34 (2.84,3.83) 
3.46 (2.81,3.78) 
3.43 (2.73,3.69)
3.31 (2.50,3.79)
3.30 (2.72,3.71) 
3.25 (2.80,3.93)
3.30 (2.67,3.89)
3.34 (2.80,4.05) 
3.25 (2.83,3.81)
3.34 (2.70,3.79) 
3.30 (2.71,3.86)
nsp=0.901 
ns p=0.969 
ns p=0.807 
ns p=0.904
Group 1 - Fluoxetine medication  Group 3 - Splint therapy  Kruskall Wallice not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *, p<0.005 **, p< 0.001
Start  = Baseline
Finish = End three months treatment 
FU1  = Follow-up 1  (six months) 
FU2  = Follow-up 2 (nine months)
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Table 79: Multidimensional pain inventory (MPD A comparison of median scores (25th,75th percentiles) (Imputation analysis)
MPI Study All groups (n=250) Group 1  (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Sig.
Patients perspective of pain
MPI - Severity Rxend
FU1
FU2
2.33 (1.30,3.66) ***
2.33 (1.30,3.37) 
2.00(1.00,3.66) *** 
# # #
2.60 (1.30,4.00)** 
2.33 (1.33,4.00) 
2.00 (1.00,4.00) 
ns(p=0.146)
2.33 (1.33,3.66) ***
2.33 (1.33,3.33)
2.33 (1.00,3.60) 
ns(p=0.110)
2.00 (0.66,3.00) *** 
2.00(0.66,3.00)
1.63 (0.58,2.66) **
2.33 (1.33,3.75) *
2.33 (1.00,4.00) 
2.15(0.92,3.75) 
ns (p=0.150)
p=0.298
p=0.406
p=0.130
MPI - Interference Rxend
FU1
FU2
1.05(0.36,2.38)  *** 
1.00(0.36,2.32) * 
0.95(0.27,2.21) ***
1.30(0.36,2.72) *** 
1.09 (0.55,2.73) 
0.90 (0.30,2.72) *
* (p=0.047)
1.16(0.54,2.54) *** 
0.82 (0.36,2.54) * 
0.90 (0.36,2.00) ** 
*(p=0.033)
0.90(0.29,2.27)  * 
0.85(0.18,2.18) ** 
0.58 (0.90,2.19) **
1.00 (0.43,2.40) 
1.00(0.43,2.50) 
1.09 (0.27,2.40) 
ns (p=0.336)
p=0.684
p=0.350
p=0.532
MPI - Life control Rxend
FU1
FU2
3.50 (2.50,4.25) ***
3.50 (2.50,4.25)
3.50 (2.75,4.50) 
ns(p=0.127)
3.50 (2.75,4.50) **
3.50 (2.50,4.50)
3.50 (2.75,4.50) 
ns (p=0.992)
3.50 (2.50,4.00)
3.75 (2.75,4.25)
3.75 (3.00,4.25) 
ns (p=0.646)
3.50 (2.50,4.25) 
3.25 (2.50,4.25)
3.50 (2.75,4.25) 
ns (p=0.338)
3.50 (2.50,4.25)
3.50 (2.50,4.56)
3.50 (2.50,4.75) 
ns (p=0.211)
p=0.952
p=0.746
p=0.909
MPI - Affective distress Rxend
FU1
FU2
3.00(2.00,4.00)  *** 
3.00(2.00,3.66) 
3.00(1.92,4.00) 
ns (p=0.406)
3.30 (2.00,4.00) ** 
3.00 (1.66,4.00) 
3.00(1.66,4.00) 
ns (p=0.717)
3.33 (2.00,4.00) ** 
3.00 (2.00,4.00)
3.33 (2.30,4.00) 
ns (p=0.118)
3.00 (1.92,4.00)
3.00 (1.65,4.00)
3.00 (1.60,4.00) 
ns (p=0.529)
2.83 (2.00,3.62) * 
3.00 (1.66,3.60) 
2.66 (1.60,3.40) 
ns (p=0.211)
p=0.590
p=0.551
p=0.257
Response of significant other
MPI - Support response Rxend
FU1
FU2
3.33 (2.32,4.33)
3.33 (2.00,4.33) 
3.00 (2.00,4.33)
3.33 (2.33,4.33)
3.33 (2.00,4.33) 
3.00 (2.00,4.33)
3.33 (2.33,5.00)
3.33 (1.83,4.66) 
3.66 (2.32,4.66)
3.00 (1.70,4.00)
3.00 (1.83,4.00)
3.00 (1.60,4.00)
3.60(2.17,4.47) 
3.33 (2.33,4.00) 
3.15(2.00,4.31)
p=0.300
p=0.491
p=0.103
MPI - Punishing response Rxend
FU1
FU2
1.00 (0,2.00)
1.00 (0.25,2.00)
1.00 (0.19,2.00)
1.00 (0,2.5)
1.00 (0.38,2.50) 
1.00)0.25,2.75)
1.25 (0.25,2.00)
1.25 (0.25,2.75)
1.25 (0.25,2.25)
1.00 (0,2.00) 
0.75 (0.25,1.75) 
0.75 (0,1.75)
1.00(0,1.75) 
0.75 (0,1.75) 
1.00(0,1.88)
p=0.394
p=0.164
p=0.511
MPI - Solicitous response Rxend
FU1
FU2
2.66 (1.33,3.83)
2.66 (1.50,4.00)
2.66 (1.50,4.00)
2.50 (1.30,4.00)
2.50 (1.66,4.08) 
2.42 (1.50,3.50)
2.66 (1.33,4.50) 
2.83 (1.66,4.50)
2.66 (1.66,4.50)
2.66 (1.50,4.08)
2.66 (1.33,4.00)
2.66 (1.50,4.00)
2.50 (1.08,3.50) 
2.66(1.50,3.83)
2.50 (1.50,3.75)
p=0.798
p=0.798
p=0.704
MPI - Distracting response Rxend
FU1
FU2
1.75(0.75,3.00) 
1.75(0.75,2.75) 
1.75 (0.75,3.00)
2.00 (0.75,2.75) 
1.75(1.00,2.75) 
1.75 (0.75,2.56)
1.50(0.75,2.75) 
1.50(0.75,3.25) 
1.50 (0.81,2.75)
1.75 (0.75,2.88)
1.75 (0.50,2.75)
1.75 (0.75,3.00)
1.75(0.63,3.00)
2.00 (0.88,3.00)
2.00 (0.75,3.25)
p=0.927
p=0.938
p=0.984
Frequency of participation in
MPI - Household chores Rxend
FU1
FU2
4.60 (3.60,5.60)
4.80 (3.60,5.60)
4.80 (3.60,5.60)
4.60 (4.20,5.40) 
5.00 (4.00,5.60)
4.60 (3.40,5.60)
4.40 (3.40,5.60) 
5.00 (3.40,5.60) 
4.60 (3.40,5.40)
4.60 (3.80,5.55)
4.80 (3.65,5.60)
4.80 (3.80,5.70)
4.60 (3.60,5.60)
4.80 (3.80,5.40)
4.80 (3.60,5.60)
p=0.903
p=0.852
p=0.806
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MPI -  Outdoor work Rx end
FU1
FU2
2.00 (1.00,3.00)
2.00 (1.00,3.00) 
2.00(1.20,3.00)
1.78 (1.29,3.00)
2.00 (1.24,2.76)
2.00 (1.40,3.25)
2.00 (1.00,3.00) 
2.00(1.00,3.20) 
2.00(1.00,3.00)
1.80 (0.85,2.60)
2.00 (0.78,3.00)
2.00 (1.00,2.80)
2.00 (0.95,3.05) 
2.00(1.15,3.00) 
2.00(1.15,3.20)
p=0.687
p=0.898
p=0.496
MPI - Activities away from 
home
Rx end
FU1
FU2
3.50 (2.75,4.25)
3.50 (2.75,4.25)
3.50 (2.50,4.25)
3.50 (2.75,4.25)
3.50 (2.75,4.50)
3.50 (2.75,4.50)
3.50 (2.75,4.25)
3.50 (2.75,4.00)
3.50 (2.50,4.25)
3.50 (2.75,4.25) 
3.38 (2.81,4.19) 
3.25 (2.63,4.13)
3.38(2.50,4.31) 
3.50 (2.44,4.25) 
3.25 (2.25,4.50)
p=0.891
p=0.913
p=0.923
MPI - Social activities Rx end
FU1
FU2
3.25 (2.30,3.75)
3.00 (2.33,3.75)
3.00 (2.32,3.75)
3.00 (2.25,4.00)
3.00 (2.33,3.66)
3.00 (2.25,3.75)
3.25 (2.50,4.00) 
3.00 (2.50,3.75)
3.25 (2.75,3.75)
3.13 (2.33,3.75)
3.00 (2.25,3.75)
3.00 (2.13,3.75)
3.29 (2.19,4.00)
3.00 (2.25,3.81)
3.00 (2.19,4.00)
p=0.498
p=0.740
p=0.362
MPI - General activity level Rxend
FU1
FU2
3.30 (2.76,3.81) 
3.37 (2.80,3.80) 
3.34 (2.73,3.87)
3.38(2.69,3.89) 
3.39(2.88,3.87) 
3.38 (2.80,3.98)
3.34 (2.84,3.83) 
3.46 (2.81,3.78) 
3.43 (2.73,3.69)
3.30 (2.72,3.71) 
3.25 (2.80,3.93)
3.30 (2.67,3.89)
3.25 (2.83,3.81) 
3.34 (2.70,3.79) 
3.30 (2.71,3.86)
p=0.969
p=0.807
p=0.904
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Kruskall Wallice not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *, p<0.005 **, p< 0.001
Rx end = End three months treatment 
FU1  = Follow-up 1  (six months)
FU2  = Follow-up 2 (nine months)
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Figure 70 : Multidimensional pain inventory median scores 
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Table 80: McGill pain questionnaire (MPOI. Beck depression index (BDD  and Kellner illness attitude scale. (Imputation analysis)
A comparison of median scores (25  and 75  percentiles)____________ ________________ _________________ ________________
Self report 
Questionnaire
Study All groups (n=250) Group 1  (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Sig-
MPQ Time
Visual analogue scale 
(VAS) (range 0-10)
Start
Finish
FU1
FU2
2.90 (1.20,5.45)
2.20 (0.80,4.95)  *** 
2.30(0.60,4.90)  *** 
1.60 (0.50,4.50)  ***
2.90 (1.20,6.03) 
2.40 (0.63,4.90) 
1.90(0.50,4.80)* 
1.50(0.50,4.80)* 
ns (p=0.054)
3.30(1.60,5.60)
2.50 (0.95,5.35) **
2.50 (0.90,4.55) * 
2.10(0.80,4.50)** 
*(p=0.005)
2.70 (1.23,4.80) 
2.10(0.7,4.50)  ** 
2.00(0.50,4.80)  * 
0.90(0.13,3.20)  ***
2.75 (0.90,5.38) 
2.20 (0.95,5.95) 
2.45 (0.50,6.60) 
2.30(0.50,5.35)  *
*(p=0.006)
p=0.881
p=0.682
p=0.506
p=0.119
ns
Present pain intensity 
(PPI) (range 0-5)
Start
Finish
FU1
FU2
2.00 (1.00,2.00)
1.00 (1.00,2.00)  *** 
1.00(1.00,2.00)  *** 
1.00 (0.50,2.00)  ***
2.00 (1.00,3.00) 
2.00(1.00,2.00)  ** 
1.00(1.00,2.00)  ** 
1.00(1.00,2.00)  **
2.00 (1.00,2.00) 
2.00(1.00,2.00)  * 
1.00(1.00,2.00)  ** 
1.00(1.00,2.00) ***
2.00 (1.00,2.00) 
1.00(1.00,2.00)  ** 
1.00(1.00,2.00)  * 
1.00(0,2.00)  ***
2.00 (1.00,2.00) 
1.00(1.00,2.00)  * 
2.00 (1.00,2.00) 
1.00(1.00,2.00)  ** 
*(p=0.005)
p=0.617
p=0.627
p=0.567
p=0.210
ns
MPQ - total % 
(range 0-100)
Start
Finish
FU1
FU2
31.00 (20.00,47.00)
27.00 (13.00,40.00)***
24.00 (12.00,42.00)***
22.00 (10.00,38.00)*** 
* * *
35.50 (23.50,47.00) 
29.00 (17.00,45.50) * 
29.00(15.25,42.50)*** 
27.00(12.50,42.50)***
31.00(19.5,40.0)
29.00 (14.5,37.0)**
29.0 (13.0,37.0) ** 
24.0(11.0,38.0) ***
30.00 (18.00,39.50) 
24.00(13.00,31.00)***
24.00 (16.00,44.00)** 
22.00(8.00,36.00)  *** 
* * *
30.00 (17.50,49.50) 
20.00(11.00,42.00)*
18.00 (9.00,44.00)**
18.00 (7.00,38.00)** 
* * *
p=0.384
p=0.423
p=0.533
p=0.552
ns
MPQ- sensory % 
(range 0-100)
Start
Finish
FUl
FU2
33.00 (21.00,45.00)
30.00 (15.00,42.00)***
27.00 (12.00,42.00)***
27.00 (12.00,42.00)***
39.00 (26.25,48.00)
33.00 (18.00,45.00) * 
33.00(17.25,14.25)** 
31.50(14.25,42.75) **
**(p=0,002)
31.00 (21.00,45.00) 
30.00(17.50,41.0)*
27.00 (14.50,42.0)*
27.0 (12.0,42.0) **
**(p=0.001)
33.00(21.00,42.00)
24.00 (15.00,37.50) **
30.00 (15.00,39.00) ** 
27.00(9.00,37.00)  ***
31.50(18.00,49.00)
21.00 (12.00,45.00) *
18.00 (9.00,45.00) **
21.00 (9.00,47.00) **
p=0.339
p=0.558
p=0.587
p=0.661
ns
MPQ - affective % 
(range 0-100)
Start
Finish
FUl
FU2
17.00 (0,42.00)
17.00 (0, 25.00)***
17.00 (0,33.00) ***
17.00 (17.00,25.00)*** 
* * *
25.00 (0, 52.00) 
17.00(0,46.00)  *
17.00 (0,42.00)  * 
12.50 (0,35.25)  ** 
**(p=0.002)
17.00 (8.00,40.50) 
17.00(0,25.00)  ** 
17.00(0,25.00)  ** 
17.00(0,25.00)  *** 
* * *
17.00 (8.00,25.00)
17.00 (0,25.00)  *
17.00 (0,25.00)
17.00 (0,25.00)  *
**(p=0.002)
17.00 (0,50.00)
9.00 (0,33.00)
8.00 (0,8.00) * 
8.00 (0,8.00) * 
ns (p=0.194)
p=0.663
p=0.905
p=0.830
p=0.903
ns
BDI
Composite score 
(range 0-45)
Start
Finish
FUl
FU2
7.00  (3.00,13.00)
6.00  (3.00,12.00)** 
6.00(2.00,11.00)***
6.00 (2.00,11.00) *** 
* * *
7.00 (2.25,13.75) 
6.00(2.00.12.50)
6.00 (2.00,11.00) ** 
6.00 (2.00,10.50) ***
7.00(3.00,11.00) 
7.00(3.00,11.00)* 
6.00(3.00,11.00)* 
5.50 (2.00,10.25)**
**(p=0.001)
6.00 (2.00,10.50) 
5.00(1.00,10.00)  * 
4.00(1.00,11.00)  * 
4.00(1.00,10.00)  * 
*(p=0.032)
8.00 (4.25,14.75)
7.00 (3.00,13.00)
6.00 (3.00,12.00) *
7.00 (3.00,13.50)
*(p=0.028)
p=0.344
p=0.106
p=0.435
p=0.121
ns  |
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Kellner All groups Group 1 Group 2 Group 3 Group 4 Sig.
Illness attitude- total 
(range 0-30)
Start
Finish
FUl
FU2
8.00  (6.00,11.00)
7.00  (6.00,11.00)
8.00 (6.00,10.00)* 
7.00 (6.00,10.00)*** 
* * *
8.00(6.00,11.50) 
7.00(6.00,11.50) 
7.00(6.00,11.00) 
6.00(6.00,11.00)  ** 
**(p=0.002)
7.00 (6.00,9.50)
7.00 (6.00,10.00)
6.00 (6.00,9.00) *
6.00 (6.00,9.00) * 
*(p=0.13)
7.50(6.00,11.00)
7.00 (6.00,10.00)
7.00 (6.00,9.00)
7.00 (6.00,10.00) 
ns (p=0.08)
8.00 (6.00,12.00)
9.00 (6.00,12.00)
8.00 (6.00,8.00) 
8.50 (6.00,11.75) 
ns (p=0.479)
p=0.206
p=0.101
p=0.077
p=0.122
ns
Hypochondriacal 
beliefs 
(range 0-15)
Start
Finish
FUl
FU2
3.00  (3.00,6.00)
3.00  (3.00,5.00)  *
3.00 (3.00,5.00)  ** 
3.00(3.00,5.00)  ***
4.00 (3.00,6.00)
3.00 (3.00,5.00)  *
3.00 (3.00,6.00)
3.00 (3.00,5.00)  **
*(p=0.006)
3.00 (3.00,5.00)
3.00 (3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  * 
ns (p=0.56)
3.00 (3.00,6.00)
3.00 (3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  * 
ns (p=0.99)
3.00 (3.00,6.00) 
3.50 (3.00,6.00)
3.00 (3.00,5.00)
4.00 (3.00,6.00) 
ns (p=0.69)
p=0.477
p=0.546
p=0.216
p=0.169
ns
Disease phobia 
(range 0-15)
Start
Finish
FUl
FU2
3.00 (3.00,5.00) 
3.00(3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  *
*(p=0.02)
3.00(3.00,5.50)
3.00 (3.00,5.50)
3.00 (3.00,5.00)
3.00 (3.00,5.00) 
ns (p=0.67)
3.00 (3.00,4.00)
3.00 (3.00,5.00)
3.00 (3.00,4.00)
3.00 (3.00,4.00) 
ns(p=0.419)
3.00 (3.00,6.00)
3.00 (3.00,5.25)
3.00 (3.00,5.00)
3.00 (3.00,5.25) 
ns(p=0.129)
4.00 (3.00,7.00)
5.00 (3.00,6.75)
4.00 (3.00,6.00)
3.00 (3.00,6.00) 
ns (p=0.273)
p=0.112
p=0.068
p=0.038
p=0.138
ns
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Kruskall-Wallis not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001***
Start  = Baseline
Finish = End three months treatment 
FUl  = Follow-up 1  (six months) 
FU2  = Follow-up 2 (nine months)
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Table 81: McGill pain questionnaire (MPQ). Beck depression index (BDD  and Kellner illness attitude scale. (Imputation analysis)
A comparison of median scores (25th  and 75th  percentiles)
Self report 
Questionnaire
Study All groups (n=250) Group 1  (n=63) Group 2 (n=63) Group 3 (n=62) Group 4 (n=62) Sig.
MPQ Time
Visual analogue scale 
(VAS)(range 0-10)
Rxend 
FUl 
FU 2
2.20 (0.80,4.95)  *** 
2.30 (0.60,4.90)  *** 
1.60 (0.50,4.50)  *** 
* * *
2.40 (0.63,4.90) 
1.90(0.50,4.80)* 
1.50 (0.50,4.80) * 
ns (p=0.054)
2.50 (0.95,5.35) **
2.50 (0.90,4.55) * 
2.10(0.80,4.50)** 
*(p=0.005)
2.10(0.7,4.50)  ** 
2.00(0.50,4.80)  * 
0.90(0.13,3.20)  *** 
* * *
2.20 (0.95,5.95) 
2.45 (0.50,6.60) 
2.30(0.50,5.35)  *
*(p=0.006)
p=0.682
p=0.506
p=0.119
ns
Present pain intensity 
(PPI)(range 0-5)
Rxend
FUl
FU2
1.00 (1.00,2.00)  *** 
1.00 (1.00,2.00)  *** 
1.00 (0.50,2.00)  *** 
* * *
2.00(1.00,2.00)  ** 
1.00(1.00,2.00)  ** 
1.00(1.00,2.00)  **
2.00(1.00,2.00)  * 
1.00(1.00,2.00)  ** 
1.00 (1.00,2.00) ***
1.00(1.00,2.00)  ** 
1.00(1.00,2.00)  * 
1.00(0,2.00)  *** 
***
1.00(1.00,2.00)  * 
2.00 (1.00,2.00) 
1.00(1.00,2.00)  ** 
*(p=0.005)
p=0.627
p=0.567
p=0.210
ns
MPQ-total % 
(range 0-100)
Rxend
FUl
FU2
27.00 (13.00,40.00)***
24.00 (12.00,42.00)***
22.00 (10.00,38.00)*** 
***
29.00 (17.00,45.50) *
29.00 (15.25,42.50)***
27.00 (12.50,42.50)***
29.00 (14.5,37.0)**
29.0 (13.0,37.0) ** 
24.0(11.0,38.0) ***
24.00(13.00,31.00)*** 
24.00(16.00,44.00)** 
22.00(8.00,36.00)  ***
20.00(11.00,42.00)*
18.00 (9.00,44.00)**
18.00 (7.00,38.00)**
p=0.423
p=0.533
p=0.552
ns
MPQ- sensory % 
(range 0-100)
Rxend
FUl
FU2
30.00 (15.00,42.00)***
27.00 (12.00,42.00)***
27.00 (12.00,42.00)*** 
***
33.00(18.00,45.00)* 
33.00(17.25,14.25)** 
31.50(14.25,42.75) **
*#(p=0.002)
30.00(17.50,41.0)*
27.00 (14.50,42.0)*
27.0 (12.0,42.0) **
**(p=0.001)
24.00 (15.00,37.50) **
30.00 (15.00,39.00) ** 
27.00(9.00,37.00)  ***
21.00(12.00,45.00)*
18.00 (9.00,45.00) **
21.00 (9.00,47.00) **
p=0.558
p=0.587
p=0.661
ns
MPQ - affective % 
(range 0-100)
Rxend
FUl
FU2
17.00 (0, 25.00)***
17.00 (0,33.00) ***
17.00 (17.00,25.00)***
17.00 (0, 46.00)  *
17.00 (0,42.00)  * 
12.50 (0,35.25)  ** 
**(p=0.002)
17.00(0,25.00)  ** 
17.00(0,25.00)  ** 
17.00(0,25.00)  *** 
* * *
17.00 (0,25.00)  *
17.00 (0,25.00)
17.00 (0,25.00)  *
**(p=0.002)
9.00 (0,33.00)
8.00 (0,8.00) * 
8.00 (0,8.00) * 
ns(p=0.194)
p=0.905
p=0.830
p=0.903
ns
BDI
Composite score 
(range 0-45)
Rxend
FUl
FU2
6.00  (3.00,12.00)**
6.00 (2.00,11.00) *** 
6.00 (2.00,11.00)***
6.00 (2.00.12.50)
6.00 (2.00,11.00)** 
6.00(2.00,10.50) *** 
* * *
7.00(3.00,11.00)* 
6.00 (3.00,11.00)* 
5.50 (2.00,10.25) **
**(p=0.001)
5.00 (1.00,10.00)  * 
4.00(1.00,11.00)  *
4.00 (1.00,10.00)  * 
*(p=0.032)
7.00 (3.00,13.00)
6.00 (3.00,12.00) *
7.00 (3.00,13.50)
*(p=0.028)
p=0.106
p=0.435
p=0.121
ns
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Kellner All groups Group 1 Group 2 Group 3 Group 4
Illness attitude- total 
(range 0-30)
Rxend
FUl
FU2
7.00  (6.00,11.00)
8.00 (6.00,10.00)* 
7.00 (6.00,10.00)*** 
* * *
7.00(6.00,11.50) 
7.00(6.00,11.00) 
6.00(6.00,11.00)  ** 
**(p=0.002)
7.00 (6.00,10.00)
6.00 (6.00,9.00) *
6.00 (6.00,9.00) * 
*(p=0.13)
7.00 (6.00,10.00)
7.00 (6.00,9.00)
7.00 (6.00,10.00) 
ns (p=0.08)
9.00 (6.00,12.00)
8.00 (6.00,8.00) 
8.50(6.00,11.75) 
ns (p=0.479)
p=0.101
p=0.077
p=0.122
ns
Hypochondriacal 
beliefs 
(range 0-15)
Rxend
FUl
FU2
3.00  (3.00,5.00)  * 
3.00(3.00,5.00)  **
3.00 (3.00,5.00)  ***
3.00 (3.00,5.00)  *
3.00 (3.00,6.00) 
3.00(3.00,5.00)  **
*(p=0.006)
3.00 (3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  * 
ns (p=0.56)
3.00 (3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  * 
ns (p=0.99)
3.50 (3.00,6.00)
3.00 (3.00,5.00)
4.00 (3.00,6.00) 
ns (p=0.69)
p=0.546
p=0.216
p=0.169
ns
Disease phobia 
(range 0-15)
Rxend
FUl
FU2
3.00 (3.00,5.00) 
3.00(3.00,5.00)  * 
3.00(3.00,5.00)  *
*(p=0.02)
3.00 (3.00,5.50)
3.00 (3.00,5.00)
3.00 (3.00,5.00) 
ns (p=0.67)
3.00 (3.00,5.00)
3.00 (3.00,4.00)
3.00 (3.00,4.00) 
ns (p=0.419)
3.00 (3.00,5.25)
3.00 (3.00,5.00) 
3.00(3.00,5.25) 
ns (p=0.129)
5.00 (3.00,6.75)
4.00 (3.00,6.00)
3.00 (3.00,6.00) 
ns (p=0.273)
p=0.068
p=0.038
p=0.138
ns
Group 1  - Fluoxetine medication  Group 3 - Splint therapy  Kruskall-Wallis not significant between groups
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy  Wilcoxon significance p<0.05 *,p<0.005 **,p<0.001***
Rx end = End three months treatment 
FUl  = Follow-up 1  (six months)
FU2  = Follow-up 2 (nine months)
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Figure 71: McGill pain questionnaire, Kellner illness attitude BDI median scores 
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Table 82: Relapse in scores since end of treatment  number of subjects and (%) N=250 
Multidimensional pain inventory (MPI)  ___________ _____________ __________
MPI Study All groups Group 1 Group 2 Group 3 Group 4 Significance
Patients perspective of pain 
and impact on daily life Time
MPI - Severity Follow-up 1  
Follow-up 2
46 (18.4%) 
39(15.6%)
10(15.9%) 
11 (17.5%)
12 (19%)
9 (14.3%)
12 (19.4%) 
7(11.3%)
12 (19.4%) 
12 (19.4%)
ns p=0.948 
ns p=0.618
MPI - Interference Follow-up 1  
Follow-up 2
50 (20%) 
40 (16%)
18 (28.6%) 
11(17.5%)
12(19%)
10(15.9%)
6 (9.7%) 
7(11.3%)
14 (22.6%) 
12 (19.4%)
ns p=0.062 
ns p=0.650
MPI - Life control Follow-up 1  
Follow-up 2
69 (27.6%)
70 (28%)
12 (19%) 
17 (27%)
16 (25.4%)
17 (27.0%)
19 (30.6%) 
18 (29.0%)
22 (35.5%) 
18 (29.0%)
nsp=0.197 
ns p=0.988
MPI -  Affective distress Follow-up 1  
Follow-up 2
51 (20.4%) 
62 (24.8%)
13 (20.6%) 
13 (20.6%)
14 (22.2%) 
22 (34.9%)
13 (21.0%) 
15 (24.2%)
11 (17.7%)
12 (19.4%)
ns p=0.938 
ns p=0.169
Response of significant 
other person to patient
MPI - Support response Follow-up 1  
Follow-up 2
42 (18.0%) 
47 (20.2%)
13 (22.0%) 
10(16.9%)
7(11.5%)
13(21.3%)
8 (14.3%) 
11 (19.6%)
14 (24.6%) 
13 (22.8%)
ns p=0.204 
ns p=0.872
MPI -  Punishing response Follow-up 1  
Follow-up 2
41 (19.0%) 
37(17.1%)
14 (27.5%) 
11 (21.6%)
10 (16.9%) 
9(15.3%)
8 (16.3%) 
6 (12.2%)
9(15.8%) 
11 (19.3%)
ns p=0.371 
ns p=0.601
MPI -  Solicitous response Follow-up 1  
Follow-up 2
56 (25.9%)
57 (26.4%)
14 (27.5%) 
9(17.6%)
17 (28.8%) 
19 (32.2%)
9(18.4%) 
11 (22.4%)
16(28.1%)
18(31.6%)
ns p=0.591 
ns p=0.239
MPI - Distracting response Follow-up 1  
Follow-up 2
44 (20.4%) 
53 (24.5%)
8(15.7%)
7(13.7%)
13 (22.0%) 
17 (28.8%)
11 (22.4%) 
13 (26.5%)
12(21.1%)
16(28.1%)
ns p=0.861 
ns p=0.232
Frequency of participation 
in common activities
MPI - Household chores Follow-up 1  
Follow-up 2
64 (25.6%) 
68 (27.4%)
15 (23.8%)
16 (25.4%)
19 (30.2%) 
19 (30.2%)
11 (18.3%) 
15 (25.0%)
19 (30.6%) 
18 (29.0%)
ns p=0.353 
ns p=0.891
MPI - Outdoor work Follow-up 1  
Follow-up 2
46 (20.4%) 
53 (23.5%)
8 (14.0%) 
14(24.1%)
12 (20.7%) 
10(17.2%)
15 (28.8%)
16 (30.8%)
11 (19.0%) 
13 (22.4%)
ns p=0.287 
ns p=0.416
MPI - Activities away from 
home
Follow-up 1  
Follow-up 2
54 (21.8%) 
51 (20.6%)
16 (25.4%) 
15 (23.8%)
11 (17.5%) 
11 (17.5%)
13 (21.7%) 
15 (25.0%)
14 (22.6%) 
10(16.1%)
ns p=0.754 
ns p=0.523
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Self report Questionnaire Study All groups Group 1 Group 2 Group 3 Group 4
MPI - Social activity level Follow-up 1  
Follow-up 2
50(20.0%)
60(24.0%)
14(22.2%) 
14 (22.2%)
9 (14.3%) 
17 (27.0%)
11 (17.7%) 
16 (25.8%)
16 (25.8%) 
13(21.0%)
ns p=0.404 
ns p=0.790
MPI -  General activity level Follow-up 1  
Follow-up 2
67 (27.0%) 
70 (28.2%)
16 (25.4%) 
19 (30.2%)
15 (23.8%)
16 (25.4%)
20 (33.3%) 
18 (29.0%)
16 (25.8%)
17 (27.4%)
ns p=0.643 
ns p=0.924
McGill pain questionnaire (MPQ), Beck depression index (1BDI)  and Kellner illness attitude scale.(Kellner)
MPQ Time
Visual analogue scale 
(VAS)(range 0-10)
Follow-up 1  
Follow-up 2
48 (21.0%) 
39(17.0%)
11 (19.6%) 
13 (23.2%)
9(15.8%) 
11 (19.3%)
14 (23.7%) 
5 (8.5%)
14 (24.6%) 
10 (17.5%)
ns p=0.637 
ns p=0.188
Present pain intensity (PPI) 
(range 0-5)
Follow-up 1  
Follow-up 2
28 (11.5%) 
24 (9.8%)
5 (8.2%) 
8(13.1%)
8 (12.7%) 
6 (9.5%)
9(15.3%) 
5 (8.5%)
6 (9.8%) 
5 (8.2%)
ns p=0.631 
ns p=0.788
MPQ - total % 
(range 0-100)
Follow-up 1  
Follow-up 2
42 (17.9%) 
39 (16.6%)
11 (19.3%) 
11 (19.3%)
11 (18.0%) 
11 (18.0%)
14(24.1%) 
8 (13.8%)
6 (10.2%) 
9(15.3%)
ns p=0.260 
ns p=0.850
MPQ- sensory % 
(range 0-100)
Follow-up 1  
Follow-up 2
39(16.6%) 
39 (16.6%)
11(19.3%)
12(21.1%)
9(14.8%) 
10 (16.4%)
14(24.1%)
9(15.5%)
5 (8.5%) 
8(13.6%)
ns p=0.130 
ns p=0.738
MPQ -  affective % 
(range 0-100)
Follow-up 1  
Follow-up 2
37(15.7%) 
30 (12.8%)
10(17.5%)
9(15.8%)
9(14.8%)
7(11.5%)
12 (20.7%) 
7(12.1%)
6 (10.2%) 
7(11.9%)
ns p=0.451 
ns p=0.890
BDI
Composite score 
(range 0-45)
Follow-up 1  
Follow-up 2
43 (17.7%) 
42(17.3%)
6 (9.8%) 
9(14.8%)
15 (24.2%) 
9 (14.5%)
11 (18.6%) 
10 (16.9%)
11 (18.0%) 
14 (23.0%)
ns p=0.291 
ns p=0.577
Kellner
Illness attitude- total 
(range 0-30)
Follow-up 1  
Follow-up 2
29(11.8%) 
31 (12.7%)
9 (14.8%) 
4 (6.6%)
3 (4.8%)
4 (6.3%)
10 (16.4%) 
12 (19.7%)
7(11.7%) 
11 (18.3%)
ns p=0.192 
ns p=0.032
Hypochondriacal beliefs 
(range 0-15)
Follow-up 1  
Follow-up 2
25 (10.2%) 
28(11.4%)
7(11.3%) 
4 (6.5%)
4 (6.3%)
5 (7.9%)
8(13.1%) 
10 (16.4%)
6 (10.0%) 
9(15.0%)
ns p=0.643 
ns p=0.209
Disease phobia 
(range 0-15)
Follow-up 1  
Follow-up 2
19 (7.7%) 
17 (6.9%)
5 (8.2%) 
3 (4.9%)
3 (4.8%) 
3 (4.8%)
3 (4.8%) 
5(8.1%)
8 (13.3%) 
6 (10.0%)
ns p=0.244 
ns p=0.605
Group 1  - Fluoxetine medication  Group 3 - Splint therapy
Group 2 - Placebo medication  Group 4 - Fluoxetine and splint therapy
Intra group analysis :Repeated measures ANOVA : p<0.05 *  p<0.005 **  p<0.001***  Inter group anaysis : Chi squared  (not significant)
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Figure 72a: MPI -  severity (FU-1,6 months) relapse since treatment end.
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Figure 73a: MPQ-VAS (FU-1,6 months) relapse since treatment end
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Figure 72b: MPI - severity (FU-2, 9 months) relapse since treatment end
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Figure 73b: MPQ-VAS (FU-2,9 months) relapse since treatment end
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9.2.4 Clinical outcome measures
9.2.4.1 Interincisal mouth opening  mean (+/- SD) measured in mm 
Graphically figures 74 and 75 reveal the clear trend in maintenance and improvement 
in mouth opening during FU phase.
9.2.4.1.1 Imputation analysis (Table 83,figure 74)
In summary, mouth opening during follow-up had improved in the overall patient 
cohort by 1mm, perhaps an almost imperceptible yet significant amount.
Analysing all groups synchronously, the GLM within-subjects effect of improved 
mouth opening were  significant F(2)=6.87,p=0.001, as were the multivariate tests 
Wilk’s lambda, F(2,248) =5.04,p=0.007, suggesting significant difference in the 
measurement of mouth opening during the follow-up phase of a significantly linear 
trend F(l)=9.57,p=0.002.
Paired sample t-tests for all groups together, showed mouth opening had improved at 
FUl (three months post therapy) by 0.57mm and at FU2 (six months post therapy) by 
0.99mm. This was significant at FUl t(249)=-2.05,p=0.04 and at FU2 t(249) =-3.09, 
p=0.002. Between FUl and FU2 an improvement was also observed the FU2 score 
0.42mm higher than the FUl score which was significant t(249)=-2.21,p=0.028.
Within each group only mouth opening improvement in group 4 (fluoxetine and splint) 
was significant F(2)=3.68,p=0.028, as were the multivariate tests Wilks lambda 
F(2,60)=3.36, p=0.041, suggesting significant differences in mouth opening during 
follow-up with a significant linear trend, F(l),5.60,p=0.021. Paired sample t-tests 
showed the measurement at FU2 to have increased by 1.52mm compared to the end of 
treatment, t(61  )=-2.3 7,p=0.021.
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However, inter group analysis, using the parametric one-way ANOVA, revealed no 
significant difference in mouth opening improvement during the follow-up phase 
between groups.
9.2.4.1.2 Completers analysis (Table 84, figure 7S)
Mouth opening during follow-up, amongst the FU completers, had improved by 
1.23mm similar to the imputation analysis. Analysing all groups synchronously, the 
repeated measures ANOVA of within subjects effect were significant F(2)= 6.5, 
p=0.002 as were the multivariate tests, Wilk’s lambda, F(2,136)= 4.8, p= 0.009, 
suggesting significant difference in the measurement of mouth opening during follow- 
up phase of a significantly linear trend F( 1,137)= 9.2,p= 0.003.
Paired sample t-tests for all groups together showed mouth opening had improved at 
FUl (three months post therapy) by 0.38mm and at FU2 (six months post therapy) by 
1.23mm. This was not statistically significant at FUl,p=0.08 but did reach significance 
at FU21 =(138), p=0.031. Between FUl and FU2 an improvement was also observed, 
the FU2 score was 0.85mm higher than the FUl score which was significant t(249) 
p=0.004. For each individual group intra and inter group analysis was not significant.
9.2.4.2 Relapse in measured mouth opening during folfow-up  (Table 85)
Although intra group McNemar analysis suggests there was a significant element of 
relapse between FUl and FU2, notably in groups 2 and 3, the non parametric 
intergroup x2 analysis revealed no significant difference in relapse between groups at 
either FUl (p=0.651) orFU2 (p=0.858).
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Table 83 : lnterincisal mouth opening mean (+/- SD)  Imputation analysis
Time All
groups
Group1  
n=63
Group2
n=63
Group3
n=62
Group4
n=62
One-way
ANOVA
End
treatment
3/12
40.28
(9.52)
39.67
(10.18)
40.52
(9.45)
41.60
(8.18)
39.34
(10.17) ns p=0.55
Follow-up 1  
6/12 (FUl)
40.85
(9.40)
* p=0.04
40.65
(10.31)
40.62
(9.26)
41.90
(8.32)
40.23
(9.70)
nsp=0.169
ns p=0.78
Follow-up 2 
9/12 (FU2)
41.27
(9.45)
**p=0.002
40.83
(10.04)
41.21
(9.54)
42.19
(8.74)
40.85
(9.60)
* p=0.021
ns p=0.84
♦♦  ns  ns  ns  *
p=0.001  p=0.061  p=0.337  p=0.572  p=0.028
Table 84 : lnterincisal mouth opening mean (+/- SD)  Completers analysis
Time All
groups
Group1 Group2 Group3 Group4 One-way
ANOVA
End
treatment
3/12
n=165
41.62
(9.22)
n=38
42.66
(9.73)
n=42
42.36
(8.71)
n=40
42.28
(8.32)
n=45
39.49
(9.93)
ns p=0.342
Follow-up 1  
6/12 (FUl)
n=145
42.00
(8.66)
ns
p=0.088
n=34
43.85
(8.12)
n=36
41.69
(9.43)
n=36
42.69
(8.54)
n=39
40.03
(8.40)
ns p=0.279
Follow-up 2 
9/12 (FU2)
n=139
42.85
(8.74)
*
p=0.031
n=33
44.00
(7.35)
n=36
42.67
(9.80)
n=34
43.62
(9.15)
n=36
41.25
(8.50)
ns p=0.565
♦   ns  ns  ns  ns
p=0.005  p=0.065  p=0.219  p=0.842  p=0.085
Table 85 : Relapse in measured mouth opening during follow-up numbers (%)
Time All groups Group 1 Group2 Group3 Group4 Significance
FUl 63
(29.4%)
(n=214)
19 (33.3%) 
(n=57)
14 (26.4%) 
(n=53)
13 (24.5%) 
(n=53)
17(33.3%)
(n=51)
ns
p=0.211
FU2 80
(37.7%)
(n=212)
20 (37%) 
(n=54)
18 (35.3%) 
(n=51)
19 (35.8%) 
(n=53)
23 (42.6%) 
(n=54)
ns
p=0.102
***p<0.001  ns (p=0.25)  *p=0.031  *p=0.031  ns(p=0.25)
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Figure 74: lnterincisal mouth opening
A comparison of mean scores showing maintenance and continued improvement in scores during follow-up.
Imputation analysis showing three month (week 12 ) treatment and follow-up at six months ( week 24) and nine months (week36).
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Figure 75: lnterincisal mouth opening
A comparison of mean scores showing maintenance and continued improvement in scores during follow-up.
Completers analysis showing three month (week 12 ) treatment and follow-up at six months ( week 24) and nine months (week36).
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Hypothesis (7): The four therapeutic groups were equally adherent to therapy.
9.3  Adherence and maintenance within treatment and follow-un
Adherence synonymous with the term compliance indicates the extent to which 
patients follow the instructions for prescribed treatment and is considered a non- 
judgemental statement of patient, prescriber and treatment, (Haynes et al,2006). 
Adherence to therapy is essential in assessing treatment efficacy and safety, 
(Shaya,2005, Formica et al,2004).Generally however, adherence rates are low with 
many patients showing resistance to taking medical therapy, (Pound,2005).It has 
been reported that patients prescribed self-administered medication take less than 
50% of the prescribed dosage, (WHO 2003, Haynes et al 2006).
Non-adherence may arise for various reasons, frequently related to inadequate, 
misunderstood or poor memory recall of treatment instructions and patient concern 
over the actual need for treatment and the feared or experienced adverse effects of 
treatment, (Houston et al,1997).Clinicians are sometimes reluctant to discuss side 
effects of treatment, nevertheless, explaining adverse effects of treatment has not 
been found to adversely effect adherence,(Haynes et al,2006).This finding is 
consistent with the accepted provision of patients with clear and adequate 
information regarding their treatment including expected side effects, (Probert,1996, 
Zakrzewska et al, 2002).This approach of providing clear and adequate information 
was followed throughout this RCT comparing medical and physical therapy in 
TMD.
Individual patient factors including behaviour, personality type, social support, 
motivation, participation or engagement in activity, age, occupation, socioeconomic 
status, education and beliefs may have an impact on adherence and require further
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investigation, (WHO,2003, White,2005). Granger et al 2005, found patients with 
high adherence were more likely to be men, less likely to smoke and likely to have 
more co morbidities. A recent study suggests high levels of independence, predict 
low levels of adherence to medication and this appears to be related to the element 
of self reliance, (Insel, 2006).The consequences of poor adherence for an individual 
may be under-treatment and hence potential decreased benefit of treatment but also 
an underestimate of side effects, (Haynes et al, 2006).This in turn causes problems 
for the clinician in determining the appropriate dosage and assessment of efficacy, 
(Connor et al,2004).
On a global level non adherence can lead to medication wastage and overall 
increased health care costs, (Cleemput et al,2002, Shaya,2005). The implication of 
non-adherence can be profound particularly in the sphere of antimicrobial therapy 
with respect to patient welfare, incompletely treated infections, the rise of drug 
resistant strains and ineffective disease management programmes, (Shaya,2005, 
Vrijens and Urquhart, 2005, Connor et al,2004).
Non adherence may also have serious consequences in life threatening or long term 
chronic conditions such as heart failure, hypertension, diabetes, HIV and multiple 
sclerosis, (Granger et al,2005, Hutchinson, 2005, Maggiolo et al,2002, Brown et al
1999).Interestingly, high levels of adherence even if only to placebo were found to 
be associated with a 35% lower mortality, improved survival, decreased morbidity 
and decreased admissions to hospital in patients with congestive heart failure, 
(Granger et al,2005).It was postulated that the reason adherence even to placebo 
may result in lower mortality might result from a general placebo response to 
expectations and belief in a particular therapy; adherence acting as a marker for 
healthier behavioural patterns hence resulting in better outcome (White,2005).
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Miller, 1997 suggest adherence to be a complex multifactorial behavioural process; 
reasons for behavioural non-adherence to physical activity, may be different to non­
adherence to medication. This could certainly be investigated in TMD comparing 
adherence to jaw exercises or splint wear and medical therapy. In this particular 
RCT, adherence did not appear to differ between physical and medical therapy.
Variable adherence to medication may lead to erratic patterns of drug exposure and 
hence inconsistent clinical response,(Vrijens et al 2005). How outpatients use their 
prescription drugs is termed ‘pharmionics’ and is now an essential element of 
biopharmaceutics together with pharmacokinetics and pharmacodynamics.(Vrijens 
et al, 2005). Apart form non-adherence, varying times of dosage and hence dosing 
intervals can effect the steady state of drug levels and assumed pharmacological 
profile (Vrijens and Goetghebeur, 2004).In order to examine adherence a reliable 
record of regular dosing frequency and timing of actual drug intake are therefore 
required, (Haynes et al,2006). Popular indirect measures of adherence including self 
report and pill counts. These were the simple techniques employed in this RCT. 
Martenyi et al, 2002, investigating fluoxetine versus placebo in PTSD assessed 
patient compliance at each visit by counting returned medication and direct 
questioning. Patients were recorded as noncompliant if they missed more than four 
consequetive days or more than ten cumulative days of study medication. The ratio 
of number of capsules to number of capsules prescribed was less than 0.8 or greater 
than 1.2. Self reporting is useful in cases of non adherence but often unreliable, 
overestimaing adherence (Haynes et al 2006, VanWijk et al ,2005). Pill counting 
which has been shown to have moderate correlation with adherence may provide 
false record of complete or nearly complete dosing history due to pill ‘dumping’ or
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discarding of tablets prior to the consultation appointment, (Urquhart 2002).
Haynes et al, 2006, systematically reviewed objective methods to improve 
adherence and their effect on clinical outcome. Techniques ranged from: patient 
education; information, improved communication between doctor and patient, 
counselling, self management plans, courses on health empowerment, reminders, 
manual telephone follow up, personal digital assistants (PDA’s)for electronic data 
capture, supervised lay health monitoring, direct observation of treatment taking, 
involvement of pharmacists, family intervention and education, psychological 
therapy, medication charts and units of medical dosage,(Haynes et al, 2006). 
Utilizing new technology, mobile phone reminders by voice or text message, paging 
systems and electronic reminders are all being evaluated, (Haynes et al, 2006)
A variety of simple interventions can improve short-term adherence whilst 
improving adherence for chronic conditions is more complex, consuming time, 
effort and resources, often requiring a combined range of interventions,(Haynes et 
al, 2006).Even the most effective intervention did not lead to large improvements in 
adherence, clinical benefit and treatment outcome. Less than half the interventions 
tested in RCTs’ improved adherence and less than a third improved outcomes. 
Benefit of interventions did not appear to be sustained beyond six months and it 
remained unclear which component of the combination were effective (Haynes et 
2006). Frequency of interaction with patients was often beneficial, however, some 
methods of monitoring adherence, instead of providing the intended positive 
encouragement may potentially lead to invasion of privacy and loss of autonomy, 
(Haynes et al,2006).
The WHO report, 2003, indicated the simplicity of the dosage regime and side 
effects were the therapy related factors that had the greatest influence on adherence
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and unlike behavioural factors, therapy related factors are amenable to passive 
intervention. Refinement of drug delivery systems in conjunction with clear 
instructions include; Calendar-blister packs or Dossett box organisers with refillable 
7-day unit of use dispensing can simplify treatment although elderly patients may 
still report difficulties, (Connor et al,2004).MEMS, medication event monitoring 
system, an electronic compilation of dosing history is described as one of the most 
reliable monitoring systems, (VanWijk et al,2005 ,Vrijens et al,2005). This method 
records the opening of the container to retrieve a tablet yet does not record what 
happens to the drug, which may still be discarded.
To avoid over estimation of adherence a more direct approach is to measure the 
level of drug within the blood stream or urine at a particular time point, (Osterberg,
2005). This technique was utilized in a study investigating the efficacy of 
Venlafaxine in Atypical facial pain, (Forssell et al,2004).
A novel approach suggested for research trials has been the use of a metabolically 
pharmacologically inert adherence marker, ingested as an integral part of the 
medication. (Insull,1984). In theory, measurement of body fluids would indicate the 
dosage of drug taken but no marker has yet been identified or produced.
Participant retention within clinical studies is always problematic and this study was 
no exception. Generally in clinical trials adherence is assumed to be high because of 
frequency of follow up, availability of free study treatment and patient selection, 
(White,2005). When patients are willing to participate and take the first step for 
inclusion in a study this indicates a positive attitude towards health care services and 
may result in increased adherence levels at baseline,(Van Wiljk,2005). This may 
provide an unrealistic perspective of adherence, within the natural treatment setting,
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due to the ‘Hawthorne effect, meaning subjects aware of the fact they are being 
observed show higher adherence due to extra attention they receive, (VanWijk et 
al,2005). Integrating patients’ perspective into treatment plans with the agreement 
that treatment is more helpful than harmful is another practical way to increase 
initial adherence,(Bissell et al,2004). Yet, despite regular counselling and 
monitoring provided at follow up appointments, this is not always enough to 
maintain patient adherence. Interestingly, in this particular RCT the majority of 
patients were lost at baseline enrolment but once actively engaged in treatment the 
actual erosion from the study was minimal. 80% of patients who commenced 
treatment completed the three month treatment phase. There was no significant 
difference in the overall adherence to therapy between the four groups. However, 
those receiving the dual treatment, occlusal appliance and medication had 
significantly less drop-outs during the study and follow-up period compared to 
single occlusal appliance therapy. Perhaps, this suggests the dual therapy approach 
to management, addressing both the physical and medical perspective, is preferred 
by patients or more simply that the increased time and attention given to dual 
therapy patients may have improved adherence and retention due to an intangible yet 
increased level of nurturing.
9.4  Withdrawal
Drop out or withdrawal from therapy is clearly the most severe form of non 
adherence. Suboptimal adherence and drop out is expensive in both time and 
resources required, increasing sample size to maintain study power,(Haynes et al,
2006). The systematic review, indicates that perhaps the most simple and effective 
intervention to improve adherence and prevent drop-out was recalling those who
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missed appointments. This is particulary important in a clinical trial and highlights 
the essential task of ensuring pateints who fail to attend appointments are contacted 
and retained in care.
Discontinuation of treatment  appears  to be relatively non-specific for disease or 
treatment but for antidepressants was found to be related to tolerability of treatment, 
patient education and quality of clinician and patient relationship, (NemerofF,2003).
A Cochrane systematic review investigated drop out rates for different 
antidepressant drugs in order to understand their relative tolerability,(Barbui et al, 
2000). Studies using SSRTs showed less participant dropout than tricyclic or 
heterocyclics but the advantage was only modest (OR 1.21(1.12-1.30). It was 
considered the antimuscarinic side effects of the tricyclics, not inefficacy, may 
account for the relatively poor tolerability  and suggested earlier RCTs’ may have 
over estimated the difference in drop out between SSRI and TCA, (Barbui et al,
2000). Controlled release antidepressants have the potential to reduce drop-out in the 
early phase due to lower peak-plasma drug concentrations compared to immediate 
release formulations and hence more favourable side effect profile. Examples 
include Venlafaxine XR (extended release) and Paroxetine CR (controlled release) 
which demonstrate a reduction in some adverse effects.(Nemeroflf, 2003).
To enhance participant adherence, increase drop-out and reduce the burden on 
patient time an internet-based design for clinical studies has been suggested as an 
alternative approach,(McAlindon et al,2003). It was proposed that this would allow 
frequent participant contact with less effort for the reporting of treatment outcome 
measures by completion of on-line computer questionnaires with out the need for 
lengthy visits to the hospital. However, one limitation is that not all patients may yet 
have access to the internet hence providing a non representative group of the
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population, (Formica et al,2004). In addition patients in some studies, including this 
RCT, still need to be examined at intervals and one looses the personal contact with 
the clinician which is known to encourage and maintain treatment adherence.
9.4.1  Withdrawal from this study
Overall adherence levels to medication and withdrawal from treatment was 
comparable to other RCT’s.
Moja et al,2006, in a systematic review analysing trials of SSRI in six trials of 
chronic daily headache, totalling 301 patients, found there was a 17.3% (27/156) 
withdrawal from SSRI compared to 15.9% (23/145) from placebo, with no 
significant difference between the two treatments OR 1.32(CI 0.66-2.64), 
(Adly,1992, Bendetsen,1996, Landy,1999, Steiner, 1998, C d,Amato, 1999a,
Polisaca,  1992).
In migraine combining four trials, totalling 161 patients, there was a 29.1% (25/86) 
withdrawal form SSRI compared to 26.7% (20/75) on placebo a non-significant 
difference between the two treatments, OR1.49 (Cl 0.7-3.6),(Adly,1992, C d’Amato, 
1999a, Landy 1999, Steiner, 1998). This compares very favourably to this study in 
TMD, where there was a 22% (11/49) withdrawal from SSRI compared to 26%
(11/53) withdrawal from placebo, OR1.07 (Cl 0.5-2.28), again a clearly non­
significant difference
Overall drop out of 18% (36/201) since commencement of treatment compares with 
15% (Bendteson,  1996). However, even considering the 49 cases which withdrew 
before commencing therapy in addition to the 36 during therapy 34% (49+36/250), 
still compares favourably to the reported drop out of 44% (Adly,1992), 41%
(Landy,1999), 38% (Steiner, 1998).
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In further TMD studies it would be interesting to compare the tolerability of the 
number of patients withdrawing from treatment between an SSRI, TCA and placebo.
9.4.2  Reasons for withdrawal
The most commonly reported reasons for withdrawal from therapy and follow-up 
varied between groups. Amongst the medication and placebo groups the most 
frequently reported reason was ‘resolution of pain’, 8/63 (12.7%) and 6/63 (9.5%) 
respectively.  In group 3, 10/62 (16.1%) did not return for therapy after the fitting of 
the appliance which was a significant cause of overall drop-out, p<0.001.
‘Resolution of pain’ as a reason for the medical groups to withdraw from therapy 
may have seemed the most favourable response for patients to give. Ideally, this 
would indicate that medication had had an immediate therapeutic response.
However, perhaps a more plausible explanation is that patients considered a positive 
outcome was the expected response and this would avoid offending the clinician and 
avoid the necessity for further medical therapy and follow up.
In considering why the occlusal appliance group did not return for follow-up may 
have been for a number of reasons. From an optimistic perspective, wearing the 
appliance may have resolved the pain and hence the patient saw no reason to return 
for further management. Conversely, the appliance may have had no effect or 
increased pain so the patient did not wish to continue with further treatment. In a 
similar vain, the patient may have found the appliance uncomfortable, not worn, 
misplaced or lost the appliance, embarrassed to admit to the clinical staff that 
treatment had therefore not been successful.
Unfortunately, a minority of patients may have seen the study as an opportunity to 
acquire an upper hard occlusal appliance free of charge. These items are an
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expensive commodity when constructed in outside dental practice. However, this 
scenario would suggest the patient felt no loyalty to the study to return for further 
treatment but merely considered the appliance as a service provided by the NHS. If 
this were the case, then one must consider how one could have improved the 
patient’s sense of commitment to the study. At the initial appointment, time and care 
was taken to build an empathic bond between clinician and patient but this was 
perhaps not necessarily enough to retain patients within the study. Occlusal 
appliances were constructed by a second clinician and perhaps there was therefore a 
unforeseen lack of continuity in the clinical care pathway for the splint only group. 
The time and effort expected of patients in a study should never be underestimated. 
As discussed earlier in Chapter 6, time taken off work may involve: lost earnings, 
lost productivity and even give rise to tension or antagonism amongst co workers 
and managers. Travel difficulties might involve; expense and distance, tiredness and 
distress caused by transport delays, strikes or closures which frequently occurred 
during the course of the trial. Re-numeration for their valuable time and travel 
expense re-imbursement were not provided for these patients. This lack of financial 
acknowledgment was perhaps reflected in the rate of erosion from the study and 
should be taken into consideration when planning a future study.
In consideration of the patient, the timing of appointments were tailored when 
possible to suit the individual participants, within the constraints of clinic hours. 
Patients frequently preferred early morning appointments before starting work so 
clinic times were rearranged to accommodate these early starting times.
The length of appointments, were not dissimilar to standard consultation and follow- 
up appointments, apart from the necessity to complete several questionnaires in the 
waiting room at three monthly intervals. Questionnaires almost inevitably became
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tedious and repetitive to the majority of patients during the course of follow-up but 
the need for completion was explained.
Hypothesis (8): There was no significant difference in adverse events between 
active and placebo medication.
9.5  Adverse events
There is currently no standard technique for identifying adverse events in clinical 
trials, (Bent et al,2006).Information provided to the patient prior to study 
participation of the possibility of experiencing side effects is known to influence 
reporting of adverse events even amongst a placebo group, (Hampton,2006).
In addition the varied methods of compiling information for example open or closed 
ended questions, short or long check-lists can lead to marked differences in the 
frequency of reported adverse events (Bent et al, 2006). In this particular RCT, a 
combination of techniques were employed, with direct questioning related to a short 
checklist and an open-ended question. The latter would tend to decrease reporting 
whilst the checklist tends to prompt memory and encourage reporting. Splawinski et 
al 2006, suggest that to increase the sensitivity for detection of drug-induced adverse 
effects statistics for efficacy and toxicity should be less stringent and trials should be 
based on superiority to an active control since placebo adverse effects tend to be 
disease and treatment specific biased by the nature of the clinical experiment. These 
criteria were partly followed in this RCT since there was both an active control, the 
occlusal splint and a placebo drug but an active drug comparator such as a TCA was 
not included and should be considered for future studies.
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9.5.2 Adverse events relating to withdrawal of medication
In relation to the number of patients withdrawing from treatment due to adverse 
effects of medical therapy, this again compared closely to studies analysing migraine 
and chronic daily headache. Moja et al,2005, in a systematic review of four migraine 
trials found a rate of withdrawal due to adverse effects from SSRI  to be 7% (6/86) 
compared to placebo 6.7% (5/75) with no significant difference between the two 
treatments, OR=1.25 (Cl 0.36-4.35), (Adly,1992, d’Amato, 1999a, Landy 1999, 
Steiner, 1998). For six studies examining chronic daily headache, withdrawal due to 
adverse effects were found to be  SSRI 3.8% (6/156) and placebo 4.1% (6/145) 
again no significant difference between groups OR1.02 (Cl 0.31-3.34) (Adly,1992, 
Bendtsen,1996, Landy, 1999, Steiner, 1998, C d’ Amato, 1999a, Polisca,1992).  This 
compares favourably to this study of TMD, SSRI 4% (2/49) and placebo 3.8%
(2/53) with no significant difference between groups OR1.08 (Cl 0.16-7.37)
9.5.3 Minor adverse events related to mediation
Overall, the minor adverse effects of medical therapy were again similar to those 
observed in the studies of SSRI in migraine and chronic daily headache. A short 
meta analysis summarising and comparing the adverse events recorded in these 
studies is summarised on the next page and reveals some marked similarities. For 
each condition analysed, there was no significant difference between adverse effects 
experienced in the placebo and SSRI groups.
The most frequently reported adverse event was insomnia. The increased likelihood 
of nausea amongst the SSRI group 5/49 (10.2%), reported in this RCT , was not the 
most commonly reported in the three following studies. However, it was also found 
to be the commonest adverse event reported in the fluoxetine group, 3/12 (25%), in
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an RCT comparing an active comparator with fluoxetine in tension type headache, 
(Walker, 1998).
Table 86: Minor adverse events of SSRTs versus placebo
Study Condition N SSRI Placebo OR (95%CI)
Adly,1992 
C d’Amato,  1999a
Migraine 84 11/48
(22.9%)
6/36
(16.6%)
1.46
(0.47-4.52)
Adly,1992
Bendtsen,1996
Chronic
daily
headache
112 17/56
(30.4%)
18/56
(32.1%)
0.92
(0.40-2.09)
This TMD study 
Leeson, 2006
TMD 201 15/49
(30.6%)
8/53
(15%)
1.79
(0.82-3.91)
Study Most frequently 
reported side effects 
(SSRI)
Most frequently 
reported side effects 
(placebo)
Adly,1992 Insomnia & anxiety 
Strange skin sensations 
Excitement & insomnia
Insomnia & anxiety 
Weakness 
Problems sleeping
C d’Amato,  1999a Pyrosis
Aesthenia
Insomnia & excitement
Aesthenia
Sleepiness
This TMD study 
Leeson, 2006
Nausea, Insomnia 
Drowsiness.
Malaise, fatigue, flu-like 
symptoms)
Headache, rash,
GIT symptoms,
Malaise, fatigue, flu-like 
symptoms.
Hypothesis (9) The improvement in pain measures at the end of the RCT are 
maintained at six and nine months follow-up.
9.6  Follow-up phase
Maintenance and amelioration in pain severity and intensity during follow-up was 
observable amongst all four treatment groups,( figure 64).
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9.6.1  Self report questionnaires : Multidimensional pain inventory
MPI scores in relation to baseline recordings clearly reveal a significant 
improvement in the patient’s overall perspective of pain, notably pain severity 
(p<0.001) amongst all individual groups. Severity, interference, life control and 
affective distress were significantly reduced (p<0.001) when analysing all groups 
together. However, individually, pain interference significantly improved in groups
1,2  and 3, p<0.001, life control, having only improved in group 1  at end of the 
treatment phase was maintained in follow-up p=0.007 with additional improvement 
in group 3 (p=0.006) at the end of follow-up. Affective distress significant in 
medical therapy groups 1,2 and 4 at the end of treatment was clearly maintained in 
group 1  at six and nine months follow-up p<0.001.Clearly the SSRI medical therapy 
group appeared to be superior in improvement and maintenance of life control in the 
marked reduction in affective distress as might be expected from antidepressant 
medication. In the placebo group life control was not significantly improved either 
at end of treatment or in follow-up and the improvement in affective distress at the 
end of treatment was gradually lost during follow-up as would be expected when the 
placebo effect is lost. No change in affective distress was noted in group 3 (splint 
only) but life control, not significant at the end of treatment, had improved by the 
end of follow-up. Life control and affective distress both improved to some extent in 
group 4 combined therapy. Median scores of all groups during follow-up were 
generally zero, suggesting maintenance of improvement. Despite the above findings 
there was no statistical significance between groups amongst outcome measures. 
Relapse was again not significant between groups with a general 15-20% relapse in 
scores during follow-up. One would again have expected greatest relapse amongst 
the group 2 as the placebo effect wore off but observations were not significant
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between groups.
Amongst all groups; VAS and PPI significantly improved during follow-up p<0.001. 
Pain response rating was maintained with no significant relapse and there was 
significant reduction in pain frequency p=0.029 and interference p=0.024 with no 
significant difference between groups.
9.6.2  Self report questionnaires : MPO. BDI and Kellner Illness attitude
The VAS used for the primary outcome analysis was recorded at three and six 
months post therapy. Interestingly, despite completion of the therapeutic 
intervention, maintenance and indeed slight improvement in scores were recorded 
during this time. The linear trend is clearly illustrated in figures 64,65, tables 
71,72,73. Although the change could be considered a negligible decrease of a mean 
0.5mm, this was nonetheless highly significant F(2)8.93,p<0.001 when analysing all 
groups synchronously.
It appeared to be group 3 , which improved most significantly during follow-up as 
indicated by intragroup analysis,  1.2mm improvement from 3.19(2.22) to 1.99 (1.78) 
in the competers analysis and 0.7mm 4.02(2.39) to 3.37 (2.42) using the imputation 
analysis. One might summise, that patients continued to improve because ,despite 
instructions to the contrary, they had continued with the occlusal appliance therapy 
post treatment phase. However, intergroup analysis suggested there was in fact no 
significant difference in the general level of improvement observed between 
individual groups. This levelling between groups was again reiterated in the analysis 
of relapse scores between groups which were once again non significant between 
groups.
Present pain intensity scores reflects the VAS in exhibiting maintenance and
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continued improvement throughout follow up amongst collective groups, p<0.001.
A report of none or mild pain increased from 154/250 (61.6%) to 168/250 (67.2%) 
by the end of follow-up. The improvement again appeared to be most profound in 
group 3  44/62 (71%) to 50/62 (80.6%) p=0.037 and group 2, 33/63 (52.4%) to 
39/63 (61.9%). However, there was no significance observed between groups.
Pain severity showed slight but significant improvement  .92,p=0.019, whilst
decreased frequency of pain clearly improved by the end of follow-up x2(2)=14.48, 
p=0.001. Similarly interference of life due to pain also improved during follow-up 
Q(2)=7.42, p=0.024. Group 4 appeared to have a significant decrease in frequency %  
(2)=7.10,p=0.029 and group 3 the greatest decrease in life interference Q(2) =7.17, 
p=0.028. However, such differences did not reach significance between the four 
study groups. An overall improvement was therefore observed with no discernable 
distinctions noted.
9.7  Clinical outcome measures
Interincisal mouth opening continued to improve in a similar manner to VAS and 
the verbal reported scores. Amongst all groups there was a significant improvement 
in mouth opening t=(249)6.87,p=0.001, with a clearly linear trend. (Tables 83,84,85, 
figures 74,75).However, these results should be viewed with caution since 
improvement is in the order of magnitude of 0.5-1.5mm and is therefore of no 
clinical relevance. Although small, improvement measured a mean 0.57mm at FU1 
(three months post therapy) and a mean 0.99mm at FU2 (six months post therapy). 
Improvement appeared most significant amongst group 4 patients with an increase 
in mouth opening of 1.52mm by end of follow-up t=(61) -2.37, p=0.021. However, 
as expected inter group analysis found the general level of improvement observed
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amongst all groups was not significantly superior in group 4 but revealed a balanced 
non significance between groups.
A significant element of relapse was noted between the first and second post 
treatment follow up  p<0.001, most notable in groups 2 and 3,p=0.031. However, 
this was once again not verified as a significant finding between groups.
The apparent improvement in mouth opening could either indicate a continued 
improvement in mouth opening over time following cessation of treatment or 
perhaps simply an observation of the regression towards the mean.
The reason for the apparent, continued improvement in outcome may have arisen for 
a number of reasons.
Firstly, it may simply reflect a regression towards the mean. Secondly, it may reflect 
an interaction of underlying factors. During the course of therapy the patient may 
have become aware of and learned to avoid aggravating factors for the condition. An 
increased vigilance or avoidance of exacerbating factors would serve to maintain or 
continue to improve outcome. Alternatively, all patients at the commencement of the 
study were given informed reassurance and advice on self-management techniques. 
Continuation of active self-management may again have led to observed 
maintenance and improvement effect. Finally, one could theorise, that allowing the 
reparative process to commence over the three month treatment phase may have 
been the impetus to initiate a more prolonged or ongoing bio psychosocial 
therapeutic response long term.
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10.0 CONCLUSION
10.1  STATEMENT OF PRINCIPAL FINDINGS -  Summary of results
10.1.1  Primary outcome measure
Overall, the results of the study are positive with all four treatment groups ;SSRI, 
bite guard, SSRI with bite guard, and placebo; showing a significant reduction in the 
primary outcome measure of pain severity (VAS) over the three month treatment 
period, p<0.0001 .The positive response to treatment may occur as a  result of the 
active treatment, a regression towards the mean, the natural history of the disease, 
the therapeutic environment and the strength of the doctor-patient relationship.
There was no significant difference in efficacy observed between the therapeutic 
groups under investigation; SSRI, bite guard, SSRI with bite guard. Therefore, this 
suggests that an SSRI (fluoxetine: Prozac) in combination with a bite guard is 
equally effective to an SSRI or bite guard alone in the treatment of chronic TMD. 
[Hypothesis la]
In comparison to placebo, there was no difference in efficacy between bite guard 
and placebo or combined therapy and placebo. However, there was evidence of a 
significant improvement in >50% pain reduction on the VAS amongst the SSRI 
group compared to placebo, with an effect size of 2.07 (Cl 1.16-3.70). This suggests 
that an SSRI (fluoxetine;Prozac) in daily oral doses of 20-40mg is more effective 
than placebo in the treatment of patients with chronic TMD. [Hypothesis lb]
10.1.1.1 >25% pain improvement at three months
Not surprisingly, all four groups achieved the more attainable >25% improvement in 
pain severity on the VAS at three months p<0.0001. However, the significant 
difference in efficacy found between fluoxetine and placebo at >50% improvement,
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was no longer observed. This suggests the SSRI may achieve a greater reduction in 
pain in more patients than placebo.
10.1.1.2 NNT analysis
The NNT for >50% pain relief (ITT analysis, N=201) were: fluoxetine:4.1 (Cl 2.5- 
17.2) stabilization appliance: 14.8 (Cl 4.3-oo), combined therapy, fluoxetine and 
stabilization appliance;7.8 (3.40-20.7)and for >25% pain relief: fluoxetine:5.6 (Cl 
2.80-76.80), stabilization appliance: 13.1 (Cl 3.80-q o ), combined therapy, fluoxetine 
and stabilization appliance;5.8 (2.90-46.1).The NNT of 4.1 or 5.6 for fluoxetine is a 
similar to previous systematic reviews for SSRI’s in pain indicating an NNT of 
6.7,(Chung,2005).
10.1.2 Patient study characteristics
Patients were predominantly female 76% (191/250); employed 67% (167/250), in 
the third decade of life, mean age 32(SD 9.6) (range 16-55).These findings were 
comparable to previously reported TMJ clinic populations, (Helkimo, 1974, 
VonKorff et al,  1988, Dworkin et al, 1990, List et al, 1999, Truelove et al, 2006). 
Demographic and epidemiological features of the study cohort were consistent with 
the patient population seen within secondary or tertiary TMJ clinics. [Hypothesis 2] 
TMD pain was typically described as a unilateral 72% (180/250), constant 74% 
(185/250), dull ache 64% (161/250), discomfort 54% (137/250), with occasional 
sharp episodes 40% (99/250), of approximately three years duration, mean 3.3 
(SD4.5) years (range (3 months-32 years). 26% (66/250) reported dental treatment 
to be a precipitating factor whilst frequently reported provoking factors included: 
chewing 77% (192/250), yawning 76% (191/250), biting 66% (164/250) and 
emotional tension 54% (134/250).
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Sleep disorders related to pain, included prevention of sleep 45% (113/250) and 
disturbance of sleep 46% (117/250). Co-morbid recurrent chronic pains included; 
headache 61% (153/250), neck ache 50% (125/250), backache 48% (121/250), 
migraine 32% (82/250) and abdominal pain 30% (74/250).
Duration, location and character of TMD pain are similar to those patients 
presenting to other secondary and tertiary TMJ clinics, [Hypothesis 3], 
(Ohrbach,1995, Dworkin and LeResche,1999, LeResche and Von Korff, 2005, 
Truelove et al, 2006)
10.1.3  Secondary outcome measures summarised
Secondary outcome measures also showed significant amelioration amongst all 
groups. This included: self report verbal rating scales of present pain intensity 
(p<0.001), frequency (p<0.001) and interference (p<0.001).This was also observed 
in the pain and psychosocial self report pain questionnaires, notably MPI: severity, 
interference, affective distress and improved life control together with MPQ: VAS, 
PPI, total, sensory and affective components. Clinical outcome measures revealed 
significant improvement in interincisal mouth opening, character of TMD pain and 
other co-morbid chronic pains.
10.1.3.1  Outcome predictors
Logistic regression analysis of outcome predictors suggested a decreased chance of a 
successful >50% pain improvement at three months, in those with a longer duration 
of TMJ pain OR=0.84 (0.71-0.99), presence of co-morbid backache at the initial 
consultation OR=0.36 (0.38-0.94), higher the score rating of: Kellner,disease phobia 
OR=0.64(0.38-0.94); MPI punishing response of significant family and friends 
OR=0.63 (0.41-0.99) and increased social activities OR=0.37 (0.18-0.76) at initial
486Ch a p t e r  x c o n c l u s io n
presentation. Positive predictors of outcome included initially high scores in MPI 
general activity level OR=3.42 (1.09-10.13), clinical VAS OR1.4(1.12-1.77) and 
abdominal pain OR=3.66(1.22-11.0).
For >25% improvement in pain at three months, only initially reported MPI; 
support of significant family or friends OR=1.26 (1.00-1.59) and outdoor activities 
OR=1.40 (1.01-1.94) were significant positive predictors of outcome.
10.1.4 Pain severity and influence on life.
A significant improvement in PPI (intensity) (p<0.001), interference (p<0.001) and 
frequency (p<0.001) of TMD pain was recorded by the clinician for all groups. 
[Hypothesis 4a].This was consistent at all time points of the study; four, eight and 
twelve weeks with no significant difference between groups.
A significant improvement in ‘self-recorded’ patients perspective of pain was 
recorded for all groups, MPI severity (p<0.001), interference (p<0.001) and affective 
distress (p<0.001) with an increased level of control in life (p<0.001). Inter group 
analysis revealed no significant difference between groups. MPQ total, sensory and 
affective components, VAS and PPI all showed significant improvement (p<0.001) 
with no significant difference between groups. [Hypothesis 4b]
10.1.5 Depression
A significant improvement in depression was recorded, using the BDI, on 
completion of the study, p<0.005, with no significant difference between groups. 
[Hypothesis 4c]
There was a reduction from a median score of 7.00 (25th and 75th percentiles 3.00- 
13.00) at the start of therapy to 5.00 (2.00-12.00) on completion of therapy. This 
indicates the majority of patients were clinically non-depressed throughout
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treatment. However, there was a broad variation in scores with come patients 
classified as suffering from severe depression at baseline. This was investigated 
further in the post hoc sub-group analysis.
10.1.6 Illness attitude and behaviour
A significant reduction in Kellner, hypochondriacal beliefs and illness attitude was 
observed for all groups, p<0.05, with no significant difference between 
groups.[Hypothesis 4d] Although the SSRI group appeared to have the most 
significant reduction in hypochondriacal beliefs this was not significant in inter 
group analysis.Kellner, disease phobia was not significantly reduced in any group.
10.1.7 TMD signs and symptoms
A significant improvement in the signs and symptoms of TMD were recorded in all 
groups on completion of the study. [Hypothesis 5a, 5b]
There was a significant reduction amongst all groups in TMJ pain, p<0.001 and 
muscle discomfort, p<0.05. A reduction in TMJ pain was not apparent in the SSRI 
group, p=0.08 but this did not reach significance in intergroup analysis. Temporalis 
muscle pain only decreased significantly in the splint only group p<0.005 but again 
this did not reach significance between groups. The combined splint and medical 
therapy group however showed the most significant reduction in reported masseter 
muscle discomfort which was significant between groups, p=0.008 and may indicate 
a synergistic therapeutic response.
The dull and sharp pains of TMD had both significantly reduced, p<0.001, by three 
months. However, in intergroup analysis the dull ache had reduced most 
significantly in SSRI (p<0.001), combined therapy (p<0.005), placebo (p<0.05) but 
not in splint only (p=0.38) which was a significant difference between groups
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(p=0.008). In addition there appeared to be an increase in reported facial, ear and 
tooth pain in the splint only groups which was significant between groups, (p=0.002, 
p=0.003, p=0.009 respectively).This unusual finding may be related to an increased 
awareness of the face, preauricular region and teeth in those wearing an occlusal 
appliance.
Interincisal mouth opening significantly improved with a clearly linear trend and no 
significant difference between the four observed groups.
10.1.8 Co-morbid pain conditions
A significant improvement in co-morbid pain conditions were recorded on 
completion of the study including; headache, migraine, neck ache, backache and 
abdominal pain, p<0.001, with no significant difference between groups.
[Hypothesis 5c, 5d] 
10.1.9 Subgroup analysis summarised
Although not significant in inter group analysis, individual groups show a trend 
towards a more significant improvement with medication in depressed categories 
and a more significant improvement in non-depressed categories in the placebo and 
splint alone groups. Results from the study therefore might tentatively suggest 
depression has an influence on several aspects of TMD.  [Hypothesis 6a] 
Unexpectedly, depression was unrelated to the duration of pain but was related to a 
slightly older age group. The depressed group had a significantly higher proportion 
of concomitant pain conditions at baseline which did not decrease as significantly as 
the non-depressed, post treatment. They also had a higher incidence of self-reported 
prevention and disturbance of sleep p<0.01 and higher emotional initiating p<0.05 
and provoking factors p<0.001 for TMD. However, other co-variates may have
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influenced this finding; psychosocial measures suggested increased hypochondriacal 
beliefs and disease phobia, whilst MPI suggested decreased life control and 
decreased activities away from home, together with an increased punishing response 
from significant family and friends amongst the depressed group.
Clearly, as in all pain conditions, depression has an interesting relationship to TMD 
which, together with sleep, psychosocial factors and particularly co-morbid pain 
conditions requires closer investigation.
There was no significant difference in pain improvement between those patients 
with high or low initial pain scores. [Hypothesis 6b] However, for those with 
initially high MPI pain scores, there was a trend for a greater reduction in pain in 
those with a high initial MPI pain score compared to those with a low initial MPI 
pain score. However, this was not confirmed by inter-group analysis. BDI improved 
significantly in low initial pain scorers but not high initial pain scorers. Illness 
attitude only improved in high pain scorers whilst headaches only significantly 
decreased in those with low initial pain scores p<0.008.
Clinical and pain history characteristics at baseline did not separate treatment 
responders from the non-responders. [Hypothesis 6c] However, demographic and 
psychosocial factors were indicative of response. A higher percentage of no 
responders were referred from the tertiary care sector suggesting more complex or 
recalcitrant TMD cases unrelated to the duration of pain. Interestingly, a higher 
percentage of divorcees were noted to be non responders the reason for this was 
unclear. Similar to the depressed category, an uncaring attitude or punishing 
response, from family and friends was higher amongst non-responders (p<0.036). 
However, dissimilar to depression, increased frequency of participation in social
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activities was higher in non-responders (p<0.036). These descriptive trends would 
certainly suggest the need for closer investigation of subgroup covariates.
10.1.10 Adherence summarised
There was a significant difference between adherence to splint wear in the occlusal 
appliance only group compared to the combined occlusal appliance and medication 
group, x2 (1) 4.78 p=0.029. [Hypothesis 7] However, there was no significant 
difference between adherence to medication in the SSRI, placebo and combined 
therapy groups. The time scale of withdrawal from treatment was not significant 
between groups. Within groups the predominant reason for withdrawal was; not 
wanting to receive splint therapy (p=0.006) or acquiring a splint and not returning to 
the study (p<0.001)
10.1.11 Adverse events summarised
There was a significant difference between SSRI and placebo medication in adverse 
events reported following the initial treatment phase at four weeks. This occurred in 
both SSRI alone OR= 2.8(1.0-7.7) and SSRI with occlusal appliance OR=2.7 (1.0- 
7.5). However, there was no significant difference in adverse events reported during 
the subsequent eight and twelve weeks of therapy. [Hypothesis 8] The most frequent 
reported adverse event was nausea in the SSRI group 5/48 (10.2%) and combined 
therapy group 8/48 (16.7%). Walker,  1998, reported a similar finding of nausea in a 
TTH study of SSRI 3/12 (25%).
10.1.12 Follow-up post RCT
Improvement occurred not only during the course of the three month 
treatment period but was maintained throughout the six and nine month follow 
up phase. [Hypothesis 9]
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Despite the discontinuation of treatment at the end of the three months, maintenance 
and amelioration in TMD pain related scores was observed amongst all four groups. 
All groups showed a continued improvement in interincisal mouth opening p<0.001 
and VAS p<0.001 during the follow-up phase. Similarly, PPI  p<0.001, frequency 
p=0.001 and interference p=0.024 significantly improved during follow-up. 
Significant improvement was observed in MPI severity p<0.001, interference 
p<0.001, affective distress p<0.001 and increased level of life control p<0.00 when 
all groups were analysed together. Within the individual groups affective distress 
was only significantly maintained in the SSRI group during follow-up p<0.001. Life 
control only significantly improved in the SSRI group p=0.007 at the end of 
treatment phase and this effect was maintained during follow-up, whilst in the splint 
group although there was no difference after treatment a significant improvement 
seemed to appear, p=0.006, during follow-up. These observations were however not 
significant between groups.
10.2  VALIDITY OF STUDY RESULTS -  STRENGTHS AND WEAKNESSES
The quality of a trial and the elimination of bias relies on clear reporting of design, 
clinical conduct and coherent analysis, (Jiini et al, 2001, Altman et al, 2001).
Internal validity is required for external validity and relates to minimizing 
systematic error or bias in: selection, performance, attrition and detection, between 
groups of patients within clinical trials, (Jiini et al, 2001).
10.2.1 Internal validity
10.2.1.1  Selection bias
Firstly, avoidance of selection bias relates to generation and concealment of 
randomised allocation to comparative groups (Altman and Bland, 1999). This was
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achieved in this study by computer generated block randomisation sequence and 
concealment from study personnel, as explained in Methods, Chapter IV. 
Stratification of randomisation can be considered when evidence suggests that 
particular characteristics are predictive of outcome, (Themeau, 1993, Keman et al, 
1999). However, TMD is multifactorial, making it complex to categorise specific 
features. Knatterand, 2002, suggest that with more than 40 study participants, there 
is a good probability of achieving balance without stratification. With the numbers 
allocated per group in this study and the evidence that there were no significant 
differences between the baseline variables, as indicated in Chapter VI, it can be 
assumed that there was a good probability of balance between the four groups 
without additional stratification. Avoidance of selection bias is therefore a strength 
of the study.
10.2.1.2 Performance bias
To prevent performance bias the subjects receive equivalent care apart from the 
treatment under investigation (Jiini et al, 2001). In this study, no additional care was 
knowingly given preferentially to one of the four treatment groups. However, those 
receiving combined therapy were naturally and unavoidably exposed to increased 
clinical time and attention, which could be considered a study weakness. 
Nevertheless, this did not appear to improve outcome.
10.2.1.3 Attrition bias
To avoid attrition bias, care is taken in dealing with protocol deviations and loss to 
follow-up, (Jiini et al, and 2001). To avoid bias, ITT and imputation analysis were 
reported, rather than only completer’s analysis, as previously discussed, in Chapter
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VI. Protocol deviations were reported to explain attrition, in Chapter IX. Avoidance 
of attrition bias could therefore be considered strength of this study.
10.2.1.4  Detection bias
This only occurs if those recording outcome are influenced by the knowledge of 
patient allocation, which is avoided by blinding the assessor and maintaining 
concealment, (Noseworthy et al, 1994). Concealment or double blinding was 
maintained with regards to drug and placebo. This was achieved by administrative 
and nursing personnel being responsible for the allocation and concealment of drug 
identity from the clinician. The latter dispensed the bottle of tablets to the patient but 
was unaware whether the bottle contained drug or placebo.
However, it was not possible to remain blind with regards to which patients were 
receiving splint or combination treatment, since the clinician providing treatment 
and assessing outcome and adverse effects were one in the same person. This may 
be considered a slight weakness of the study.
10.2.1.5. Multiplicity and multiple outcomes (Type 1 errors)
Multiplicity refers to the plethora of possible data comparisons in a RCT (Altman et
al, 2001). Multiple comparisons or analysis of the same data reduce statistical power
and increase the risk of false positive or type one errors, when a difference attributed
to the intervention is more probably due to chance, (Altman et al, 2001). Sources of
multiplicity may arise from numerous factors including: the use of multiple outcome
measures, multiple intervention groups, repeated measures over time and subgroup
analysis, (Peduzzi et al, 2002, Pocock et al, 2002). All varieties of multiple outcomes
have obviously been utilized in this study, which potentially could have been
considered a study weakness. However, as in most clinical trials, multiple outcomes
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are required. An individuals response to treatment is multifaceted and clearly within 
a RCT analysing a range of aspects is important, (Peduzzi, 2002). Secondary 
outcomes such as improvement in interinscisal mouth opening or improvement in 
other concomitant chronic pains, introduces extra variability. Nevertheless, 
secondary analyses are important to our understanding of the condition even though 
it is a less direct measure of effect, (Moja et al, 2005).
Analysing data at different time points and using a range of rating scales increases 
the number of comparisons. This is clearly observed in the analysis of this RCT, 
where data was analysed not only at treatment completion but at monthly intervals 
throughout treatment and three month intervals post treatment follow-up. 
Additionally a vast range of rating scales were employed. The mass of findings 
produced can result in misleading findings of significance occurring by chance 
(Altman et al, 2001)
Prespecified and prioritised outcome measures are therefore required to avoid some 
of the inherent problems of multiplicity from post hoc data interpretation (Proschan 
and Waclauriw, 2000, Peduzzi et al, 2002). The trial should be powered and 
monitored on the basis of a single primary outcome variable with all other outcomes 
defined as secondary or tertiary, (Peduzzi et al,2002). This advice was followed in 
this RCT where there was a clear primary outcome measure of >50% pain 
improvement on the VAS and all other outcomes classified as secondary, hence 
reducing the risk of type one errors and increasing the studies strength.
10.2.1.6  Treatment sample size (Type 2 errors)
Small sample sizes, with insufficient power to detect important differences between 
drug and placebo, may lead to false negative, type two errors, (Altman et al, 2001). 
Kjaergaard et al, 2001, suggest trials of less than 30 subjects per group artificially
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inflate estimates of treatment effect. In a systematic review of SSRI in migraine and 
TTH the median sample size for randomised groups was 50 (interquartile range 39- 
55). However, the mean drop-out rate was 20%, ranging from 20% to greater than 
40%, so the effective sample size was in fact smaller,(Moja et al,2005).
The number of individuals exposed to a drug should obviously be kept to a 
minimum, since although potentially beneficial the drug may also be in-active or 
indeed harmful. Studies using active comparators tend to require larger numbers of 
patients than placebo controlled trials possibly exposing more patients to potential 
harm, (Emanuel and Miller, 2001). Empirical evidence suggests placebo controls 
reduce the number of symptomatic individuals in a RCT producing an inverse 
relationship between sample size and detectable population effect size, (Linde et al, 
2003, Leon, 2001). However RCT, whether large or small, if adherent to strict 
criteria yield high quality results close to the average for treatment studies, (Juni et 
al, 2001).
In this placebo controlled TMD study the initial numbers per group were 62 or 63 
and at the end of three months treatment were 38 to 43. Sample size could perhaps 
have been even larger to detect more significant differences. The majority of patients 
withdrew at baseline. This may have been avoided by ensuring patients with 
minimal pain at baseline were not included in the study and further efforts made to 
decrease attrition from the study at baseline outset, to increase power and design 
sensitivity.
10.2.2  External validity -  strengths and weaknesses in relation to other studies
External validity, otherwise termed ‘generalisability’ relates to the ‘applicability’ of 
results to other situations or clinical settings and is dependant on the provision of 
adequate study information (Altman et al, 2001).
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Care was taken throughout study reporting to provide as much relevant information 
with regards to the study cohort as possible. The demographic and epidemiological 
features of the study cohort were comparable to the worldwide TMD clinic 
population, suggesting results could be extrapolated to a broader clinical setting, as 
discussed in Chapter VI.  Future research studies should however utilise the 
RDCTMD criteria for patient assessment, which are now used internationally and 
have been validated for TMD research, (Dworkin and LeResche, 2001).In defence 
of the approach undertaken in this study, the assessment did fulfil the criteria at the 
time of study design of a dual axis approach examining both the clinical history and 
examination together with psychosocial measures. Use of the RDCTMD in the 
future, would however allow direct comparison of subgroups with other worldwide 
cohorts of TMD patients.
10.2.2.1  Study design structure- in relation to other studies
This was a four armed (factored), prospective, parallel design, double blind for 
medical therapy, RCT. A cross over design, utilising the same subjects twice, has 
the advantage of eliminating the between patient factors which can cause 
considerable variation in pain perception and reporting,(Louis et al,1984, Jones 
Kenward,1989, Ratkowsy 1993,Senn, 1993) This decrease in variance and increased 
statistical power reduces the number of patients required,(Louis et al, 1984). This 
type of design was employed in the well constructed, double blind RCT 
investigating the efficacy of Velafaxine in AFP, incorporating an interposed two 
week wash out period, (Forssell et al,2004).
However, cross over design is not generally recommended for antidepressant 
medication, within the field of depression, since the favourable response may persist 
for months after discontinuation of the treatment, (Prien, 1994). This ‘carry over
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effect’ may result from the prolonged action of medication or metabolites, change in 
the central or peripheral nervous system, behavioural or psychological response over 
time and hence altered response to subsequent treatment, (Moja et al, 2006). Such 
factors may also relate to the treatment of TMD pain and parallel group design as 
utilized in this RCT hence avoids concerns related to the ‘carry-over effect’ and is 
hence a strength of the study design.
10.2.2.2 Adherence measures -  in relation to other studies
No venous blood samples were collected at treatment visits to determine serum 
levels of fluoxetine and its metabolite norfluoxetine, as was undertaken in the study 
of Venlafaxine in AFP (Forsell et al 2004). Although a useful measure of adherence, 
this may also have disadvantages since patients generally dislike extra blood tests 
which additionally would have increased laboratory expenses.
Alternatively, MEMs may be used or diary record cards to indicate medication 
adherence as discussed in chapter IX.
10.2.2.3 Adverse effects -  in relation to other studies
The same investigator assessed adverse events and efficacy outcomes. However, this 
discrepancy was also noted amongst other SSRI trials in TTH and migraine, (Moja 
et al, 2005).In future studies extra personnel would need to be employed to assess 
adverse events and efficacy outcomes separately to avoid any potential bias.
10 3 RFSITFTS IN THE CONTEXT OF RELATED RESEARCH
This study has not clearly indicated a significantly measurable difference in efficacy 
between medical and physical therapies either alone or in combination.
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Failure to demonstrate a difference between two treatments is not necessarily proof 
of equivalent effect for the intervention under investigation, (Hotopof et al, 1997, 
Jones et al, 1996). Regardless of outcome, the results of a RCT have an important 
application in clinical research when interpreted in the context of earlier studies, 
related research and existing evidence, (Clark et al,  1998).
10.3.1  Medical therapy in TMD
Although there are no previous studies published comparing SSRI medical therapy 
with splints there have been other studies assessing the efficacy and tolerability of 
SSRTs in the treatment of tension type headache (TTH) and migraine, analysed in a 
systematic review,(Moja et al, 2005). This is particularly pertinent, since long-term 
studies suggest TTH to be closely related to TMD, (Egermark et al, 2001, Magnusson 
et al, 2005,). The similarities are currently being investigated, (Orbach,2006).
Four studies compared fluoxetine versus placebo, (Adly et al,1992, C d’Amato et 
al,1999, Polisca et al, 1992 and Steiner et al, 1998).Three studies compared 
fluoxetine versus amitriptyline, (Oguzhanoglu et al, 1999,Walker et al,1998, 
Krymchantdowski  et al, 2002,).Reassuringly, similar to the response observed in 
this current RCT, Moja et al, 2005, found SSRFs only to have similar efficacy to 
placebo in the treatment of migraine headache over the two months of treatment.
There is some evidence that SSRI’s are well tolerated with respect to minor adverse 
events but this did not have an impact on total number of dropouts in this RCT of 
TMD or earlier studies, (Moja et al, 2005). Bank, 1994 and Langermark and 
Olessen, 1993 in studies of SSRI in migraine and tension type headache reported a 
20% or more loss to follow-up. Greater than 30% loss was reported (Steiner,  1998, 
Walker et al 1998 and Krymchantowski, 2002); whilst greater than 40% was
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recorded by (Adly 1992, Landy, 1999.) This relates favourably to the 18% reported 
in this TMD study.
It has been shown that during the first part of treatment patients are more tolerant of 
adverse events because of the perceived benefit of taking medication whilst three 
months ensures that the patient gains sufficient clinical benefit, (Moja et al, 2005). 
The issue of long-term treatment of greater than three months could be investigated 
further in TMD. However, the recommendation that antidepressants are prescribed 
for six months is based on evidence measuring their pharmacological effect in 
depressed patients and not for the treatment of chronic pain, (Paykel and Priest,
1992, Montogomery et al, 1988, Guaiana et al, 2004).
In addition, length of follow up could be extended. Moja et al, 2005, recommends a 
twenty four week length of follow up suggesting twelve weeks is too short to 
achieve an effect. Further follow up of this particular cohort of TMD patients could 
be undertaken, particularly in relation to relapse and the use of concomitant 
analgesics. The relative probability of relapse can only be investigated by 
lengthening the period of follow-up to 5years, ten years or perhaps beyond.
Other trials have used TCA instead of SSRI. When compared to TCA, SSRI’s were 
less efficacious in the treatment of TTH. TCA significantly reduced headache 
duration by 1.26 hours/day and marginally reduced headache indices but the 
reported adverse events were greater. It was reported that results were based on short 
term trials so results may not generalise to longer term treatment beyond three 
months. However, this is an interesting finding since previous studies using the 
TCA, amitryptyline and dothiepin in mixed chronic facial pain both showed a 
favourable reduction in pain (Feinmann and Harris, 1984, Sharav et al, 1987). 
Although, in a more recent study of facial pain, Amitryptyline was found to have no
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significant reduction in pain severity but significant reduction in the perception of 
stress, (Raigrodski et al, 2001).
The differences in selectivity of SSRI and TCA could be related to differences in 
efficacy but the mechanisms of efficacy in TMD, orofacial and headache prevention 
and pain relief remain unclear, (Ansari,2000). Research is required to establish and 
more fully understand drug dosage response in orofacial and TMD pain particularly 
in relation to the length of maintenance and relapse prevention.
Amitryptyline or an alternative TCA, with less antimuscarinic side effects, could 
certainly be considered as an active comparator in terms of clinical efficacy in future 
TMD studies. This suggestion was also put forward for patients with chronic TTH 
(Moja et al, 2005).
The effect of SSRI’s in pain is not due to a direct antidepressant effect, (Sindrup and 
Jensen, 2000). Moja et al, 2005, suggests avoidance of the confounding effects of 
antidepressant treatment could be achieved by comparison of the SSRI with a non­
antidepressant prophylactic drug or non-pharmacologic preventive treatment. This 
was in fact the approach undertaken in this research study comparing SSRI with a 
bite guard and combined therapy. An RCT which evaluated the efficacy of an SSRI 
versus CBT, in a group of mixed chronic facial pain and TMD, showed pain 
reduction at three months with fluoxetine compared to placebo which was 
maintained on cessation of drug therapy, (Harrison et al,  1997).However, a further 
RCT evaluating an SNRI, venlafaxine, did not find a significant reduction in pain 
severity but moderate pain relief with decreased need for analgesic consumption 
amongst the active group. Unfortunately, this current TMD study did not quantify or 
document additional analgesic use during the three month course of treatment.
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No studies were identified comparing SSRI with a drug other than an antidepressant 
or with a non-pharmacological physical treatment as utilized in this study of 
physical splint therapy versus SSRI medical therapy.
10.3.2  Occlusal appliance therapy in TMD
Numerous studies have investigated the use of bite guards in the treatment of TMD. 
Since commencement of this RCT, several systematic reviews and met-analyses 
have been published in the field concluding that there is insufficient evidence to 
support the role of occlusal appliances in TMD, (Raphael and Marbach, 1997, Dao 
et al, 1998). Dao et al, 1998 suggested until more is known of the aetiology and 
natural history of TMD, splints were useful adjunctive therapy. Forsell et al, 1999, 
in an extensive systematic review concluded that although evidence for occlusal 
adjustment was lacking, splints showed some benefit in TMD. Kriener et al, 2001, 
assessing 10 occlusal studies, optimistically concluded there was sufficient evidence 
to support splint use in the management of localised myalgia and arthralgia. 
However, the majority of results do not justify definite conclusions about efficacy of 
splint therapy, (Raphael, 2001, Ekberg and Nilner, 2002, Turp et al, 2004, Forssell,
2004). Current opinion suggests there is weak evidence that stabilization appliances 
are more effective than other splints in reducing muscle and joint pain, (Ekberg et 
al,2003, Magnusson et al, 2004, Wilkinson,2005). Al-Ani et al, 2006, however, in a 
Cochrane systematic review, did not find significant evidence to confirm whether 
stabilization splints can reduce pain caused by painful TMD.
This TMD study has also not been able to provide any further conclusive findings. 
Future research, into splint usage in TMD could incorporate a waiting list control 
group but more importantly focus on which target subgroups benefit most from 
splint therapy. In particular, level of bruxism and sleep patterns could be analysed as
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covariates. In fact, much research is already being done in relation to TMD, sleep 
bruxism, splint therapy and antidepressant medical therapy (Lavigne et al, 2005).
10.4  CLINCIAL SIGNIFICANCE -  MEANING OF THE STUDY
Clinical significance is defined as a return to normal functioning, (Jacobson et al, 
1999). Apart form effect size and NNT, group differences provide limited 
information on individual response to treatment and clinically meaningful 
improvement in symptoms, (McQuay and Moore, 1999).
At the end of the three month treatment, a statistically significant overall 
improvement in the VAS of 2.5cm (5.77cm(SD2.29) to 3.25cm(SD2.41),p<0.001) 
for completers or 1.7cm based on an imputation analysis (5.77cm (SD2.29) to 
4.06cm (SD2.57), p<0.001 ), may not lead to a return of normal function for specific 
individuals. Even with a more direct clinical measure of interincisal mouth opening, 
a statistically significant improvement (p<0.001) of 2.81mm (38.81(SD 9.36) to 
41.62(SD9.22) for completers and (p=0.018) 1.38mm from 38.90(SD9.35) to 
40.28(SD9.52) based on imputation analysis, may not again necessarily imply 
clinical significance.  Reliable change in a patient’s condition can be difficult to 
quantify. To demonstrate ‘recovery’ the statistical change in the condition must be 
within ‘normal range of function’ but a statistical change in a condition such as 
TMD may still render the patient ‘dysfunctional’, ‘improved but not recovered’. 
Therefore discrete cut-off points can misclassify individuals into false positive, 
falsely recovered.
There is diversity in the presentation of TMD even within the normal population.
Patients range from the completely healthy, functioning, asymptomatic, to
functioning symptomatic, mildly dysfunctional to moderate or severe dysfunctional.
For this reason subgroup analysis was performed to try to determine if there were
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any significant differences in outcome according to level of depression, level of pain 
severity at base line and characteristics of those categorised as responders to therapy. 
Although trends were demonstrated, that could be investigated further, no clear 
indicators were proven.
Ultimately, clinical significance of treatment relates to the qualitative satisfaction of 
the patient with therapy, quantitative decrease in pain and increased functional 
ability. These may vary subjectively for a particular group of patients or between 
individual patients.
Information on benefit-to-risk ratio for a specific individual is derived from research 
data using NNT which incorporates baseline readings with therapeutic effect,
(Altman, 1997). Transposing the results of research to different clinical settings 
might be problematic when patient characteristics differ considerably form the 
typical trial participant. Hotopof et al, 1999 suggested patients with headaches 
should be studied in real life situations and again this could be extrapolated to the 
condition of TMD. The potential benefit and harm of an intervention must also be 
considered in the light of the patients preferences for therapy, (Altman et al, 2005).
10.4.1  The individual TMD patient
Customised clinical treatment and care pathways have always seemed an anathema to 
the empathetic clinician. Nowadays, there is almost an obsession with developing rigid 
care pathways, management protocol and guidelines. However, one must never 
overlook the obvious. Patients are distinct individuals who cannot be 
compartmentalised into organised categories. This is especially true when dealing with 
a condition such as TMD where aetiology is currently deemed complex and 
multifactorial. At present, the clinician must rely on evidence based medicine derived
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from systematic reviews of RCTs, together with clinical experience and intuition, to 
gauge the most appropriate treatment for the individual patient.
Randomisation as a standard design feature of clinical trials is aimed at determining 
treatment effect for a particular disease or condition within a population sample, 
(Altman et al, and 2001). Knowing how to apply study findings to individual 
patients is more complex however since randomisation does not always lead to 
unbiased estimates of treatment effect when important, yet unrecognised covariates 
are neglected, (Altman et al,2001, Liu et al,2005). In an attempt to address this issue, 
Ford and Norrie, 2002, examined the use of covariates in the potential benefit or risk 
for an individual subject exposed to a particular treatment. Pocock et al, 2002, 
examined baseline data, subgroup analysis, covariate-adjusted analysis and baseline 
comparisons; whilst the impact of population heterogeneity on estimated treatment 
effect was predicted using a set of simulated logistic regression models,(Lui et al,
2005).
Research suggests, treatment beneficial in some subjects may indeed be ineffective 
or even harmful to others with specific characteristics, and clinical response to 
treatment and drug metabolism may be influenced by environmental and biological 
factors,(Liu et al,2005).Environmental factors may include; climate, smoking and 
alcohol consumption whilst biological factors may include: genetics, age, gender, 
race and ethnicity.
Individuals may have significant differences in rate of drug metabolism, clinical 
response to drug and side effects, (Burroughs et al, 2002). 35% of the population do 
not respond to p blockers and 30% do not respond to statins, (Tanne, 1998). Modem 
biomedicine and advances in human genomics may distinguish genetic susceptibility 
to drug treatment, an enhancement or reduction in sensitivity. (Liu et al, 2005). 
Genetic polymorphism has been found to influence positive and adverse reactions to
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antidepressants and antipsychotics leading to suboptimal treatment in individual 
patients, (Kirchheiner et al, 2003). With genomics, rather than waiting weeks to 
determine whether a drug is effective for a particular patient, the most appropriate 
treatment can be implemented immediately, (Cardon et al, 2000). This may allow 
choice of drug treatment specific to the patient’s genotype, potentially identifying 
the right drug and dose for each individual, (McCarthy and Hilfiker, 2000)
Predicting drug response could potentially save time, money and even lives.
Racial and ethnic variation also affects response to medication due to difference in 
metabolism for example; codeine is more effective in East Asians than Caucasians, 
(Burroughs et al, 2002). In another study, using the SSRI, paroxetine, to treat mood 
and anxiety disorders, Hispanics and Asians had a lower response rate. However, 
Asians had the highest full response and Hispanics the lowest. The latter also 
showed the higher placebo response but adverse effects were similar across groups, 
(Roy-Byrne et al, 2005). With antipsychotic medication white Caucasians required a 
higher dose of medication than Asians and Hispanics to achieve similar blood levels, 
(Burroughs et al, 2002).
Similarly, heterogeneity in the population including genetic polymorphism may 
influence an individual’s response to TCA and SSRI in the treatment of TMD. 
Philips et al, 2001, conducted a study to show the clinical implications of gender in 
acute TMD, concluding that biopsychosocial differences amongst gender would 
suggest that certain treatments are more beneficial between respective males and 
females. In recent years, research has also suggested there may be a genetic 
component to TMD, (Feng et al, 2004).
Individual variation in the characteristics of the condition and coping strategies may 
also be relevant in TMD. Raigrodski et al, 2001, investigated the effect of 
amitryptyline on bruxism in a four week cross over study design and found that the
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drug did not decrease pain intensity but was useful in the management of the 
perception of stress levels associated with sleep bruxism.
Molina et al, 2000, analysed the profile of TMD bruxers and TMD non bruxers 
amongst five year consecutive referrals. The chief complaints of  joint noises, facial, 
TMJ, head and cervical pain were recorded in both groups. However, severity of 
bruxism behaviour dictated an increased need and utilization of health services 
including increased consultations, increased occlusal splint usage and increased need 
for mediation; analgesics, muscle relaxants and antidepressants. The study 
confirmed that pain is the major complaint of TMD patients with bruxism and 
reinforces the view that different subgroups of TMD and severity levels of bruxism 
exist. Differentiation of subgroups by questionnaire assessment of bruxism severity 
was suggested in order to direct the approach to therapy.
Results from the subgroup analysis of this study might tentatively suggest 
depression has a role to play in response to therapeutic outcome in TMD. 
Rammelsburg, 2003, in longitudinal studies reported muscle disorders, classified 
using the RDC to be mainly chronic or fluctuating pain conditions with 31% 
remission. Psychopathology appears to be associated with muscle disorders rather 
than disc or joint disorders (Kight, Gatchel and Wesley, 1999).
A disturbance in sensory function amongst TMD patients’ has also been reported, 
(Svensson et al, 2005).
Gender, genetic components, altered sensory function, level of bruxism, associated 
psychopathology and depression are just a few of the examples of the plethora of 
individual variables and confounding factors in TMD. The age, duration of pain, 
previous contact with health care services and therapies received, health locus of 
control, past history and experience of pain, lifestyle and daily commitments, 
psychological behavioural and coping strategies are but a few of the endless list
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which all impact on the individuals ability to respond to the therapy provided at a 
particular point in time.
1 0 .5   R E S E A R C H   S T U D Y   I M P L I C A T I O N S   F O R  C L I N I C I A N S  A N D  
P O L I C Y   H O L D E R S
The research study implies that a significant improvement in outcome measures is 
achievable in TMD patients provided with therapy within a research study, 
conducted in a specialist centre. The cohort receiving care had suffered from TMD 
for a mean 3 years yet the condition was amenable to improvement. This 
improvement was then sustained for up to a year, even after discontinuation of 
therapy, whilst patients were maintained under review within the research study. 
What remains unclear is which interventive therapy is the most beneficial.
Although all groups improved significantly, SSRI may have produced a larger effect 
than placebo. For the majority of indices measured the therapeutic groups appear to 
be equally effective to placebo; which may indicate a regression towards the mean, a 
natural history improvement amongst the cohort of individuals being observed or 
mainly a placebo response related to the intervention, manner and environment in 
which the intervention was provided and the patient-clinician interaction established 
during the study period.
The implication for the clinician is that improvement, to some extent, is independent 
of the actual therapy provided but may instead rely more fundamentally upon the 
relationship established between patient and clinician. However, such findings could 
engender complacency in planning management strategies. Such an assumption is of 
course, also potentially dangerous since differential diagnosis or underlying 
pathology could be overlooked. The existence and diagnosis of secondary pathology 
was demonstrated within this study population. Uninformed or bland reassurance
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could be detrimental in prolonging the correct diagnosis or delaying appropriate 
treatment. However, well informed reassurance and explanation from a specialist, 
following a careful history and examination, reduces fear and anxiety and therefore 
increases the patient’s ability to accept the diagnosis. The doctor-patient relationship 
can therefore has a very positive influence, in providing an active impetus to the 
healing process. This in turn acts as a foundation upon which the patient can then 
more readily collaborate with the clinician in learning coping strategies and self-care 
management.
The implications for policy holders also requires consideration. Referral of patients
to a specialist centre, who on average had experienced pain for a mean 3 years,
showed significant improvement in their condition which was maintained, at up to a
year post therapy, when reviewed within a specialist environment. Superior efficacy
of medication, splint or combined therapy in the management of TMD was not
elucidated. This does not necessarily suggest equivalence but also does not give a
clear indication as to the most appropriate therapeutic approach. One must therefore
consider which intervention was the most cost effective in the short and long term
and also consider the profound placebo effect of specialist intervention.
An estimate of costs indicates a very similar economic outlay. A monthly supply of
Fluoxetine is £30, hence £ 90 when given for three months. Alternatively, laboratory
fees and impression material for a hard acrylic bite guard are similar, in the region of
£90. Both groups of patients require regular follow-up, the latter requiring more time
consuming fitting and adjustment of the appliance. A simple cost analysis does not
therefore favourably distinguish one group from another.
All groups revealed significant improvement in the short-term at the three month
completion of therapy and also during the six and nine month follow up. Long-term
follow up at 10 years is being considered for this study and would be a useful tool to
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explore if either group show a significant prolonged therapeutic effect. In the 
meantime, the second consideration is not necessarily what treatment should be 
provided but by whom should patients be managed?
One popular approach is to consider that GDP’s and GP’s are appropriately trained 
and equipped to deal with both acute and chronic TMD within the primary care 
setting, hence reducing hospital waiting lists and allowing the hospital specialist to 
concentrate on complex and intransigent cases. However there are several as yet 
unresolved, fundamental criticisms to this approach. Firstly, lack of remuneration 
and time available to GDP’s to undertake such care within an already hectic NHS 
practice. Time constraints could be problematic since an inadequate history may 
mask the underlying cause of pain. Treating the superficial symptoms rather than the 
whole individual could be detrimental in the long-term. The pain may become more 
entrenched requiring far greater reserves of NHS time and increased utilization of 
health care resources for further chronic pain conditions.
In reality, chronic TMD is still considered by many a specialist field, reflected in the 
vast number of referrals from primary, secondary and tertiary care settings. Requests 
range from queries or confirmation of diagnosis, secondary opinions and advice on 
management or requests for further management within a specialist environment. 
Education at both the undergraduate and postgraduate level including lectures, 
seminars, practical courses, journal articles and on-line CPD resources can all aid in 
the dissemination of information to the primary care sector. Conversely, an 
information overload particularly from the internet can provide conflicting and 
confusing advice. The evidence based medicine approach to TMD can be difficult to 
disentangle for both the busy practitioner and patient. This can lead to unnecessary 
orthodontics and occlusal rehabilitation which still occurs on a far too regular basis. 
Inappropriate care can be detrimental to the healing process and can sometimes lead
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to worsening of the TMD pain which becomes more recalcitrant to therapy and 
requires greater reserves of specialist time and effort in the long-term. Specialists do 
therefore have a role, not only in providing EBM education programmes but also in 
providing the necessary informed advice, both to the patient and the primary care 
practitioner, to relay the correct diagnosis, eliminating differential diagnoses and 
suggesting appropriate management.
In particular, there is a need for the patients to actively participate in their care, to 
learn to self manage their own chronic pain, (VonKorff, Glasgow and Sharpe,2002). 
To successfully achieve this aim one must first establish the patient’s current level 
of knowledge, understanding and beliefs. Their satisfaction with the diagnosis given 
and previous treatment provided should be gauged together with the current impact 
of pain on quality of life, their expectations of treatment and overall goals. In 
collaboration with the patient, a positive and achievable, individually tailored, self­
management plan can then be established. The Department of Health, 2002, “expert 
patient” programme can be a useful, adjunctive tool for encouraging patient 
education and self care. This includes the development of written and electronic self- 
care patient information, telephone guidance, the promotion of self-care protocols, 
national and local training programmes. A proposed scheme of TMD management 
utilizing both primary and secondary care resources has been illustrated in figure 76. 
Where facilities allow, a multidisciplinary pain team can be beneficial for the more 
complex TMD or mixed oro-facial pains. The group can be composed of a range of 
specialists for instance: ENT, Neurology, Psychiatry, Dental, Maxillofacial and Oral 
Surgery. The correct informed advice on management is known to help 40-60% of 
TMD patients (White and Schiffman,  1991). A brief survey of patients attending for 
TMD consultation appointments at the EDH, 2004, revealed favourable comments,
confirming patients acknowledged their condition was being taken seriously, within
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a specialist environment, which enhanced a therapeutic response. In addition, the 
referring practitioner can be provided with an appropriate level of support and 
advice by letter or additional e-mail or telephone contact. The majority of patients 
can then be referred back to and managed by the primary care practitioner, who can 
provide the suitable continuity of care required, sometimes extending over several 
years. Delegation of management to appropriately trained hygienist or therapist may 
also be appropriate when allocated a suitable length of time for the teaching of TMD 
conservative advice and self-care management skills. Involving Dental hygienists 
has previously been shown to be an effective use of resources, Magnusson et al,
1999 and Drangsholt,  1999. Ultimately, long-term management for a large 
proportion of patients with TMD could be managed within the primary care setting. 
However, some patients; within the EDH referral population an estimated third; 
require therapeutic intervention within the hospital environment. This may be a 
series of 3-4 appointments for occlusal appliance therapy or medical therapy before 
discharge to the primary care setting. A small minority of patients require utilization 
of other resources available within the hospital notably those with pathology 
necessitating arthroscopic surgical intervention or those with psychological distress 
or dysfunction requiring liaison psychiatric assistance or psychological intervention 
particularly CBT individually or within groups.
Regardless of therapeutic mode, six month or yearly review may sometimes be required 
to ensure damage limitation for those in need of occasional reassurance and or 
monitoring of ongoing therapy, particularly those otherwise at risk of seeking 
inappropriate, irreversible treatment elsewhere. Not discharging certain patients too 
early can therefore prevent or avoid relapse or escalation in pain which could require far 
greater resources to control at a future point in time. Guidelines for management are 
important provided they simply remain guidelines so that clinicians within the confines
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of evidence based practice are able to provide and adapt treatment to the benefit of the 
individual patient.
Another important consideration is the research component of TMD. Unless the 
condition of TMD can be investigated further in a specialised pain unit one can 
never unravel the complexity of subgroups and their most appropriate management. 
However, once the aetiology and risk factors have been fully elucidated then patients 
can be confidently seen outside a specialist environment. In the meantime it would 
be almost impossible to monitor patients in the primary care setting not enrolled in a 
research programme. This would result in lost opportunities to further our 
understanding of this condition and would be detrimental to the future care of our 
patients.
10.6  UNRESOLVED QUESTIONS. RECOMMENDATIONS  AND 
FUTURE RESEARCH
10.6.1  Occlusal appliance therapy
The hard occlusal appliance, although efficacious both alone and in combination 
with medication, did not show superiority to medication or indeed placebo therapy. 
One possibility is that other types of occlusal appliance may have additional benefits 
in terms of ease of fabrication and usage. A comparison of resilient versus hard 
occlusal appliances could be considered, particularly when one appreciates the 
influence of the cognitive awareness theory on splint action and the reduced costs 
involved in construction. A recent study suggested self-care treatment alone or in 
combination with soft and hard occlusal appliances resulted in all patients improving 
over time, Truelove et al, 2006. However, a more detailed study of the effect of 
different appliances could still be undertaken.
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From clinical experience, current practice and the confirmation of this recent study, 
it remains prudent to always introduce patients to the most conservative treatment 
measure of self-care advice initially, as indicated in the proposed TMD management 
programme, (figure 76). It may become clearer following subgroup analysis which 
patients benefit most readily from the additional intervention of occlusal appliances. 
However, at present one could consider those with a clenching or bruxism habit 
sometimes with observable damage to the intra oral tissues and or symptoms of 
TMD on waking. When or if occlusal appliance therapy is indicated in a particular 
individual, then, from the perspective of patient comfort, cost, time, ease of 
fabrication, adjustment and seemingly equivalent efficacy, a resilient soft appliance 
should be considered before embarking on the construction of a hard flat plane 
appliance.
10.6.2  Antidepressant medication
Superior efficacy of medical therapy to occlusal therapy was not demonstrated. This 
may suggest equivalence in efficacy or may also have been due to the choice of 
medication, an SSRI rather than a TCA. If sleep bruxism does play a role in TMD 
perpetuation then the SSRI may inadvertently have aggravated this condition rather 
than the more sedative TCA, as discussed in detail in Chapter VII. However, the 
SSRI did reveal superior efficacy to placebo, >50% pain relief at three months, so 
some individuals clearly benefited from the medication. The subgroup analysis 
suggested those suffering from depression and initially high levels of pain may 
respond more readily to the medical therapy although this did not reach significance 
between groups but may warrant further investigation. Interestingly, MPI life control 
and affective distress did appear to decrease most significantly amongst the SSRI 
group. Where medication is indicated for a patient and there is a significant sleep
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disturbance a TCA may still be the drug of choice. Otherwise, an SSRI can be 
beneficial in some patients, particularly when wishing to avoid the antimuscarinic 
side effects of the TCA. A direct comparison of a TCA and an SSRI in TMD, 
utilizing a RCT design has not been undertaken and remains an unresolved issue 
which would be very interesting to determine. However, the influence of clinical and 
psychosocial subgroups of TMD on outcome, together with covariates related to 
high initial levels of pain, depression, alterations in sleep pattern and co-morbid pain 
conditions would need to be incorporated into any analysis. Liu et al,2005 suggest a 
two stage trial to first distinguish ‘responders’ and then a second trial aimed at this 
group would increase the power of efficacy and require fewer participants with 
treatment aimed at a specified population.
In designing TMD clinical trials for the future, the recognition of the numerous 
covariate effects would enable researchers to identify individual responders or 
subpopulations that will react favourably to therapy; providing both more efficient 
and cost effective research trials and treatment.
Future studies need to focus on subgroup analysis in an attempt to extricate the 
various sub-entities within the conglomerate of TMD. For example more stringent 
subgroup analysis, not only in relation to arthralgic and myalgic components of 
TMD but also for example utilizing this and other TMD cohorts for MPI mapping 
into chronic pain groups proposed by Rudy and Turk,  1987 or utilizing the chronic 
graded pain scale (Forsell et al,) .This may help to elucidate patterns of therapeutic 
response amongst those with specific clinical and psychosocial pain characteristics. 
Further covariates are numerous but may include: sleep, nocturnal bruxism and 
clenching, level of depression, co-morbid pain conditions particularly TTH, as well 
as the more unusual including perhaps the season in which research is undertaken 
for example winter versus summer, the influence of the clinician’s character, study
515Ch a pter x c o nclusio n
environment and most importantly issues related to patient levels of distress, 
dysfunction and quality of life.
Overall the strengths of the study are those of a well conducted RCT with acceptable 
internal and external validity within the sphere of EBM. The study was conducted 
before the advent of the recent explosion in comprehensive guidelines on conducting 
RCT’s but fulfils the criteria outlined by CONSORT. Methodological flaws would 
include the information sheet and consent form which would now have been written 
in a much more detailed manner. However, the patients were not disadvantaged by 
this but were given clear, coherent information throughout the course of the study.
In future studies, ideally additional personnel would be required including at least 
three calibrated clinicians one providing treatment, one assessing adverse effects and 
compliance and the third assessing treatment outcome, blind not only to drug 
therapy but to all therapeutic interventions, so decreasing the likelihood of detection 
bias.
In relation to compliance, rather than relying on self report and pill counts, future 
studies could utilise some of the newer techniques discussed in Chapter IX. The 
simplest would be diary cards, whilst online internet records, electronic pill counters 
or regular blood tests could all be considered.
Although the length of time patients were followed up post therapy was a strength of 
this study, it is envisaged that further follow-up will be undertaken with this 
particular cohort to determine long term follow-up at 10 years. Patient recall and 
attendance for a clinical review appointment, although useful in physically assessing 
patient signs of TMD for comparison to baseline and end of therapy, is clearly 
expensive and largely impractical. A questionnaire or telephone follow-up of self 
report symptoms is much more cost effective in terms of both patient and clinician 
time.
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Further RCT are necessary to continually improve our knowledge and understanding of 
the field particularly in relation to sub-group analysis. Global interaction and 
cooperation is also required to pool resources, research knowledge and capabilities on 
the epidemiology, aetiology, diagnosis and management which in turn will lead to a 
better understanding of the field.
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566Appendix 1 -  Consent form for the Facial Arthromyalgia study
567EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
FACIAL ARTHROMYALCIA 
(TMD)STUDY
University of London  I—   ....  —  ■
JOINT RESEARCH OP THE DEPARTMENTS OP MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
- I agree to take part in this study on facial arthroinyalgia treatment.
- I have received and read the information sheet explaining the study.
- I understand I shall be asked to attend the Eastman Dental Hospital 
at regular intervals/ approximately six times/ over a period of three 
months and to attend follow up sessions over the nine months imnediately 
following my treatment.
- I shall be asked to fill in a number of questionnaires as part of the 
study.
- I understand I cannot choose which treatment I have but that I can 
withdraw from the treatment at any time.
SIGNED  DATE
P a tien t:.........
Please print in 
capital letters
Interviewer:...
Please print in 
capital letters
CONSENT FORM
W itn ess
(Member of Facial Arthroinyalgia team)
Position:
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569EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
FACIAL ARTHROMYALGIA
(TMD) STUDY
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
INFORMATION SHEET
What  is  Facial  Arthromyalgia?
All  our  investigations have shown that you have no sign of disease  in 
your joints.
Most  toothache and other  dental  problems  are fairly straight  forward 
and  respond to standard  treatment.Other pains may persist  for a time 
changing in  intensity according  to how you  feel.Treatment  is varied 
and  different  individuals may respond to staking medication, wearing a 
splint,stress management  or  learning how to  relax.
This  leaflet  tells you more  about  the pain you have  and how this 
project may help you.
The most  likely diagnosis  of your pain  is  a condition known as:- 
Facial Arthromyalgia  (Temporomandibular  joint  dysfunction syndrome)
This  is  a continuous or  intermittent  dull  ache with or without 
occasional severe attacks  affecting your jaw joint and  its muscles. 
You may also experience clicking noises  in the  joint,difficulty 
opening the mouth and  tenderness  or spasm in  the jaw muscles  in the 
immediate  area  around  the joint  or extending  into  the head  and down 
into  the neck.
Ear  symptoms  of  a  sense  of  fullness,buzzing,popping and  dizzieness 
may  also occur.
Study  into  Facial  Arthromyalgia  management.
This  study  aims  to  find out the most  effective means of  treatment  for 
this  condition.lt  is  a  trial  comparing Medical  and  Physical  splint 
therapy alone or together.
Medical  therapy  involves  taking one of  two tablets being used  in the 
trial.Antidepressants  are not given because we  think you are  depressed 
but because  it has been  shown  that  these drugs help relieve pain and 
are not  addictive.
Physical  splint  therapy  involves wearing an  individually made acrylic 
appliance on the upper teeth in order  to relieve  the joint  and muscle 
pain.
All  those taking part  in the study will be randomly allocated  to one 
of  the treatment groups.
If you have any  further questions  about  the  study,a member of  the research 
team will  be glad to answer any queries.
570Appendix 3 -  Letter to general medical and dental practitioner
To inform them of their patient’s potential participation in the Facial 
Arthromyalgia study
571EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
FACIAL ARTHROMYALGIA
(TMD) STUDY
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
Professor Malcolm Harris 
Dr. Charlotte Feimnann 
Mr. Richard Ibbetson 
Mbs Rachel Leeson 
Mr. Paul ONeilly
g g j
m
Re:  ,  DOB:
Address:____________________ »   Ref.  No.:.
Dear
Thank you for referring the above patient whom I saw on behalf of the Facial Arthromyalgia project team 
on______________________*
£Qi
HE£i
EMHl
SH:
572Clinical  Examination:
Radiographic  Examination:
A diagnosis of Facial Arthromyalgia ( TMJ dysfunction syndrome) was made. At present the department is 
undertaking a project involving patients with this complaint and the above patient has very kindly agreed to 
take part in this trial.
The aim of the study is to compare the effectiveness of Medical Physical or combined Medical and 
Physical therapy in the management of this condition.
The study is a randomised ( double blind for drug treatment) controlled trial in which patients will be 
allocated to one of four groups: fluoxetine ( Prozac), placebo, full coverage occlusal splint or splint plus 
fluoxetine.
The initial duration of the study is three months, during which time there are regular review appointments IQ 
assess the treatment progress and care of the individual. There are then two follow up appointments at three 
month intervals. The patient would of course be able to withdraw from the treatment at any time during the 
course of the trial.
Your patient has shown interest in taking part in this project I would therefore be grateful if you could let 
me know if there is any reason you would not be happy for this patient to enter into the trial.
Thank you for your co-operation and help in this matter.
The department will of course endeavour to keep you informed of the progress of this patient, whilst 
reaving treatment undir our cue.
Yours sincerely,
Miss Rachel Leeson,
REGISTRAR,
DEPARTMENT OF ORAL AND MAXILLOFACIAL SURGERY.
573Appendix 4 Letter to Heads of Department within the Eastman 
Dental Hospital requesting referral of patients.
Action flow chart to illustrate proposed attendance 
plan for selected patients
574EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
FACIAL ARTHROMYALGA
(TMD)STUDY
University of London  ■"   .......
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORALSURGERY AN) CONSERVATIVE DENTISTRY
The Departments of Conservative Dentistry and Maxillofacial and Oral Surgery are jointly undertaking 
a research project into temperomandibular joint dysfunction (Facial Arthromyalgia). Patients selected 
from the Conservation, Periodontal and Prosthetics departments will be entering a trial to compare the 
use of a full coverage occlusal splint versus medical management of the condition.
I would be most grateful if you could collect patients referred with pain in one or both TMJs, with or 
without clicking, limitation in opening or tenderness in the associated musculature.
Unsuitable patients are
• those with significant untreated dental disease.
• those undergoing extensive or complex restorative treatment
• those where history of the joint condition appears long and intractable
Suitable patients should have
• reasonable plaque control.
• sufficient teeth to allow construction of a stable occlusal splint.
We shall then send the selected patients appointments for a joint assessment and information on the 
project
Thank you very much for your help in this matter.
Professor Malcolm Harris 
Me Richard Ibbetson 
Dc Charlotte Feinmann 
Miss Rachel Leeson 
Me Paul O'Neily
Dear
Yours sincerely,
Miss Rachel Leeson,
REGISTRAR,
DEPARTMENT OF ORAL AND MAXILLOFACIAL SURGERY.
The Institute has Charitable status and is a Company Limited by Guarantee.  Registration No. 490351, London
575ACTION FLOW CHART
RECRUITMENT REQUEST LETTERS WRITTEN TO PARTICIPATING 
HEADS OF DEPARTMENT
CONS PERIO PROSTHETICS
Select:-
Dentate
Suitable partially dentate
Pain in one or both TMJs +/- clicking, limitation
in opening or tenderness in associated
musculature
Eliminate:-
Undergoing extensive or complex restorative 
treatment
Extensive and active caries or periodontal 
disease
Intractable or longstanding TMJ pain
1
Names, telephone numbers to project team and appointment posted
i  ,
FIRST ATTENDANCE
Joint assessment 
Pain proforma 
Pain questionnaire 
Dental examination 
Radiographs
ELIMINATE
ACCEPT
Leaflet given 
Sign consent form 
Random allocation
Drug - Prozac  Placebo  Splint + Drug  Splint
Blood Test 
  ^
Book next appointment
576Appendix 5 -  A reminder and thank you letter to participating 
general dental practitioners
577EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
FACIAL ARTHROMYALGIA
(TMD) STUDY
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
Professor Malcolm Harris 
Dr. Charlotte Feinmami 
Mr. Richard Ibbetson 
Min Rachel Leeson 
Mr. Paul O'Neiliy III
Dear Sir/ Madam,
Further to our letter in January/ February, 1995,1 am writing to remind you of the 
Temporomandibular joint dysfunction (Facial Arthromyalgia) research project, 
presently being undertaken at the Eastman Dental Hospital.
Patients with pain in one or both TMJ’s, with or without clicking, limitation in opening 
or tenderness in associated musculature would be gratefully received. However, those 
patients who have had extensive treatment for this condition, will not be suitable for 
our trial. Treatment includes comparison of full coverage occlusal splint with medical 
management, which is randomly allocated to the patient.
May I take this opportunity to thank you for patients you have already referred. Please 
do not hesitate to send us further cases.
Referral address: Miss Rachel Leeson,
Oral Surgery Department 
Eastman Dental Hospital 
 
Thank you for your help in this study.
Yours sincerely,
Miss Rachel Leeson,
REGISTRAR,
DEPARTMENT OF ORAL AND MAXILLOFACIAL SURGERY.
578Appendix 6 Appointment letters
New patient letter for an initial assessment
Letter for a further appointment following failed 
attendance
Reminder letter for three month follow-up 
appointment
Reminder letter for six month follow-up appointment
Reminder letter for nine month follow-up 
appointment
579EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
FACIAL ARTHROMYALGIA
(TMD) STUDY
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AM) CONSERVATIVE DENTISTRY
Prof«Mor Malcolm Harris 
Me Richard Ibbctson 
Dc Charlotte Fefamann 
Miss Rachel Leeson 
Me Paul O'NeiBy
Dear
An appointment has been made for you to attend our clinic for an initial assessment
on :__________________ _____________________ at:______________________ _
location:____________________________________________________________ _
This clinic is for patients with jaw joint and muscle problems.
In order to make a diagnosis we need to see you for a long fust appointment A detailed history is 
recorded, a dental examination is carried out and X-rays are taken. You will also be asked to fill in a 
pain questionnaire.
At present the Eastman Dental Hospital is carrying out a study into the most effective treatment of pain 
associated with the jaw joint, comparing the use of bite splints and medication, both of which have 
had reported success in the past
If, after your first appointment it is felt you would be a suitable candidate for this study the project 
will be explained to you in more detail and a leaflet given to you.
If you are willing to participate you will be randomly allocated to one of the groups. It will be 
necessary for you to be available for approximately six appointments on a Thursday over a period of 
three months and follow up appointments arranged after a further three months and six months time.
We look forward to meeting you at the first appointment If you are unable to attend please ring to 
cancel  or  change  the  appointment  time if necessary.
Thank you for your co-operation.
Yours sincerely,
Eastman Facial Arthromyalgia Project 
Department of Oral and Maxillofacial Surgery.
The Institute has Charitable status and is a Company Limited by Guarantee.  Registration No. 490351, London
580EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
FACIAL ARTHROMYALGIA
(TMD) STUDY
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
Professor Malcolm Harris 
Dr. Charlotte Feinmann 
Mr. Richard Ibbetson 
Miss Rachel Leeson 
Mr. Paal O'NeUIy
Date:
Hospital No:
Dear  ______________ ,
As you failed to attend your appointment on_________________________
I am writing to ask if you would like to be given another appointment on the Facial 
Arthromyalgia clinic.
We have appointments available for a Tuesday morning between 8:30am - 12:30pm 
and on a Thursday afternoon between 2:00pm and 4:30pm. If you would like to 
arrange an appointment during these times, please do not hesitate to contact me on 
.
Looking forward to meeting you.
Yours sincerely,
Eastman Facial Arthromyalgia Project, 
Department of Oral and Maxillofacial Surgery.
581EASTMAN DENTAL INSTITUTE
FOR ORAL HEALTH CARE SCIENCES
University of London
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
Date:
Hospital no:
Dear —  ■   *
This is just to confirm that you are due for your 3 month review appointment on:
at
At this appointment you will be asked to fill out a questionnaire on your progress 
throughout this trial. If you are unble to make this appointment or have any queries 
please contact us on .
Yours sincerely,
Eastman Facial Arthromyalgia Project,
Joint Department of Oral and Maxillofacial Surgery.
Professor Malcolm Harris 
Dr. Charlotte Fehmtann 
Mr. Richard Ibbetsoo 
Mbs Rachel Leeson 
Mr. Paul O'Neiily
FACIAL ARTHROMYALGIA
(TMD)STUDY
582EASTMAN DENTAL INSTITUTE 
FOR ORAL HEALTH CARE SCIENCES
FACIAL ARTHROMYALGIA
(TOD) STUDY
University of London  I— ■ ■ ■ ■ ■         ■ -»
JOINT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTISTRY
Date:___________ .
i
Hospital no:____________ .
Dear_________________ ,
This is just to confirm that you are due for your 6month review appointment on:
___________________________ at______ .  '
At this appointment you will be asked to fill out a questionnaire on your progress 
throughout this trial. If you are unble to make this appointment or have any queries 
please contact us on .
Yours sincerely,
Eastman Facial Arthromyalgia Project,
Joint Department of Oral and Maxillofacial Surgery.
Professor Malcolm Harris 
Dr. Charlotte Feinuunn 
Mr. Richard Ibbetson 
Miss Rachel Leeson 
Mr. Paul O'Neilly
W. 
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FOR ORAL HEALTH CARE SCIENCES
FACIAL ARTHROMYALGIA
(TMD) STUDY
University of London  J
KXCT RESEARCH OF THE DEPARTMENTS OF MAXILLOFACIAL AND ORAL SURGERY AND CONSERVATIVE DENTICTRV
Date:___________
\
Hospital no:____________ .
Dear_________________ ,
This is just to confirm that you are due for your 9 month review appointment on:
At this appointment you will be asked to fill out a questionnaire on your progress 
throughout this trial. If you are unble to make this appointment or have any queries 
please contact us on .
Yours sincerely,
Eastman Facial Arthromyalgia Project,
Joint Department of Oral and Maxillofacial Surgery.
Professor Malcolm Harris 
Dr. Charlotte Feinmann 
Mr. Richard Ibbetson 
Min Rachel Leeson 
Mr. Paul O’Neilly
W  
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584Appendix 7 -  Self-report pain questionnaires
-  The Multidimensional Pain Inventory (MPI)
-  The McGill Short form Pain Questionnaire (SF-MPQ)
-  The Kellner Illness Attitude Scale (Kellner)
-  The Beck Depression Inventory (BDI)
585MVLTTPEMEHSIQIHAL FA1H PiYEHTORY
Date:
Name:
First Initials Surname/Family name
Age:____________________________ ,
Sexi_________________________________ B
Mala site of pala:
When did pain start?:_______________ g
iM fiastim
An important part of our evaluation includes iwammafion of pain from yqur 
perspective because you know your pain better than anyooe else. The following 
questions are designed to help us learn more about your pain and bow it affects your
Under each question is a scale to mark your answer. Read each question carefully and 
then cirde a cumber on the scale under that question to indicate how specific question 
applies to you. An example may help you to understand better bow you should answer 
these questions.
Example
How nervous are you when you ride in a car when the traffic is heavy?
If you are not at aO nervous when riding in a car in hdavy traffic, you would want to 
circle the number 0. tfyou are very nervous when riding in a car in heavy traffic, you 
want to circle the number 6. Lower numbers would be used for less nervousness, and 
higher numbers for more nervousness.
life.
Hot at all 
nervous
0 2  3  4  5  6
‘  Extremely
nervous
Go to next page
586Section I
1   Rate the level of pain at the present moment.
0  1   2  3  4  5  6
No pain  Very intense pain
2  In general, how much does your pain interfere with your day to day activities?
0  I  2  3  4  5  6
No interference  Extreme interference
3  Since the time your pain began, how conch has your pain changed your ability to 
work?  t Tick here if you have retired for reasons other than your pain.
0  1  2  3  4  5  6
No change  Extreme change
4  How much has your pain changed the amount of satisfaction or enjoyment yon get 
from taking part in social and recreatiooal activities?
0  1  2  3  4  5  6
No change  Extreme change
5  How supportive is your spouse of agrifficant other person to you in relation to
your pain?
0  1  2  3  4  5  6
Not at all  Extremely
supportive  supportive
6  Rate your overall mood during the past week.  c
0  I  2  3  4  .  5  6
Extremely  Extremely
low  high
7  How much has your pain interfered with your abffity to get enough sleep?
0  1   2  3  4  5  6
No interference  Extreme interference
587S  On avenge, how severe has your pain been during the last week?
0  1   2  3  4  5  6
Not at all  Extremely
severe  severe
9  How able are you to predict when your pain wiD start, get better, or get worse'
0  1  2  3  4  5  6
Not at all  Venrableto
able to predict  predict
10  How much has your pam changed your ability to take part in recrestiooal and 
other social activities?
%
0  1  2  3  4  5  6
No change  Extreme change
11  How much do you Emit your activities in order to keep your pain from getting 
worse?
0  1   2  3  4  5  6
Not at all  Very much
12  How much has your pain changed the amount of satisfaction or enjoyment you 
get from your family-related activities?
0  1  2  3  4  5  6
No charge  Extreme change
13  How worried about you b your spouse or significant other person because of
your pain?
0  1   2  3  4  *   5  6
Not at all  Extremely
worried  worried
14  During the past week how much control do you fed that you have had over your 
life?
0  1   2  3  4  5  6
No control  Extreme control
588IS  On an average day, how much doea your pain vary (increase or decrease)?
0  1   2  3  4  5  6
Remains  Changes
the same  a lot
16  How much suffering do you experience because of your pain?
0  1   2  3  4  5  6
No  Extreme
suffering  suffering
17  How often are you able to do something that helps reduce your pain?
0  1   2  3  4  5  6
Never  Very often
18  How much has your pain changed your relationship with your spouse, family, or 
significant other?
0  1  2  3  4  5  6
No change  "  Extreme change
19  How much has your pain changed the amount of satisfaction or enjoyment you 
get from work?      Tick here if you are not working at present.
0  1  2  3  4  5  6
No change  Extreme change
20  How attentive is your spouse or wgpifirtnr other person to you because of your 
pain?  <
0  I  2  3  4  *   6
Not at all  «   Extremely
attentive  attentive
21  During the past week how much do vou fed that you’ve been able to deal with 
your problems?
0  1   2  3  4  5  6
Not at aQ  Extremely
well  well22  How much control do you fed you have over your pain?
0  1   2  3  4  5  6
No control  A great deal
at all  of control
23  How much has your pain changed your ability to do household chores'9
0  1   2  3  4  5  6
No change  Extreme change
24  During the past week, how successful were you at coping with stressful situations 
in your life?
0  1  2  3  4  5  6
Not at all  Extremely
successful  successful
25  How much has your pain interfered with your ability to plan activities?
0  1   2  3  4  5  6
No change  Extreme change
26  During the past week, bow irritable have you been?
0  1   2  3  4  5  6
Not at all  Extremely
irritable  irritable
27  How much has your pain changed or interfered with your friendships with people 
other than your fimafy?
0  1  2  3  4  5  6
No change  *  Extreme change
28  During the past week how tense or anxious have you been?
0  1   2  3  4  5  6
Not stall  Extremely
tense or anxious  tense or anxious
590Section T!
In this section, we are interested in knowing how your spouse or significant other 
person responds to you when he or she knows that you are in pain  On the scale listed 
below each question, circle a number to indicate how often vour spouse or significant 
other person responds to you in that particular way when you are in pain. Please 
answer all of the 14 questions.
I  Ignores me.
0  1  2  3  4  5  6
Never Very often
2  Asks me what be/she can do to hdp.
0
Never
2  3  4  5  6
Very often
3  Reads to me.
0  1  
Never
2  3  4  5  6
Very often
4  Gets irritated with me.
0
Never
2  3  4  5  6
Very often
5  Takes over my jobs or duties
0  1  
Never
2  3  4 , 5 6
Very often
6  Talks to me about something ebe to take my mind off the pem.
0
Never.
2  3  4  5 . 6
Very often
5917  Gets frustrated with me
0  I  2  3  4  5  6
'Never  Very often
S  Tries to get me to rest
0  1  
Never
2  3  4 5  6
Very oft en
9  Tries to mvohr roe in some activity.
0  1  2  3  4  S  6
Never Very often
10  Gets angry with me.
0
Never
1   2 4  5  6
Very often
11  Gets me pain medication.
0  1   2 
Never
3  4  5  6
Very often
12  Encourages me to w ort on a hobby.
0  1 2   3
never
5  6
Very often
13  Gets roe something to eat or drink.
0  I 
Never
2  3  4 1 5  6
Very often
14  Turns the TV on to take my oand off the pan.
0  1  
Never
2  3 5  6
Very often
592Section fll
Listed below are 24 common activities. Please indicate bow often you would do etch 
of these by circling a number on the scale below each activity  Please complete all 24 
questions
1   Wash dishes.
0  I  2  3  4  5  6
Never Very often
2  Mow the lawn.      Tick hern if you do not have a lawn to mow.
0
Never
2  1 4 $   6
Very Often
3  Go out to eat.
0
Never
2  3  4  5  6
Very often
4  Play cards or other games.
0
Never
2  3  4  5  ^ 6
Very often
0
never
2  3  4  5  6
Very often
6  Work in the garden.__ ,Tfck here if you do aot^ave a garden.
0
Never
2  3  4  5  6
Very often
7  Go to a movie.
0
Never
2  3  4  5  6
Very often
59315  Take a trip
0  1  2  3  4  5  6
Never  Very often
16  Go to a park or beach.
0  1  2  3  4  5  6
Never  Very often
17  Do the laundry.
0  1  2  3  4  5  6
Never  Very often
18  Work oo a needed household repair.
0  1  2  3  4  5  6
Never  Very often
594SHORT FORM McGILL PAIN QUESTIONNAIRE
Section 1.
Please answer this section with reference to the pain you usually suffer from. If a word 
does not describe your pain, tick “NONE” next to that word. If a word does describe 
your pain, indicate whether you experience this sensatioo to a “imkT, “moderate” or 
“severe” degree, by ticking next to the relevant word. Please make sure you place a 
tick in one of the categories for each word.
SEVERE
THROBBING
NONE
0)
MILD
1>
MODERAT
2)
SHOOTING 0) 1) 2)
STABBING 0) 1) _   _ 2)
SHARP 0) 1) 2)
CRAMPING 0) 1) 2)
GNAWING 0) 1)  _ 2)
HOT-BURNING 0) I) 2)
ACHING °> 1) 2)
HEAVY 0)  _ 1) 2)
TENDER 0) IV  __ 2)
SPLITTING 0) 1) 2)
TIRING-
EXHAUSTING 0) 1)
4
2)
SICKENING 0) I)
•
2)
FEARFUL 0) I) 2)
PUNISHING-
CRUEL 0) 1) 2)
595SwfteB-li
Please answer this section with reference to the pain you have RIGHT AT THIS 
MOMENT.
A)  Draw a line through the scale below to indicate where your pain is at the moment-
(e.g.  -------/-------- ), imagining that the line indicates a ladder going from oo pain to
the worst possible pain.
NO  WORST
-----------------------------------------    POSSIBLE
PAIN  PAIN
B)  Tick next to ONE of the following words to indicate how intense your pain is at the 
moment.
0  NO PAIN
1   MILD
2  DISCOMFORTING
3  DISTRESSING
4  HORRIBLE
5  EXCRUCIATING
596m atw  A ttifrda S tile 
K tflnir
No  R utiy  Sometimes  Often  Most of the time
1 2   3  4  5
1.  Do you believe thtt you hove a physical disease, but the doctors have oot 
diagnosed it correctly?
1  2  3  4  5
2.  When your doctor tells you that you have no physical disease, do you refuse to 
believe him/her?
1   2  3  4  5
3  When you have been told by the doctor what be found, do you soon begin to
believe that you may have developed a new iflncss?
1   2  3  4  5
4.  Are you afraid that you may have cancer?
1  2  3  4  5
5.  Are you afraid that you may have heart diseaie?
1  2  3  4  5 i
6  Are you afraid that you may have another serious  illness0
1   2  3  4  5
597BDI
This questionnaire consists of 21 groups of statements. After reading each group 
of statements carefully, circle the number (0,1,2 or 3) nest to the  statement in 
each group which best describes the way you have been feeling the past week and 
today. If several statements within a group seem to apply equity well, circle each 
one.
Be sure to read al the statements in each group before making your choice.
1.  0  I do not feel sad
1  I fed sad
2  I am sad all the time and I cm’t nap out of it
3  I am oo sad or unhappy that I can’t stand it
2.  0  I am oot particularly discouraged dbout the future
1   I fed discouraged about the future
2  I fed that I have nothing to took forward to
3  I fed that the future is hopeless and that things can't improve
3  0  I do not fed Glee a failure
1  ! fed I have feBed more dun the avenge person
2  AsilookbockonnqrKfeallcanseeisakjt offinbres
3  I fed I am a complete fedure as a person
4.  0  Igetasamchamfefocboooutofthmgsaslusedto
1  I don’t eajoy things the wqr I used to
2  I doa*t get radnlirihctiooo* ofmgfofog anymore
3  I an dnsatafied or bored with nmythmg
5.  0  I don’t fed particularly guity
1   I fed frity  a good pmt of the time
2  I fed quite guilty most of the time  4
3  I fed guilty afl of the time
6.  0  I don’t fed I am being punhhsd
1   I fed I may be pumdbed
2  I expect to be puddmd
3  I fed I am bring punished
5987  0  I don't fed disappointed in myself
1   1  am disappointed in mysdf
2  I am disgusted with mysdf
3  I hate mysdf
8  0  1  don't feell am any worse off than anybody else
1   1  am critical of mysdf for my weaknesses or mistakes
2  I blame mysdf aO the thne for my faults
3  I blame mysdf for everything bad that happens
9  0  I don't have any thoughts of tdffing mysdf
1   I have thoughts ofH h g  mysdf but 1 would not carry them out
2  I would Hike to kfl myself
3  I would kiD mysdf if! had the chaooe
10  0  I don't cry any more than usual
1   I ay more now than I used to
2  I cry all the time now
3  I used to be able to cry but now I can't cry even though I want to
11  0  I am no more M ated now than ! ever am
1   I get annoyed or irritated more eaaly than I used to
2  I fed M ated alik e time now
3  I don't get M ated *  dl by the things that osed to M ate me
12  0  1  have not lost interest in other people
1  I am leas interested in other people than I osed to be
2  I have lost mod efmykMarmt ia other people
3  I have loat dicfmyim crnat in other people
4
13  o  I make deddoas as w el aa ! M r could
1   I put off making dsdafoas more thaa I med to
2  I have greater dfficuky in making dedpioos than before
3  1  can't make dedsaooa anymore
14  0  1   doo’^fed I look any worse than I used to
1   I am worried that I am looking oU or unattractive
2  I fed that there are permanent changes to my appeaiance that make me 
look unattractive
3  I believe that I look ugly
59915  0  1 can work about as well as I used to
1   It takes an extra effort to get started at doing something
2  I have to push myself very hard to do anything
3  I can't do any work at alt
16  0  ( can sleep as weO as usual
1   I don't sleep as well as I used to
2  I wake up 1-2 hours earlier and find it hard to get back to sleep
3  I wake up several hours earlier than I used to and cannot get back to 
deep
17  0  I don’t get any more tired than usual
1   I get tired more easily than I used to
2  1 get tired from doing almost anything
3  1 am to tired to do anything
IS.  0  My appetite is oo worse than usual
1   My appetite is not as good as it used to be
2  My appetite is much worse now
3  I have no appetite at aO anymore
19  0  I haven't lost much weight, if any. lately
1  I have lost more than 5 pounds (2 kilos)
2  I have lost more than 10 pounds (4 kilos)
3  1 have lost more than 15 pounds (7 kilos)
I am purposely trying to lose weight by eating less:  YES_____  NO.
20.  0  I am no more worried about my health than usual
1   I am worried about physical prebtems'sucfa as pains, upset stomach or
2  I am very worried about phyacal problems and it's hard to think of 
much else
3  I am so worried about my physical problems that I cannot think about 
anything else
21.  0  I have not noticed any recent changes in my interest in sex
1  I am less interested in sex than 1 used to be
2  1  an much less interested in sex than I used to be
3  I have lost interest in sex completely
600Appendix 8 -  Eastman Dental Hospital modified 
Facial Pain proforma
601EASTMAN DENTAL INSTITUTE
FACIAL ARTHROMYALGIA 
(TMD) STUDY
Study code
Patient’s Name.
Hospital number
Patient1 8 study number 
Date
day  month  yaar
0-K )
one
(1M 0)
Sex:..............
Date of birth:.
(21-22)
male,  tamale,  (24)
(2M 0)
day  morrt/)  year
Present marital status:.............................................................single,  married,  divorced,  widowed,  pi)
Employed:  yes,  no,  m
Occupation (// tmmpkjyed please state last occupadonjt____________________________________
(34-36)
Referred by:  GDP,  GMP,  apsctaMit,  self.
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603Original predpHatlng factori# (2 1 -2 2 )
Relief
Relieved by
RELATED FACTORS 
Sleep......................
Joints
Ear#
popping..
buzzing..
deafness
dental..................................................... emotional upset.................................. (27)
physical traum a..................................... --- m none........................................................ (26)
infection.................................................. (26)
Provoked by
biting....................................................... (29) hot food/drink....................................... 05)
chewing.................................................. (30) coid food/drink..................................... 06)
talking...................................................... 01) cheese.................................................... 07)
yawning.................................................. _T . 02) chocolate............................................... 08)
hot weather............................................. 031 alcohol................................................... 09)
cold weather........................................... 04) emotional tension................................. (40)
Other
(41-0
re s t........................................................... (43) alcohol................................................... (46)
heat  ........................................................ . (44) pressure  ................................................ (47)
chewing  ................................................. (45) an alg esics............................................. (46)
Other
H M O )
no
problems,
cannot get  disturbed 
to steep,  sleep,
earty morning  - 
wakening.
Right  Left
clicking................................... □ (5263) limited opening................ .........D  »
sticking..................................
dislocation............................
— L O
' □
(5466)
(9667)
bruxism....................
...................
RigM  Left
Oro-Fadal Symptoms
burning tongue....................
disturbed taste....................
disturbed salivation.............
disturbed denture tolerance
(9 M 0 ) 
(61-62) 
esse
m
m
(67)
m
disturbed occiusai comfort
areas of sensory loss........
areas of paraesthesia........
m
(70)
(71)
604CONICAL EXAMINATION: ORO-FACIAL
Grom facial asymmetry:........ yes,  no, oe
Swelling
(incdcata on diagram):..............yee,  no, psi
Tenderness on palpation 
(Indicate on diagram):.................yes,  no, 0*
Tenderness in ears 
(Indicate on diagram):  yes,  no, (27)
TMJ
Oral Cavity
Buccal mucosa 
—ulcer.................
—frictional keratosis □ □
1(2148
tender........................... n
Left
Q ® » sticking.................. H
dick (opening)...................n I   |  POOD deviation................ ..........n
dick (donuts) .......n 1   lows seeking.................. ..........n
crepitus....................... .......n □  <34*
interlndsai opening (mm)
—abrasion 
—other__ □
pa® )
pa*
H M D
<4*431
m
□
Lingual mucoea abnormal:...........................................................................................yes,  no, hs
Ridging of tongue:........................................................................................................ yes,  no, m
Ridging of buccal mucosa:      ...yaa,  no, pd
(BaUuaa  -   —*   *   — o eea* .....................................................................................*»«,*♦...................saossa,  normal,  laouoao,  pa)
Angle dasa (Dental):
Overbite (mm):........
Ovar|et(mm)c...........
2H ,  34  ea
..  I  l l  ew» □ men
TEETH (pteaae cirela as appropriate)
•   7   6   5  4   3   2  1
•   7   6   5  4   3   2   1
carious cavities
•   7   6   5   4   3   2   1
fl  7  8  S  4  3  2  1
1  2  3  4   5  6  7
□ (2U 2)
• mm
1  2   3   4   5   6   7  6   (4M0)
I  (2142)
1  2   3  4   5  6  7   6   (2400)
1  2  3   4  5  8  7  8  (40-55)
unerupted
8   7  6   5  4   3   2   1 
8   7  6  5   4   3   2   1
(2142)
1  2   3   4   5  6   7   8   (2440) 
1  2   3   4   5  6   7   8
605PAIN TREATMENT
Scanty
oral surgeon
GMP...........
GOP
Treated with 
analgesics
antibiotics
fillings.........................
extirpation of dental puip.
forceps extraction  ........
surgical exploration  .......
surgical extraction..........
bite-raising appliance.......
ocdusal adjustment  .......
PAST HISTORY
07)
oe
< 3 *
(46)
we □ □
□  □  □  □
os
(5 3 )
M
(50
neurologist------------------------------------Q  ho
psychiatrist    ------------------------------ □  m
ENT surgaon__________________ Q „
Other    _____________  wwe
tranquiliisers
dentures
shortwaNsdiathsnny.
osteopathy ..............
acupuncture............
TMJ infection.-.........
TM J operation  .........
Other__________
W7)
we
m
(57)
(50
as
ise
MEDICAL HISTORY
migraine.................................................
neck pain.................................................
back pain..................................................
cheat pain  ......- .......... ..........................
ipttticcoion ii.M .m ir t.u ^ T .i  — □
abdominal pain..........— —  I
dysfunctional uterine bleeding  .....—  | 
glandular fever      □
oe
00
01)
oo
00
oe
oe
oe
07)
earache..
pruritus...........................................   □
      □   □
_□
drug e n e r g y ...  -------------- " L J
speoiyr  .  ............
*  * T
rheumaiic fever.
oe
oe
wo
ws
we
we
we
we
WS47)
HOSPITAL ADMISSION Cunant Mcdtoation... Drug and Docs jpfeeseghwdetaity
606INVESTIGATIONS
Blood Proaaura... 
Radiography  if
OPT________
tranapharyngeal 
OM_______
_ J » »  
□  «,
□( 56)
Haematology  prior  to  staitinodruQ  therapy
m------------------------------Q
  □ FBC-
ESR. □
RESULTS
plain  tomography., 
arthrography------
D
C T   s c a n .
(8 6 )
m
vm
m
(69
( 61)
HhF........ ( 63)
MS U * d F *
( 62) m s
—
as
DIAGNOSIS
facial arthremyaigla.. r*!  n   n |  j  I  I  (2946)  O th e r- - - - - - - - - - - - - - - - - - - - - - - - - - - - 1 — 1
TREATMENT PLAN
Admit  to  trial -yea,  noj  pi)
D
Random  allocation  (o groups  • • •
Physical therapy only_________________ Bite splint
Medical therapy only__________________Fluoxetine or Placebo  Q
Physical and Medical therapy  cosbined_Bite Splint ♦ Fluoxetine|  [
6076
0
8
TREATMENT FEOW CHART
WEEK Appt.
number
Drug
(60)
Drug & Splint 
(30)
Splint
(30)
Appt.
number
Assessment 1   <--------------------   Assess  and  allocate  ---------------------->
  <------------- Blood  Test--------------------> 1
0 2
• Check blood results
• Start 20mg drug
1  • Check blood results
• Start 20 mg drug
• Impressions
• Inter-occlusal 
records
• Impressions
• Inter-occlusal 
records
2
1
2 • Splint fitted • Splint fitted 3
3
4 3 • Review medication • Review medication
• Splint review
• Splint review 4
5
6
7
8 4 • Double medication • Splint review
• Double medication
• Splint review 5
9
10
11
12 5 Repeat questionnaire  break code &modify  treatment if necessary 6
24 6 Repeat  questionnaires  ( follow up) 7
36 7 Repeat  questionnaires  ( follow up) 8Appendix 9 —  Follow-up forms
-  Pain assessment
-  Clinical examination
-  Splint and / or medical analysis
-  Medication record
-  Medication adverse events
Completion during -  3 month treatment phase
1 month  (4 weeks)
2 months (8 weeks)
3 months (12 weeks)
- 6 month follow-up phase 
6 months 
9 months
609FOLLOW UP
OWE I  I  I  I  I 
________ day  month  year
Date of last appointment 
Interval:............................ (3 M 1 )
da/  month  year 
.days,  weeks,  months,  (39
CURRENT
PROBLEMS:
PAIN/DISCOMFORT:
SOCIAL/FAMILIAL:
EMOTIONAL:
None;  Mild;  Moderate;  Severe 
None;  Mild;  Moderate;  Severe 
None;  Mild; Moderate;  Severe
INTERFERENCE WITH LIFE: Y / N
OTHER  NONE;  Headache,  Migraine, Tinnitus;  Neck Pain;  Back Pain;  Irritable Bowel;
CURRENT  Pelvic  Pain; Dysfunctional  Uterine Bleeding;  Pruritus;  M.E.;
SYMPTOMS:  Other:
DESCRIPTION OF PAIN 
Character
discomfort..................
dull ache......................
burning........................
Frequency:............
eh
sharp....
EH »
stabbing.
\  i »
throbbing
never.
Severity
WORSE;  IN  PAIN;  IMPROVED; PAIN FREE.
(27)   □
  D*
  □   -
occasionally,  often,  aiways4 ^
Site and radiation
left...................
right...............
midline..........
bilateral........
Other:  ____
(3M9
Please indicate
TM J.........................................................|  I  P9
face  .......................................................|  |  01 >
scalp.......................................................I  |  09
e ars.........................................................E H   0®
teeth........................................................ Q   00
jaws and alveolus................................................09
palate.....................................................Q J   09
gingiva................................................... Q J   07)
tongue.....................................................Q J   09
* •  □
09
Other
(3 0 -5 1 )
EXAMINATION:  T.M.JL:  OPENING  MM:  NOISE:  RT.; LT.;  NIL  TENDER:  RT.;  IX;  NIL
610SPLINT  ANALYSIS
SEUHT 
Lost.... 
Broken.. 
At home.
Comfortable to wear... 
Uncomfortable to wear.
Compliance with wearing splint....................... Yes No
Stability of occlusion in relation to splint........... Good
Moderate
Poor
Adverse clinical signs of wearing splint:-
Poor oral hygiene
Gross plague/calculus deposits□
Gingival....... Inf  lannation
Swelling 
Bleeding 
Ulceration
Action taken;-  Splint adjustment/Oral hygiene instruction/Hygienest appt, 
Splint adjustment:- Significant/Moderate/Non 
Splint therapy to:- Continue/Discontinue 
Next appointment:
DRUG  ANALYSIS
Compliance with taking medication  yes  NO 
(as stated by patient)
Adverse effects  Yes  No
(if yes please specify on chart)
Drug therapy to :- Continue/Discontinue
Dosage:
Next appointment:
611MEDICATION
Other analgesics:
BASELINE
Name. Quantity
Name.
Name.
Quantity
Quantity
1st MONTH
Treatment drug
TREATMENT PHASE
Quantity
Other analgesics:
Name.
!
1
Quantity
Name. Quantity
Name. Quantity
6122nd  MONTH
Treatment drug
Other analgesics:
Name........................
Name........................
Name........................
3rd MONTH 
Treatment drug
Quantity
Quantity
Quantity
Quantity
Quantity
Other analgesics:
Name.........................
Name........................
Name.........................
Quantity
Quantity
QuantityADVERSE EVENTS
Rash
Nausea
Vomiting
Diarrhoea
Anorexia
Headache
Nervousness
Insomnia
Anxiety
Tremor
Dry mouth
Dizziness
Hypomania
Drowsiness
Convulsions
Fever
Sexual dysfunction
Sweating
Other
If Yes,  specifyAppendix 10 —  Construction and adjustment of full coverage occlusal 
bite guard
615EASTMAN DENTAL HOSPITAL 
FULL OCCLUSAL COVERAGE BITE GUARD -  Construction and fitting.
This appliance provides a reversible form of therapy in which there should be no 
permanent occlusal changes. All the teeth in the maxillary arch are covered with 
heat cured acrylic and provide a hard, flat surface to engage all opposing teeth 
without dictating a mandibular position on closure.
On occasions mandibular appliance may be preferred firstly in patients with 
significant horizontal overlap of anterior in a severe class II or class III incisor 
relationship, or secondly where tooth loss has occurred in the mandibular arch 
and the appliance provides temporary replacement for the tooth in the 
mandibular arch and then desired occlusal requirements.
The aim is for opposing teeth to achieve stable, simultaneous contact with the 
appliance on mandibular closure. A gradual anterior rise is incorporated 
sufficiently steep to separate posterior teeth during excursive jaw movements to 
avoid non working side interferences and protecting posterior teeth from adverse 
occlusal damage.
Construction
A set of impressions are taken with an interocclusal wax record. The study casts 
poured in stone are mounted in a semi adjustable articulator to achieve 
intercuspal position. The occlusal splint is waxed incorporating a shallow incline 
anteriorly and thinning to approximately 1mm thickness over the occlusal surface 
of distal molars. The acrylic fits over the incisal edges of the maxillary anterior 
teeth by 1mm to ensure upper anterior teeth are not protruded labially. No 
additional clasps are required as natural indents on teeth provide the necessary 
retention. Further retention may be improved by also extending the acrylic over 
the buccal surface of short posterior teeth.
The appliance is then invested and processed in heat-cured acrylic resin to 
provide a hard, durable, flat surface. It is then returned to the articulator for 
further adjustment before polishing.
Adjustment
Once seated, the splint will require adjustment to achieve the correct occlusal 
relationship. Splint adjustments in the retruded axis position or as close to this 
position as possible are made first. Each posterior tooth should have a minimum 
of one contact with the appliance but indentations should not be created at the 
site of occlusal contact. Adjustments are then made for excursive movements 
with the aim of providing a shallow anterior guidance just sufficient to separate 
posterior teeth on lateral excursive movement of the mandible.
The patient may report the appliance to feel too tight at the initial appointment but 
encourage the patient to persevere with the tightness as the appliance will 
become looser within a short time of wear.
The patient should be reviewed after a fortnight for further adjustment and then at 
monthly intervals up to three months for minor alterations to the appliance and to 
assess progress of signs and symptoms.
Rachel Leeson
616Face bow recording for occlusal appliance construction
617Occlusal appliance adjustment
618